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Abstract 
Osteoarthritis (OA) is the most common form of arthritis. Affected individuals 
commonly suffer with chronic pain, joint dysfunction, and reduced quality of 
life. OA also confers an immense burden on health services and economies. 
Current OA therapies are symptomatic and there are no therapies that 
modify structural progression. The lack of validated, responsive and reliable 
biomarkers represents a major barrier to the development of structure-
modifying therapies.  
MRI provides tremendous insight into OA structural disease and has 
highlighted the importance of subchondral bone in OA. The hypothesis 
underlying this thesis is that novel quantitative imaging biomarkers of 
subchondral bone will provide valid measures for OA clinical trials. The 
Osteoarthritis Initiative (OAI) provided a large natural history database of 
knee OA to enable testing of the validity of these novel biomarkers.  
A systematic literature review identified independent associations between 
subchondral bone features with structural progression, pain and total knee 
replacement in peripheral joint OA. However very few papers examined the 
association of 3D bone shape with these patient-centred outcomes. 
A cross-sectional analysis of the OAI established a significant association 
between 3D bone area and conventional radiographic OA severity scores, 
establishing construct validity of 3D bone shape. 
A nested case-control analysis within the OAI determined that 3D bone 
shape was associated with the outcome of future total knee replacement, 
establishing predictive validity for 3D bone shape. 
A regression analysis within the OAI identified that 3D bone shape was 
associated with current knee symptoms but not incident symptoms, 
establishing evidence of concurrent but not predictive validity for new 
symptoms. 
In summary, 3D bone shape is an important biomarker of OA which has 
construct and predictive validity in knee OA. This thesis, along with parallel 
work on reliability and responsiveness provides evidence supporting its 
suitability for use in clinical trials.  
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Chapter 1 Introduction  
1.1 Background  
Osteoarthritis (OA) is the commonest arthritis and is one of the leading 
causes of chronic pain, disability and socioeconomic burden in the world. In 
the United Kingdom and United States of America OA affects 8.5 million[1] 
and 26.9 million[2] people respectively. The prevalence of OA increases with 
age and obesity and is therefore expected to increase in prevalence in our 
ageing and increasingly obese population. The prevalence amongst 
Individuals aged 45 and older of any OA is estimated to increase from 26.6% 
currently to 29.5% by 2032. During the same interval, the number of 
individuals seeking a clinical review for peripheral OA is estimated to 
increase by 26,000 per million by 2032[3].  
In adults above the age of 45 years, the individual prevalence of both knee 
[4] and hip [5] OA is as high as 28%. Together knee and hip OA are 
currently the eleventh greatest contributor to global disability, and it is highly 
likely that this is an underestimate of the true burden of OA. OA accounted 
for 10% of disability-adjusted life-years (DALYs) due to musculoskeletal 
conditions[6]. Approximately 2% of all sick days are attributable to knee OA 
and amongst individuals of working age, those with knee OA have twice the 
risk of sick leave and a 50% increased risk of disability pension compared 
with the general working population[7]. The pain and dysfunction of OA 
confers a substantial socioeconomic burden in developing countries of 1.0-
2.5% gross domestic product[8]. Therefore OA represents a massive and 
rapidly increasing burden on individuals on health services and on society as 
a whole.  
While the majority of patients report chronic pain, the burden of OA is 
intensified by the limitations of current non-surgical therapy with only 30% of 
people with OA reporting satisfaction with their analgesia[1, 9]. The mainstay 
of current non-surgical therapy involves a patient-centred package of non-
pharmacological and pharmacological therapies for reducing pain and 
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improving function before considering surgery. These are limited to a 
moderate effect size at best[10] and may have significant toxicities. For 
example oral paracetamol[11] and non-steroidal anti-inflammatory drugs( 
NSAIDs)[12] are commonly prescribed and are associated with greater risk 
of cardiovascular, gastro-intestinal and renal adverse events[13]. This is of 
particular significance to a population of OA which tends to be older with 
more prevalent comorbidity  
Attempts to develop a disease modifying osteoarthritis drug (DMOAD) have 
been hindered by the failure to demonstrate a substantive improvement in 
symptoms whilst also inhibiting structural deterioration of the OA joint. While 
recent trials report inhibition of structural progression, there are 
methodological limitations with these. Therefore there are currently no 
licensed structural-modifying therapies although these are highly desirable.   
This may in part reflect the insensitivity and limitations of existing measures 
of structural progression. These are used to determine eligibility for, and as 
primary outcome measures in DMOAD trials[14]. These structural severity 
and progression measures have primarily been based upon two-dimensional 
projection images of conventional radiography which rely upon surrogate 
measures of cartilage loss. Therefore while the need for prevention and 
novel effective treatment strategies for OA is of vital importance, the demand 
for better biomarkers for determining the effectiveness of prospective 
DMOADs is of equal importance. 
OA has traditionally been considered to be primarily a disease of cartilage 
and hence the focus has been on modifying this tissue. Historic attempts at 
developing DMOADs have focused primarily on preventing hyaline articular 
cartilage loss, in an attempt to provide “chondroprotective” therapies. 
However typical clinical OA is a pathology of multiple tissues and therefore 
more recently, other tissues have been targeted including the subchondral 
bone which is the bone that supports the articular cartilage and  which plays 
an integral role in the pathogenesis of OA[15].  
Although the diagnostic criteria for OA developed by in 1957 incorporated 
osteophytosis and subchondral sclerosis as a distinctive feature of OA, the 
subchondral bone is relatively understudied compared to cartilage. However 
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there is an increasing acknowledgement that it is involved in the 
pathogenesis of early and late-OA through both biomechanical and 
biochemical pathways. SCB is a dynamic structure which adapts to 
increased applied load by homeostatic remodelling of the trabecular SCB, 
changes in SCB mass and expansion of the SCB surface area, to name 
three examples. However SCB changes may also herald deterioration in 
nearby joint tissues especially the articular cartilage which highlights the 
importance of biomechanics and SCB in the aetiopathogenesis of OA.  
SCB has a well-connected population of osteocytes that perceive load and 
respond to microdamage through mechanotransduction of load and 
apoptosis resulting in a biochemical orchestration of osteoblasts (bone 
forming cells) and osteoclasts (bone resorbing cells) that carry out 
homeostatic ‘reparative’ remodelling which occurs in a biphasic response. 
There is an initial increase in bone turnover in response to microfractures 
with a net bone resorption with associated loss of bone volume and 
increased porosity in the junction between the cartilage and bone which 
permits pathological ‘cross-talk’. As further SCB accumulates the bone 
remodelling cells and their biochemical signalling fail to achieve repair and 
become maladaptive. A subsequent reparative net bone formation response 
occurs but this is with hypomineralised osteoid with a reduced stiffness 
relative to the bone volume formed and this is associated with an alteration 
in bone shape. This biomechanical deterioration in SCB drives deterioration 
in adjacent joint tissues especially cartilage and OA develops. A better 
understanding of what represents pathological change in SCB and the 
biomechanical and biochemical pathways involved in the pathogenesis of 
OA may permit the identification of individuals most at risk of OA but also 
targets for bone-modifying therapies. 
Conventional radiography (CR) is unable to capture the severity of the multi-
tissue involvement in joints with OA joints. This is particularly important 
because many of the trials of prospective disease modifying agents in OA 
have attempted to recruit a homogenous population that are likely to exhibit 
structural progression by selecting people with CR-defined OA. 
Unfortunately these patients may lack uniformity in terms of joint tissue 
involvement because CR is insensitive to tissue pathology like bone marrow 
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lesions (BMLs) which have important prognostic implications and are 
associated with worse structural and symptomatic outcomes. 
MRI-determined quantitative and semi-quantitative measurements of joint 
tissue in OA have started to be used as clinical outcome measures in 
structure-modification trials. This reflects the opinion of the Osteoarthritis 
Research Society International working group that recommended MRI 
cartilage morphology assessment be used as a primary structural end point 
in clinical trials which also acknowledged the rapid evolution of quantitative 
MRI assessments of subchondral bone and synovium. Therefore using MRI 
biomarkers of joint structure in OA represents a significant improvement in 
sensitivity to clinically significant structural pathology, responsiveness and in 
its correlation with pain compared with CR biomarkers. However we have 
not yet harnessed the full potential of MRI biomarkers and utilised all MRI 
has to offer. 
There are several examples of 2D and 3D imaging biomarkers that have 
been described for bone and cartilage which highlight the importance of 
SCB. The SCB is important in the pathogenesis of OA including SCB shape. 
3D bone imaging biomarkers have not been formally investigated as part of 
a biomarker validation process. The importance of modelling the shape of 
the knee bones with statistical shape modelling, active shape modelling and 
active appearance modelling is the analysis of bone shape may permit the 
validation of novel bone imaging biomarkers with improved responsiveness 
profile than existing imaging biomarkers for prospective use in OA 
modification trials. 
 
The hypothesis underlying this thesis was that MRI evaluation of the SCB 
would provide a number of unique biomarkers of patient-centred OA 
outcomes for future therapeutic trials of disease modifying OA drugs. The 3D 
knee bone shape was examined in large cohorts for its construct validity by 
comparing it with conventional radiographic measures and for its criterion 
validity by examining it’s association with knee replacement and current and 
incident knee symptoms.  
This thesis describes the independent association of imaging-defined OA 
subchondral bone biomarkers with patient-centred outcomes of OA and then 
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more specifically describes the validity of 3D bone shape. The association of 
3D bone shape with knee replacement provided evidence of predictive 
validity. The association of 3D bone shape with current but not with incident 
persistent knee symptoms provided evidence of concurrent but not 
predictive validity. The association of 3D knee bone structure of OA with 
conventional radiographic OA measures provided evidence of construct 
validity. This work further underpins the value of quantitative bone measures 
in future therapeutic trials of disease modifying osteoarthritis drugs.  
1.2 Structure of the thesis 
The hypothesis underlying this thesis was that MRI evaluation of the SCB 
would provide a number of unique biomarkers of patient-centred OA 
outcomes for future therapeutic trials of disease modifying OA drugs 
1.2.1 Chapter 2: Literature review 
This was a narrative literature review covering OA and focussing on bone 
the osteoarthritis initiative (OAI) and semi-quantitative and quantitative 
imaging analysis. The unique resources of this thesis are the OAI and 
quantitative imaging of bone shape. 
1.2.2 Chapter 3 A systematic review of the relationship between 
subchondral bone features, pain and structural pathology in 
peripheral joint osteoarthritis. 
This was a systematic literature review of the relationship between imaging-
assessed subchondral bone features, pain and structural pathology in 
peripheral joint osteoarthritis. This highlights that subchondral bone plays an 
integral role in the pathogenesis of OA and that subchondral bone shape is 
independently associated with structural progression, joint replacement and 
pain incidence in knee OA. This highlights that bone shape is important  but 
understudied and bone represents a valid target in the prospective treatment 
of OA. 
1.2.3 Chapter 4 The relationship between clinical characteristics, 
radiographic osteoarthritis and 3D bone area 
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This is a cross-sectional analysis of the relationship between clinical 
characteristics, CR measures of OA and OA-attributable 3D bone area. This 
identifies construct validity of bone area as it is significantly associated with 
CR measures such as osteophytes. However these CR measures do not 
substantively explain the variance in the OA-attributable 3D bone area which 
may reflect the additional information provided by 3D MRI when describing 
subchondral bone shape. 
1.2.4 Chapter 5 The relationship between three-dimensional knee 
MRI bone shape and total knee replacement – a case control 
study 
This is a nested case-control analysis within the OAI, of the relationship 
between 3D bone shape and the outcome of TKR. This identifies that a more 
advanced structural severity in 3D bone shape is associated with the 
outcome of TKR. This provides evidence of predictive validity of bone shape 
in regards to the outcome of TKR which reflects both pain and structural 
progression of OA. 
1.2.5 Chapter 6 The relationship between 3D MRI bone shape and 
knee osteoarthritis symptoms in knees with and without 
radiographic knee osteoarthritis. 
Chapter 6 is an analysis of the relationship between 3D bone shape and the 
outcomes of prevalent frequent knee symptoms (PFKS) and incident 
persistent knee symptoms (IPKS).  This analysis incorporates knees without 
ROA but at risk of OA and all knees within the OAI. There was no 
association of 3D bone shape vectors with either PFKS or IPKS in knees 
without radiographic OA. However 3D bone shape vectors are associated 
with concurrent frequent knee symptoms of OA but not with incident 
persistent symptoms amongst all knees within the OAI that include those 
with radiographic OA.  This provides evidence of concurrent validity for the 
association between 3D bone shape and knee symptoms.  
 
1.2.6 Chapter 7 Discussion, future directions and conclusions 
- 7 - 
This chapter discusses the results of this thesis, the conclusions that can be 
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Chapter 2 Literature Review 
This chapter reviews the current epidemiology of OA, the natural history and 
definitions of OA. The description of OA and historic trials of prospective 
therapies in OA previously relied on X-ray and focussed on cartilage 
measurement. MRI is better but we still have not utilised all of the 3D 
information provided by MRI. The best personalised biomarkers in OA are 
currently imaging biomarkers and the process of validation of biomarkers 
and the use of MRI is discussed. Finally the chapter also describes two 
novel resources, the Osteoarthritis Initiative[16] and automated statistical 
shape modelling. This explains the resource and technology used with 
modern quantitative analysis to develop novel imaging biomarkers of bone 
that may provide novel valid measures for clinical OA trials. 
2.1 Introduction  
Osteoarthritis (OA) is the most common arthritis and is a leading cause of 
global chronic pain, disability and socioeconomic burden. OA affects 8.5 
million people in the United Kingdom[1]. In adults above the age of 45 years, 
radiographic and symptomatic knee OA have a prevalence of 19-28% and 7-
17% respectively. The epidemiology and natural history differ between joints 
and individuals. The prevalence of OA increases with age and obesity..  
2.2 Defining OA and subtypes 
OA refers to structural deterioration of synovial joints that in early stages 
may initially involve individual tissues, which in the context of appropriate 
risk factors may evolve, by a complex cascade of biomechanical and 
biochemical pathologies, into the typical whole joint multi-tissue pathologies 
seen in typical painful clinical OA. This includes changes to the hyaline 
articular cartilage, the underlying subchondral bone, the meniscal 
fibrocartilages (in the knee) and the synovium.  
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2.2.1 The problems with defining OA 
Definitions of OA have derived from epidemiological studies and clinical 
trials where OA may be defined using clinical findings (joint symptoms and 
examination findings) alone, the presence of imaging-assessed pathology, 
or a combination of the two. Only 50% of knees with radiographic OA (ROA) 
have symptoms[17] and activity-related pain of OA may occur in a prodromal 
phase before the incidence of ROA[18]. Therefore in research studies of OA, 
a more specific definition of OA can be achieved by any combination of  joint 
imaging-assessed structural pathology (e.g. Kellgren Lawrence grade 2, a 
definite radiographic osteophyte –Figure 1)[19] and clinical findings and 
laboratory tests (e.g.Table 3)[20-22].  
While conventional radiography (CR) is feasible, it is limited in its utility by its 
relatively insensitive detection of structural pathology in tissues other than 
bone (Figure 1). 
Amongst individuals within the Framingham cohort above the age of 50 
years, with no pain and normal knee radiography, 88% of individuals had at 
least one OA tissue lesion in the knee on magnetic resonance imaging (MRI) 
[23]. MRI can visualise  the true three dimensional multi-tissue joint 
pathology of OA[24, 25]  and these MRI-detected structural changes (Figure 
2), which are more closely associated with patient reported pain[26]. 
Ultrasound (US) also has the capacity to acquire 3D images and, for 
example, has been shown to detect many more osteophytes than CR in 
hand OA[27, 28]. These modern imaging studies highlight that many of our 
concepts and definitions of OA have been based on an inaccurate imaging 
phenotype. Therefore there is currently no generally agreed-upon ‘gold 
standard’ for defining cases of OA, and the epidemiology of OA varies 
according to the definition of OA for any specified joint. 
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Figure 1 Conventional knee radiography 
 
 
Table 1 The Kellgren Lawrence grade 
Grade Features of Osteoarthritis 
Grade 0 No radiographic features 
Grade 1 Doubtful joint space narrowing,                           
possible osteophytic lipping 
Grade 2 Possible joint space narrowing,                            
definite osteophytes 
Grade 3 Multiple osteophytes,                                          
definite joint space narrowing,                               
some sclerosis,                                                 
possible deformity of bone contour 
Grade 4 Large osteophytes,                                               
marked joint space narrowing,                               
severe sclerosis,                                                 
definite bone deformity 
 
This was first described by Kellgren and Lawrence[19] 
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Figure 2 Knee MRI demonstrating multi-tissue involvement 
 
Medial tibial bone marrow lesion (long arrow) and macerated medial 
meniscus (short arrow). (Reprinted by permission from Macmillan Publishers 
Ltd: Nature Clincal Reviews [29] Copyright 2009.) 
Table 2 The prevalence of MRI-detected knee lesions and crepitus 
 
MCL / LCL – medial and lateral collateral ligaments of the knee 
MTF / LTF /PF – medial tibiofemoral  / lateral tibiofemoral / patellofemoral 
(Reprinted by permission from Elsevier Ltd: Osteoarthritis and cartilage [30])  
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2.2.2 Early OA 
The concept of early OA is imprecisely defined. Incident ROA has provided 
one operational concept of early OA. However both structural changes and 
symptoms of OA precede the incidence of ROA. As mentioned, at least one 
structural lesion of knee OA is present on MRI of people over 50 years 
without ROA or knee pain [23]. By the time knee ROA is detectable, 10% of 
knee hyaline articular cartilage is lost [31]. Incident knee ROA is preceded 
by prodromal symptoms of pain on twisting or pivoting and pain on standing 
by 39 and 25 months respectively[18]. Pain on stair climbing appears to be 
the first mechanical symptom to manifest amongst knees with ROA and at 
risk of ROA[32].  
It is very likely that problems such as isolated cartilage defects and meniscal 
tears are early structural lesions that progress to clinical OA, though these 
are not currently classified as early OA. Compositional measures using 
special MRI sequences can also demonstrate glycosaminoglycan loss 
before MRI can detect morphological changes [33, 34]. So substantial 
evolution of the concept and alternative definitions of “early” OA are 
required. 
2.2.3 Inflammatory OA 
OA is not considered to be a classical inflammatory arthritis because of 
features including a relative paucity of neutrophils in synovial fluid, a lack of 
subchondral bone erosions and no evidence of systemic inflammation or 
features of autoimmunity; these features were used to distinguish OA from 
the archetypal inflammatory arthritis, rheumatoid arthritis (RA). Clinicians 
may refer to inflammatory OA as the discrete very swollen joints seen in 
some patients with hand OA. But it is likely that there is much more 
widespread synovitis than is appreciated clinically. Modern imaging with its 
more accurate detection of synovial hypertrophy and effusion has changed 
our understanding of the frequency of inflammation in OA joints[35]. Using 
contrast-enhanced MRI, extensive synovitis is prevalent in most knees 
(>85%)[36-38] and hands (68%)[39] with established OA that met the 
respective OA joint criteria (Table 3).  
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Erosive OA refers to a group of patients with radiographic erosions, and the 
term is often used synonymously with inflammatory OA (though not all OA 
inflammation is associated with erosions). The overall prevalence of erosive 
OA is unclear, and the prevalence of erosions varies somewhat according to 
their definition and the imaging modality employed for detection. In two 
cohorts of women selected for erosive hand ROA, erosions were identified in 
17-18%, 35% and 61% of small joints using CR, ultrasonography and MRI 
respectively[28, 40]. When defined radiographically, erosive hand OA 
appears to have a greater association with obesity, hypertension, 
dyslipidaemia and the metabolic syndrome relative to non-erosive hand 
OA[41, 42]. 
2.2.4 Generalised OA 
An imprecisely defined phenotype is where multiple OA joints are present in 
an individual, that may referred to as generalised or also polyarticular OA. It 
is well recognised that a history of hand OA confers an increased risk of hip 
and knee OA, a history of knee OA confers a higher risk of hip OA and vice 
versa. These associations are independent of confounding factors of age, 
gender and BMI[43]. Generalised OA also conferred a greater risk of knee 
OA structural progression[44]. Generalised OA has been more frequently 
observed in women than men and with increasing age and is associated with 
poorer function, disability, quality of life and mortality than OA involving 
fewer joints[45]. Whether generalised OA reflects an accumulation of 
adverse biomechanical environments in adjacent joints or load 
compensation from other joints or systemic factors such as genetic tendency 
or obesity is not well understood [45].  
2.3 Epidemiology and risk factors 
The epidemiology of OA is complex which reflects the variation in the 
applied definition[46], the specific joint involved and the heterogeneity of the 
OA phenotype[47]. Epidemiological studies, particularly analyses of large 
prospective cohorts, provide important information about risk factors that in 
turn provide insight into the aetiology of OA. This is supported by several 
well recognised associations with the prevalence and incidence of OA in 
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peripheral joints. These include both non-modifiable (e.g. age, gender, 
trauma, alignment and genetic predisposition) and modifiable risk factors 
(e.g. obesity, occupational injury). Modifiable risk factors are prospective 
interventional targets for treatment and prevention.  
2.3.1 Prevalence  
The knee, hip and hand are most frequently affected joints and the 
prevalence of OA increases with age, which is the most important risk factor 
for OA prevalence[2]. This may represent a senescent impairment of tissue 
regeneration in addition to a cumulative effect of other risk factors 
associated with ageing. Approximately 14% of adults older than 25 years 
and 34% of adults older than 64 years have clinical OA of one joint or 
more[2]. Symptomatic OA of the knee, hip and hand are more prevalent in 
females[4, 48-51]. The population prevalence of OA of the hip and knee in 
the UK is also greater with than without obesity (Figure 3)[52]. However in a 
meta-analysis of OA prevalence studies in adults older than 55 years, 
women have higher knee and hand OA prevalence but there is no significant 
gender difference for hip OA. In the same meta-analysis no significant 
gender differences were observed in the prevalence of knee, hip or hand OA 
amongst adults below 55 years of age[53]. Women tended to have greater 
prevalence of OA when non-radiographic (e.g. clinical) methods were used 
for defining OA.  
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Figure 3 Population prevalence of Hip and knee OA with and without 
obesity 
 
The population prevalence is expressed as percentage of the population 
above the age of 45. The English Longitudinal Study of Ageing (ELSA)  - a 
large multicentre and multidisciplinary study of people aged 50 and over and 
their younger partners, living in private households in England – was chosen 
as the basis for the prevalence models. Sample members are drawn from 
respondents to the Health Survey for England (HSE). Study members have 
a face-to-face interview (a computer-assisted personal interview followed by 
a self-completion questionnaire) every two years of the study and a nurse 
assessment every four years. This particular survey was chosen because 
the sample used in ELSA was designed to be nationally representative and 
since osteoarthritis is rare under 50 years of age.  
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In adults aged 45 years and older in the American Johnston County project 
and Framingham cohorts, the prevalence of knee ROA was 28% and 19% 
respectively, whereas the symptomatic knee OA prevalence was 17% and 
7% respectively[4, 51]. In adults aged 60 years and older 37% and 12% had 
knee ROA and symptomatic knee OA respectively[48]. In the UK 18% of 
adults above the age of 45 have self-reported knee OA.  In a meta-analysis, 
a history of prior knee injury increased the risk of prevalent knee OA four 
fold[54]. 
In adults of 45 years or more in the USA Johnston County project the 
prevalence of hip ROA was 28% whilst symptomatic OA was 9%. In adults in 
the UK over 45 years 11% have self-reported hip OA.  In adults over the age 
of 60 years the clinical ACR criteria for hand OA (Table 3) was met by 
8%[49], whilst typical hand OA symptoms were reported by 22% of adults 
over 70 years of age[50]. Amongst adults above the age of 50 the 
prevalence of symptomatic foot and ROA was 17%[55].  
2.3.2 Incidence 
Generic risk factors for the incidence of the knee, hip and hand OA include 
age and female gender[43]. Occupational exposure to increased 
biomechanical stresses increases the risk of hip and knee (after adjusting for 
age, gender, body mass index and previous trauma)[56, 57]. Participation in 
sporting activities [58, 59] and the presence of OA in other joints increases 
the risk of incident hip and knee OA[43]. 
2.3.2.1 Age and Gender 
The age and sex-standardized incidence rates of symptomatic OA in adults 
of 20 years and older are quoted as per 100,000 person years: these are 
240, 88 and 100 for the knee, hip and hand respectively[60].  
The incidence of symptomatic OA of the knee, hip and hand increases with 
age, with women having higher rates than men, particularly after 50 years of 
age. Amongst women the incidence of clinical OA of the hip and knee 
increases rapidly between 50 and 75 years and then decreases thereafter. 
However incident clinical hand OA peaks in women in peri- and post-
menopausal years between 55 and 60 years and decreases thereafter[43]. 
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Amongst men the incidence of clinical OA of the knee, hip and hand 
increases from 50 to 75 years and then decreases. A meta-analysis and 
large primary care database reported a greater risk of OA incidence 
amongst women for the knee, hip [53] and hand[43] respectively (Figure 4). 
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Table 3 American College of Rheumatology radiological and clinical 
criteria for osteoarthritis of the knee and hip 
Hand (clinical) 
 
Osteoarthritis if 1, 2, 3, 4 or 1, 2, 3, 5 are present: 
1 Hand pain, aching, or stiff ness for most days of previous month 
2 Hard tissue enlargement of two or more of ten selected joints* 
3 Swelling in less than three metacarpophalangeal joints 
4 Hard tissue enlargement of two or more distal interphalangeal joints 
5 Deformity of two or more of ten selected hand joints* 
Hip (clinical and radiographic) 
 
Osteoarthritis if 1, 2, 3 or 1, 2 ,4 or 1, 3, 4 are present: 
1 Hip pain for most days of previous month 
2 Erythrocyte sedimentation rate of less than 20 mm in the first hour 
3 Femoral or acetabular osteophytes on radiographs 
4 Hip joint space narrowing on radiographs 
Knee (clinical) 
 
Osteoarthritis if 1, 2, 3, 4 or 1, 2, 5 or 1, 4, 5 are present: 
1 Knee pain for most days of previous month 
2 Crepitus on active joint motion 
3 Morning stiff ness lasting 30 min or less 
4 Age 38 years or older 
5 Bony enlargement of the knee on examination 
Knee (clinical and radiographic) 
 
Osteoarthritis if 1, 2 or 1, 3, 5, 6 or 1, 4, 5, 6 are present:  
1 Knee pain for most days of previous month 
2 Osteophytes at joint margins on radiographs 
3 Synovial fluid typical of osteoarthritis (laboratory) 
4 Age 40 years or older 
5 Crepitus on active joint motion 
6 Morning stiff ness lasting 30 min or less 
*Ten selected joints include bilateral second and third interphalangeal proximal joints, 
second and third proximal interphalangeal joints, and first carpometacarpal joint. 
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Figure 4 The incidence of OA 
 
 
Age and gender-specific incidence rates (/1000 person-years) of knee 
osteoarthritis (OA) (black), hip OA (red), and hand OA (green). Solid, All 
population; short dash line, women; long dash line, men 
SIDIAP (http://www.sidiap.org) is anonymised primary care 
electronic medical records of a highly representative sample of patients 
attending GPs in Catalonia (North-East Spain), covering a population of 
about 5 million patients. SIDIAP contains primary care records for>5 
million people from Catalonia (Spain). Participants aged ≥40 years with an 
incident diagnosis of knee, hip or hand OA between 2006 and 2010 were 
identified using International Classification of Diseases (ICD)-10 codes 
.Reproduced from Annals of Rheumatic disease, Prieto-Alhambra D, et al. 
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2.3.2.2 Obesity 
Obesity increases the biomechanical load upon weight-bearing joints which 
may explain its independent association with the incidence of knee ROA[61]. 
Obesity is the strongest potentially modifiable risk factor in meta-analyses 
and confers more than a three-fold greater risk of incident knee OA [62-64] 
and a greater risk of knee OA pain incidence[65] and structural 
progression[66]. Obesity is associated with incident hand OA[67] and self-
reported knee OA but interestingly not hip OA[68, 69]. There is conflicting 
evidence as to whether obesity is associated with structural progression of 
the hip or knee but there is no association between body mass index and 
hand OA pain or structural progression[70]. Obesity directly increases the 
biomechanical load in weight-bearing joints that may also promote the 
production of proinflammatory cytokines (including adipokines) that mediate 
the catabolic processes of OA[71, 72].  
2.3.2.3 Joint injury 
Joint injury can cause damage to articular cartilage, bone, meniscus and 
rupture of the anterior cruciate ligament, all of which can cause a 
biomechanically adverse environment within the joint that predisposes to 
further deterioration of the joint tissues. Joint injury is associated with 
subsequent incident knee pain in a systematic review and meta-analysis of 
cohort studies[65] and also a nine-fold greater odds of progression to end-
stage knee ROA in 48 months, amongst knees without baseline knee 
OA[73].  
2.3.2.4 Bone shape and malalignment 
There is increasing evidence that OA is a consequence of the failure to 
effectively dissipate adverse biomechanical forces within a susceptible joint. 
Bone shape within joints has long been recognised as a predisposing factor 
for adverse biomechanics. The presence of an aspherical femoral head (a 
cam-deformity) is associated with femoro-acetabular impingement and is 
associated with delamination of the acetabular cartilage and confers up to a 
ten-fold greater risk of end-stage hip OA within 5 years[74]. Similarly the 
expansion of the three-dimensional shape of tibial and femoral bones is 
associated with incident knee ROA[75]. Malalignment of the knees unequally 
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distributes load across the medial and lateral femoro-tibial joint compartment 
which results in a varus (bow-legged) or valgus (knock knees) deformity.  
The compartment with the greater load as a consequence of the 
malalignment is more likely to develop ROA and structural progression of 
cartilage damage[76, 77].  
 
2.3.2.5 Genetics and epigenetics 
Genetic studies within family-based studies and extreme OA phenotypes 
have confirmed the strength of genetic predisposition to OA. The 
identification of genes associated with OA through association studies confer 
only small effect sizes [78] but single-nucleotide polymorphisms (SNP) have 
been associated with established risk factors such as obesity (FTO [78, 79]) 
and hip bone shape (FRZB [80]). One SNP near the NCOA3 gene reached 
genome-wide significance level[81]. The NCOA3 gene is clinically important 
because it is expressed in articular cartilage and its expression was 
significantly reduced in damaged cartilage compared to normal cartilage in 
femoral heads removed at the time of hip replacement[81]. As OA is likely a 
complex polygenic problem, genomics alone will be unlikely to stratify 
individuals into who will or will not develop OA, but may lead to the 
development of new therapeutic targets for individual joints[82].  
 
Epigenetic studies have indicated the disruption of cartilage homeostasis 
may reflect environmental factors promoting abnormal expression of genes 
that disrupt the anabolic and catabolic processes that regulate cartilage 
integrity. The alteration in gene expression of anti-inflammatory or pro-
inflammatory cytokines, articular cartilage proteins, matrix proteases and 
transcription factors may be involved in the pathogenesis of OA and 
represent important novel therapeutic targets [83]. 
2.3.3 Structural progression 
Structural progression is usually defined as imaging evidence of structural 
deterioration in a joint, though soluble biomarkers may also reflect this 
process. Conventionally these have been surrogate measures of cartilage 
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damage from CR. Radiographic structural progression can be assessed by 
measuring joint space narrowing (JSN) using semi-quantitative tools like the 
OARSI atlas [84, 85] or quantitative tools. The Kellgren Lawrence grade[19] 
is a composite measure of JSN, osteophytes, subchondral sclerosis that is 
described on an ordinal scale (Figure 1,Table 1). Joint space width is used 
as a surrogate for assessing cartilage thickness but in the knee it reflects a 
construct of reduction in hyaline articular cartilage thickness along with 
meniscal extrusion and degeneration[86]. The Kellgren Lawrence scoring 
does not represent an interval variable where individual categories are 
equidistant from each other. Therefore it is important to recognise that the 
proportion of knees that progress from one grade to the next are not 
comparable for all starting points in the scale.  
With its three dimensional visualisation of joint tissues, MRI has broadened 
concepts of structural progression.  The quantification of MRI cartilage 
volume affords advantages over CR because structural loss of cartilage can 
be detected in the pre-ROA phase[87] and in end-stage OA, after the total 
loss of joint space width (‘bone on bone’ or  Kellgren Lawrence grade 4)[88]. 
As well, MRI demonstrates structures other than cartilage (Table 2,Figure 2) 
that might be used to measure structural progression such as bone marrow 
lesions (BMLs) or bone shape.  
The structural progression measured by ROA of knee, hip and hand OA is 
typically slow and takes place over several years but can also remain stable 
over years [89-92]. Structural progression varies by joint affected. In knees 
the mean annual risk of progression of KL grade is 5.6% ± 4.9% and mean 
rate of joint space narrowing is 0.13 ± 0.15mm/year, with change occurring 
in only a small group of “progressors” in a 12-month observational study and 
a 30 month randomised controlled trial[93, 94]. The same observation was 
made when structural progression was analysed in the OAI.  
It is important to understand the inertia of the trajectory of radiographic 
structural progression in knee OA that has been described by Felson and 
colleagues. A nested case control analysis within the OAI described  case 
knees as those with incident ROA (KL=2, a combination of incident JSN and 
osteophytosis) by the end of the first year of follow up and control knees 
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which maintained a stable KL grade of 2 during the first year. This was an 
elderly obese population. Both incident ROA (KL 2) and stable ROA (KL 2) 
knees were examined subsequently for progression of JSN (OARSI grade) 
or KL grade in the following (2nd) year.  13.7% and 4.1% of knees developed 
a higher KL grade in the incident and stable groups respectively. 25.8% and 
6.1% of knees developed progression in JSN in the incident and stable 
group (with JSN grade 0 or 1) respectively(Table 4)[92]. 
After adjustment for sex, race, baseline age, BMI, clinic site, physical activity 
survey of the elderly, quadriceps strength and alignment the incidence group 
had a four and five fold greater odds of KL grade and JSN grade progression 
than the stable group. This suggests that in adults with a mean age of 61 
years and mean BMI of ~29, radiographic structural progression is not 
phasic but an inciting event precipitates a trajectory of structural 
deterioration with inertia. 
Table 4 The inertia of knee osteoarthritis radiographic progression  
 Incident JSN 










% with JSN 
progression 




74.2% 93.9% 86.3% 95.9% 
JSN – joint space narrowing, KL – Kellgren Lawrence 
Data collected from the Osteoarthritis Initiative (OAI) 
 
MRI-determined cartilage volume loss in knee OA progresses at a mean rate 
of 4% per annum and more than half of all knees are “progressors”[95]. Loss 
of cartilage volume occurs more rapidly with increasing age, body mass 
index, lower limb muscle weakness but also with co-existing structural 
changes such as BMLs and meniscal damage[95, 96] (Figure 2). Muscle 
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weakness has not been considered to be a risk factor for structural 
progression based upon a systematic review of studies using CR and not 
MRI[44]. 
 
2.3.4 Symptom progression 
Studies that refer to OA ‘progression’ generally refer to structural 
progression, though sometimes progression to joint replacement is used as 
a surrogate for presumed worsening of pain and structure. OA symptom 
progression is not well defined and could refer to progression of pain 
severity or the new incidence of pain within individuals usually in cohort 
studies. Pain can be serially measured using numeric rating or visual 
analogue scales or using standardised questionnaires that ask patients to 
quantify pain severity. Amongst knees with ROA, little change is observed in 
knee pain over six years [97] except when large increases in radiographic 
structural severity are observed[98]. BMLs and bone shape are 
independently associated with future increases in knee pain severity[99-101] 
and incident knee pain[102] respectively. The probability of joint replacement 
is increased by increasing severity of joint pain[103], increasing ROA 
severity[104] and MRI-demonstrated BMLs, cartilage and meniscal damage 
and synovitis that indicate joint failure[103, 105].  
2.3.5 Secondary osteoarthritis 
The term ‘primary’ or idiopathic OA is less frequently used now, perhaps 
because we understand the frequency of pre-OA lesions (like meniscal 
damage) that would often not be detected in routine clinical practice and for 
which patients often have no knowledge (probably arising from minor or 
forgotten trauma). However OA does occur secondary to other diseases. 
Congenital or developmental causes include bone dysplasias such as 
epiphyseal dysplasia, localised diseases such as Perthe’s disease of the hip, 
congenital hip dislocation and slipped femoral epiphysis. Endocrinological 
predisposing diseases include acromegaly, diabetes mellitus, 
hyperparathyroidism and hypothyroidism. Metabolic predisposing diseases 
include haemochromatosis, ochronosis (alkaptonuria), Gaucher’s disease 
and Wilson’s disease. Finally neuropathic (Charcot joints), calcium 
- 25 - 
deposition diseases (primary pseudogout), haemoglobinopathies and other 
bone and joint diseases may also cause secondary OA.  
2.3.6 Impact of osteoarthritis 
Individuals with OA suffer pain which is associated with disability and 
reduced quality of life. The impact of OA on an individual’s function, mood, 
relationships, occupation and leisure activities may be extensive. Workers 
with OA reported more frequent pain, greater use of healthcare resources 
and costs, reduced productivity and poorer quality of life as self-rated OA 
severity increased[106]. 
One in eight individuals with OA suffer self-reported unbearable pain and 
one in five give up holidays, hobbies and leisure activities. One third of 
people with OA retire early, give up work or reduce the number of hours they 
work because of their condition. Those who retire early do so an average of 
8 years early. Furthermore two thirds of people with OA report an increase in 
their own costs including travel and treatment which in total  equates to a 
mean of £480 per person each year[1].  
OA is the most common worldwide cause of mobility disability and it is 
increasingly accountable as a cause for years lived with disability and 
limitation of quality of life[6].  
The lived experiences of people with OA can be influenced for better or for 
worse by one or a combination of the following: functional impairment, 
attitudes towards OA symptoms, personal perceptions of OA and perceived 
perceptions of other people towards OA. Favourable changes in any of 
these may improve the lives of those living with OA[107] (Figure 5). A 
systematic review of generalised OA indicates this is associated with poorer 
quality of life, function and increased disability compared to an OA 
monoarthritis[45]. Increasing OA joint burden is also associated with 
increasing risk of depression[108].  
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Figure 5 The factors affecting lived experiences of OA 
 
A line of argument diagram. Four concepts can act in isolation or in 
combination to influence the experiences perceived by the person with OA. 
Reprinted with permission of Taylor and Francis [107]. 
2.3.7 Health economic impact 
OA is associated with pain, disability, absenteeism and early retirement. The 
socioeconomic burden ranges from one to two-and-a-half per cent of gross 
domestic product in developed countries[8].  The economic burden of OA on 
society and health services is tremendous. This is generated through a 
combination of direct and indirect costs. Individuals with OA have double the 
rate of absenteeism compared with controls in North American [109] and 
Swedish population based cohorts [7]. The mean total direct and indirect 
costs are two to three fold higher [109] and there was a 40–50% increased 
risk of disability pension in comparison with the general population[7].  
In the UK between 1991 and 2006, 25845 hips and 23260 knees underwent 
total joint replacement[110]. The estimated mortality-adjusted lifetime risk of 
total hip replacement (THR) at age 50 was 11.6% for women and 7.1% for 
men. For total knee replacement (TKR) the risks were 10.8% for women and 
8.1% for men[110]. OA represents more than 93% of all joint replacement 
indications and the total annual cost of joint replacements is estimated at 
£852 million in the UK in 2010[111]. 
2.3.8 Mortality 
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Case series of individuals with OA have utilised different methods to 
describe the effect of a diagnosis of OA on mortality. Conflicting results have 
been reported by two different analyses, reporting an increased mortality 
and normal mortality rates conferred by a diagnosis of OA compared with 
national statistics of the general population[112, 113]. Symptomatic OA of 
the hip and knee was reported to confer approximately a two-fold greater 
risk of cardiovascular (CV) and dementia-associated deaths compared with 
the general population. While this association did not adequately adjust for 
the confounding effects of disability and comorbidity in the general 
population, walking disability was found to be a major risk factor for mortality 
amongst individuals with OA[112]. A subsequent population cohort reported 
that OA did not confer a greater risk of CV events but disability was 
independently associated with this outcome after adjusting for the presence 
of symptomatic and asymptomatic ROA[114]. An analysis of the 
Framingham population cohort reported that hand OA did not confer a 
greater risk of mortality but symptomatic hand ROA conferred a greater risk 
of CV events than asymptomatic hand ROA. A cohort in North America, 
designed to describe osteoporotic fractures and recruited from secondary 
care, described a greater risk of all cause and CVD mortality conferred by 
the presence of hip ROA compared to the absence of ROA of the hip. This 
effect was independent of poor physical function but the causal effect was 
significantly explained by poor physical function [115]. Therefore a greater 
burden of OA and subsequent disability may be important risk factors for 
mortality.  
2.4 Pathogenesis and pathological features 
There are multiple tissues that are essential components of diarthrodial 
(synovial) joints. Each tissue has its own composition and structure which 
plays an important functional role in effectively dealing with mechanical 
loads encountered during life. The hyaline articular cartilage is a tissue 
capable of distributing and transferring impressive load across diarthrodial 
joints without sustaining significant structural deterioration[116]. This 
cartilage affords a gliding surface for the joint which is almost frictionless and 
which permits load transmission during dynamic activity. It is the unique 
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mechanical and morphological properties of hyaline cartilage that permit it to 
fulfil its complex functional demands[116-118]. Subchondral bone is also 
integral to the maintenance of the integrity of articular cartilage and works in 
concert with this cartilage to effectively dissipate load by a process of load-
sensitive remodelling (see Section 2.6).  
OA is a syndrome of deterioration of synovial joints that is characterised by 
focal and progressive loss of the hyaline articular cartilage of joints, bone 
changes beneath the cartilage, synovial inflammation and debilitating pain.  
There is no single pathway of pathogenesis but in order for a structurally 
normal joint to become osteoarthritic, this requires a sufficient burden of joint 
tissue structural damage, biomechanical adversity along with a varying 
combination of risk factors (see epidemiology). These inflammatory, 
metabolic and genetic contributory factors may drive a subsequent 
heterogenous cascade of biomechanical and biochemical pathologies that 
overwhelm normal repair processes and establish the joint ‘failure’ that 
presents as clinical OA.  
This pathogenesis is likely to progress through a sequence of stages that 
can be described macroscopically using MRI studies and microscopically 
using histological studies.  
 
2.4.1 Macroscopic 
In early asymptomatic stages only individual tissues are likely to be involved 
and cartilage defects[119], meniscal degeneration[120] and BMLs[121] are 
all known to be present amongst individuals without knee OA symptoms. 
These lesions (see Figure 2, Table 2) are associated with incident knee 
ROA[122] and structural progression of cartilage volume or thickness 
loss[123-125]. It is likely that a ‘domino effect’ occurs where an inciting event 
such as a meniscal tear predisposes to cartilage loss, adjacent bone marrow 
lesions, meniscal extrusion and malalignment which establishes a 
progressive biomechanical adverse environment within the joint.  
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2.4.2 Microscopic 
OA represents whole-joint ‘failure’. Normal joint structure and function 
depend upon the ability of constituent tissues to perceive and respond to 
stress, strain and load. This is particularly true of the articular cartilage and 
subchondral bone. The cells within these tissues ensure the joint’s ability to 
receive and dissipate stress is maintained by homeostatic reparative 
processes. This includes the chondrocytes that maintain a substantial 
extracellular matrix. Chondrocytes synthesise molecules to restore the 
cartilage matrix, but also produce pro-inflammatory cytokines (e.g. 
interleukin-1) and tissue destructive enzymes (e.g. metalloproteinases) 
which decrease anabolic matrix synthesis (Figure 6)[126]. This matrix 
consists of a collagenous extracellular matrix, that consists of proteoglycan 
and elastin fibres. Cartilage and joint structural integrity and function are lost 
as a net catabolic process is established during the OA process. An 
extension of the calcified cartilage zone increases biomechanical forces 
across the cartilage and adjacent bone. Biomechanical derangements within 
the joint can stimulate the production of further catabolic enzymes. In parallel 
with these cartilage derangements the cellular activity in subchondral bone 
changes, probably to attempt to adjust to biomechanical forces. This results 
in resorption and the production of an increased volume of immature 
unmineralised bone. This may compromise the biomechanical support for 
the overlying cartilage which may augment the biomechanical forces 
transmitted through cartilage resulting in further damage. Furthermore an 
increased permeability at the junction between the articular cartilage and 
bone (osteochondral junction), driven by microcracks in the cartilage and 
subchondral angiogenesis, exposes the cartilage to an abnormal 
biochemical environment (Figure 7)[15]. Synovial inflammation is 
precipitated by cartilage debris and catabolic mediators entering the synovial 
cavity. Synovial macrophages produce some of the chemokines and 
metalloproteinases that degrade cartilage (Figure 6). This in turn amplifies 
synovial inflammation, creating a potentially vicious cycle between these 
tissues.  
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Figure 6 Pathogenesis of OA 
 
The role of proinflammatory cytokines in the pathophysiology of OA. The 
levels of cytokines are elevated in OA and downregulate anabolic events 
and upregulation of catabolic and inflammatory responses. This results in 
structural damage.  Reprinted by permission from Macmillan Publishers Ltd: 
Nat. Rev. Rheumatol. [126], copyright (2011). 
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Figure 7 Pathogenesis of OA – osteochondral disruption 
 
Molecular cross-talk at the osteochondral junction. A vascular channel is shown breaching from the subchondral bone (SCB), through the 
calcified cartilage (CC) into the non-calcified cartilage (NCC). Channel contents include macrophages, osteoclasts, osteoblasts and a blood 
vessel (BV). Cells within the channel interact through cytokines, growth factors and other signals that stimulate angiogenesis, nerve growth 
and sensitisation, osteoclastic activity and new bone formation. Importantly, these local interactions are enhanced in OA by signals across 
the osteochondral junction. With disruption of the tidemark, subchondral tissues become exposed to factors produced by articular 
chondrocytes nearer the joint surface, such as vascular endothelial growth factor (VEGF), and potentially to influences from the synovium. 
(Reprinted by permission from Elsevier Ltd: Bone [15])  
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2.4.3 Pain and measuring pain in OA 
OA is one of the most common causes of chronic pain and pain is the most 
common symptom of OA. Pain is the primary reason for patients seeking 
medical help with OA and involves peripheral and central nociceptive 
mechanisms. Pain is important to recognise for its characteristics to 
accurately diagnose OA but also to appreciate its likely origin as any 
successful treatment must ideally target the source of pain. This section 
describes the origin of pain in OA, the characteristic pain of OA, the 
structural associations and likely determinants of pain and finally attempts to 
treat pain.  
2.4.3.1 The pathogenesis of pain 
OA pain is generated from damaged joint tissues where irritative chemical, 
mechanical or thermal stimuli precipitate afferent nociceptive neurons to 
depolarise and send nociceptive signals to the sensory cortex via the dorsal 
horn of the spinal cord.  
Nociceptors within a joint vary by joint tissue and by stage of OA. Healthy 
diarthrodial joints have nociceptive fibres richly innervating the synovium and 
subchondral bone. These fibres also innervate the joint capsule and 
ligaments and the outer edge of the menisci in the knee but the cartilage is 
aneural and avascular in normal joints[127]. Therefore in normal joints and in 
early OA, the cartilage is unlikely to be the source of pain. However as OA 
progresses there is neurovascular invasion which provides cartilage with the 
potential for nociception[15](2.6.1.2 Subchondral bone and the 
osteochondral junction).  
Activity-related pain of OA is typically present in a prodromal phase of ‘early’ 
OA before the incidence of ROA[18]. This pain in early OA is typically 
mechanical [128]and may reflect the increased load upon SCB denuded of 
shock-absorbing cartilage and increased intra-articular pressure with a joint 
effusion. Cartilage degradation products also promote a secondary synovitis 
and joint inflammation which involves the release of cyclooxygenases, lipo-
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oxygenases, leukotrienes,  phospholipases and nitrous oxide that are 
involved in pain mechanisms. 
In acute pain, a peripheral nociceptor receives a stimulus and transduces 
this into an afferent sensory neurone action potential that relays with a spinal 
neurone for onward transmission to the thalamus and thereafter the sensory 
cortex. There are serotonergic and noradrenergic pathways within the 
central nervous system that provide descending inhibition to modulate and 
reduce the signal that is conveying the acute pain. However in chronic pain, 
greater sensitivity in the peripheral nociceptor can increase this signal and 
this is called peripheral sensitisation. Examples of mediators of peripheral 
sensitisation include neuronal growth factor (NGF), substance P, calcitonin 
gene-related peptide (CGRP), neuropeptide Y (NPY) and vasoactive 
intestinal peptide (VIP).  
Central pain neurological mechanisms play an important role in the 
perception of pain. Increased nociceptive transmission from the spine to the 
sensory cortex can be increased due to inhibition of the inhibitory central 
descending pathways and this is called central sensitisation. Central 
sensitisation has many determinants and can be influenced by comorbidities 
including mood disorders, loneliness and sleeping problems in OA. 
The enhanced pain experienced in response to a given stimulus reflects 
neural plasticity in the chronic pain of OA which involves both peripheral and 
central sensitisation. This is demonstrated by saline injections into the tibialis 
anterior muscle of patients with OA causing more intense pain than 
individuals without OA[129]. 
In more advanced forms of OA neuropathic pain may be involved whereby 
altered spontaneous and evoked activity from peripheral neuronal injury 
results in pain without the typical mechanical stimulus of OA pain. This 
unpredictable intense pain[128] is perhaps the most debilitating of OA[130]. 
2.4.3.2 OA pain and its structural associations 
OA pain is well known to be poorly associated with conventional 
radiographic structural knee OA severity. Only 50% of knees with 
radiographic OA (ROA) have symptoms[17]. Little change in pain is 
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observed in knees with ROA over six years[97] except when large increases 
in ROA structural severity are observed[98].  
CR is not as sensitive or specific in detecting structural pathology and 
progression as magnetic resonance imaging (MRI)[23, 86]. The OA joint 
tissue lesions detected by MRI (e.g. cartilage defects, meniscal tears, bone 
marrow lesions - see Figure 2) are prevalent in knees without ROA [23] and 
these are associated with incident symptoms [131] which highlights the 
importance of peripheral joint structural lesions in the pathogenesis of 
nociception. In particular a recent systematic literature review highlighted the 
important associations of MRI-detected synovitis and bone marrow lesions 
(BMLs) with knee OA pain[132]. An increase in the number or size of BMLs 
was associated with increasing knee pain, whilst a decrease in BMLs was 
associated with reduced knee pain[26]. BMLs are consistently associated 
with knee pain [26, 100, 133-135]. The pathophysiology by which BMLs may 
cause pain is unknown but this might include ischaemia from a decreased 
blood supply, subchondral microfractures, and raised intraosseous 
pressure[136-138]. 
Numerous other structural associations with pain have been demonstrated 
including SCB attrition (see 2.6.3) [135, 139], synovitis [135] and meniscal 
tears[135]. 
Demonstrating the longitudinal role of BMLs and synovitis in pain 
pathogenesis is more feasible because these lesions appear and disappear 
or regress. Meniscal tears and SCB attrition do not reverse. 
2.4.3.3 OA pain and measuring pain 
Pain is a characteristic feature of OA and is typically activity-related or 
mechanically-exacerbated and is relieved by rest. OA pain is 
characteristically intermittent in large OA knee cohort observational 
studies[140]  but as OA becomes more advanced, patients report pain with 
different qualities (such as “a burning sensation”) which may reflect 
neuropathic pain, and central pain mechanisms including sensitisation may 
reduce pain thresholds.  
Pain can be quantified using different methods and these include the visual 
analogue scale for pain (VAS), the numeric rating scale for pain (NRS), the 
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McGill pain questionnaire (MPQ), the Intermittent and Constant 
Osteoarthritis Pain (ICOAP) and the Western Ontario and McMaster 
Universities Arthritis Index (WOMAC).  
Pain severity can be described using the pain VAS, NRS, pain quality can be 
assessed with the MPQ and the time course of pain can be described by the 
ICOAP. The WOMAC is used to evaluate the pain, stiffness, and physical 
functioning of the joints of patients with OA of the hip and knee.  
The pain VAS is a unidimensional continuous measure comprised of a 
horizontal or vertical line which is usually 10 centimetres in length and 
anchored by two descriptors, one for each symptom extreme. 
The NRS is a segmented numeric version of the VAS where a respondent 
must select integers (0–10) that reflects the intensity of their pain. There are 
also anchoring terms describing pain severity at the extremes of the 11-point 
numeric scale.  
The MPQ identifies qualities of pain associated with distinct nociceptive 
disorders and neuropathic pain disorders like OA and also can measure the 
effectiveness and efficacy of pain interventions. This is a multidimensional 
pain questionnaire designed to measure pain intensity as well as the 
sensory, affective and evaluative aspects of pain in adults with chronic pain 
such as in OA. Four subscales evaluate the sensory, affective and 
evaluative, and miscellaneous aspects of pain 
The ICOAP is another multidimensional OA-specific measure for 
comprehensively evaluating pain in people with hip or knee OA. This 
includes the impact of pain on mood, sleep, and quality of life pain as well as 
measuring the intensity and frequency of pain.  It is an 11-item scale 
evaluating 2 pain domains: a 6-item scale evaluates intermittent pain while a 
5-item scale evaluates constant pain. 
The WOMAC is another multidimensional OA-specific measure for 
comprehensively evaluating the pain, stiffness, and physical functioning of 
the joints of patients with OA of the hip and knee. The WOMAC measures 
five items for pain (score range 0–20), two for stiffness (score range 0–8), 
and 17 for functional limitation (score range 0–68). Physical functioning 
questions cover activities of daily living[141]. 
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2.4.3.4 Novel approaches to measuring and treating pain in OA   
While structural joint pathology and inflammation are recognised as 
important contributing factors to pain, OA pain pathophysiology is relatively 
poorly understood. The mechanisms of peripheral and central sensitisation 
and neuropathic pain contribute to OA pain severity are important in the 
maintenance of pain and facilitate the conversion of acute pain into chronic 
pain. The role of the central nervous system in pain is highlighted by the 
observation that 10-20% of people with knee OA have persistent severe pain 
after total knee replacement[142-144]. Pain may therefore be a 
consequence of multiple mechanisms and this may explain why the 
response to conventional OA pain treatments, which often target one 
specific pain mechanism, is often inadequate.  
Quantitative sensory testing (QST) is an example of a mechanism that 
assesses the mechanisms of pain involved and a phenotyping of pain. This 
evaluates somatosensory evoked responses to innocuous or noxious stimuli 
using several modalities including  controlled chemical, thermal, mechanical 
and/or electrical. These stimuli are applied by an examiner to an anatomical 
test site such as a joint until the subject indicates pain. The subject’s 
responses to the stimuli locally can be used to assess peripheral 
sensitisation. The subject may also report pain at a nearby or distant location 
from the applied stimulus which may imply central sensitisation. These 
methods are being used to develop strategies for measuring the pain 
mechanisms involved in OA pain perception and the relative impact of 
peripheral and central sensitisation, descending pain control, and referred 
pain. This may permit patient phenotyping for targeted therapy directed at 
the underlying pain mechanism. 
One of the major mediators of peripheral sensitisation and pain in animal 
models of OA is nerve growth factor (NGF). The monoclonal antibody 
tanezumab provides a blockade of the NGF mechanism and in a 
randomised controlled trial in humans a sustained improvement in knee pain 
was demonstrated and therapy was essentially well tolerated. Unfortunately, 
trials were suspended due to increased rates of joint replacement[145] but 
investigation is now underway again. 
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In summary OA pain is a complex construct of tissue damage, peripheral 
sensitisation, central sensitisation and neuropathic pain. While OA pain has 
important structural associations with MRI-determined structural pathology 
these other mechanisms must be acknowledged as important determinants 
of OA pain.  
2.5 Management  
2.5.1 Clinical features 
NICE and EULAR guidelines advise that appropriate symptoms, clinical 
findings and age at onset can be used to clinically diagnosed OA[146-148]. 
Activity related joint pain reported in patients over the age of 45 with less 
than 30 minutes of morning joint stiffness can be considered to have OA 
without further investigation. The likelihood is increased further by risk 
factors (see Epidemiology and risk factors) and joint-specific examination 




X-rays and laboratory analysis of blood and synovial fluid are not necessary 
for the clinical diagnosis of OA. However in the presence of atypical features 
that suggest the presence of diagnoses other than OA, these tests may be 
used for differential diagnosis of inflammatory arthritis, septic arthritis or 
malignant bone pain[148]. These features include, rapid progression of 
symptoms, a hot swollen joint or prolonged morning stiffness of more than 
one hour 
2.5.3 Treatment 
Recent years have seen the emergence of a large number of evidence-
based guidelines from important musculoskeletal organisations. These are 
based on the published literature, expert opinion and, to a lesser extent, 
patient opinion (all three sources are valid for comprehensive guidelines). 
There is generally broad agreement across these guidelines in which 
therapies they recommend, though some discrepancies are obvious. 
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2.5.3.1 Nonpharmacological interventions 
Guidelines for the management of OA unanimously recommend the 
provision of health education and to encourage self-management. All 
individuals with OA should comprehend their arthritis reflects a failed repair 
process usually arising due to several joint insults, their personal risk factors 
(e.g obesity) and their prognosis. This information should be reinforced at 
subsequent consultations and with both electronic and written resources.  
All patients with OA should be offered advice on exercise that initially 
focusses on local muscle strengthening and then general aerobic fitness 
thereafter. A Cochrane review finds that land based knee and hip exercise 
programmes can reduce pain and improve physical function[149, 150]. 
Exercise programmes must be tolerable and realistic to promote adherence 
and should therefore be tailored to the severity of the OA at presentation.  It 
is unlikely that a patient with painful knee OA, that cannot perform a straight 
leg raise, will significantly benefit from walking without quadriceps 
strengthening first. Exercise programmes for individuals with significant 
muscle weakness should begin with low-impact exercises such as cycling on 
exercise bikes and walking laps in a swimming pool. Depending upon each 
individuals capability, the ‘dose’ of exercise should be titrated up.  
Overweight or obese individuals should be offered a dietician’s review or 
dietary advice because weight loss is associated with reduction in pain and 
better function (though there is little evidence for benefits on structural 
progression)[151, 152]. Aids and devices (for example, splints for base of 
thumb OA and devices for opening jars) help with everyday activities. 
Recommended footwear for individuals with OA includes shoes with no heel 
elevation, thick shock-absorbing soles and adequate plantar arch support.  
In summary, the multi-disciplinary patient-centred combination of exercise 
self-management and education should set realistic goals with regular 
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2.5.3.2 Pharmacological interventions 
The first-line pharmacological treatments are topical NSAIDs and oral 
paracetamol due to their favourable risk:benefit ratio. However recent 
evidence suggests that paracetamol may have greater toxicity than is 
generally appreciated, and be a less effective analgesic in OA than 
previously thought[10, 154](Table 6) 
In one study, after 13 weeks of regularly taking either ibuprofen or 
paracetamol three times a day for knee OA, one in five participants lost more 
than 1g per decilitre of haemoglobin[13]. A systematic review identified a 
dose-response effect on cardiovascular, gastrointestinal and renal adverse 
events[11] 
Topical capsaicin is a chilli pepper extract that depletes neurotransmitters in 
sensory terminals and attenuates the central transmission of peripheral pain 
impulses from the joint. It is generally recommended as supplementary 
analgesic for hand and knee OA and is again safe.  
Treatments may vary in efficacy according to the anatomical location of OA; 
most of the published evidence derives from knee OA trials, both 
nonpharmacological and pharmacological interventions are used, separately 
but more commonly in combination, in the treatment of OA(Table 5). 
Should further analgesia be required, practitioners should consider oral 
NSAIDS, selective COX-2 inhibitors and then opiates, acknowledging the 
greater risk of toxicity particularly with increasing age and co-morbidities. 
Nutraceuticals, including glucosamine sulphate and chondroitin sulphate 
products, are natural compounds consisting of glycosaminoglycan unit 
components and glycosaminoglycans respectively. Despite the substantial 
volume of published evidence, they are often not recommended due to the 
lack of certainty of clinically important analgesic or structural benefits. 
However nutraceuticals have been reported to afford small benefits in pain-
relief in low quality trials[155, 156].  
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Table 5 Summary of the latest evidence based guidelines for OA treatments 
 
Reprinted by permission from John Wiley & Sons Ltd: Prescriber, Table reproduced from [157]
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Table 6 Relationship between effect size for pain relief and quality of 
randomized controlled trial 
 
NSAIDs – non-steroidal anti-inflammatory drugs 
IAHA – intra-articular hyaluronic acid 
GS – glucosamine 
CS – chondroitin sulphate 
ASU -Avocado soybean unsaponifiables 
Jaded - a procedure to independently assess the methodological quality of a 
clinical trial 
ES – effect size. This is a standard mean difference between 
groups (e.g., treatment vs placebo). ES is calculated by dividing 
the mean difference between treatments by the standard 
deviation of the difference. It is, therefore, a number without 
units that can be used for cross-study comparisons. Clinically 
ES >0.2 is considered small, ES>0.5 is moderate and ES> 0.8 is 
a large effect. 
(Reprinted by permission from Elsevier Ltd: Osteoarthritis and Cartilage [10] 
 
The intra-articular injection of corticosteroids is a useful short-term adjunct in 
the treatment of moderate to severe OA pain, which may facilitate muscle 
strengthening and exercise. Hyaluronan (HA, or hyaluronic acid) is a high 
molecular-weight glycosaminoglycan, a naturally occurring synovial fluid and 
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cartilage component. It provides the visco-elastic properties of synovial fluid 
that may provide lubricating and shock absorbing properties. Intra-articular 
HA is not recommended for OA by the NICE guideline[148]; in contrast the 
ACR guideline conditionally recommends its use in individuals older than 74 
years with knee OA pain that is refractory to conventional pharmacological 
therapies[158].  
 
2.5.3.3 Joint surgery 
Surgical intervention in OA may include arthroscopic surgery or partial or 
complete joint replacement. Arthroscopic debridement and lavage are not 
recommended as treatment for OA, except when there is a clear history of 
true mechanical locking of an osteoarthritic knee. However joint surgery 
should be considered if a patient with OA suffers persistent symptoms 
despite adequate use of the non-pharmacological and pharmacological 
interventions described above. In this circumstance clinicians should 
consider an orthopaedic referral to primarily consider joint replacement.  
2.5.4 Conclusions 
OA represents a process of joint failure with a great variety of risk factors 
and complex pathogenic pathways. OA confers a huge burden on individuals 
and health economies alike which is expected to increase in ageing and 
increasingly obese populations. Current treatments for OA consist of 
moderately effective non-pharmacological and pharmacological pain-
relieving therapies. There are currently no licensed structure-modifying 
therapies. Joint replacement reduces pain but joint prostheses have a finite 
life expectancy and revision surgery offers less favourable outcomes.  
2.6 Subchondral bone in OA 
The subchondral bone (SCB) is the bone tissue adjacent to the hyaline 
articular cartilage of diarthodial (synovial) joints. The SCB can be divided 
into two regions, the SCB plate and the subchondral trabecular bone (Figure 
10). The osteochondral junction (OCJ) is the interface between the rigid 
skeleton and the articular cartilage [159] and consists of the deeper calcified 
and non-calcified cartilage, the tidemark, the cement line and SCB plate 
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which is cortical bone (Figure 8,Figure 9,Figure 10). The OCJ is an important 
interface between the subchondral and synovial compartments and plays an 
integral role in maintaining normal joint physiology but also in the 
pathogenesis of OA.  
Beneath the plate is the subchondral trabecular bone of the epiphysis which 
contains sensory nerves, blood vessels, endothelium and haemopoeitic 
bone marrow. The bone and cartilage form an osteochondral functional unit 
which is responsible for effectively dissipating forces associated with joint 
movement in order to maintain the integrity of the joint. 
Figure 8 The structure of articular cartilage and subchondral bone 
 
Diagrammatic representation of the zones of articular cartilage and 
subchondral bone. Reprinted by permission from BioMed Central: BMC 
Musculoskeletal Disorders, Lyons et al [159].
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Figure 9 The anatomy and histology of joint tissues 
 
Normal joint structure and osteochondral junction. Photomicrograph showing osteochondral junction in a medial tibial plateau from a 
patient without arthritis. Scale bars represent 100 μm. NCC — non-calcified cartilage; CC — calcified cartilage; SCB — subchondral 
bone; Sp — subchondral bone space; V — vascular channel. Arrows denote tidemark; dotted line indicates the osteochondral 
junction. (Reprinted by permission from Elsevier Ltd: Bone [15])
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Figure 10 The structure of articular cartilage and subchondral bone in a 
normal human joint.  
 
The structure of articular cartilage and subchondral bone in a normal human 
joint. CC, calcified cartilage; NCC, non-calcified cartilage; SBP, subchondral 
bone plate; STB, subchondral trabecular bone. Arrows denote the tidemark; 
the dotted line indicates the cement line. Reprinted by permission from 
BioMed Central: Arthritis Research & Therapy, Li et al[160]. 
SCB plays a supportive physiological role in maintaining and sustaining the 
viability of hyaline articular cartilage through biomechanical and biochemical 
pathways[161]. The SCB provides biomechanical support through shock-
absorbing and supportive functions for protecting the cartilage. SCB 
physiologically undergoes continuous bone remodelling as part of an 
adaptive mechanism to appropriately dissipate load through bone. This 
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involves a tightly regulated homeostatic process of bone matrix formation 
and resorption, which is driven by osteoblasts and osteoclasts respectively 
with no overall change in the shape of the bone. Change in shape, 
architecture and integrity of the subchondral bone is associated with 
ineffective dissipation of load and subsequent biomechanically driven 
structural deterioration of the SCB and cartilage and the onset of OA.  
In healthy joints there is convincing evidence that the vascular SCB provides 
biochemical support by the delivery of nutrients to the avascular cartilage 
through small channels that span the OCJ[161, 162]. The limited 
permeability for biochemical ‘cross-talk’ afforded by the integrity of the OCJ 
in healthy joints [163] is characteristically compromised in OA where 
osteochondral junction channels form which are associated with increased 
biochemical and cellular ‘cross-talk’ between SCB and cartilage[164]. This 
interaction is associated with important biochemically driven pathological 
deterioration of the SCB and cartilage and the onset of OA. 
The role of the SCB in the biomechanical and biochemical pathogenesis of 
OA will be discussed below in terms of change in macroscopic SCB shape, 
SCB architecture and SCB cellular and biochemical effectors on a 
microscopic level. 
2.6.1 Subchondral bone cellular changes in OA 
The evidence describing the role of the SCB in OA pathogenesis at a cellular 
level is discussed here. 
2.6.1.1 Subchondral bone remodelling 
In the healthy joint bone turnover is a continuous process of modelling and 
remodelling carried out by bone forming osteoblasts and bone resorbing 
osteoclasts. These cells are not ‘permanent’ residents of the bone and are 
recruited and derived from their prospective progenitor cells when ‘demand’ 
requires the remodelling of bone. This is a carefully balanced homeostatic 
process intended to maintain the integrity of the osteochondral unit.  
Remodelling involves resorption of ‘old bone’ by osteoclasts and the 
replacement with new osteoid secreted by osteoblasts. The first stage 
involves osteoclastic recruitment and activation which causes bone 
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resorption. Subsequently osteoblast precursors are recruited which 
proliferate and mature into osteoblasts before producing new bone matrix 
(osteoid). This matrix is then mineralised to produce new bone which 
finalises the bone remodelling (Figure 11).  
Osteocytes are a third cell type and are the most abundant cell type in bone 
and are ‘permanent’ residents of bone, derived from osteoblasts. They have 
a dendritic morphology with extensive connectivity throughout the 
mineralized matrix of bone. They reside within the mineralised bone matrix in 
lacunae where they are integrated into the bone structure, able to perceive 
mechanical load and are connected to other osteocytes in a multicellular 
network via the lacunar-canalicular system. This is believed to represent the 
means by which osteocytes act as bone mechanosensors and respond to 
mechanical stimuli to maintain the integrity of SCB by coordinating 
osteoblastic and osteoclastic activity (Figure 16). These physiological 
pathways carefully balance catabolism and anabolism of the osteochondral 
unit to repair damaged tissue. When the extent of damage exceeds the 
capacity to repair it, the imbalance in the anabolic and catabolic molecular 
and cellular pathways leads to the pathogenesis of OA.
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Osteoclasts–osteoblast interactions in the basic multicellular unit (BMU). (A) Osteoclasts (OC) differentiate from OC precursors (OCP) 
under the influence of MCSF and RANKL produced by osteoblast (OB) lineage cells including osteocytes. As OCs create a resorption 
pit, growth factors, including TGFb and IGF1, are released from the bone matrix. These growth factors may recruit mesenchymal 
osteoblast progenitors and promote their differentiation into mature cells that secrete osteoid to fill the area of resorbed bone. Some 
OBs differentiate further into matrix-embedded osteocytes. IGF1, insulin-like growth factor 1; MCSF, macrophage colony stimulating 
factor; RANKL, receptor activator of NF-kB ligand; TGFb, transforming growth factor b. Reprinted by permission from Elsevier Ltd: 
Trends Mol Med, Charles et al [165]
                  Resorption  Reversal            Osteoid formation Mineralisation 
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Subchondral bone is a dynamic structure and mechanical stimulation is a 
major environmental regulator of SCB, which remodels in response to load. 
Wolff’s law describes this concept by stating SCB responds and adapts to 
repeated load. Increased load is associated with SCB microfractures which 
are repaired by homeostatic remodelling to maintain the integrity of the 
SCB[166]. Similarly SCB also remodels with decreased load such that in 
zero gravity, cosmonauts in space for six months experience significant 
reduction in tibial cortical and trabecular bone mass measured by 
quantitative computerised tomography[167] and dual-energy X-ray 
absorptiometry[168].  
Osteocytes are the putative mechanosensors[169] that coordinate the 
remodelling. This is supported by a study where ablation of osteocytes (but 
not osteoblasts) in mice resulted in a resistance to disuse-induced bone 
resorption when the hind limbs are unloaded[170]. The pathway of 
mechanotransduction is not clearly described but in-vitro studies report 
osteocyte vesicular ATP release is proportional to the magnitude of loading 
and may be an acute mediator of mechanical signalling[171].  
Osteocytes may promote osteoclastic resorption through the same 
biochemical mechanisms used by osteoblasts (Figure 12).  
Osteoclastic differentiation and activation is promoted when receptor 
activator of nuclear factor kappa Beta ligand (RANKL) binds to its receptor 
(RANK) on osteoclasts and their precursors. Osteoprotegerin (OPG) is a 
decoy receptor of RANKL and hence inhibits osteoclastic activity and bone 
resorption. Osteocytes in vitro respond to unloading with a greater 
expression of RANKL than OPG[172] which is likely to increase osteoclastic 
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Figure 12 The RANKL and OPG system 
 
 
RANKL expressed by osteoblast lineage cells binds to RANK on the surface 
of pre-osteoclasts and mature osteoclasts, resulting in increased bone 
resorption via an increase in osteoclast differentiation, activity, and survival. 
OPG is a 'decoy receptor', also produced by osteoblasts, that binds to 
RANKL, preventing RANKL binding to RANK and thereby inhibiting 
osteoclastic bone resorption. It is the balance of RANKL and OPG that 
determines the ultimate rate of bone resorption. A high rate of bone 
remodeling may be due  to an excess of RANKL over OPG. (Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology 
[175]. Copyright 2011). 
 
 
- 51 - 
 
 
Figure 13 The osteocytic response to microdamage in SCB 
 
Schematic summary of the role of osteocytes in triggering bone resorption. 
A) Microcracks in bone caused by fatigue loading lead to highly localized 
osteocyte apoptosis (shown in white) surrounding the microcrack. B) Recent 
studies show that surviving osteocytes immediately neighboring the region of 
apoptosis upregulate production of pro-osteoclastogenic signals (i.e. 
RANKL, and others). Springer Calcif Tissue Int, Osteocytes: master 
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Microfractures, microcracks or microdamage are well recognised and 
prevalent features of OA which involves the trabecular bone, the SCB plate 
and the calcified cartilage.[176, 177] They are observed after 
overloading[178] and may be linear or diffuse[166]. Typically there is local 
osteocyte apoptosis in the region of the microcrack (Figure 13). 
The osteocytes that survive in the adjacent regions to the region of 
apoptosis then upregulate osteoclastogenic signals including RANKL. 
Osteocytes that are unaffected and at a significant distance from the 
microcrack do not upregulate osteoclastogenic signals. Therefore there is 
focal osteoclast recruitment and bone resorption as part of a microdamage 
repair process (Figure 13). Osteocytes appear to respond to the linear form 
of microcracks by promoting remodelling with osteoclastic bone resorption of 
the compromised tissue followed by the formation of new osteoid by 
osteoblasts (Figure 13). However osteocytes do not promote remodelling to 
diffuse areas of microdamage[166]. This supports the concept that OA 
represents a failure to meet the demands for ‘repair’ of the joint tissues. SCB 
microdamage is considered to be involved in the pathogenesis of OA both at 
initiation and progression stages as the accumulation of SCB microdamage 
exceeds the rate of repair[176]. Repeated loading of canine femurs was 
associated with an accumulation of such microdamage. A threshold effect 
was observed whereby the elastic modulus (stiffness) decreased after a 
sufficient accumulation of microdamage in the trabecular bone was accrued 
which implicates microdamage in biomechanical model of OA 
pathogenesis[179].    
Another pathway that may permit osteocytes to coordinate remodelling is via 
the canonical Wnt signalling pathway, which promotes osteblastic maturation 
and bone formation[180]. Sclerostin is an inhibitor of a co-receptor low-
density lipoprotein receptor-related protein 5 (LRP5) of the canonical Wnt 
signalling pathway and hence it inhibits bone formation[181]. Osteocytes 
produce Wnts and sclerostin[172]. In vivo experiments in rat ulnar bones 
indicate that sclerostin is produced in abundance in unloaded states which 
inhibits new bone formation. When ulnar load increases 
mechanotransduction by osteocytes dramatically reduces sclerostin 
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production which disinhibits the osteoblastic bone formation and hence new 
bone formation commences (Figure 14)[181]. 
Immobility and zero gravity in humans are well-recognised risk factors for net 
bone loss[167, 168]. Amongst postmenopausal women with and without 
immobility , sclerostin levels were significantly greater amongst immobile 
women and conferred significantly reduced bone formation biomarker  and 
quantitative bone volume of the calcaneum[182].   
Human femoral head specimens, from joints with OA undergoing 
arthroplasty, had significantly reduced bone osteocyte expression of 
sclerostin and increased osteoblast activity compared to  normal controls. 
This highlights the importance of sclerostin and its potential role in the 
osteocyte-coordinated pathogenesis of OA [183]. Therefore osteocytes have 
the potential to sense and adapt to the mechanical demands upon the SCB 
by coordinating bone formation and resorption via osteoblastic and 
osteoclastic regulation with RANKL/OPG and Wnt/sclerostin(Figure 15, 
Figure 16). However these homeostatic processes fail in OA.  
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Figure 14 Sclerostin mediation of LRP5 signalling during mechanical 
loading 
 
The role of sclerostin in Lrp5 signalling before and after mechanical loading. 
(Bottom) Before loading in the unstimulated state, dendritic osteocytes 
secrete plenty of sclerostin (purple circles). This inhibits Wnt signalling in the 
overlying osteoblasts by LRP5 receptor antagonism.  
(Top) After mechanical loading, in the stimulated state, there is a substantial 
reduction in sclerostin levels which increases LRP5 availability for Wnt 
binding, which disinhibits the canonical Wnt intracellular signalling pathway 
that promotes bone formation. Reprinted with permission of American 
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Figure 15 The mechanism by which osteocytes may coordinate bone 
remodelling 
 
Osteoclasts (OCs) and osteoblasts (OBs) within a cancellous BMU are 
shown as being derived from precursors (pOC and pOB). (?) sclerostin may 
also stimulate RANKL expression by osteocytes. Reprinted by permission 
from John Wiley & Sons Ltd: J Bone Miner Res, [184]  
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Figure 16 The mechanism by which osteocytes may coordinate bone homeostais through mechanotransduction. 
 
Osteocytes may orchestrate functional adapation in the subchondral bone by a process of mechanotransduction. This image 
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2.6.1.2 Subchondral bone and the osteochondral junction 
In early knee OA SCB remodelling involves a net osteoclastic resorption 
(2.6.2.2 Early OA). This includes an initial thinning of and channel formation 
through the SCB plate in early OA  in  canine [186, 187] and rabbit cruciate 
ligament transection models[188]. Channels within the SCB plate can be 
seen extending towards the cartilage with osteoclasts at the advancing edge 
in human tibial plateau explants at the time of knee replacement for OA[189].  
This SCB plate resorption ultimately compromises the selective porosity of 
the normal OCJ after the OCJ channels completely traverse the OCJ [164, 
176].  
When intact the OCJ only permits the passage of nutrients but the presence 
of OCJ channels permits pathogenic biochemical ‘cross-talk’ between SCB 
and the cartilage and synovial compartment. This ‘cross-talk’ heralds the 
cartilage catabolism associated with a neurovascular invasion of the 
cartilage from the SCB. Osteoclasts and catabolic biochemical agents from 
the SCB also pass into the cartilage through the OCJ channels. This process 
results in cartilage fibrillation and fissuring which may progress so that 
fissuring occurs down to these OCJ channels. This permits biochemical and 
cellular interaction of the synovial compartment with the SCB and vice versa 
which promotes further catabolism within the osteochondral unit (Figure 17). 
These processes may increase the failure of the osteochondral unit  to 
effectively dissipate load. This may increase loading within the joint, driving 
further SCB microdamage and SCB remodelling which may promote a 
vicious cycle of structural deterioration within the osteochondral unit.  
The incursion of these neurovascular structures may extend into the non-
calcified articular cartilage, osteophytes and even inner regions of 
menisci[190, 191]. Typically there is calcification and ossification of the 
cartilage around these channels which in part drives extension of the 
calcified cartilage region and the tidemark which may cause further 
biomechanical adversity, loading and microdamage for the SCB. Therefore 
the vascular incursion of cartilage heralds structural progression.  
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Figure 17 The pathological changes in the osteochondral unit in OA 
 
Complex changes in the bone–cartilage unit increase the flow of fluid and solutes in osteoarthritic joints. In OA, the permeability of the 
bone–cartilage unit is increased, through subchondral angiogenesis and the development of cartilaginous cracks and fissures, and 
patches of uncalcified cartilage that extend into the calcified layer. An increase in hydraulic conductance also leads to fluid exudation 
and further damage to the articular cartilage. OA subchondral bone osteoblasts have an activated phenotype characterized by 
production of IL-6, MMPs and angiogenic factors. Articular chondrocytes lose their stable phenotype and express markers of terminal 
differentiation. The tidemark—the demarcation line between calcified and articular cartilage—shifts upwards, representing a thinning 
of the articular cartilage, thereby increasing strain in the bone–cartilage unit. Reprinted by permission from Macmillan Publishers Ltd: 
Nat Rev Rheumatol [164], copyright 2011.
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The role of the SCB in the pathogenesis of OCJ channel formation and the 
neurovascular incursion is discussed here.  
Osteoclastic activity is increased in OA SCB and may be responsible for the 
migration of osteoclasts into the cartilage from subchondral pits[192], 
through the SCB plate OCJ channels towards the joint surface. These 
osteoclasts release multiple matrix metalloproteinases (MMPs) and 
cathepsin K which may degrade the articular cartilage matrix and promote 
the incursion of neurovascular channels into the articular cartilage[193, 194]. 
The formation of OCJ channels is typically associated with an infiltration of 
inflammatory cells (e.g. macrophages) into the SCB marrow spaces[189] 
which is likely to promote osteoclastic activity along with catabolic ‘cross-talk’ 
that drives cartilage degradation[164].  
Osteoblasts in osteoarthritic SCB plates may also remotely promote the 
degeneration of articular cartilage by ‘cross talk’. Firstly OA osteoblasts may 
promote the vascular invasion of articular cartilage by SCB because they 
have an upregulated expression of the angiogenic growth factor hepatocyte 
growth factor which appears to cross the OCJ from the SCB into cartilage in 
early OA (before significant cartilage damage is present)[195]. Secondly in 
vitro experiments of osteoblasts, isolated from bones affected by OA, 
express cytokines that promote remodelling that appeared to inhibit the 
expression of chondroprotective genes (e.g. aggrecan) in chondrocytes 
whilst promoting the expression of genes for MMPs[196]. This indirectly 
promotes cartilage catabolism. 
Chondrocytes are also capable of responding to increased load and by 
mechanotranduction release several pathogenic molecules including 
vascular endothelial growth factor (VEGF) which drives osteoclastogenesis 
in the SCB and migration of osteoclasts into the cartilage where they 
express MMPs[189]. However the capacity of chondrocytes to repair and 
remodel the extracellular matrix that surrounds them is comparatively limited 
relative to the bone matrix and its cellular components[197]. 
Both angiogenesis and neurogenesis are linked by common pathways that 
are stimulated by the release of proangiogenic factors like VEGF and beta-
nerve growth factor (beta-NGF) in response to chondrocyte loading. This 
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drives the incursion of sensory and sympathetic nerves along with new blood 
vessels into a previously avascular and aneural cartilage[189, 198]. There is 
increased nerve growth factor expression within these vascular channels 
which drives sensory nerve growth.  
Sensory innervation and vascular incursion of hyaline articular cartilage has 
been observed across a spectrum of early to advanced OA[198]. This 
provides a plausible mechanism  for nociception and biochemically mediated 
progression in structural degeneration of the articular cartilage.  
The formation of osteophytes and normal skeletal development have 
remarkably analogous mechanisms which are discussed here to explain the 
rationale for the SCB representing a treatment target in OA (2.6.4 Can the 
OA Subchondral Bone be therapeutically targeted?).  
In-vitro studies indicate chondrocytes mediate physiological skeletal 
development by conversion of cartilage into skeleton (endochondral 
ossification). These mechanisms are in many ways analogous with 
pathogenic mechanisms in OA which includes signalling via Wnt 
pathway[180]. For endochondral ossification in the developing skeleton to 
occur chondrocytes produce MMPs which degrade cartilage and promote an 
invasion of healthy cartilage, by new blood vessels along with osteoclasts 
and osteogenic cells, mediated by vascular endothelial growth factor 
(VEGF). The activation of osteoclasts appears to be essential for 
subsequent endochondral ossification[199, 200].      
Osteophyte formation occurs by an analogous process of endochondral 
ossification, initiated by vascular invasion of cartilage along with 
osteoclastogenesis [201-203] and concomitant increased bone turn over. 
However the notable exception to this analogy is that osteophytosis occurs 
in the mature skeleton (Figure 18).  
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Figure 18 Osteophyte formation in the mature skeleton 
 
Sites of angiogenesis in the OA knee. a | The structure of the normal knee (left) 
and sites of angiogenesis in OA (right). The synovium is continuous with the 
periosteum and apposed to cartilage. The meniscus merges with the 
collagenous capsule. Subchondral bone contains marrow spaces. The tidemark 
between calcified and noncalcified cartilage is indicated by a dashed line. b | 
Osteoclasts and chondroclasts (brown) cut channels through the tidemark at the 
osteochondral junction and invade the normally avascular cartilage. Channels 
are occupied by vascularized mesenchymal tissue and endochondral 
ossification results in a bone cuff surrounding the channel. Pre-existing blood 
vessels are shown in orange, neovasculature in red, and chondrocytes as green 
circles. c | A fissure from the articular surface communicates with subchondral 
bone spaces. Vascularized mesenchymal tissue extends from the subchondral 
bone through the fissure and over the articular surface forming pannus. d | 
Osteophyte formation resulting from cartilage deposition. Reprinted by 
permission from Macmillan Publishers Ltd: Nat Rev Rheumatol.[190], copyright 
2012  
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2.6.2 Subchondral bone architecture and remodelling in OA 
The supporting trabeculae of the subchondral trabecular bone, arise from 
the SCB plate and provide important shock-absorbing function to the 
overlying cartilage by dissipating force across the joint surface with a gradual 
transition of strain and stress. The trabecular bone is a dynamic structure 
and, through the process of bone remodelling, adapts to the applied 
mechanical forces. Julius Wolff, a surgeon and anatomist from Berlin, 
described the relationship between bone geometry and mechanical 
influences on bone in 1892. Wolff’s hypothesis states that the material 
properties and distribution of bone are determined by the direction and 
magnitude of applied load so that it is a better structure to resist such loads 
[197]. He similarly hypothesised that a reduction in applied load to a bone 
will result in a bone catabolism such that bone structure is intended to only 
withstand the loads applied to it. 
Functional adaptation of bone, as proposed by Wollf, is mediated by the 
cells in bone. This includes osteocytes that are putative mechanosensors 
(along with chondrocytes), osteoclasts and their progenitors that resorb bone 
and osteoblasts that deposit bone matrix (see 2.6.1 Subchondral bone 
cellular changes in OA). The remodelling adaptation within the SCB ensures 
that biomechanical load is effectively dissipated through the osteochondral 
functional unit. Any alteration to the material properties of either the articular 
cartilage or the SCB that sufficiently impairs the ability to effectively dissipate 
load, is associated with the synchronous structural degeneration in cartilage 
and SCB[197, 204] involving biomechanical and biochemical pathways. 
Controversy remains over whether the bone or the cartilage is the first 
structure to ‘fail’ in the natural history of human OA. This section describes 
the pathological changes in SCB architecture in both early and established 
OA and highlights a biphasic response in SCB observed in animal models 
with significant similarities in humans. This section also describes the 
potential for SCB as an early target in the prevention of OA and previous 
attempts at targeting the bone as a treatment in OA.  
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2.6.2.1 Established OA and structural progression 
The diagnostic criteria of ROA published in 1957 by Kellgren & Lawrence 
identifies subchondral sclerosis and osteophyte formation as pathognomonic 
of OA[19]. The Altman atlas also recognises subchondral sclerosis as a 
dichotomous outcome[84]. The architectural changes of this change will be 
discussed here. 
Sclerosis implies a hardening or stiffening of the subchondral bone which 
has been hypothesised to represent a failure of SCB to dissipate load which 
promote cartilage degeneration.  
In knee OA with established subchondral sclerosis, trabecular bone 
microarchitecture, mass and density can be measured using dual-energy x-
ray absorptiometry (DXA), fractal signature analysis (FSA) [205],  
quantitative computed tomography[187], magnetic resonance imaging [206]  
and histologically [207] to determine the correlation with this pathognomonic 
feature. Joint tissue samples have also be assessed mechanically [207]. 
Amongst 3048 knees in the Framingham OA cohort, radiographic 
subchondral sclerosis was independently and strongly associated with 
ipsilateral increase in bone mineral density(BMD)[208]. A greater BMD was 
independently associated with subsequent joint space narrowing in the 
medial compartment[208, 209] and cartilage defect development[210]. 
FSA characterises the complicated histomorphometry of SCB by providing a 
description of trabecular SCB microarchitecture and directional physical 
properties from trabecular size, number, spacing and cross-linking on 
radiographic images[211, 212]. 
Buckland-Wright and colleagues observed that increasing severity of knee 
ROA and JSN was associated with thicker trabeculae with less space 
between trabeculae[212] (Figure 19) 
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Figure 19 Thicker and less well spaced trabeculae 
. 
Part of a macroradiograph of an OA knee joint showing subchondral 
sclerosis showing trabeculae. These are thicker and less well spaced than in 
normal bone.  Reproduced from Annals of Rheumatic diseases, Buckland-
Wright et al, 55,1996, [212]. with permission from BMJ Publishing Group Ltd 
 
In 138 knees with symptomatic and ROA, a higher baseline vertical or lower 
baseline horizontal trabecular fractal signature was strongly and 
independently associated with progression in JSN over three years[211]. 
Furthermore amongst knees awaiting joint replacement, increased SCB 
sclerosis, as represented by decreased trabecular spacing was 
independently associated with a lower minimum JSW [213]. 
Lo and colleagues examined the MRI knee scans of 482 participants of the 
Osteoarthritis Initiative. Increasing JSN grade was associated with 
increasing proximal tibial SCB BMD, trabecular thickness, trabecular 
number, bone volume fraction (a measure of SCB sclerosis) and reducing 
inter-trabecular spacing [206]. Bone volume fraction is the proportion of 
trabecular tissue volume within a defined volume of bone (Figure 20). Similar 
observations are made using volumetric computed tomography of knee and 
hips with OA[214, 215]. 
A longitudinal study by Dieppe and colleagues observed an association 
between increasing signal in the subchondral bones of knees (a surrogate of 
bone turnover) with established OA and subsequent increasing JSN ( a 
surrogate of cartilage loss)[216].  
- 65 - 
 
Figure 20 Increasing bone volume fraction of OA SCB 
 
These are 3D reconstructed images of the subchondral bone in a normal (A) 
and OA (B) femoral heads. Reprinted by permission from Elsevier Ltd: 
Osteoarthritis and cartilage [215]. 
 
Radin and Rose in 1973 identified that increasing load placed through rabbit 
knees was associated with SCB trabecular microfracture[217],  reversible 
stiffening of the SCB[218] accompanied by the earliest osteoarthritic 
changes in chondrocyte metabolism. Radin and Rose hypothesised but 
never proved that the increased volume and thickness of the SCB in OA was 
associated with increased stiffness which increased shear forces in the 
overlying cartilage which led to cartilage degeneration [219].  
Radin and Rose assumed that bone volume is the only determinant of SCB 
stiffness. However other physical properties of SCB such as apparent 
density (reflecting the mineralized bone structural density in g/cm3) and the 
extent of microdamage accumulation are also major determinants of the 
mechanical properties and stiffness of SCB [179] (see 2.6.1.1 Subchondral 
bone remodelling).  
Subsequent studies, that are described below, demonstrated that a greater 
volume of hypomineralised bone conferred a lower SCB stiffness after 
adjusting for bone volume fraction. 
In humans the SCB of femoral heads removed at the time of total hip 
replacement for end stage OA were compared with normal autopsy controls 
using histological and biomechanical analyses. 
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Amongst femoral heads with OA, a significantly increased bone volume 
density with a reduction in mineralisation is observed [220, 221]. A 
significant excess of type I collagen is synthesised in the OA SCB, and the 
deposited collagen was significantly  less mineralised with a substantially 
reduced calcium to collagen ratio [222]. While femoral heads with OA have 
significantly more hypomineralised SCB than controls, this appears to confer 
a significantly lower SCB stiffness only after adjusting for bone volume 
fraction[207]. This implies that the stiffness per unit of the hypomineralised 
bone volume is reduced. Apparently conflicting results were published by 
Pugh and colleagues who described significantly increased stiffness in SCB 
adjacent to subtle (histochemical) cartilage damage in cadaveric femoral 
heads compared to cadaveric femoral heads. However it is important to note 
that there was no adjustment for bone volume fraction and none of the 
femoral heads had subchondral sclerosis or macroscopic OA with ages 
ranging from 20-66 years[223].  
Finally Day[224] and colleagues and Ding[225] collectively observed that 
amongst proximal tibia removed from cadavers micro-computed 
tomography, those with cartilage damage had increased bone volume 
fraction, trabecular thickness and reduced trabecular spacing compared to 
those without cartilage damage. Ding ensured those with and without OA 
were age- and gender-matched. Day mechanically tested the proximal tibiae 
of cadavers and despite the increase in bone volume fraction, the stiffness 
(tissue modulus) was reduced by 60% compared to SCB without overlying 
cartilage damage[224, 226]. This was attributed to the hypomineralisation of 
the SCB as a consequence of increased bone turnover and remodelling. 
Similar findings have been observed by Burr and Li and colleagues[227, 
228].   
An association between increasing histological SCB turnover, bone volume 
fraction and trabecular thickness with increasing severity of overlying 
cartilage degeneration was described in end-stage human OA by Matsui and 
colleagues in tibial condyles and Klose-Jensen and colleagues in femoral 
heads  removed at the time of joint replacement [229, 230].  
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In summary these analyses highlight the typical changes of established and 
progressive OA as being increased  BMD, bone volume fraction, trabecular 
thickness, trabecular number and decreasing trabecular spacing. The 
mechanical stiffness per unit of bone volume fraction is significantly reduced.   
 
2.6.2.2 Early OA 
While the SCB architectural changes of established and end-stage OA are 
well described in humans, the early changes of OA in humans are less well 
described. Identifying and studying humans at the point when the cartilage 
and subchondral bone begin to ‘fail’ or deteriorate is challenging and 
obtaining tissue for histological analysis is unethical. Therefore there has 
been significant reliance on animal models and comparison with in vivo 
studies in crude and imprecise but practical definitions of ‘early’ OA. These 
analyses highlight the importance of SCB changes in the initiation of OA. In 
contrast to the net osteoblastic expansion of bone volume fraction, the initial 
response is a net osteoclastic resorption of bone which correlates with the 
initial bone response to damage as part of the homeostatic repair 
mechanism (see 2.6.1.1 Subchondral bone remodelling). However this and 
subsequent formation of abnormal bone is associated with cartilage 
deterioration and OA initiation. 
Animal models 
Surgically induced cartilage ‘groove’ damage on the femoral condyles of  
Beagle dogs whilst avoiding damage to the underlying SCB caused OA 
pathology to develop in both the femoral and tibial tissues [231, 232]. 
Anterior cruciate ligament transection (ACLT) in the same animals caused a 
an unstable joint with similar OA-pathology  consequences. ACL injury is a 
well-recognised risk factor (see 2.3.2.3 Joint injury) for knee OA and may 
result in increased joint loading. When the two dog models were compared 
with micro computed tomography of the tibial plateau, both models reported 
increased thinning and porosity of the SCB plate as well as the onset of 
cartilage damage[233]. This implies that irrespective of mechanism of 
induction , the net bone resorption and onset of cartilage damage is intrinsic 
to the process of OA [234].  
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In mice models knees were injected with collagenase or iodoacetate to 
cause cartilage deterioration[235-237] or they underwent ACLT to induce an 
unstable joint[238]. The tibiae were subsequently analysed using micro-
computed tomography and histology to examine the bone changes during 
the follow up. In the early stages of the OA models a similar SCB resorption 
occurred [235, 237, 238]. Similar results are observed in ACLT of rats[239] 
rabbits [188] and cats[240] with thinning of the SCB plate. It is important to 
note that in the cat ACLT model, the SCB plate remained thin[240], however 
that rats, rabbits and in meniscectomised guinea pigs a subsequent recovery 
and thickening of SCB bone was observed [188, 239, 241] indicating a 
biphasic response in the SCB.  
Finally invasive ACLT in mixed-breed dog- [187] and non-invasive ACLT in 
mice- [242] models of knee OA have been used for the longitudinal analysis 
of SCB BMD measured using quantitative computed tomography. These 
models identified that the BMD significantly decreases in the initial period 
after ACLT. In the mouse ACLT model, trabecular bone loss was evident 
after seven days but there was partial recovery by 28 days and by 56 days 
significant new (non-native) bone formation was evident with a new steady 
state [242]. This biphasic response in SCB with initial resorption may also 
reflect the period after injury where antalgic disuse may reduce load and 
induce net bone resorption as well (see 2.6.1.1 Subchondral bone 
remodelling) 
In summary these models of early OA bone resorption and reduced bone 
volume fraction are distinguished from the sclerotic appearances seen in 
later stages of OA described above and in human femoral heads[222, 230] 
and canine ACLT knees [243]. 
Humans 
Observational studies of human ‘early’ OA have identified comparable  initial  
SCB resorption  with a suggestion of second phase of net bone formation in 
the SCB.  
Bolbos and colleagues reported a significantly lower bone volume fraction in 
the SCB of knees with early OA (KL grade 1-2) compared to healthy controls 
(KL grade 0) using high-resolution MRI[244].  
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Klose-Jensen and colleagues analysed the bone volume fraction, bone 
turnover in SCB regions with varying degrees of overlying cartilage damage 
in femoral heads removed at the time of hip replacement for OA or from 
controls without a history or evidence of joint disease. The analysis identified 
that in regions with no or mild cartilage deterioration, the SCB had 
significantly increased bone turnover and a lower mean bone volume 
fraction (which did not meet clinical significance) than controls while the 
most advanced cartilage loss had both significantly increased bone turnover 
and bone volume fraction than controls[230].  
Van Meer and colleagues observed that BMD significantly decreases in the 
SCB of the tibia and femur of knees after ACLT in humans. There is a 
subsequent significant increase in the BMD after the second year but this 
does not exceed baseline[245]. Although these knees did not have OA 
ACLT is a known risk factor for OA (see 2.3.2.3 Joint injury). 
The presence of increased bone turnover in early OA is supported by 
soluble biomarkers as well. Petersson and colleages identified a significantly 
higher serum level of a bone turnover marker (bone sialoprotein) amongst 
knees with than without incident ROA[204].  
 
2.6.2.3 Does subchondral bone failure precede cartilage failure? 
The osteochondral unit represents a functional unit of interdependent joint 
tissues. In established OA, these tissues each play a role in the  
biomechanical and biochemical pathways of pathogenesis. However an 
unanswered question is whether the deterioration or failure to repair in one 
tissue precede deterioration in the other as part of the cascade of OA 
pathogenesis.   
Radin and colleagues observed that increased load in rabbit knees caused 
increased stiffness in SCB before substantial changes in the adjacent 
cartilage[218]. This led Radin and colleagues to hypothesise that SCB 
pathology and increased stiffness caused increased shear forces in the 
overlying cartilage which led to cartilage degeneration[219] 
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A number of human studies supports the theory that SCB pathology 
precedes cartilage degeneration. A cross-sectional study of knee MRI scans 
of post-menopausal women without knee OA symptoms, indicated that 
meniscal tears were associated with increased tibial bone area but not 
cartilage volume[246]. Tibial total bone area (tAB) has been discussed 
earlier(2.6.3 Bone shape and subchondral bone MRI features in OA). The 
major limitation of this study is that it assesses cartilage in cross-section 
which does not exclude a preceding period of cartilage loss.  
A longitudinal study of adults with a mean age of 45 years without symptoms 
of knee OA had serial knee MRI measurements. An increasing baseline 
tibial bone area was associated with subsequent greater loss of cartilage 
volume on follow up[247]. This study also does not exclude a preceding 
period of cartilage loss which may have preceded MRI-detectable changes 
in tibial bone area. 
However the most convincing evidence addressing whether bone pathology 
may precede cartilage damage is from animal models where histological 
assessment of the SCB and cartilage tissues is more accurate in early OA.  
The following three models using Beagle canine knees illustrate that a 
common osteochondral degeneration of OA occurs after different initial joint 
insults including ACLT or isolated damage to either the articular cartilage or 
SCB.  
The primary cartilage damage model involved small superficial grooves 
being surgically made on the weight-bearing region of the femoral condyles 
without damaging the SCB (Figure 21). Joint reassessment occurred after 
10 weeks of forced joint loading[231, 232].  
The ACLT model involved the surgical transection of the ACL in the same 
aged dogs to increase loading in both SCB and cartilage .  
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Figure 21 Primary Cartilage injury model 
 
Schematic clarification of methods used. A: Localization of grooves made 
exclusively in the femoral condyles in the groove model. B: Selected regions 
that were analysed in the tibia using micro-CT. 1: cylinder in medial 
epiphysis; 2: cylinder in lateral epiphysis; 3: cylinder in metaphysis; 4: 
diaphysis. Reprinted by permission from BioMed Central: BMC 
Musculoskeletal Disorders, Sniekers et al [233]. 
 
For ACLT and primary cartilage damage knees, micro-computed 
tomography of the tibiae identified increased SCB plate thinning and 
porosity[233]. However the ACLT knees formed osteophytes from 10 weeks 
onwards whilst the primary cartilage damage knees first formed osteophytes 
at 20 weeks. Both models had histological evidence of cartilage 
degeneration in the tibia at 20 weeks. Bone resorption and incident cartilage 
damage are common consequences of the two OA models[234]. 
There are two OA models of initial ‘isolated’ SCB damage. The first used 
Beagle dogs of the same age as the ACLT and cartilage damage models. 
They received a patellofemoral impact inducing a trochlear bone marrow 
lesion but no cartilage damage on MRI of the knee was detected. 
Subsequent osteochondral biopsies from the femoral trochlea at six months 
identified cartilage degeneration[248]. The authors acknowledge that the 
MRI may have been insensitive to structural early cartilage damage. 
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The second ‘isolated’ SCB damage model involved tibial osteotomy, in 
significantly younger Beagle dogs, that conferred a valgus abnormality or a 
sham operation and a control group. Macroscopic and histologic analyses 
were made at seven and 18 months follow up which confirmed primarily 
medial femoral condyle cartilage degeneration.  
Models of spontaneous OA in guinea pigs identified that SCB BMD in the 
medial tibia reduced before histological evidence of adjacent cartilage 
degeneration occurred[249]. 
In summary this evidence identifies that a common pathway to OA can be 
achieved by an initial failure of either SCB or cartilage.  However while there 
remains controversy about whether bone or cartilage OA pathology 
represents the inciting event in human OA, cartilage is likely to deteriorate at 
the same time as SCB (see Figure 22).  
2.6.2.4 Architectural associations with OA risk factors 
The association of architectural changes of the SCB with OA risk factors is 
described here.  
There are no studies in humans describing the association of obesity with 
trabecular architecture. However amongst humans with established knee 
OA, the BMD of the medial and lateral plateau is significantly greater on the 
side with greatest biomechanical load as a consequence of 
malalignment[250, 251] or meniscal damage[252]. Injury and anterior 
cruciate ligament transection are definitely associated with changes in SCB 
BMD in animal models as described above [187, 242]. In humans similar 
changes are seen after ACLT[245].  
In summary OA SCB architectural changes are associated with OA risk 
factors. 
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Figure 22 An evidence-based hypothetical sequence of SCB OA 
pathology 
 
Anterior cruciate ligament (ACLT), bone volume fraction (BVF), 
osteochondral junction (OCJ). This sequence was formulated using the 
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2.6.3 Bone shape and subchondral bone MRI features in OA 
Change in bone shape such as flattening of the SCB (attrition) on 
conventional radiography has long been known to clinicians to be associated 
with OA symptom and structural progression[253]. Changes to the bone and 
joint geometry can adversely affect the congruity of the joint surfaces and 
impair the effective dissipation of load through the joint tissues which may 
overload the articulating tissues and promote their deterioration as part of 
the pathogenesis of OA (2.6.1.1 Subchondral bone remodelling, 2.6.1.2 
Subchondral bone and the osteochondral junction). 
Bone shape changes can now be quantified on two-dimensional 
conventional radiographic imaging as well as on three-dimensional 
tomographic imaging such as magnetic resonance imaging (MRI). MRI 
therefore provides a three-dimensional evaluation of SCB pathology in OA 
which includes shape, bone marrow lesions, osteophytes, cysts and attrition. 
These will all be discussed here including their association with OA risk 
factors and OA structural severity. 
2.6.3.1 Bone shape of the knee 
2.6.3.1.1 Knee subchondral bone cross-sectional area 
While bone shape has been less studied than BMLs due to quantification 
issues, the area of subchondral cortical bone that constitutes the articulating 
region of the bone on one side of a diarthrodial joint can be quantified from 
tomographic imaging such as MRI using laborious manual segmentation 
techniques (2.10 Statistical Shape modelling). The formal nomenclature 
used to describe the total subchondral bone area is tAB[254].The bone most 
frequently segmented for bone area in the literature is the tibial plateau, due 
to its relatively flat shape and distinct cartilage margins. This bone area, 
measured as a cross-sectional bone area of an axial image of the tibia 
(Figure 23) has been described by Jones and colleagues in observational 
studies amongst the healthy population and those with and at risk of knee 
OA[31]. It can be divided into medial and lateral tAB (Figure 23) 
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Figure 23 Segmented axial medial and lateral tibial plateaus 
 
Tibial plateau bone area measurement by taking the mean of the area at 
different axial levels  [255]. 
 
Bone area is associated with body size but also OA risk factors and these 
are discussed here. It is important to note that height and gender  are 
determinants of bone area in healthy knees [256, 257]. In particular height 
accounts for 70% of the variance in tAB in knees indicating an allometric 
relationship between height and tAB[257]. This is a logical relationship as 
the greater the height, the larger the area will be required to dissipate the 
greater load. Furthermore, while there are gender differences in tAB, the 
majority of the variance in the  difference in tAB between genders is 
explained by difference in height[256].  
Amongst older adults tAB increases in size to a smaller extent than in 
developing children. The tibial tAB in healthy women, with a mean age of 57 
years, increases by 0.8-1.2% per annum over 2.5 years [258]. Amongst 
male and female adults with a mean age of 64 years and with OA knee the 
medial and lateral tAB increase by a mean of 2.2% and 1.5% in two years 
respectively[259]. The significance of these differences should be 
considered in the context of the coefficient of the variance (measurement 
error) quantified as 2.3% for the medial tibia tAB, and 2.4% for the lateral 
tibia tAB. Amongst healthy knees only 18-21% had an increase in tAB above 
measurement error[258]. 
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Obesity is independently prospectively associated with the incidence of ROA 
knee in the Framingham cohort and is therefore an established risk factor for 
knee OA[61]. Obesity may cause OA incidence (see 2.3.2.2 Obesity) as a 
result of increased joint loading. Obesity is associated with the medial and 
lateral tAB of the tibia [260]. Individuals with obesity (body mass 
index>30kg/m2) also had greater medial tibial tAB in comparison with 
individuals with normal body mass index (18.5-24.9kg/m2). Furthermore 
obesity was independently associated with an increase in medial tibial 
tAB[259] and a longitudinal increase in cartilage defects[261]. Body mass 
index explained 7.3% of the variance in the mean annual percentage change 
in the medial and lateral tAB as described above[259] which implies obesity 
is a significant determinant of tAB change. However while the mean 
magnitude of tAB change is of a similar order of magnitude as the 
measurement error (2.3%) further evidence is required to confirm obesity is 
a determinant of tAB. While a biomechanical cause for an association 
between obesity and tAB would be logical in the context of Wolff’s law, both 
tAB and obesity may also share the same determinants such as a genetic 
aetiology.  
In support of Wolff’s law is the observation that tibial bone area appears to 
expand in response to increased applied load. The loss of integrity of the 
meniscal tissue within the knee impairs the capacity for the knee to 
effectively dissipate load. As a consequence the adjacent structures, 
including the articular cartilage and SCB are subject to increased load. It is 
therefore fitting that tibial tAB is highly correlated with ipsilateral meniscal 
surface area[262]. Furthermore ipsilateral meniscal extrusion and tears are 
independently associated with a larger tAB in cross-sectional observational 
studies[246, 263-265]. In a two year longitudinal study of 117 patients with 
knee OA, baseline extrusion of the medial meniscus was independently 
associated with a longitudinal expansion of the medial tibial tAB[265]. A 
limitation of this longitudinal analysis include the actual changes in tAB being 
small relative to the coefficient of the variance (measurement error) and the 
longitudinal model used height as a ratio (body mass index) not a metric 
measure which may result in inadequate adjustment of a major confounding 
factor.  
- 77 - 
Individuals with anterior cruciate ligament (ACL) tears have an independent 
association with larger tibial tAB than those without ACL tears in cross-
sectional analysis [266]. Furthermore malalignment is independently 
associated with a larger tibial tAB  change in the compartment with greater 
biomechanical load conferred by the malalignment[267, 268]. For example 
the medial tibial tAB was 10% larger in varus than neutrally aligned knees 
with OA[267]. Acknowledging the limitations of the existing literature, these 
findings support the role of load in SCB remodelling in the pathogenesis of 
OA.  
A statistically independent association of tAB has been described with the 
severity of radiographic OA[259, 269]. Subsequent medial cartilage volume 
loss[210] and knee replacement[270] has been described independent of 
age, gender and body mass index. Therefore expansion of axial tibial cross-
sectional bone area (tAB) is associated with knee OA severity, risk factors 
for structural progression and with structural progression itself but limitations 
conferred by a relatively large coefficient of the variance (measurement 
error) confirm the requirement for further validation of tAB as a biomarker of 
OA and a potential target for disease modification. 
2.6.3.1.2 Three-dimensional knee bone shape 
Eckstein and colleagues in chondrometrics have also utilised a different 
method of quantifying bone area over the tibia but also the femur and patella 
using manual segmentation derived from serial magnetic resonance (MR) 
images. This employs image segmentation and analysis algorithms[271] and 
is described later(2.10.2 The two- and three dimensional shape modelling for 
determining joint shape). Using this method similar gender differences in 
tibial bone area are also observed[262]. This segmentation method for 
measuring tAB describes a similar expansion in tAB seen in the medial tibia 
in varus malalignment but the same expansion is observed in the medial 
femur[267].  
Imorphics have developed an automated segmentation method for defining 
the three dimensional shape of knee bones using the next generation of 
statistical shape modelling called active appearance models. This permits 
the quantification of the undulating three dimensional surfaces of the tibia, 
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femur and patella tibial based upon three-dimensional MRIs. As such the 
tAB can be quantified for each of the articulating surfaces of bones and the 
three dimensional shape of bones can be quantified on a continuous vector 
scale that describes the difference in shape between OA and no OA. The 
methods describing this are below (2.10.2 The two- and three dimensional 
shape modelling for determining joint shape).  
Hunter and colleagues in Imorphics identified that changes in tAB in the 
femur, tibia and patella over 24 months all predicted incident knee ROA in 
the Osteoarthritis Initiative. Admittedly the limitations of this analysis include 
it was a nested case-control study without matching for body mass index. 
Neogi and colleagues in Imorphics described the baseline three dimensional 
bone shape vector values for the tibia, femur and patella  predicted incident 
knee ROA in the Osteoarthritis Initiative. Admittedly the limitations of this 
analysis include it was a nested case-control study but it did adjust for 
important covariate determinants of OA. 
 
2.6.3.1.3 Two-dimensional proximal tibial shape  
Nakamura and colleagues identified that stratifying tibial osteophyte 
morphology on conventional knee radiography (normal, horizontal, upward 
and downward -Figure 24) was significantly correlated with MRI-determined 
medial meniscal extrusion and degeneration. This association was not 
significant in the lateral compartment. While bone shape was associated 
with joint degeneration, only 8 knees had downward osteophytes, there was 
no adjustment for confounding factors and the analysis was cross-sectional 
which restricts any inferences about a causal role of bone shape[272]. 
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Figure 24 Medial tibial osteophyte morphology 
 
Medial tibial spur classification on X-ray. The shapes of the medial tibial 
spurs on X-ray were classified into four types. (Reprinted by permission from 
Elsevier Ltd: Magn Reson Imaging [272]). 
 
2.6.3.1.4 Two-dimensional distal femoral shape 
The shape of the distal femur, in particular a shallow femoral trochlear 
groove, has been associated with ‘premature’ OA in the context of a case 
series of 31 individuals with multiple epiphyseal dysplasia[273]. Stefanik and 
colleagues examined the shape of the femoral trochlea in 881 knees from 
the Multicenter Osteoarthritis Study (MOST) study. Knees with a flatter 
lateral trochlea (a shallower femoral trochlear grove) had an independent 
association with patellofemoral joint bone marrow lesions and cartilage 
damage[274]. 
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Amongst knees with OA and normal, varus or valgus alignment, the femoral 
condyle shape varied most obviously in valgus malalignment when 
examining the geometry (angles, axes and tangents) of conventional 
radiographic images and axial MRI slices of distal femurs. The shape 
difference between knees with OA and controls was most noticeable in the 
lateral femoral condyle of valgus knees. There was no significant difference 
in shape of the femoral condyles between controls and varus knees with OA. 
This implies increased biomechanical load may cause shape change[275].  
2.6.3.1.5 Two-dimensional shape of the tibiofemoral joint 
Haverkamp and colleagues used statistical shape modelling to describe the 
shape of the distal femur and proximal tibia on conventional knee 
radiography in a cross-sectional sample of 609 women’s knees in the 
Rotterdam cohort. The femoral and tibial width and the elevation of the 
lateral tibial plateau was independently associated with the presence of knee 
ROA and the bone widths were associated with diffuse cartilage 
defects[276].     
Bredbenner and colleagues analysed the surface geometry of the tibia and 
femur in 12 individuals who were considered to have no risk of knee OA and 
12 individuals with risk of OA from the Osteoarthritis Initiative. The surface 
geometry was segmented using statistical shape modelling and differences 
in surface geometry of the tibiae and femurs were found to be significantly 
different between those at and those not at risk without adjustment for 
confounders[277]. This analysis involved very small numbers and it should 
be noted that some individuals within the control arm of the OAI have 
evidence of knee ROA at baseline which limits any inferences from this 
analysis.  
2.6.3.1.6 Patellar shape 
Patella shape itself has not been associated with patellofemoral OA. 
However a medial tilt of the patella upon the femoral trochlea was 
associated with a reduction in WOMAC pain score severity amongst adults 
aged 25 to 60 in a community-based cross-sectional sample[278]. 
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2.6.3.2 Bone shape of the hip  
While risk factors for hip OA include a history of increased hip loading[279] 
or injury[280], increasing age[43], being female[43] and inherited 
genes[281], the geometric shape of the hip is now recognised to be an 
independent prospective risk factor for the development of ROA hip rather 
than being a consequence of OA itself. The evidence-base for this is 
described here. 
2.6.3.2.1 Femoroacetabular impingement 
Femoroacetabular impingement (FAI) is a pathological condition where there 
is impingement between the acetabulum and the femoral head during 
movement of the hip. The first of two types is where the presence of an 
aspherical femoral head (a cam-deformity) creates an abnormally shaped 
junction between the femoral head and neck and this additional material 
causes the impingement upon the acetabulum (Figure 25,Figure 26). As the 
asphericity of the femoral head increases so does the alpha angle which can 
be measured on conventional radiography of the hip (Figure 26).  This 
impingement is associated with delamination of the acetabular cartilage and 
confers up to a ten-fold greater risk of end-stage hip OA within 5 years[74]. 
‘Pistol grip’ deformity described by Doherty and colleagues also refers to 
similar asphericity of the femoral head and a risk factor for FAI[282]. A 
second possible form of FAI is the ‘pincer’ form the labrum of the 
acetabulum covers more of the femoral head than usual and causes 
impingement. 
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Figure 25 Radiographs of a normal hip and a hip with cam lesion 
 
In a normal hip, the concavity of the femoral head-neck junction (green 
arrow) allows an extensive range of hip movement without impingement of 
the femur against the acetabular rim. In cam lesion femoroactebular 
impingement, the loss of this concavity at the anterosuperior head-neck 
junction (red arrow) results in impaction of the femur against the acetabular 









- 83 - 
Figure 26 Mechanisms of cam impingement 
 
Mechanism of cam impingement. a,b | A spherical femoral head provides the 
hip with a wide range of motion. c,d | A cam abnormality (asterisk) can cause 
impingement (arrow) against the acetabular rim, especially during flexion 
and internal rotation of the hip. The α angle is indicated in a and c. 
(Reprinted by permission from Macmillan Publishers Ltd: Nat Rev 
Rheumatol [284] copyright 2013) 
 
2.6.3.2.2 Acetabular dysplasia 
Acetabular dysplasia has a European prevalence of 3.4% [285] and is also 
associated with prevalent hip OA. In the left panel (Figure 27) an 
incongruent type I hip has a shallower acetabulum than normal which 
increases the freedom of movement of the femoral head which may overload 
the labrum, which can shear from the acetabular bony rim[286]. In the right 
panel (Figure 27) a congruent type II hip has a ‘short roof’ acetabulum which 
does not cover the femoral head sufficiently. This may confer increased load 
upon a reduced area of the articular surface and cause possible ‘fatigue’ 
fracture.[286]. 
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A prospective longitudinal study by Reijman and colleagues within the 
Rotterdam study identified that over a mean of 6.6 years follow up, 9.3% 
developed incident hip ROA. The presence of baseline acetabular dysplasia 
conferred a 4.3 fold greater odds of incident hip ROA than those without 
dysplasia and this association was independent of OA risk factors[287]. 
Lane and colleagues also observed an association of mild acetabular 
dysplasia with subsequent incident hip ROA during approximately nine years 
of follow up in a cohort of post-menopausal females[288].   
 
Figure 27 Acetabular dysplasia and its association with OA hip 
 
Schematic diagram of the hip joint architecture. a | Hip dysplasia 
pathophysiology of the acetabular rim in the incongruent type I hip (left 
panel). In this configuration, the hip has a shallower, more vertical 
acetabulum and a greater radius of curvature than normal. This architecture 
increases the freedom of movement of the femoral head, leading to 
overloading of the labrum, which can shear from the acetabular bony rim. 
(Reprinted by permission from Macmillan Publishers Ltd: Nat Rev 
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2.6.3.2.3 Two dimensional modelling of the femoral head 
 
Shape recognition is an important function of statistical shape modelling and 
was first used for practical purposes for automated facial recognition. This 
involves a computer programme being trained to precisely and reliably 
recognise the edges of similar structures presented as images. Once 
trained, an automated statistical shape model of shape and shape 
change[289] can be used to capture subtle shape changes based on 
conventional radiography. 
 
Gregory and colleagues analysed a subgroup of the Rotterdam study with 
110 hips without hip ROA (KL grade <2) at baseline that were followed up 
after six years. This consisted of 55 cases of hips that progressed by 3 or 
more KL grades during the follow up and these were matched with controls 
based upon age and gender but not body mass index. Statistical shape 
modelling of the proximal femur identified significant subtle shape changes 
between cases and controls[290]. The inadequate matching or adjustment 
for BMI remained a major confounding factor. 
 
Lynch and colleagues examined the proximal femoral shape from 
conventional hip radiography over eight years amongst approximately 350 
elderly caucasian women without hip ROA at baseline. Using active shape 
modelling some subtle shape features were independently associated with 
incident hip ROA amongst 100 cases and 250 controls that did not develop 
hip ROA in a case-control analysis[291].  
 
Waarsing and colleagues examined serial DXA images of hip joints in 161 
individuals with established hip OA (ACR criteria), taken two years apart. A 
statistical shape model identified various features of the two-dimensional 
shape of the femur and acetabulum that were independently associated with 
structural progression and severity of the hip ROA[292]. This is the most 
convincing evidence of the three studies of an association between shape 
and structural progression. Therefore shape change of the hip joint is 
relevant in OA hip 
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2.6.3.4 Subchondral bone marrow lesions 
Bone marrow lesions (BMLs) are the most studied SCB pathology to date. 
These are not detectable on conventional radiography and are best detected 
on T2-weighted (proton-density-weighted) fast spin echo images on MRI 
where they are non-cystic ill-defined hyperintensities (Figure 28)[293]. They 
are most frequently identified at sites of greater mechanical load, such as 
where malalignment loads the joint[294], where meniscal degeneration 
exists[295], in association with ACL tear [245, 266] [296] and with obesity 
[99, 121]. BMLs are histologically described as regions of ‘localised 
infarction reaction’[297] with active and chronic remodelling processes[298, 
299]. The increased turnover within BMLs reflects typical trabecular 
remodelling of OA. This is confirmed by the SCB histomorphometric 
changes within BMLs including a hypomineralised region of increased bone 
volume fraction with increased thickness of trabeculae but with reduced 
trabecular number and spacing[297, 298]. This makes areas of SCB affected 
by BML more susceptible to attrition where the bone becomes flattened or 
depressed[300] and the overlying cartilage more susceptible to 
degeneration. BMLs are typically found to be topographically adjacent to 
regions of histological cartilage degradation[299] and this correlates with the 
in-vivo imaging findings. BMLs in-vivo are common findings on MRI knee 
scans in the SCB of moderate to severe OA where their incidence increases 
with greater knee ROA severity[294] and they are associated with adjacent 
cartilage damage[301]. Clinical studies have identified that larger BMLs are 
more common in painful than non-painful knees[134]. The development of 
new BMLs has been associated with new onset knee pain[121]. BMLs, 
unlike bone attrition, can regress over time and can be found in individuals 
without structural ROA[121, 302].
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Figure 28 Subchondral bone marrow lesions in the femoral trochlea 
 
The bright white changes identified by the arrows are bone marrow lesions. (Reprinted by permission from Elsevier Ltd: Radiologic 
Clinics of North America [303]). 
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2.6.3.5 Subchondral bone attrition 
SCB attrition is the flattening or depression of the SCB adjacent to the joint 
surface(Figure 29). The evidence suggests that MRI SCB attrition may be a 
reflection of tibiofemoral compartment-specific mechanical load. This is 
because the tibiofemoral compartment receiving the greatest biomechanical 
load from malalignment[304, 305] and meniscal extrusion and degeneration 
[305] is significantly more frequently affected by MRI-determined SCB 
attrition. BMLs share these same load-associations and it is fitting that BMLs 
are highly associated with and predict incident bone attrition 
longitudinally[300]. SCB with BMLs may be more susceptible to this 
‘collapse’ and flattening because of the reduction in stiffness afforded by the 
hypomineralised SCB found within BMLs[297, 298](2.6.2.1 Established OA 
and structural progression). The prevalence of SCB attrition increases with 
greater Kellgren Lawrence grade radiographic structural severity of OA[306] 
and is independently associated with greater overlying cartilage 
loss[307].Bone attrition is independently associated with knee pain[139]. 
There is inconclusive evidence describing whether MRI-determined attrition 
is associated with obesity or not and there is no evidence describing MRI-
determined attrition incidence after ACL rupture.  
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Figure 29 Subchondral bone attrition and osteophytosis 
 
Subchondral bone attrition in the lateral tibiofemoral compartment. 





The term osteophyte may refer to three kinds of ‘osteophyte’. The first is a 
traction spur or enthesophyte, formed where tendons and ligaments insert. 
The second is an inflammatory spur or syndesmophyte formed where 
ligaments and tendons insert to bone as seen in ankylosing spondylitis. The 
third is the osteochondrophyte of OA which can form at the margins of 
diarthrodial joints, apophyseal joints and vertebral bodies. From hence forth 
osteophyte refers to an osteochondrophytes of OA. Osteophytes are a 
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characteristic feature of OA and are fibrocartilage-capped bony outgrowths 
originating from the periosteum of the cortical bone at the joint 
margins[308](Figure 29). They form as a consequence of stressors such as 
mechanical load and the process is driven by cytokines and growth factors. 
These promote the proliferation of mesenchymal stem cells in the 
periosteum to differentiate into chondrocytes as part of chondrogenesis[308].  
Hypertrophic mature chondrocytes are subsequently replaced with 
osteoblasts that mediate bone formation by endochondral 
ossification(2.6.1.2 Subchondral bone and the osteochondral junction). 
Like the other SCB pathologies, the presence of osteophytes are associated 
with increased mechanical load as a consequence of ACL tear[309], 
malalignment[305, 310] and meniscal damage[272, 311]. Osteophytes are 
also associated with x-ray severity[312] and cartilage damage[313]. The 
evidence describing an association  with pain is inconclusive. There is no 
evidence describing the presence or absence of an association with obesity 
and MRI-determined osteophytes.  
 
2.6.3.7 Subchondral bone cysts 
SCB cysts are frequently found in knees with OA and are recognised as one 
of the hall-mark features on conventional radiography. They are considered 
to represent bone trauma. Their typical appearance on unenhanced MRI is a 
well-defined rounded area of fluid-like intensity[293]. However these are 
strictly cyst-like lesions and not pure cysts because the histological findings 
of these lesions do not include an epithelial lining[314] and they enhance on 
contrast enhanced MRI.[315]  
The histological features are of bone trauma containing increased bone 
turnover, necrotic bone fragments which and are lined by a nonepithelial 
fibrous wall[314, 316]. The histomorphometric changes within these SCB 
cysts include a hypomineralised region of increased bone volume fraction 
which is similar to BMLs[316]. Femoral heads excised at the time of joint 
replacement had higher bone volume fractions with higher total SCB cyst 
volume[317]. Accordingly, SCB cysts are most frequently found adjacent to 
or within BMLs[315] and they develop longitudinally within BMLs amongst 
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patients with or at risk of knee osteoarthritis[318]. They may form as a 
consequence of increased load as they are more prevalent in knees with 
ACL tears[296] and their prevalence increases with increasing severity of 
knee OA[319]. Degeneration of articular cartilage is associated with the 
presence of adjacent SCB cysts[315, 316]. There is no evidence describing 
the association of MRI-determined SCB cysts with obesity, malalignment or 
meniscal damage. 
In summary MRI-detected SCB lesions are associated with the histological 
and histomorphometric features of OA, risk factors for OA and OA structural 
severity and pain. 
 
2.6.4 Can the OA Subchondral Bone be therapeutically targeted? 
The collective evidence described above (2.6 Subchondral bone in OA) 
indicates the importance of subchondral bone in the pathogenesis of OA at a 
macroscopic level with bone shape, in terms of bone architecture and at 
cellular level.  
2.6.4.1 Anti-resorptive drugs 
SCB is an attractive treatment target given the known pathology of increased 
bone turnover associated with an excess of bone resorption initially and a 
subsequent increase in hypomineralised bone volume fraction with reduced 
stiffness and associated cartilage degradation. 
2.6.4.1.1 Bisphosphonates 
Anti-resorptive agents such as bisphosphonates inhibit osteoclasts and bone 
remodelling process[320] and may subsequently be chondroprotective. 
Animal models of OA in rats and dogs have identified a beneficial effect of 
several bisphosphonates in the context of high bone turnover through their 
impact on subchondral bone which includes inhibition of remodelling, 
osteophyte formation along with decreased vascular invasion of calcified 
cartilage, cartilage degradation and pain[239, 321-324]. This appears to be a 
class effect and zoledronic acid has also been shown to have a 
chondroprotective effect in rabbits[325].  
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In humans the effects of bisphosphonates on symptoms and structural 
progression have varied. The Knee OA Structural Arthritis (KOSTAR) study 
tested the efficacy of 5mg/day, 15mg/day or 50mg/week of risedronate in its 
effect on symptoms (WOMAC and patient global assessment) and structural 
progression (JSN using fluoroscopically positioned, semiflexed-view 
radiography)  in patients with medial knee OA (determined by radiographic 
JSN) over two years. This was a phase III randomised placebo-controlled 
trial which found no significant difference in symptoms or structural 
progression between risedronate at any dose  and placebo. This study did 
not account for the heterogeneity of the OA population regarding 
subchondral bone abnormalities because patients were selected on the 
basis of conventional radiography which is insensitive to the detection of 
SCB pathology like BMLs (2.9 Magnetic resonance imaging). Furthermore 
an evaluation of the sensitivity to change of JSN as an outcome measure for 
structural change suggests that these studies were significantly 
underpowered to show a response[326]. However some potentially 
beneficial effects have been noted. A dose-dependent reduction in 
biomarkers of cartilage degradation  at 6 months of therapy was noted (C-
terminal cross-linking telopeptide of type II collagen) which was associated 
with a slower knee OA structural progression based upon JSN[327]. On 
trabecular analysis of the SCB on conventional radiography in individuals 
with significant JSN during KOSTAR, there was loss of trabeculae in the 
placebo and 5mg/day groups while there was preservation of vertical 
trabeculae with 15mg/week of risedronate and an increase in vertical 
trabeculae with 50mg/week indicating a dose-dependent preservation of 
SCB integrity[328]. 
The British study of risedronate in structure and symptoms of knee OA 
(BRISK) investigated risedronate at a dose of 5mg/day or 15mg/day in a 1-
year prospective, double-blind, placebo-controlled study. Symptoms were 
measured with WOMAC and patient global assessment and structural 
progression was measured with radiographic JSN. This trial included knees 
with medial knee OA[329]. This was a significant improvement in the 
patient’s global assessment and a trend towards attenuation of JSN and 
improvement in WOMAC but this was not significant. 
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Cartilage degradation and bone resorption markers were significantly 
decreased in the risedronate arms. Similar criticism applies to BRISK and 
KOSTAR for inadequate powering for the sensitivity to change of the 
outcome measure JSN. No study has examined cartilage volume as an 
endpoint in a bisphosphonate OA trial.  
The only randomised placebo-controlled trial using MRI, that investigated 
symptomatic knee OA with concurrent BMLs, identified that zoledronic acid 
reduced the size of BMLs and knee pain at 6 months. However the pain 
reduction was not maintained at 1 year and BML size had a trend towards a 
smaller size[330]. 
The Fracture Intervention Trial (FIT) was a randomised placebo-controlled 
trial of alendronic acid for osteoporosis. The effect of alendronic acid on 
anterior vertebral radiographic osteophyte progression was described.  
Alendronic acid significantly reduced osteophyte progression but there was 
no data on pain[331]. 
Carbone and colleagues performed a cross-sectional study of the Women in 
the Health, Aging and Body Composition Study. Postmenopausal women 
with and without knee OA symptoms (n=818), underwent MRIs of their 
knees and 214 were taking anti-resorptives. Overall anti-resorptive use was 
not associated with pain but alendronic acid use was associated with 
significantly less severe pain (WOMAC). Alendronic acid and oestrogen 
therapy were associated with significantly less SCB attrition and BML 
prevalence in the knee on MRI in comparison with women not 
receiving these medications[332]. 
Amongst participants of the Osteoarthritis Initiative cohort with moderate 
knee OA (Kellgren Lawrence 2-3) and a numeric rating scale (NRS) of pain 
of four or more out of ten, individuals taking bisphosphonates received a 
significant reduction in pain NRS at follow up at years two and three but not 
four. There was also a trend towards reduced JSN at year four follow up 
(p=0.06).  
Cauley and colleagues described a large randomised placebo-controlled trial 
of annual zoledronic acid for the treatment of pain owing to back pain or 
fracture in postmenopausal women with osteoporosis. Zoledronic acid 
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significantly reduced the number of days with patient-reported back pain 
over a 3-year period which was independent of incident fracture[333]. This 
may indirectly reflect the capacity of zoledronate to reduce OA pain.  
Koivisto and colleagues describe a randomised placebo-controlled trial of 
zoledronic acid for the treatment of lower back pain (LBP) in individuals with 
modic changes which are bone marrow pathologies associated with the 
presence and persistence of LBP. Zoledronate significantly reduced LBP at 
one month and NSAID use at one year[334]. This may indirectly reflect the 
capacity of zoledronate to reduce OA pain.  
Furthermore there have been improvements in symptoms and progression 
of disease at certain locations and reduction in subchondral bone 
lesions[328-331]. 
In summary there is evidence supporting the potential for bisphosphonate 
being disease modifiers of symptoms and structural change in specific 
phenotypes of OA with SCB pathology. However more robust assessment 
with better outcome measures (e.g. MRI measures) in adequately powered 
trials are still required to establish the efficacy of bisphosphonates in OA.  
 
2.6.4.1.2 Strontium 
More recently the effect of strontium ranelate on structural progression (JSN) 
and knee pain (WOMAC) in knee OA was assessed in a randomised 
placebo-controlled trial over three years. This is the Strontium Efficacy in 
Knee OsteoarthrItis trial (SEKOIA). This identified a small reduction in both 
JSN and total WOMAC and WOMAC pain with 2g/day[335].  
Pelletier and colleagues published an analysis of a subgroup of the SEKOIA 
that had MRI scans. This analysis concluded that at 36 months, there was a 
significant reduction in BML size score in 25-40% (similar to the effect of 
zoledronate) which also correlated with reduced cartilage volume loss in the 
medial compartment[336]. 
A post-hoc analysis of pooled data from two strontium trials for osteoporosis  
was performed to determine the efficacy of strontium in treating structural 
progression and symptoms of patients with spinal OA. The TReatment Of 
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Peripheral OSteoporosis (TROPOS) and Spinal Osteoporosis Therapeutic 
Intervention (SOTI) trials. After three-years there was no significant 
difference in vertebral osteophyte scores but an improvement in back pain. 
An improvement of one point or more on a likert scale, was significantly 
more frequent with strontium therapy[337]. 
Strontium has also demonstrated a reduction in cartilage defects and 
subchondral bone thickening in a randomised placebo-controlled trial in an 
ACLT model of OA in dogs[338]. 
The evidence supporting the potential for strontium to modify structural 
progression and pain in OA suggests strontium may be an effective therapy 
for OA knee. However strontium is associated with increased cardiovascular 
risk which limits its future utility. 
2.6.4.2 Calcitonin 
Calcitonin is a hormone that antagonises the effect of parathyroid hormone 
(PTH) in its bone resorptive effects. It has demonstrated the potential to 
improve symptoms and structural progression in OA in humans and animals. 
18 Rabbits having surgically induced knee OA (e.g. ACLT) were randomised 
to receive calcitonin IM or placebo. The structural progression of OA based 
on histological and imaging was attenuated in the calcitonin group compared 
to placebo[339]. In ACLT models of OA in dogs, calcitonin inhibited the SCB 
trabecular resorption compared with the placebo arm. The preservation of 
SCB integrity was associated with a significant reduction in cartilage 
defects[340].  
In humans intranasal calcitonin was administered in an open-label study of 
220 women who fulfilled the criteria of having post-menopausal 
osteoporosis, with at least moderate regular pain in a knee with moderate 
radiographic OA (Kellgren Lawrence two or three). After three months of 
therapy there was significant improvement in WOMAC pain perception, 
stiffness and function and these were maintained to the end of the trial at 
one year. How much of this was placebo effects is unknown[341]. A small 
randomised placebo-controlled trial of oral calcitonin reported an 
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improvement in function and reduced cartilage degradation biochemical 
biomarkers[342]. 
2.6.4.3 Parathyroid hormone 
Parathyroid hormone (PTH) is considered to promote matrix synthesis and 
inhibit the maturation of chondrocytes[343] that have been associated with 
endochondral ossification (the process of osteophyte formation). There are 
no human studies of parathyroid hormone in OA but in animal models after 
meniscal or ligament injuries in mice, a placebo controlled trial of teriparatide 
(recombinant human PTH) demonstrated less chondral damage and 
increased bone volume fraction in the teriparatide arm[344]. Similar 
improvements in trabecular thickness accompanied by chondroprotective 
effects  have been demonstrated in rabbit OA models[345]. 
2.6.4.4 Vitamin D 
Vitamin D is known to be important in bone metabolism and previous 
observational studies have suggested increasing levels above 36 ng/mL was 
associated with beneficial effect[346, 347]. Therefore a 2-year randomized, 
placebo-controlled trial of supplementing vitamin D levels in symptomatic 
knee OA to elevate serum levels to more than 36 ng/mL was performed. 
There was no significant difference between vitamin D and placebo groups 




SCB plays an integral role in the pathogenesis of OA from the earliest 
through to the most advanced stages of OA. The likely sequence of events 
in SCB that lead to OA have been summarised (Figure 22).  SCB 
pathologies are associated with conventional OA risk factors that over load 
joints but SCB shape and imaging abnormalities are independent risk factors 
for OA themselves before clinical OA develops and as it progresses (Table 
7). Therefore SCB represents an important tissue in OA and potentially an 
important biomarker and target for prospective disease modification.  
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Table 7 The association of subchondral bone changes with knee & hip OA risk factors 




X-ray Severity Cartilage 
damage 
Trabecular 
bone mass,  
BMD or BVF. 
(CR/DXA/qCT 
or MRI) 








BML (MRI) Not associated 
[121] 
[23] 
 +[99, 121] 
+[245, 266] 
[296] 
+[294] +[295] + [294] + [301] 
Osteophytes  
(MRI) 






n/a +[304, 305] +[305] +[306] +[307] 
Cyst (MRI) +[23] n/a n/a +[296] n/a n/a +[319] +[315] 
tAB (MRI) 
+ [258] +[256, 257] + [260] [259] + [266] + [267, 268] 
+ [246, 263-
265] 
+ [269] [353] 
2D Shape   n/a n/a +[275] +[272] +[276] +[74] 
Bone mineral density (BMD), bone volume fraction (BVF), conventional radiography (CR), dual-energy X-ray absorptiometry (DXA), quantitative 
computed tomography (qCT), not available (n/a), an association is present with positive correlation (+). 
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2.7 Biomarkers validation and surrogate measures 
2.7.1 Biomarkers and surrogate measures 
A biomarker is something that can be measured (relatively) easily which tells 
us information about the presence, severity or progress of a disease 
process. This can include a chemical that can be measured in blood or 
urine, a genetic marker or in the case of this research a quantifiable imaging 
feature such as bone area or bone shape. An example of a biomarker used 
in rheumatology is C-reactive protein. As inflammation increases, the blood 
concentration increases. Many biomarkers provide at most a rough 
indication of the process that they are being used to measure, and very few 
are effective at predicting the future progress of disease. Biomarkers are 
therefore disease-centred variables and represent one end of a spectrum. At 
the other end of the spectrum are patient-centred variables which are 
variables that reflect how a patient ‘feels, functions or survives’. These guide 
clinical decision making and are primary endpoints in clinical trials. For 
example in knee OA the end-stage of OA is treated with a total knee 
replacement which is a measure of ‘joint survival’. However the time from the 
onset of OA to the time of a joint replacement may be more than three 
decades which is too long for any clinical trial. Therefore surrogate 
measures of the patient-centred outcome are required and these are 
referred to as surrogate outcome measures. 
In order to be used as a surrogate outcome measure, a biomarker must 
demonstrate sufficient validity. Validation of a biomarker is a continuous 
incremental process and demonstrating validity is not all or nothing event. 
Validation requires certain domains to be assessed and once a threshold is 
exceeded then the biomarker may be used as a surrogate measure of how a 
patient feels, functions or survives[354]. One strategy used for biomarker 
validation is the Outcome Measures in Rheumatology (OMERACT) filter 
described by Boers and colleagues which will be described here[355]. 
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2.7.2 Validation of biomarkers using the OMERACT filter 
The OMERACT filter encapsulated the concepts of validity by requiring truth, 
discrimination and feasibility and this is described in the OMERACT hand 
book[356].  
Truth requires that the biomarker measures the patient centred outcome it is 
intended to measure in an unbiased and relevant way. Truth summarises the 
concepts of face, content, construct, and criterion validity. Truth may also be 
referred to as internal validity.  
Discrimination requires that the biomarker should be able to discriminate 
between situations of interest or different groups at one time point such as 
prognosis, or states at different times by measuring change. This 
discrimination summarises the demonstration of reliability and sensitivity to 
change or responsiveness respectively. This incorporates the concept of 
precision. This is important because precision errors should be sufficiently 
low in relation to the magnitude of expected change for a given marker 
during the natural history of change in the biomarker of a disease. If the 
measurement noise or error is high relative to the actual change in the 
biomarker (signal) being measured then a poor noise to signal ratio limits the 
utility of the biomarker. 
Feasibility requires that the biomarker can be applied easily, acknowledging 
the constraints of time, money, and interpretability. Feasibility summarises 
an important stage in the selection of biomarkers, that may determine a 
biomarkers success. For imaging biomarkers this should evaluate the 
practicalities of using a biomarker including cost, burden upon the patient 
being imaged, equipment requirement, and overall ease of use are 
appraised. The feasibility has to be balanced against the need for a 
comprehensiveness and  adequate coverage of the OA outcome. The 
challenge is to maximize feasibility by reducing the demands of the 
biomarker to the minimum required for validity.   
The following defines the components of validation with a specific focus on 
imaging biomarkers for OA. 
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2.7.2.1. Face and Content validity 
Face validity requires that the biomarker of OA should on the face of it reflect 
the OA outcome of interest. In order to demonstrate content validity, there 
should be evidence from qualitative research demonstrating that the 
biomarker measures the OA outcome or concept of interest. This should 
include evidence that the domain(s) of the OA biomarker are appropriate 
and comprehensive relative to its intended measurement of OA outcome 
and the population of OA that this is intended to apply to. For imaging 
biomarkers of OA (and their proposed scoring system or scale) they should 
capture the intended pathophysiologic features of OA such as pain.  A 
review of the evidence for validation should consider this association from all 
perspectives including the researcher, clinician and patient. 
2.7.2.2 Construct validity 
In order to demonstrate construct validity, there should be evidence that the 
concept of the OA biomarker(s)  should conform to a priori hypotheses 
regarding logical relationships that should exist with other measures or 
characteristics of OA and OA patient groups. Construct validity requires that 
the biomarker is a measure of the OA domain it is intended to measure. This 
is generally assessed by comparing the prospective OA biomarkers 
measure with other measures of the same OA domain. For example for a 
structural imaging biomarker of OA to have construct validity it should 
correlate or be associated with another structural measure of OA such as 
the KL grade or JSN or provide similar results. The judgement of the 
strength of association determines the strength of evidence of construct 
validity along with the number of measures of OA that it correlates with. This 
differs from criterion validity for OA biomarkers because criterion validity 
reflects the strength of association between an OA biomarker and an OA 
gold standard or ‘criterion’. However with constructs, there is no gold 
standard.  
2.7.2.3 Criterion validity  
Criterion validity reflects the extent to which a biomarker directly predicts a 
patient outcome or the existing gold standard biomarker of the patient 
outcome.  
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For example if total knee replacement (TKR) is the OA patient outcome of 
interest and computed tomographic (CT) measurement of bone width is the 
gold standard for predicting TKR, an OA MRI biomarker can demonstrate 
criterion validity if it correlates well with the CT bone measurement (the gold 
standard or ‘criterion’). However for many OA patient outcomes criterion 
validity cannot be measured because there is no gold standard.  
Therefore criterion validity can also be demonstrated if the MRI biomarker is 
directly predictive of TKR which becomes the ‘criterion’.  
Criterion validity can be divided into concurrent validity and predictive 
validity. Concurrent validity describes cross-sectional associations between 
OA biomarkers and the outcome of interest such as joint replacement. 
Predictive validity reflects a longitudinal relationship where an OA biomarker 
measurement at baseline is associated with a subsequent or future outcome 
of joint replacement.  
 
2.7.2.4 Responsiveness 
The capacity of an OA biomarker to validly detect or measure a significant 
change over time is described as responsiveness. In order to demonstrate 
responsiveness the biomarker should first be expected to change in a way 
that is concordant with other OA biomarkers of the same process.   
Thereafter estimates of the standardised change in the biomarker over time 
such as the effect size or the standardised response mean, can be used to 
describe and quantify responsiveness. Furthermore the correlation between 
change in a validated biomarker and change in the new biomarker can be 
assessed by measuring the area under the curve (AUC) of the Receiver 




This may be referred to as stability whereby the day-to-day variability of the 
measurement of the biomarker as a consequence of actual variation in the 
tissue structure being imaged or the measurement error of the biomarker  
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may contribute to measurement noise. One way of testing this is to use a 
test-retest reliability of the biomarker. If the biomarker will be measured by 
one individual only then the reliability can be expressed as an intra-observer 
reliability or intra-rater agreement. If the biomarker is measured by several 
observers then the reliability should also be expressed as an inter-observer 
reliability or inter-rater agreement. The level of agreement can be expressed 
as intra-class correlation coefficient (ICC) or a weighted Kappa coefficient 
(Kw). It can also be expressed as a coefficient of the variance of the same 
measure (CoV) which is a relative standard deviation and is expressed as a 
percentage and reflects the noise to signal ratio. This is particularly relevant 
when automated measurements of the biomarker are made. 
In summary there are many components that are required to validate a 
biomarker as a surrogate measure of a patient-centred outcome. Validity is 
not binary but is a continuous process and therefore appraisal of evidence is 
required to suitably validate biomarkers.  
2.8 Biochemical biomarkers 
Biochemical biomarkers of OA have the potential to contribute to the 
diagnosis of OA, the delineation of phenotypes, the quantification of tissue 
burden and prognosis and to measure the efficacy of therapeutic 
interventions. However even the best described biochemical biomarkers 
(cartilage markers) lack sufficient discriminative capacity and validity to be 
used to facilitate the clinical trial design, diagnosis and estimation of 
prognosis in individuals with OA or to be used as surrogate outcome 
measures in intervention trials[357].  
Important molecules in joint tissue metabolism and pathogenesis of OA have 
potential as biochemical biomarkers of OA. These include enzymes, 
cytokines and the constituents of the extracellular matrix that include 
collagen and proteoglycan precursors and degradation products that are 
released into biological fluids. These may first be released locally into the  
synovial fluid of the joint with OA and then systemically into the blood and 
urine. The concentration in these compartments may reflect cartilage, 
subchondral bone and synovial metabolism which may be used as a 
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measure of joint tissue degradation and formation. The advantages and 
disadvantages of this approach are now discussed. 
The majority of connective tissue components of joints are frequently 
present in many other tissues in the body and therefore the systemic 
measurement of  concentrations of these components in the blood and urine 
will reflect the healthy tissue turn-over of the whole body (systemic 
metabolism) and not specific joint pathology of OA. This may be particularly 
relevant when the pathologic turnover in small joints of the hand is less than 
the physiologic turnover in all of the other larger joints. Furthermore systemic 
biochemical marker concentrations are subject to systemic distribution, 
metabolism and excretion. The volume of distribution may vary with body 
mass index and the metabolism and excretion may vary with varying 
degrees of renal and hepatic dysfunction that are prevalent amongst people 
with OA. Systemic concentrations may also vary with food intake, physical 
activity, and when multiple joints and other connective tissues are involved. 
Therefore these systemic biomarkers may not accurately capture the 
specific local tissue pathology when only a few joints are affected by OA and 
their utility may be greater in generalised OA.  
Measuring biomarker concentrations in synovial fluid may offer a more 
accurate representation of OA pathology within specific joints. However 
variation in joint movement and intermittent synovitis may cause 
concentrations of biomarkers to vary over time.  
The National Institutes of Health-funded OA biomarkers network has 
classified specific biomarker definitions into five categories to improve the 
development and analysis of OA biomarkers; Burden of disease, 
Investigative, Prognostic, Efficacy of intervention and Diagnostic (BIPED) 
[358]. A recent systematic review classified 26 biochemical markers of 
cartilage, bone or synovial metabolism by the BIPED categories[357]. The 
best performing, most frequently and broadly described biochemical 
biomarkers are in the context of knee and hip OA and are considered to be a 
measure of collagen degradation (urinary C-terminal telopeptide II, serum 
cartilage oligomeric protein). There is evidence of predictive validity of these 
two biomarkers for incidence of knee ROA [359, 360] and progression of hip 
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and knee ROA[361] in longitudinal cohort studies having adjusted for age, 
gender and BMI. However biochemical markers have little ability to predict 
symptoms[360]. The performance of the other biomarkers e.g. serum 
hyaluronic acid and urine/serum N-terminal peptide 1, could not be 
adequately evaluated due to a lack of evidence. Despite the considerable 
research efforts made to determine if they can be used for as surrogate 
measures for diagnostic purposes or to reflect how a patient feels, functions 
or survives, the authors of the systematic review [357] concluded that none 
of the available biomarkers had sufficient discriminative properties to be 
used for these purposes. The same conclusions have been drawn by the 
European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis also draw the same conclusion[362].  
Currently none of these biochemical markers, are sufficiently discriminating 
to be used as surrogate outcome measures[363].  
2.9 Magnetic resonance imaging  
Conventional radiography (CR) is unable to capture the severity of the multi-
tissue involvement in joints with OA joints. This is particularly important 
because many of the trials of prospective disease modifying agents in OA 
(DMOADs) have attempted to recruit a homogenous population that are 
likely to exhibit structural progression by selecting people with knee 
Kellgren-Lawrence grades ≥2. Unfortunately  these patients may lack 
uniformity in terms of joint tissue involvement because CR is insensitive to 
tissue pathology like bone marrow lesions (BMLs) which have important 
prognostic implications and are associated with worse structural and 
symptomatic outcomes (2.4.3.2 OA pain and its structural associations). 
Amongst individuals within the Framingham cohort above the age of 50 
years, with no pain and normal knee radiography, 88% of individuals had at 
least one OA tissue lesion in the knee on magnetic resonance imaging (MRI) 
[23]. This included an osteophyte, cartilage damage and BML prevalence of 
72%, 68% and 50% respectively. MRI is more sensitive to osteophytes and 
cartilage damage than conventional radiography[364]. Therefore appropriate 
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stratification and  monitoring of these tissue pathologies among patients with 
OA requires MRI.  
MRI offers several advantages including the ability to examine the presence 
and extent of tissue pathology in each of the joint tissues in OA[25]. The 
quantification of MRI cartilage morphometry in knee OA has demonstrated 
good evidence of reliability and responsiveness and there is some evidence 
of its predictive and construct validity[365, 366]. This includes loss of 
quantitative cartilage volume being a potential predictor of total knee 
replacement (TKR). The measurement of subchondral BMLs and synovitis in 
knee OA has also demonstrated good responsiveness for semiquantitative 
MRI assessment[366]. Further data is required to accurately quantify the 
BMLs and synovitis and to determine whether these demonstrate predictive 
validity of outcomes such as TKR. 
The disadvantages of MRI include that the acquisition is more time-
consuming and expensive than plain radiography. However in terms of 
clinical trials, the greater responsiveness of tissue measures might mitigate 
the additional costs because fewer patients may be required to demonstrate 
a structure-modifying effect.  
MRI-determined quantitative and semi-quantitative measurements of joint 
tissue in OA ( 2.11Imaging biomarkers in OA) have started to be used as 
clinical outcome measures in structure-modification DMOAD trials. This 
reflects the opinion of the Osteoarthritis Research Society International 
(OARSI) working group  that recommended MRI cartilage morphology 
assessment be used as a primary structural end point in clinical trials which 
also acknowledged the rapid evolution of quantitative MRI assessments of 
subchondral bone and synovium[367].  
Therefore using MRI biomarkers of joint structure in OA represents a 
significant improvement in sensitivity to clinically significant structural 
pathology, responsiveness and in its correlation with pain compared with CR 
biomarkers. However we have not yet harnessed the full potential of MRI 
biomarkers and utilised all of the three dimensional tomographic information 
that MRI has to offer. 
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2.10 Statistical Shape modelling, active shape modelling and 
active appearance modelling 
Man-made or manufactured  shapes are relatively easy to describe and 
identify in two or three-dimensions. However describing the shape of 
naturally occurring organs like joints that adapt to their environment is much 
more challenging but represents an important source of in vivo information. 
This is because the shapes are often complex, asymmetrical structures and 
there is significant variation between individuals at a population level.  
Historically defining the shape of similar tissues or organs has been 
achieved by the process of manual segmentation. This is a labour-intensive 
and time-consuming process which requires that the edge of the structure of 
interest (e.g. a cartilage plate or SCB area seen on an MRI slice) be drawn 
around to define the shape of it. However computers can be trained to 
recognise shape using ‘machine vision’. If the geometric properties of the 
target tissue are manually segmented in a  substantial population of training 
set images, the segmented regions of interest can be analysed for their 
geometric (shape) properties using statistical analysis to create a statistical 
shape model (SSM). This ‘trained’ SSM is a shape-recognition model that 
has learnt what shape to look for in a subsequent target image.  This 
process involves the analysis of geometric shape identifying landmarks on 
the edge of the target tissue that are consistent at a population level.  These 
are referred to as consistent landmarks and their automated application to 
subsequent target images can automate the segmentation and substantially 
reduce the labour-intensive approach of manual segmentation. One of the 
first applications for this shape recognition was in the application of facial 
recognition in 1998.  How well the training set represents the variation in 
shape in the target image population is one of the determinants of how well 
the model can segment the shape accurately. Where multiple MRI slices are 
available for one joint, the cartilage plate or SCB area can be segmented on 
serial adjacent slices which permit a 3D shape reconstruction to be made 
(2.10.2.3 Segmented three dimensional bone area, cartilage thickness and 
volume).   
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The next generation of shape recognition involved an additional statistical 
model that incorporates the variation in characteristics in the target images. 
These are called active shape models(ASM)[289]. An ASM involves a local 
search algorithm which relies upon the same pure edge-based approach of  
the SSM. However the model actively seeks to update the fit of the model to 
the target image (without using the grey-scale texture) to ensure the best fit 
is achieved which brings the model closer to the correct solution (Figure 30). 
Hutton and colleagues used this for the purposes of detecting cephalometric 
landmarks[368].  
Figure 30 Active shape model and local searching 
 
In the first image the model at the beginning has been synthesised by the 
ASM. The model then attempted to constrain the edge of the shape using 
learned consistent landmarks. However local searches for all landmarks are 
evaluated at different positions perpendicular to the model surface in the 
second image and the new best landmark positions are identified . The ASM 
model parameters and landmarks are then updated to minimise the 
distances between the model landmarks and the actual shape. Reprinted by 
permission from Elsevier Ltd: Medical Image Analysis [369] - 2009) 
 
Finally the latest generation of shape modelling is the active appearance 
model (AAM). These also actively seek to keep to a minimum  the difference 
between the actual shape of a new target image and one synthesised by the 
AAM. This is achieved not only by local searches of the shape (as in ASM) 
but also by using a model of grey-scale texture on either side of the edge of 
the shape. The model learns, from training sets, what grey-scale texture to 
expect on either side of the learned edge by analysing the greyscale 
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changes in a rim of 5-6mm spanning either side of the learned edge in a 
perpendicular manner to the edge. This ensures the appearance of the grey-
scale texture is actively searched  to optimise the shape automated 
segmentation. In the tissues of the knee, for example, the MRI signal 
provides a grey-scale variation which may have darker signal in the cartilage 
overlying the SCB and brighter signal in the bone. By learning from training 
samples, the AAM can actively define shape more accurately. This is the 
technology that has been applied in defining bone shape and bone area in 
the subsequent Chapters 4-6. 
 
2.10.1 The applications of shape modelling 
The advantages of analysing the shape, or the change in shape of tissues 
based on imaging is that this can provide three-dimensional morphological 
data that can be used non-invasively to describe human physiology  and 
pathophysiology in vivo. Tissue shape can indeed be a directly involved in 
the pathogenesis of disease(2.6.3.2.1 Femoroacetabular impingement).  In 
states of disease shape may be particularly important when planning 
interventions with narrow therapeutic windows such as surgical resection of 
cancer or radiotherapy. It may also be useful when creating prostheses. 
Finally shape and volume can be determined by shape models and these 
may provide important prognostic information if suitably validated. Examples 
of how statistical shape modelling, active shape models and active 
appearance models have all contributed to these are described below.  
The physiological shape changes in the tracheobronchial tree[370] and liver 
[371] during breathing have been modelled in order to better understand the 
changes in these organs during bronchoscopy and surgery. The shape 
change in the levator ani during straining[372] has also been modelled. The 
shape change in mandibles during development has also been measured 
with models longitudinally to describe growth of bone[373]. The shape of the 
larynx has also been modelled to describe the association of shape with 
pitch of voice as part of natural variation[374]. The variation in the shape of 
brains during development[375] and during ageing[376] have also been 
performed to describe these physiological processes.  
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The left atrium is known to remodel and dilate in atrial fibrillation. This shape 
change in the left atrium in atrial fibrillation is believed to be associated with 
the outcome of cerebrovascular accident. Therefore shape modelling has 
been used by Cates and colleagues to describe the shape changes in the 
chambers of the heart[377]. 
Echocardiographic imaging of the fetal heart is an important component of 
screening for congenital abnormalities. In order to improve the sensitivity of 
screening it has been proposed that active appearance models of the heart 
chambers may add important diagnostic information to the screening 
process and these models have been trained. 
Vertebral fractures are important causes of morbidity. However while 
conventional radiography is inexpensive and accessible it is relatively 
insensitive to detecting osteoporotic fractures compared to computed 
tomography which is more expensive and less accessible. The shape 
change of vertebrae seen on conventional radiography may be subtle but 
the detection of a fracture affects clinical management and may prevent 
morbidity. The shape change associated with small fractures may be subtle 
and therefore active appearance models are being trained upon 
conventional radiographs to try to improve the sensitivity of fracture 
detection.[378, 379]. 
Brain tissue shape has also been used to identify associations between 
brain tissue shape and conditions like attention-deficit hyperactivity 
disorder[380], schizophrenia[381, 382] and psychiatric disorders[383]. 
Planning radiotherapy is very important. Irradiation of noncancerous tissue 
may cause significant iatrogenic comorbidity. Shape models may improve 
the anatomical spatial awareness and minimise complications of therapy in 
head and neck malignancy[384] as well as prostate malignancy[385]. 
Tumour pathology can also be detected focally within an organ using shape 
modelling for more targeted therapy[385]. 
Training for surgical interventions such as hysteroscopy can be provided by 
modelling the shape of multiple real uterine cavities and converting this 
information into a simulator or virtual hysteroscopy for trainee surgeons[386]. 
Planning surgical interventions with computer-assisted surgery is an 
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evolving area of research. Pre-operative planning in neurosurgery with 
segmented brain images may be improved with 3D models of the brain, that 
provide localization, targeting, and visualization of tumours that can be used 
to simulate planned interventions[387] (Figure 31). Pre-operative shape 
modelling from ultrasound can also be used to assist planning in hip 
replacement[388, 389], for anterior cruciate ligament reconstruction[390, 
391]. 
 
Figure 31 3D Segmentation of tissues of the brain 
 
A model of a patients head and segmented brain regions. Reprinted by 
permission from John Wiley & Sons Ltd: Journal of Magnetic Resonance 
Imaging [387].  
 
In order to improve the fit and comfort of hearing aids, a better shape fit in 
the external auditory meatus is required. Designing custom-made hearing 
aids to fit the external auditory meatus using shape models has been 
described.[392] 
Prognostic information may be obtained from shape modelling of medical 
images. For example the volume of the prostate in prostate cancer is a 
strong predictor of treatment outcome especially if this volume is combined 
with a baseline prostate-specific antigen level[393]. Cam deformity of a 
femoral head on conventional radiography is also predictive of ten-fold 
greater risk of end-stage hip OA within 5 years[74]. 
In summary the field of shape modelling has already identified important 
applications in medical practice in terms of improving our understanding of 
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physiology and pathophysiology in humans. Shape models may also 
improve prognostic accuracy and interventional precision and permit 
personalised medicine by making custom-made prostheses. This technology 
and its application in the field of OA will be described in the next section.  
2.10.2 The two- and three dimensional shape modelling for 
determining joint shape, cartilage volume and bone area 
The shape of the subchondral bone has been identified as being associated 
with risk factors for OA, the structural progression of OA and it is an 
independent risk factor for incident OA and joint replacement (2.6.3 Bone 
shape and subchondral bone MRI features in OA, 2.11.1.2.5 Quantitative 
bone area and three-dimensional bone shape). However most of the 
assessments of bone shape used to demonstrate these associations have 
been based upon two-dimensional images alone or with reconstruction into 
three-dimensional shapes. While imaging biomarkers are the best 
personalised biomarkers ( 2.11 Imaging biomarkers in OA), more responsive 
biomarkers are required for the purposes of clinical trials, and three 
dimensional shape may provide novel imaging biomarkers of cartilage and 
subchondral bone shape, this section discusses the existing imaging shape 
biomarkers. 
2.10.2.1 Segmented bone shape on conventional radiography 
Agricola and colleagues have used SSM to describe the 2D shape of the 
SCB in the hip joint including the femoral head and acetabular shape to 
describe the association with OA progression in a nationwide prospective hip 
OA cohort study [394]. 
Waarsing and colleagues described the association of knee bone 2D shape, 
determined by SSM, with the presence or absence of cartilage defects[276]. 
Lynch and colleagues examined the association of incident hip OA with 
variations in 2D proximal morphology, assessed by ASM [291]. 
2.10.2.2 Segmented two dimensional tibial bone area 
Jones and colleagues have described the cross-sectional bone area of the 
tibia described in observational studies amongst the healthy population and 
those with and at risk of knee OA [31]. Bone area was calculated from axial 
- 112 - 
MRI slices of the tibial bone plateau (Figure 23) that were closest to the joint. 
The medial and lateral tibial bone areas were then measured from these 
directly using manual segmentation to provide the cross-sectional bone 
areas. An average of the three areas was used as an estimate of the tibial 
plateau bone area (tAB)[263, 395, 396]. 
 
2.10.2.3 Segmented three dimensional bone area, cartilage thickness 
and volume 
Eckstein and Chondrometric’s colleagues have also quantified cartilage 
volume, cartilage thickness and bone area over the tibia but also the femur 
and patella using laborious manual segmentation derived from serial 
magnetic resonance (MR) images, and analysis algorithms[271]. This 
Cartilage thickness has also been segmented  ( 
Figure 32) which can be used to provide a reconstruction of the femoral and 
tibial cartilage plates in three dimensions. Eckstein and colleagues have 
defined the different regions (Figure 33,Figure 34), and subregions within the 
knee (Figure 33,Figure 34). For bone area (tAB), the medial and lateral 
femur, tibia and patella are consistently divided into different subregions that 
can be appreciated below for the femur and tibia.  Notably the central region 
of the femur is identified as the ‘weight bearing’ region which is distinct from 
the femoral trochlea of the patellofemoral joint or the posterior femur (Figure 
33,Figure 34). The tibia is divided into medial and lateral regions and these 
two are further subdivided into five subregions (Figure 34). 
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Figure 32 Measuring cartilage thickness 
 
Examples of the coronal measurement of cartilage thickness using 
segmentation. cLF (central lateral femur), cMF (central medial femur). 
Reprinted by permission from John Wiley & Sons Ltd: NMR Biomed from 
[397] 
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Figure 33 Reconstruction of tAB of the medial and lateral tibia and 
femur 
 
b) Reconstruction of the femoral bone only and of the tAB of the above 
cartilages 
c) Reconstruction of the tibial bone only and of the tAB of the above 
cartilages 
Springer Calcif Tissue Int, Medial-to-lateral ratio of tibiofemoral subchondral 
bone area is adapted to alignment and mechanical load, 2009 Eckstein et al, 
reprinted with permission of Springer Reproduced from [267] 
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Figure 34 Regions and subregions of the knee - chondrometrics 
 
Three-dimensional reconstruction of the tibial and femoral subchondral bone 
with subregional division. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Rheumatology [398] Copyright 2012 
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Figure 35 Regions and subregions of the knee - Arthrovision 
 
Division of the three-dimensional tibial and femoral subchondral bone into 
subregions. Reprinted by permission from BioMed Central: Arthritis 
Research Therapy, Pelletier et al [123] 
 
Pelletier and Arthrovision colleagues have similarly segmented the cartilage 
plates in order to calculate femoral and tibial cartilage volume by segmenting 
the tibiofemoral compartment using shape modelling [123](Figure 35). They 
have also used cartilage thickness and maps of the findings. 
In summary there are many examples of 2D and 3D imaging biomarkers that 
have been described above. The SCB is important in the pathogenesis of 
OA including SCB shape. The importance of modelling the shape of the 
knee bones with SSM, ASM and AAM is it may permit the validation of novel 
imaging biomarkers with improved responsiveness profile than existing 
imaging biomarkers for prospective use in OA modification trials. 
2.11 Imaging biomarkers in OA 
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Joint imaging has permitted the direct and indirect description of articular 
tissues and their structural pathology. The quantitative and semi-quantitative 
descriptions of the imaged articular tissue structural pathology, morphology 
and composition have provided measures or biomarkers of physiological and 
pathophysiological processes that are specific to the joint and are these 
imaging biomarkers are currently the best personalised biomarkers in OA.  
Conventional radiography (CR) provides two-dimensional projection images 
that only directly visualise bone and are insensitive to structural pathology 
and longitudinal change in this. Therefore imaging biomarkers derived from 
unstandardised radiographic protocols are typically subject to significant 
measurement error, poor responsiveness and structural changes are poorly 
correlated with the clinical syndrome. Nevertheless, with appropriately 
standardised radiographic protocols the measurement of joint space 
narrowing from CR is the current standard for determining structural 
progression in OA.  
MRI provides three-dimensional tomographic imaging which greatly 
improves the sensitivity to detecting structural pathology of all joint tissues 
and longitudinal change in this. Imaging biomarkers derived from MRI are 
subject to less measurement error, better responsiveness and structural 
pathology correlation with the clinical syndrome. MRI measures have greatly 
contributed to the description of the natural history of knee OA and the 
identification important structural pathologies of tissues within the ‘whole 
joint’ that are associated with important clinical and structural outcomes in 
knee OA. 
Imaging biomarkers, unlike systemic biochemical markers (2.8 Biochemical 
biomarkers), are joint-specific and have been used in longitudinal 
observational studies to describe the natural history of OA. This process has 
demonstrated that several of these measures have concurrent and 
predictive validity regarding clinically important outcomes such as structural 
progression, pain and joint replacement. The variety, validation, advantages 
and disadvantages of imaging biomarkers are described here. 
2.11.1 Quantitative measures in OA 
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The structural pathology of OA can be described using quantitative 
measures. These measures are not used in routine clinical practice but they 
may be used as a structural outcome measures and for clinically meaningful 
outcomes like symptoms and joint replacement. These measures are 
described here.  
2.11.1.1 Conventional radiographic quantitative measures 
2.11.1.1.1 Continuous joint space width and joint space narrowing 
The measurement of joint space width (JSW) and joint space narrowing 
(JSN) by conventional radiography (CR) quantifies the interbone distance 
between opposing bones of any diarthrodial (synovial) joint. This section will 
primarily focus on the knee. JSW for the tibiofemoral joint is between the 
femur and the tibia. JSW and JSN are considered to be surrogate measures 
for hyaline articular cartilage thickness or loss respectively. However JSN is 
in fact a composite of cartilage loss and meniscal degeneration and/or 
extrusion.  
Weight-bearing is necessary to displace synovial fluid, to juxtapose the 
opposing articular cartilage surfaces and to maintain a similar cartilage 
compression and hence reproducible joint positioning between 
examinations. In routine clinical practice knee radiographs are typically 
weight-bearing in extension. Weight-bearing knee radiographs have a 
significantly smaller medial minimum JSW than non-weight-bearing 
radiographs[399]. 
Any interbone measurement with this protocol may be affected by variation 
in the degree of knee flexion, rotation (of the femur or tibia), medial tibial 
plateau alignment and magnification (Figure 36). Magnification is a product 
of the position of the knee relative to the x-ray beam and x-ray film. 
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Figure 36 Positioning of the subject for the fixed flexion and Lyon-
Schuss radiographs and examples of good and poor alignment of 
the medial tibial plateau with the X-ray beam 
 
The interbone measurement may be affected by variation in the degree of 
knee flexion and rotation of the femur or tibia. Reproduced from Annals of 
Rheumatic diseases, Le Graverand et al, 2008, [94]. with permission from 
BMJ Publishing Group Ltd. 
 
A full extension knee radiograph can also artificially increase apparent 
cartilage thickness[400] and is less reproducible than semi-flexed knee 
views[401, 402]. Therefore in order to improve the measurement noise to 
signal ratio and minimise the effect of repositioning error or inter-occasion 
variation (reliability), serial monitoring of JSW should be made by a 
standardised radiographic positioning with weight-bearing flexion protocols 
of which there are several; 
Fluoroscopic protocols such as  
 the Lyon-Schuss protocol takes a posteroanterior view of the knee 
with the pelvis, thigh and patellae of the patient being flush with the 
film cassette which is in the same plane as the tips of the great toes 
and confers an approximate fixed knee flexion of 20 degrees[403]. 
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This method appears to have a better sensitivity to change in JSW 
because this affords better alignment of the medial tibial plateau 
(Figure 36) [94, 402, 404] and does not require magnification 
correction unlike anteroposterior methods[403]. The limitations of this 
method include increased cost and patient irradiation and hence 
protocols without fluoroscopic-guidance were developed including the 
fixed-flexion[402] and metatarsophalangeal[405]. 
Non-fluoroscopic protocols include:  
 A postero-anterior view of the knee with the cassette in the same 
plane as the 1st metatarsophalangeal joint[406]. However the degree 
of knee flexion is not standardised.  
 A fixed degree of knee flexion and foot rotation and position of the 
knee relative to the x-ray beam and film can be standardised for each 
subject using a consistently-placed SynaFlexer plexiglass knee 
positioning frame[402] (Figure 42). 
 Finally a modified Lyon-Schuss protocol combines the positioning of 
the Lyon-Schuss with the use of the Synaflexer frame without the 
fluoroscopy[407]. 
While the sensitivity to change is improved when the medial tibial plateau is 
parallel to the X-ray beam a suggested alternative without fluoroscopic-
guidance is to acquire multiple radiographs of each knee to ensure the best 
projection image is achieved[408]. A quality control approach for tibial 
plateau alignment was incorporated in the Osteoarthritis Initiative 
radiography protocol. Where radiographs of insufficient quality were 
identified, participants were invited to have multiple knee radiographs ( 
2.12.4 Knee radiography protocol[409]) 
Metric JSW can be measured manually from CR with a graduated ruler, 
calipers, or using semi-automated computer software[410, 411].  
Furthermore the minimum interbone distance (mJSW) can also be measured 
as a measure of greatest JSN[412]. It can also be measured at location-
specific locations at or in relation to specific anatomical landmarks[413]. In 
knees without and with ROA knee, mJSW and location-specific JSW had 
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optimal responsiveness respectively[413]. However despite the best efforts 
to minimise repositioning errors, the minimum inter-occasion variation 
(standard deviation of the difference between test-retest measurements of 
mJSW) was approximately 0.1mm in the methods with best 
repeatability[402, 414]. This represents a smallest detectable difference of at 
least 0.2mm. Considering that the mean rate of annual knee JSN is 0.13 ± 
0.15mm/year, with change occurring in only a small group of 
“progressors”[93, 94], this represents a significant measurement noise to 
signal ratio and highlights the lack of responsiveness of this measure.   
CR JSN is also limited by the fact that JSN is not a specific measure of 
hyaline cartilage loss but a composite measure of the degeneration of two 
tissues. JSW is a construct of degeneration and extrusion of the menisci as 
well as hyaline articular cartilage degeneration[86].  
Furthermore a systematic literature review of relevant structural progression 
defined by JSW identified considerable heterogeneity in definition of loss of 
metric JSW required to be defined as a ‘progressor’[415]. There is no current 
consensus of opinion on which threshold represents an accurate definition.  
Despite these limitations CR continuous JSW or JSN remains the 
recommended measurement for measuring structural change according to 
the Osteoarthritis Research Society International Food and Drug Agency 
(OARSI FDA) OA assessment of structural change working group[367].  
The validity of JSN as a clinically and structurally important measure of OA 
is supported by the following evidence. Knee JSN occurring over five years 
is predictive of future knee replacements as much as 15-years later[104, 
416]. Degenerative meniscal changes at baseline in knees are predictive of 
JSN two years later[417]. Degenerative changes of knee hyaline articular 
cartilage, menisci and meniscal extrusion are also predictive of JSN 30 
months later[418].  Subchondral bone changes of OA include increased 
turnover and bone marrow lesions. A bone turnover biomarker is predictive 
of subsequent JSN in knees with symptomatic and ROA[419]. JSN of hand 
OA is associated with BMLs[420]. Amongst 942 patients with symptomatic 
knee OA, a lower baseline metric mJSW and greater JSN over four years 
was predictive of greater deterioration in pain, function and quality of life 
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after suitable covariate adjustment[421]. Metric JSW responsiveness 
(measured using the Synaflexor)[402] has been compared with the 
responsiveness of cartilage volume in the progressor cohort of the OAI over 
12 months in 150 knees. The conclusion from the authors was that the most 
responsive JSW and MRI cartilage volume measures were comparable at -
0.32 and -0.39 respectively (expressed as standardised response 
means)[413, 422]. This may in part be explained by the slow rate of cartilage 
progression in conjunction with the equally poor measurement to noise ratio 
of the cartilage volume measurement method. The greatest rate of cartilage 
volume loss was  -2.5% per annum[422],  but the coefficient of the variance 
(the noise to signal ratio on inter-occasion measurement error) of cartilage 
volume segmentation ranged from 3 to 5% (see the web appendix of this 
citation[422]). This is comparable to radiographic JSN coefficient of the 
variance [412] which may explain the  limitations of measurement noise to 
signal ratio of these methods. A superior coefficient of the variance for the 
measurement of cartilage volume is quoted by Eckstein et al. of 2.4-
3.3%[423] indicating a better method for cartilage volume assessment. 
A meta-analysis of the responsiveness of JSW confirmed that this was 
significantly better with trials with flexed knees with greater than two years of 
duration (SRM =0.71). The intra-reader and inter-reader intra-class 
correlation coefficients were excellent and coefficient of the variance 
estimates were approximately 3%[424].  
The implications of this are that trials based on JSW as an outcome 
measure require follow up periods of at least two years and due to the 
relative insensitivity to change and poorer reliability, require large numbers 
of patients per arm to adequately power the study which represents a major 
barrier to performing trials of prospective disease modifying agents. This 
highlights the inadequacy of JSN as the current OARSI FDA standard of OA 
structural progression measurement and the need for better biomarkers. 
2.11.1.1.2 Continuous (metric) alignment 
Alignment of joints can be assessed using clinical and radiographic 
methods. This section will focus specifically on the knee. Knee alignment 
can be measured clinically using a goniometer as it is in the Osteoarthritis 
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Initiative at baseline or using lower limb conventional radiographs. 
Radiographic knee alignment can be classified in two ways. The most 
commonly used method is the mechanical axis which requires a full-length 
lower limb radiographic image and measures the hip-knee-ankle angle[425]. 
This is the femur-tibia angle formed by the intersection of a line connecting 
the centre of the femoral head with the middle of the knee and another line 
connecting the middle of the ankle joint with the middle of the knee joint. The 
second method is the anatomic axis which is the angle formed by the 
intersection of a line through the middle of the tibial shaft and a line through 
the middle of the femoral shaft[426]. 
A systematic literature review of the concurrent and predictive validity of 
knee OA malalignment as a measure of radiographic and MRI structural 
severity and progression identified that increasing goniometer-measured 
malalignment was associated with concurrently greater osteophytes and 
JSN[427]. Continuous varus and valgus malalignment of the knee measured 
by radiographs was concurrently associated with greater cartilage 
degeneration on MRI[428]. The systematic review in 2009 also concluded 
that continuous baseline radiographically-determined alignment was 
predictive of radiographic and MRI-determined structural progression in 
longitudinal studies. This along with more recent literature provides evidence 
of predictive validity of continuous malalignment which will be described here 
in terms of radiographic followed by MRI structural progression outcomes.  
Baseline alignment, in knees with symptomatic ROA, was independently 
associated with longitudinal progression in medial and lateral JSN with varus 
and valgus malalignment respectively[429, 430].   
Baseline malalignment severity, in 117 knees with symptomatic ROA, was 
associated with a dose dependent increase in rate of MRI cartilage volume 
loss (either tibial or femoral) in the medial and lateral compartments, with 
increasing varus and valgus malalignment respectively over two years[431].  
Baseline varus malalignment severity, in 293 knees without evidence of 
tibiofemoral cartilage defects at baseline, was independently associated with 
a dose dependent effect on incident medial WORMS cartilage defects 
(2.11.2.2.2 Knee semi-quantitative measures). Baseline malalignment also 
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reduced the risk of incident cartilage defects in the compartment receiving 
less load over 30 months[77]. The same  observation that varus and valgus 
malalignment ‘off-loads’ the lateral and medial compartments respectively 
and reduces the odds of cartilage damage over two years, was made 
amongst knees with ROA[432]. 
Loss of medial cartilage thickness and volume were both independently 
associated with continuous varus malalignment in 250 knees with 
established OA but the valgus deformity was associated but not 
independently with lateral cartilage loss of the same measures[433].  
Sharma and colleagues reported that continuous valgus deformity is not 
independently associated with lateral cartilage loss[77, 433]. These analyses 
only included 55 knees with valgus. Felson and Cicuttini and colleagues, 
included up to 881 knees with valgus deformity and reported independent 
associations between longitudinal lateral cartilage loss and categorical  [76]  
and continuous [431] valgus malalignment respectively. The risk of incident 
OA and progression of knee OA utilised ROA and MRI measures and found 
categorised valgus deformity (in 881 knees) was independently associated  
with MRI cartilage loss, and increasing severity of radiographic JSN and 
meniscal degeneration[76]. Therefore there is  good evidence that varus and 
valgus malalignment are independently predictive of structural progression.  
Continuous malalignment also has predictive validity regarding future 
symptoms and total knee replacement. Valgus malalignment at baseline is 
also independently associated with persistent knee symptoms of OA or total 
knee replacement after six years [434] and when incorporated in phenotypic 
stratification, confers a greater risk of structural progression[435]. 
Varus alignment is associated with pain severity in cross-sectional analysis 
[436] and malalignment is associated with incident bone marrow lesions in 
the biomechanically loaded compartment[437]. 
More recently the femur-tibial angle, obtained from fixed-flexion knee films, 
with adjustment for sex-specific varus shift was found to be as good as the 
long-limb radiograph and better than goniometry in predicting change in 
cartilage thickness over two years[438].  
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In summary CR quantitative imaging biomarkers have been validated as  
measures of clinically and structurally important outcome measures. 
However despite great efforts to optimise the responsiveness of JSN, the 
current standard for measuring structural progression, the insensitivity of this 
measure to change represents a significant barrier to discerning the potential 
for disease modification and advancing the treatment of OA. More 
responsive biomarkers are therefore required. 
 
2.11.1.2 MRI quantitative measures 
There are broadly two strategies for the quantification of MRI OA structural 
pathology. Quantitative MRI measures are described here and semi-
quantitative MRI measures below (2.11.2.2 MRI semi-quantitative 
measures). While semi-quantitative measures use an ordinal scale, 
quantitative measures quantify tissue characteristics such as cartilage 
thickness[439] or volume[440] which typically uses segmentation 
techniques.  
The imaging sequences required for quantitative measures differ from semi-
quantitative grading because spatial resolution is more important and the 
precise distinction of the osteochondral interface and cartilage surface is 
essential.  This is because most quantitative analyses involve the 
segmentation of tissues which are usually performed manually or using 
semi-automated methods. These methods can be labour intensive and 
require expert analysis, specialised computer software, special training of 
segmenters and quality control procedures[441]. 
Quantitative measures were found to be more sensitive to change than 
semi-quantitative measures[442]. As a consequence the measurement of 
longitudinal structural change with semi-quantitative measures has evolved 
[443, 444] to offer comparable longitudinal sensitivity to change[366].  
 
2.11.1.2.1 Quantitative morphologic measurement of cartilage thickness & volume 
In order to quantitatively measure cartilage thickness or volume, 
segmentation of the joint tissues on MRI is required. This can be 
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reconstructed into femoral and tibial cartilage volumes or used to measure 
cartilage thickness ( 
Figure 32).The precision and reliability of the different segmentation 
methods is good[366, 397, 445]. From the segmented cartilage and bone, 
several measures can be made based upon the division of the joint into 
regions determined by a panel of experts[271](2.10.2 The two- and three 
dimensional shape modelling for determining joint shape). Segmentation of 
the tissues, particularly the cartilage, permits the calculation of the following; 
the total area of the SCB (tAB), the area of the cartilage surface (AC), the 
tAB covered by the AC (cAB) and the denuded area of SCB (dAB) which is 
expressed as percentage of tAB not covered by AC. Finally both volume of 
cartilage (VC) and cartilage thickness (ThC) can be quantified[446]. These 
can be calculated for each defined joint region and subregion (Figure 
34,Figure 35)[398]. 
These two measures have excellent reliability as demonstrated by a meta-
analysis of studies. This included a coefficient of the variance of 3% for both 
inter- and intra-reader reliability. Inter- and intra-reader intra-class correlation 
was excellent[366].  
The responsiveness to change of cartilage thickness and volume have been 
analysed in a broad range of observational studies[95, 431, 447-449]. A 
meta-analysis of the responsiveness of MRI-determined quantitative 
cartilage measures to cartilage loss[366] indicated a greater sensitivity to 
change than an equivalent meta-analysis of radiographic JSW[424]. In direct 
comparisons of the two methods, MRI-determined cartilage measures were 
more responsive than CR JSW as well[95, 448]. 
Cartilage thickness can be described using a thickness map of the femur 
and tibia.. 
The rate of cartilage thickness or volume loss is increased in the context of 
typical OA risk factors and severity measures. This includes obesity[95, 
123], meniscal degeneration[123], malalignment[433, 450], frequent 
pain[448, 451] and evidence of greater radiographic structural severity[123, 
451-454]. 
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The validity of cartilage loss as a clinically meaningful biomarker have been 
reported. Denuded area of SCB (dAB) is associated with knee pain in cross-
sectional studies[455, 456] and predictive of incident knee pain in 
longitudinal studies[456]. Knees with greater rates of tibiofemoral cartilage 
loss were more likely to subsequently  receive  total knee replacement than 
at lower rates[270, 457]. In a nested case-control study within the OAI, the 
rate of cartilage loss in the two years prior to TKR accelerated[458]. 
Variable thresholds of cartilage loss have been used to determine significant 
from insignificant structural progression. This threshold has been determined 
by the subregional change in healthy joints[459], the precision of cartilage 
quantification[433] and the smallest detectable change[447] in cartilage 
quantification. 
In summary MRI-determined quantitative measures of cartilage loss are 
validated biomarkers of clinically important outcomes such as joint 
replacement, pain and incident pain and are associated with typical risk 
factors for OA. These measures are more responsive than CR-determined 
measures. 
2.11.1.2.2 Quantitative compositional measurement of cartilage 
While morphological MRI sequences permit the three-dimensional 
measurement of joint tissues, more advanced MRI sequences can be used 
to characterise and quantify the ultra-structural or biochemical composition 
of articular cartilage.  These assessments of tissue composition may be 
used to identify and quantify degenerative changes in cartilage that precede 
morphologically defined cartilage loss of OA.  
Healthy cartilage consists of collagen fibres and proteoglycans which are 
‘core proteins’ with glycosaminoglycan (GAG) side chains. Collagen fibres 
are organised in an anisotropic manner in different layers of cartilage (Figure 
8) which confers it’s load-dissipating mechanical properties. Early 
biochemical alterations in the natural history of OA include 
glycosaminoglycan (GAG) depletion, increased permeability to water[460] 
and loss of the anisotropy of the extra-cellular matrix network in animals 
[461, 462] and humans[463, 464]. These alterations can not be detected 
with standard morphologic magnetic resonance sequences (Figure 37).  
- 128 - 
Compositional sequences such as diffusion weighted imaging and T2 
mapping procedures are sensitive to the loss of anisotropy of the matrix 
network. Delayed Gadolinium Enhanced MRI of Cartilage (dGEMRIC) [465] 
and glycosaminoglycan chemical exchange saturation transfer  (gagCEST). 
dGEMRIC are biomarkers of glycosaminoglycan concentration within the 
cartilage. dGEMRIC has been demonstrated construct validity histologically 
and biochemically in human and animal cartilage[466-469]. In vivo spatial 
variation in cartilage signal, in particular circumstances, reflects variations in 
cartilage GAG concentration[470]. MRI scans are performed 90 minutes 
after the contrast is administered and dGEMRIC has good reproducibility 
with an intra-class correlation coefficient (ICC 0.87-0.95)[471].  
In case-series analysis of knees undergoing partial meniscectomy, the 
baseline dGEMRIC values were associated with incident JSN and 
osteophyte formation[472]. In longitudinal analysis the cartilage thickness 
change was inversely associated with dGEMRIC[473](Figure 37). 
Furthermore dGEMRIC is sensitive to weight loss[474]. Therefore dGEMRIC 
is probably the best-understood compositional sequence with the greatest 
validation but further validation is required before this can be used as a 
surrogate measure of OA clinical outcomes such as pain and joint 
replacement. 
Clinical studies for the validation of gagCEST as a biomarker of cartilage 
degeneration in OA are lacking. Other quantitative compositional imaging 
biomarkers of cartilage composition lack precision data but include T1-
weighted sodium MRI[475], and computed tomography of the knee after 
intra-articular cationic contrast injection[476]. 
In summary compositional MRI sequences represent quantitative MRI 
cartilage measures that have potential to complement the existing and better 
validated morphological assessments of cartilage 
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Figure 37 MRI compositional cartilage maps of the tibiofemoral joint 
 
An MRI shows a decrease in the dGEMRIC index particularly in the weight 
bearing areas at the central and posterior tibia (large white arrows). 
Reprinted by permission from Elsevier Ltd: Osteoarthritis and cartilage [34] 
 
2.11.1.2.3 Quantitative bone marrow lesions  
Bone marrow lesions can be segmented using semi-automated methods 
that first segment the cartilage-bone interface, the BML itself and then 
quantify the volume of the BML by using multiple slices of the joint(Figure 
38). The importance of segmenting the cartilage bone interface is to ensure 
the BMLs are within a predefined distance from the bone cortex to ensure 
they are truly subchondral. The calculated BML volume was associated with 
adjacent cartilage thickness and full thickness cartilage loss[477]. Bone 
volume has been quantified using similar methods and found to correlate 
with increased bone volume fraction[298]. BML volume has also been found 
to be associated with pain severity and JSN at baseline and to be predictive 
of JSN progression in longitudinal analyses[100]. 
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Figure 38 Bone marrow lesion segmentation 
 
Segmented knee MRI scans. The red lines identify the bone boundary and 
the yellow lines surround areas of high signal intensity (BMLs). Reprinted by 
permission from BioMed Central: Arthritis Research Therapy, Driban et a 
[100] 
2.11.1.2.4 Quantitative trabecular morphometry 
The structure of bone is complex (2.6 Subchondral bone in OA). Quantitative 
assessment of macrostructural characteristics, such as geometry and shape 
of bones are important biomarkers of (OA2.6.3 Bone shape and subchondral 
bone MRI features in OA). Macrostructural SCB mineral density (BMD) is an 
important biomarker of OA and this can be quantitatively assessed using 
conventional radiographs, dual-energy x-ray absorptiometry (DXA) and 
computed tomography (CT), especially volumetric quantitative (qCT) 
Microstructural assessments of the trabecular SCB have greatly improved 
our understanding of the pathogenesis of OA(2.6.2 Subchondral bone 
architecture and remodelling in OA). Methods for this microarchitectural 
assessment include micro- computed tomography (micro-CT), high-
resolution computed tomography (hrCT), micromagnetic resonance (micro-
MR) and high-resolution magnetic resonance (hrMR). Microarchitectural 
features can be quantified based on segmentation and three-dimensional 
methods and the main measurements include bone volume fraction, 
trabecular thickness, trabecular number, thickness and spacing  
- 131 - 
Bone volume fraction (BV/TV) or bone mineral density (BMD) is the most 
important parameter for describing trabecular microarchitecture and is 
defined as the bone volume divided by its total volume (%). BVF is an 
approximation of subchondral sclerosis(Figure 20).  
Trabecular number (TbN) is a three-dimensional measure calculated from 
micro-CT images. Trabecular thickness (TbTh) is expressed as the mean 
trabecular thickness. Trabecular spacing or trabecular separation (TbSp) is 
calculated as the mean distance between trabeculae (µm). The changes in 
these measures in OA and their association with clinical OA have been 
described earlier(2.6.2 Subchondral bone architecture and remodelling in 
OA). 
2.11.1.2.5 Quantitative bone area and three-dimensional bone shape 
Bone area (2.6.3.1.1 Knee subchondral bone cross-sectional area) and 3D 
bone shape (2.6.3.1.2 Three-dimensional knee bone shape) have been 
discussed earlier. 
2.11.1.2.6 Meniscus and effusions 
Meniscus and effusions can both be segmented using similar technology to 
cartilage and bone segmentation. These are in their infancy relative to bone 
and cartilage. 
In summary quantitative measures of OA have been used across a range of 
imaging modalities. Compared to semi-quantitative measures, quantitative 
systems use a more complex, technology dependent and time-consuming 
approach for assessing structural pathology. However the continuous 
measures may be more sensitive to change making them better outcome 
measures. The most validated OA quantitative measures are for the knee 
and include cartilage volume and thickness. The current standard for 
measuring structural progression in knee OA is radiographic JSN. 
Regardless of these measures no biomarker demonstrates a strong 
association with both structural progression and clinically meaningful 
symptoms. More sensitive and validated biomarkers are therefore desirable. 
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2.11.2 Semi-quantitative measures of structural OA 
The structural pathology of OA can be measured using semi-quantitative 
scoring systems. These scoring systems are not used in routine clinical 
practice but are frequently used in longitudinal or cross-sectional 
observational studies and interventional trials. They may be used as 
selection criteria to enrich a cohort with a relatively homogenous structural 
severity of OA (e.g. an identical KL grade)[92] or as a structural outcome for 
measuring structural progression such as a semi-quantitative cartilage 
defect score[478].  
Conventional radiographic measures whether they are semi-quantitative or 
quantitative are limited by the fact that they are less responsive, reliable and 
sensitive to whole-joint structural pathologies and their structural progression 
than MRI and they are less well correlated with the clinical syndrome. In 
particular CR is insensitive to the detection of OA structural pathology 
associated with pain (e.g. BMLs and synovitis)(2.4.3.2 OA pain and its 
structural associations). Therefore large changes in semi-quantitative 
structural scoring are often required to represent clinically meaningful 
change. For example only increases of two more KL grades(Table 1) in 
knees over 4 to 5 years is associated with increasing pain and 
dysfunction[98]. 
Unlike quantitative measures that use continuous scales, semi-quantitative 
measure use an ordinal scale e.g. 0-3 which may be described as absent, 
mild, moderate or severe. The structural change required to move from one 
grade to the next may not be uniform along the scale (e.g the change 
between zero and one, and between one and two) and therefore these may 
not be interval variables. Acknowledging these limitations, semi-quantitative 
measures are more convenient, more rapidly scored and do not require no 
complex imaging analysis technology. Therefore they are a more feasible 
and are an  approximation of quantitative structural measures. The different 
forms of semi-quantitative measures of structural OA are described here. 
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2.11.2.1 Conventional radiographic semi-quantitative measures 
2.11.2.1.1 Kellgren Lawrence grade  
The most frequently used CR semi-quantitative system to identify and grade 
OA is the Kellgren–Lawrence (KL) score. This is a widely accepted scale 
which can be applied to peripheral and axial joints but is most frequently 
used for the knee[19]. This is a composite measure of JSN, osteophytes, 
subchondral sclerosis that is described on an ordinal scale (Table 1,Figure 
1). The presence or absence of OA is typically defined as grade two or 
higher.  The advantages of KL score are that it incorporates the severity of 
structural pathology in more than one tissue in this multi-tissue whole joint 
disorder. The baseline knee KL score is predictive of knee joint replacement 
in the OAI[479]. Knees demonstrating an increase in KL grade compared to 
stable KL grade over one year have greater odds of further increases in KL 
grade in the following year [92], but only increases of 2 more KL grades in 
knees over 4 to 5 years is associated with increasing pain and 
dysfunction[98]. However the disadvantages of KL scoring are that it 
depends upon the presence of osteophytes which can change with minor 
changes in the rotation of a knee and the standardisation of rotational 
positioning of the knee is difficult. The KL grade does not represent an 
interval variable where individual categories are equidistant from each other 
in severity. Therefore it is important to recognise that the proportion of knees 
that progress from one grade to the next are not comparable for all starting 
points in the scale. The OA threshold of KL 2 has been inconsistently 
defined in longitudinal studies which have led to some heterogeneity in 
definitions of OA. Almost all definitions of KL 2 require a definite osteophyte, 
some do not mention JSN, some require JSN while others require the 
absence of JSN[480]. In the Framingham Osteoarthritis study where X-ray 
and MRI scores were available for 189 knees, KL grade 2 without JSN 
(OARSI JSN = 0) and with JSN (OARSI JSN =1) had substantial semi-
quantitative WORMS weight-bearing TFJ cartilage loss in 4% and 44% of 
knees respectively[481]. This highlights the importance of the difference in 
KL2 definition. It is also noteworthy that KL grade 3 requires definite joint 
space narrowing but this may range from mild to nearly bone on bone 
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narrowing. Therefore KL grades may encompass a broad spectrum of 
pathology and the ordinal KL scale is not an interval variable. 
Felson and colleagues analysed a cohort of 842 knees with established 
ROA in at least one knee from the MOST study. Structural progression was 
defined after 30 months of follow up using OARSI JSN[84] (with half grades) 
to define structural progression. Had KL grade been used to define structural 
progression, less than half of all those determined as having JSN structural 
progression would have been detected by a change in KL grade. Therefore 
KL grade is relatively insensitive to structural progression than JSN[481]. 
This has led to the suggestion from Felson and colleagues that an additional 
‘definite osteophyte only’ grade should be distinguished to determine ROA 
incidence and for structural progression to focus on JSN[482].  
In conclusion KL grade is insensitive to clinically meaningful change in 
symptoms and is less sensitive to structural change than ordinal OARSI JSN 
but it is still an independent predictor of knee joint replacement. Variations in 
KL grade definition amongst different studies may represent important and 
latent differences in structural severity between studies.  
2.11.2.1.2  The Osteoarthritis Research Society International (OARSI) atlas 
classification  
The Osteoarthritis Research Society International (OARSI) atlas 
classification grade ROA of the knee, hip and hand. It provides distinct 
scoring systems for each joint and describes JSN, osteophytes with a semi-
quantitative score (0-3) and the presence or absence of subchondral 
sclerosis, cysts and attrition but also joint malalignment [84]. In the knee the 
features are identified by their presence in the medial and lateral tibiofemoral 
compartments (Figure 39). 
Amongst 276 knees in the MOST study, OARSI knee JSN was significantly 
associated with progressive WORMS cartilage damage, meniscal damage 
and extrusion after adjusting for age, gender and BMI[418]. Knees with 
higher OARSI grades of JSN had thinner cartilage in the medial TFJ than 
those without JSN[483]. This provides evidence of predictive and construct 
validity of OARSI JSN. 
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The inter-rater and intra-rater reliability and the sensitivity to change 
(standardised response mean) was compared between categorised metric 
JSW, KL grade and OARSI JSN grade for 1759 x-rays from three trials and 
two cohorts. Categorised metric JSW had better reliabilities and sensitivity to 
change than the other two ordinal measures[484]. Disease progression may 
be defined as an increase in KL, JSN or osteophyte grade. However JSN 
had the lowest inter-observer variability[485].  
Cross-sectional analysis of 696 people from the MOST study and 336 
people from the Framingham OA cohort examined the association of pain 
severity and consistency with ROA grade of KL, OARSI JSN and OARSI 
osteophyte grades. To avoid typical confounders, knees were compared 
within individuals with discordant pain severity and consistency between 
knees. All three ROA measures were associated with these pain measures 
but OARSI JSN grade and KL grade had greater association with OA pain 
than OARSI osteophyte grade[486]. 
Other examples of scoring systems utilising atlas scoring systems include 
Nagaosa and colleagues’ for knee OA, the Kallman[487], Verbruggen[488] 
and Dougados  scoring systems[489]. These scoring methods have been 
compared with KL grade and demonstrated to have similar reliability and 
sensitivity to change and may be used to detect hand ROA change over time 
[489]. 
Therefore OARSI JSN grade has construct validity and offers advantages 
over KL grade in terms of its reliability and responsiveness and its 
association with pain relative to OARSI osteophyte grade.  
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Figure 39 Altman Atlas semi-quantitative scoring 
This is the Altman atlas: semi-
quantitattive scoring system for radiographic OA [84]  
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2.11.2.1.3  Categorical Alignment of the knee  
A systematic literature review of predictors of radiographic structural 
progression identified that categorical varus and valgus malalignment of the 
knee (Figure 40) is  independently associated with structural 
progression[428].  
Figure 40 Alignment of the knee 
 
These images explain the different forms of  knee malalignment. Reprinted 
by permission from Elsevier Ltd: Rheum Dis Clin North Am [490] 
 
Incident radiographic OA (KL≥2) was associated with categorical 
malalignment (varus and valgus) which was specific to obese and 
overweight individuals and not with normal BMI[491]. Amongst obese 
women, malalignment (valgus or varus) was associated with greater risk of 
incident radiographic OA (KL≥2) over 2.5 years [492]. Amongst 315 knees 
largely without OA and concurrent obesity, the categorised malalignment of 
the knees was not associated with tibial cartilage volume loss or tibiofemoral 
chondral defects longitudinally on MRI over 2.4 years after adjustment for 
confounding factors[268]. This implies that the increased load of 
malalignment and obesity may contribute to greater risk of incident ROA and 
these two predictors of OA may interact[493].  
- 138 - 
In a population of mostly obese individuals at risk of OA, categorised varus 
but not valgus was associated with incident tibiofemoral ROA after adjusting 
for age, gender and body mass index [494]. 
While ROA progression (KL increase ≥1 grade) has been associated with 
varus but not valgus malalignment [491], this is a relatively insensitive 
measure of structural progression as previously described (See 2.11.2.1.1 
Kellgren Lawrence grade) and therefore the association with valgus 
malalignment with better structural measures was explored. This included 
larger studies, of 881 knees using more responsive structural measures, 
which reported independent associations between categorised valgus 
deformity and incident knee ROA and progression of knee OA with 
radiographic JSN and MRI cartilage and meniscal degeneration[76]. 
Increasing severity of varus and valgus malalignment in ROA knee were 
also associated with greater risk of progression in the biomechanically 
loaded compartment[494, 495].  
Therefore there is good evidence that categorical varus and valgus 
malalignment are independently predictive of structural progression and may 
be involved in structural incidence of knee OA when combined with obesity.  
2.11.2.2 MRI semi-quantitative measures 
The semi-quantitative strategy for the quantification of MRI OA structural 
pathology is described below but a comparison with quantitative MRI 
measures described above (2.11.1.2 MRI quantitative measures) will first be 
made.  
Trained readers can semi-quantitatively describe the severity of OA 
structural pathology on MRI using an ordinal scale (e.g. 0,1, 2 and 3) without 
the arduous segmentation, additional image processing and special imaging 
sequences required for quantitative analysis of joints. The whole joint semi-
quantitative scoring systems may take up 50 minutes per knee for a reader 
and therefore they remain research tools that are not used during routine 
clinical practice where only qualitative reporting is standard.  
Semi-quantitative measures, that may not be interval variables, are designed 
to approximate the 3D quantitative structural pathology of OA on ordinal 
scales. The difference in responsiveness of these two measure types was 
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highlighted when describing changes in BMLs and cartilage in knees over 24 
months. Quantitative measures were found to be more sensitive to change 
than semi-quantitative measures[442]. As a consequence the measurement 
of longitudinal structural change with semi-quantitative measures has 
evolved  to incorporate ‘within-grade’ scoring changes to improve 
longitudinal sensitivity to change [443, 444]. Severe malalignment has since 
been identified as predictive of ‘within grade’ but not whole grade 
progression in cartilage loss supporting this rationale[496].  
While ‘within-grade’ scoring changes are  now commonly used, the 
disadvantage of this is that this process demands that the reader is 
unblinded to order of serial image acquisition[496] which may introduce bias. 
Despite these limitations a meta-analysis of the responsiveness and 
reliability of semi-quantitative and quantitative measures of BMLs and 
cartilage in knee OA found that the pooled standardised response means for 
both methods were adequate-to-good and  comparable[366]. The random-
effects pooling of intrareader and inter-reader intraclass correlation 
coefficients for each tissue indicated excellent reliability. The intrareader and 
inter-reader kappa values were also moderate to excellent. 
Semi-quantitative measured in cross-section may offer and advantage over 
metric quantitative measurements. This is because lesion size may vary 
according to the absolute size of the person whilst semi-quantitative 
measures are relative to the size of the joint. 
The optimum MRI protocol for the purposes of semi-quantitative analysis 
differs for quantitative MRI analysis. Peterfy for example selected 
unenhanced pulse-sequences for optimum semi-quantitative evaluation of 
each component of knee OA[497]. While for quantitative evaluation protocols 
with better spatial resolution are more important for the precise distinction of 
the osteochondral interface and cartilage surface for segmentation. 
In terms of the validity of semi-quantitative MRI knee scores in relation to 
pain, two systematic reviews indicated moderate associations of pain with 
BMLs and synovitis or joint effusion[132, 365]. Felson’s BML score was 
associated with knee pain and incident knee pain was associated with an 
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increase in BML score. Furthermore a linear positive relationship between 
BLOKS maximal BML size and WOMAC pain score has been observed[498] 
In terms of validity of semi-quantitative MRI knee scores in relation to the 
prediction of MRI-determined structural progression. Progression of cartilage 
deterioration is greater in individuals with a raised BMI of 30 or more in a 
longitudinal observational study[499]. Cartilage deterioration also progresses 
in longitudinal studies in the context of synovitis[500], BMLs[500], meniscal 
damage[501] and prevalent cartilage damage[500]. 
2.11.2.2.2 Knee semi-quantitative measures 
The following text describes the semi-quantitative assessment of the knee in 
OA with scoring systems for individual tissues as well as whole organ 
assessment .  
Individual tissues of the knee can be semi-quantitatively assessed such as 
the synovium. A precise anatomical description of synovitis of the whole-
knee is only possible on contrast enhanced images and Guermazi and 
colleagues have an example of a synovitis scoring system (0-2) which is 
assessed at 11 sites to achieve this[502]. On unenhanced MRIs semi-
quantitative scoring systems are also described individually for  BML size (0-
3) [133] the degeneration of cartilage (0-4) [353], meniscus (0-3)[503] and 
ligaments (0-3)[30].  
While OA is a ‘whole organ’ disease the extent of the structural involvement 
is best captured by ‘whole organ’ scoring systems, of which there are four 
well-described systems all of which are based on MRI without contrast. 
The first comprehensive scoring system was described in 2004 by Peterfy 
and colleagues[504]. This was named the Whole ORgan Magnetic 
Resonance iMaging Score (WORMS) and it has been extensively used in 
MRI studies worldwide.  This includes the Framingham Knee Osteoarthritis 
study[23], the Osteoarthritis Initiative[505] and the Multicenter Osteoarthritis 
Study (MOST)[307].  
This provides a system based upon the division of knees into complex 
subregions (Figure 41) rather than using a lesion-oriented system. 
Cumulative scores for each lesion type in each compartment and at a whole 
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subregion are considered together which may simplify analysis and 
interpretation of data. This is because a lesion based approach may be 
compromised if lesions coalesce or split during longitudinal observation. 
Furthermore this is the only whole joint scoring system to include 
subchondral attrition (Table 9).   
Kornaat and colleagues in 2005 introduced the Knee OA Scoring System 
(KOSS)[506]. This describes similar OA features as the WORMS but with 
different subregional division and without attrition, bursitides, loose bodies 
and ligament abnormalities (Table 9). The KOSS scores knees according to 
the following anatomical areas. The medial and lateral:  
 patella facets (divided by the patellar crest) 
 femoral trochlear facets 
 femoral condyles (excluding the trochlear grove) 
 tibial plateaus 
The menisci, effusion size, synovitis and Bakers cysts are also included.  
Unlike WORMS each lesion grade is differentiated by the lesion size. 
Furthermore subchondral cysts, BMLs and cartilage condition are 
individually scored for each KOSS subregion unlike the WORMS which 
scores these cumulatively. KOSS scores meniscal subluxation (unlike 
WORMS) but both KOSS and WORMS score meniscal morphology.  
 
In 2008 Hunter and colleagues introduced the Boston-Leeds OA Knee Score 
(BLOKS) which, unlike WORMS, applies a lesion-oriented system to BML 
scoring[498] which is more conducive to longitudinal analysis of individual 
lesions. The division into subregions is based upon weight-bearing regions 
of the knee rather than the patellofemoral joint (Figure 41)  
Controversy remains regarding whether the WORMS or BLOKS is a better 
validated outcome measures in knee OA. When comparing longitudinal 
changes in BLOKS and WORMS scores in 113 knees, WORMS BML 
measurements had a stronger association with cartilage loss than BLOKS 
BML scoring. BLOKS meniscal tear and signal abnormality assessment was 
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better for predicting cartilage loss than the WORMS meniscal scoring. 
Neither scoring system was superior at cartilage assessment[507].  However 
comparison of WORMS and BLOKS scores amongst 71 subjects indicated 
that unlike BLOKS BML score, WORMS BML score was not associated with 
pain and was less strongly associated with cartilage loss[498]. 
In 2011 Hunter and colleagues developed the MOAKs (MRI OA Knee score) 
system. The design was informed by the relative advantages and 
disadvantages of the existing scoring system. The MOAKS incorporates a 
subregional assessment, a refinement of the BML and meniscal scoring and 
removed redundant features in the scoring of BMLs and cartilage[508]. It is 
now being used in the Osteoarthritis Initiative. 
The WORMS and MOAKs systems similarly divide the femur and tibia into 
anterior, central and posterior regions while the BLOKS system divides the 
femoral condyles into trochlear and weight-bearing regions. The WORMS, 
BLOKS and MOAKS scoring systems share a similar delineation of medial & 
lateral regions of the femur (Figure 41).  
Some of the ordinal measures used in these systems are not interval 
variables and therefore the structural progression required to progress from 
one grade to the next may or may not be uniform (Table 8). The 
acknowledgement that the sensitivity to change of quantitative measures 
was greater than semi-quantitative measures, led to a change of scoring 
occurred. This included scoring “within-grade” changes between longitudinal 
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Figure 41 Anatomical regions used in WORMS MOAKS & BLOKS 
 
Anatomical subregions used in WORMS, MOAKS and BLOKS 
semiquantitative scoring systems for knee OA. a | WORMS and MOAKS 
divide MRI data for the femur and tibia into anterior (A), central (C) and 
posterior (P) subregions for scoring of knee OA features. b | BLOKS 
separates assessment of knee OA features of femoral condyle into trochlear 
and weight-bearing subregions. c | The medio–lateral division of the femur 
defined for all three scoring systems. Abbreviations: A, anterior; BLOKS, 
Boston–Leeds Osteoarthritis Knee Score; C, central; MOAKS, MRI 
Osteoarthritis Knee Score; P, posterior; SS, subspinous; WORMS, Whole 
Organ Magnetic Resonance Imaging Score. (Reprinted by permission from 
Macmillan Publishers Ltd: Nat Rev Rheumatol [509], copyright 2013). 
Table 8 The ordinal scales of semi-quantitative scoring systems may or 
may not be interval variables 
 Grade 0 Grade 1 Grade 2 Grade 3 
BML size scoring – extent of regional involvement 
BLOKS [498] 
 
0% <25% 25-50% >50% 
MOAKS [508] 0% <33% 33-66% >66% 
Meniscal extrusion over the edge of the tibial plateau 







MOAKS [508] <2mm 2-2.9mm 3-4.9mm >5mm 
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Table 9 Comparison of the four knee whole organ semi-quantitative scoring systems 
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In conclusion semi-quantitative MRI measures have greatly contributed to the 
description of the natural history of knee OA and the identification structural 
pathologies of tissues within the ‘whole joint’ that are associated with important 
clinical and structural outcomes in knee OA. 
Compared to quantitative measures, semi-quantitative systems use a simpler 
and quicker process for assessing structural pathology than segmentation of 
tissues but the ordinal scales used may be less sensitive to change and 
interpretation of change in score progression should acknowledge if the scales 
are interval variables or not. The most validated OA semi-quantitative measures 
are for the knee.2.12 The Osteoarthritis Initiative 
2.12 Summary of the OAI 
2.12.1 Background  
Osteoarthritis (OA) is the most common form of arthritis. Its major symptoms are 
pain and stiffness which negatively impact individuals` ability to perform activities 
of daily living. There is discordance between symptom and radiographic changes 
Only 50% of knees with radiographic OA (ROA) have knee OA symptoms[17]. As 
obesity increases worldwide and coupled with an ageing population, it is 
anticipated that the burden of OA will become a major problems for health 
systems. 
No proven disease –modifying therapies are available for OA and current 
treatment is exclusively directed at symptomatic pain relief.  
The structural progression measured by radiographic OA of knee, hip and hand 
OA is typically slow and takes place over several years but can also remain 
stable over years [89-91]. In knees the mean annual risk of progression of KL 
grade is 5.6% ± 4.9% and mean rate of joint space narrowing is 0.13 ± 
0.15mm/year, with change occurring in only a small group of “progressors”[93, 
94]. Radiographic improvement is atypical.  
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Magnetic resonance imaging provides the ability to visualise joints in three 
dimensions. The quantification of MRI cartilage volume affords advantages over 
conventional radiography because structural loss of cartilage can be detected in 
the pre-radiographic phase of OA[87] and in end-stage OA, after the total loss of 
joint space width (‘bone on bone’ or  Kellgren Lawrence grade 4)[88]. 
In light of the slow natural history of OA progression, long follow up times are 
required to study OA and its variable clinical outcomes. It has proven very 
expensive to conduct trials and the lack of suitable biomarkers of diseases 
activity have meant that past attempts have been unsuccessful in studying 
disease progression.  
2.12.2 Overview and aims 
The broad aims of the OAI are to develop a prospective cohort suitable for 
investigating the natural history of the entire spectrum of knee OA. This includes 
those ‘at risk’ of knee OA, with early or pre-clinical knee OA, with established 
knee OA and those with endstage knee OA. In order to understand this evolution 
of OA, this cohort will collect imaging, biochemical, genetic and clinical biomarker 
data from participants representing and progressing through the different stages.  
This will permit the investigation of the relationship of these biomarkers with the 
evolution of OA which may identify risk factors for the evolution through each 
stage. There is also the potential that some of these biomarkers may be validated 
as surrogate outcome measures of how patient’s joints feel, function and survive 
in the process.  
The OAI also aims to determine the validity of radiographic, magnetic resonance 
imaging and genetic measurements as potential biomarkers and surrogate 
endpoints for knee OA. The initial objective was to recruit about 5000 participants 
with either clinically significant knee OA or those at high risk of developing OA 
along with a set of ‘normal’ controls for biomarker reference purposes.  
In total 4796 participants (age range 45-79) were recruited into the OAI cohort 
and entered into the study at baseline and were assessed annually thereafter. 
Each participant was sub-divided into three subcohorts (1) the progression group 
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(n=1389 (29%)), who had symptomatic and radiographic knee OA on enrolment, 
(2) the incidence group (n=3285 (68%)), who did not have definite knee OA on 
enrolment, but were considered at elevated risk of knee OA during the study, and 
(3) the control group (n=122 (3%), who did not have knee symptoms, knee 
radiographic OA or any risk factors. 
2.12.3 Inclusion criteria 
The overall recruitment goal was to obtain approximately equal numbers of males 
and females, to be aged between 45-79 and at least 23% from ethnic minorities. 
Prevalent symptomatic OA definition for OAI encompasses both presence of 
frequent knee symptoms (FKS) and radiographic features and is similar to the 
ACR criteria for clinical knee OA[22]. As symptoms of knee OA are often 
intermittent and many years may elapse before they become monotonic/chronic, 
there is no clearly defined point of onset. Degenerative changes precede and 
predict the incidence of radiographic knee OA[122] therefore there are limitations 
to the existing definition of the OA progression group. 
To be in the Progression subcohort participants are required to have in at least 
one knee both the following: 
Frequent knee symptoms (defined as having had had knee pain in the last 12 
months for at least one month) and radiographic knee OA defined as a definite 
tibiofemoral osteophytes (OARSI grade 1-3 equivalent to K-L grade ≥ 2 on a fixed 
flexion radiograph.  
Incident subcohort classification is having no symptomatic OA in either knee but 
at risk of developing symptomatic OA. Incidence is defined as the first occurrence 
in either knee of both FKS and radiographic OA in the same knee. 
For feasibility of recruitment and to enrich each stratum so that reasonable 
number of incidents would be recorded age-eligible persons would be classified 
as high risk depending on age band. 
Age 45-79: participants need to have FKS or frequent use of medication for 
treatment of knee symptoms (use of all types of medication on most days of a 
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month in the past 12 months), or infrequent knee symptoms (pain, aching or 
stiffness in or around the knee at any time in the past 12 months but not on moist 
days for at least one month) and should have at least one eligibility risk factor. 
Age 50-69:  any of FKS or frequent use of medication as above or be overweight 
or have 2 or more eligibility risk factors. 
Age 70-79: any of FKS, frequent use of medications or at least one risk factor 
List of risk factors  
 Knee symptoms which can be any of FKS or infrequent  and frequent use 
of medication 
 Overweight (greater than 93kg in males and 77kg in females aged 45-69 
and greater than 97kg in males and 81kg in females between 70-79 years 
old) 
 Knee injury defined as history of knee injuring causing walking difficulties 
for at least one week. 
 Knee surgery defined as any history of knee surgery  
 Family history of total knee replacement in a biological parent or sibling 
 Heberden`s nodes  
 Repetitive knee bending 
 Age 70-79  
The control subcohort is defined as those having no pain, aching or stiffness in 
either knee in the past year, no radiographic OA (OARSI osteophyte grade=0 
and JSN grade =0) and no eligibility risk factors. 
 
2.12.4 Knee radiography protocol 
For the purposes of the OAI, the non-fluoroscopic fixed flexion SynaFlexer 
plexiglass knee positioning frame (Figure 42) protocol[402] was adopted as the 
primary method for serial measurement of JSN in the OAI protocol[510]. This was 
chosen because a fixed flexion weight-bearing protocol is required for JSW to be 
a valid indirect measure of cartilage thickness[402, 511]  and the chosen method  
demonstrated comparable repeatability precision for JSW measurement [402, 
512] with fluoroscopically-guided protocols[402, 513] (see 2.11.1.1.1 Continuous 
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joint space width and joint space narrowing)  and provides consistency in terms 
of the image of the knee over time[514]. 
Fluoroscopic methods were also considered too costly and impractical for the 
OAI protocol but a subcohort of the progressor subcohort had Lyon Schuss 
protocols added to test whether there was a difference in sensitivity to the 
measurement of JSN (pg 20 of protocol [515]).  
Figure 42 Non-fluoroscopic fixed flexion SynaFlexer plexiglass knee 
positioning frame protocol 
 
Non-fluoroscopic fixed-flexion radiographic knee protocol with 10° caudal beam 
angulation to ensure alignment of the beam with the medial tibial plateau. A 
standardized degree of knee flexion (20°) and external foot rotation (5°) are 
achieved with use of the SynaFlexer calibration and positioning frame Springer 
European Radiology, Fixed-flexion radiography of the knee provides reproducible 
joint space width measurements in osteoarthritis, 2004 Kothari et al, reprinted 
with permission of Springer[512].  




While the majority of knee radiographs were taken without fluoroscopic guidance 
and the alignment of the tibial plateau is integral to the sensitivity of serial 
radiographs for measuring joint space narrowing (see 2.11.1 Quantitative 
measures in OA), a quality control technique was employed to ensure that 
radiographs failing to meet this and other quality criteria were repeated by inviting 
participants to return for repeat imaging (page 11 and 18 of the OAI Radiographic 
operations manual [409]) 
 
2.13 Thesis aims 
The aim of this thesis was first to describe the association of imaging-detected 
subchondral bone features of OA with the outcomes of joint replacement, 
structural progression and pain in the common sites of peripheral OA. The 
hypothesis underlying this thesis is that subchondral knee bone 3D shape, 
defined using 3D knee MRI segmentation, would demonstrate association with 
existing radiographic measures of structural knee OA pathology and with patient-
centred knee OA clinical outcomes of total knee replacement and knee OA 
symptoms. These associations were examined in the largest observational cohort 
of knee OA in the world, the Osteoarthritis Initiative. By demonstrating these 
associations, this would potentially provide evidence of construct, predictive and 
concurrent validity of this novel bone shape biomarker. This may provide a more 
discriminative biomarker and surrogate measure of important patient-centred 
outcomes for future therapeutic trials of disease modifying osteoarthritis drugs.  
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Chapter 3 A systematic review of the relationship between 
subchondral bone features, pain and structural pathology in 
peripheral joint osteoarthritis. 
3.1 Introduction 
It is now well established that OA is a  “whole-organ disease” and not a cartilage-
centric condition. Hyaline articular cartilage is the most studied of all joint tissues 
in osteoarthritis (OA) but despite targeting this tissue there are no licensed 
disease modifying OA drugs (DMOADs). In Chapter 2 the integral role that 
subchondral bone plays in the pathogenesis of knee osteoarthritis (OA) has been 
described. The imaging-determined OA subchondral bone features are 
associated with risk factors of OA, OA severity and pain (described in Table 7). 
The subchondral bone is intimately associated with hyaline cartilage deterioration 
and it is therefore a tissue of great interest, however subchondral bone remains 
relatively understudied in comparison with cartilage.  
Conventional radiographs are known to be relatively insensitive to the structural 
features of OA[23],  in part because they do not assess three-dimensional (3D) 
bone structure[516] (as described in Chapter 4 The relationship between clinical 
characteristics, radiographic osteoarthritis and 3D bone area). A number of non-
conventional radiographic imaging modalities accurately demonstrate in vivo 
SCB pathological changes, including magnetic resonance imaging (MRI), 
computed tomography (CT), dual-energy X-ray absorptiometry (DXA), 
scintigraphy and positron emission tomography (PET)[23, 25, 365, 517-521]. 
Hunter and colleagues found a moderate association between bone marrow 
lesions BMLs, structural progression and longitudinal change in pain in a 
systematic review focused on MRI biomarkers and knee OA [365]. In another 
systematic review Kloppenburg and colleagues examined associations between 
MRI features and knee pain, but not structural pathology[132].  
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Therefore a comprehensive review of the literature was performed on 
subchondral bone structure assessed with all non-conventional radiographic 
imaging modalities, examining the common sites of peripheral OA and describing 
the relationships between imaging-detected subchondral bone features and joint 
replacement, structural progression and pain. 
3.2 Aims  
A systematic literature review of the association of imaging-detected subchondral 
bone features of OA with the outcomes of joint replacement, structural 
progression and pain in the common sites of peripheral OA. Imaging was defined 
as all non-conventional radiographic imaging modalities. 
3.3 Methods  
3.3.1 Systematic literature search 
A systematic literature search of Medline (from 1950), EMBASE (from 1980) and 
the Cochrane library databases until September 2014 was performed for original 
articles reporting relationships of non-radiographic imaging-assessed 
subchondral bone pathologies with joint replacement, pain or structural 
progression in knee, hip, hand, ankle and foot OA. The bone pathological 
changes include bone marrow lesions (BMLs), osteophytes, attrition, cysts, as 
well as changes in shape, bone mineral density, bone morphometry (bone 
volume fraction, trabecular number, spacing and thickness), and bone signal 
from positron emission tomography (PET) and scintigraphy.  
Non-conventional radiographic imaging referred to magnetic resonance imaging 
(MRI), computed tomography (CT), dual-energy x-ray absorptiometry (DXA), 
scintigraphy and PET. However while this PhD has a major focus on bone shape 
modelling and conventional radiography is not known to be insensitive to bone 
shape, the search term ‘bone shape’ was not restricted to non-conventional 
radiographic imaging. 
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A full description of the search terms used is recorded in Table 10andTable 11. 
The final search was restricted to humans. There was no language restriction 
and abstracts were not excluded. Exclusion criteria included case reports, 
surgical intervention studies or trials of surgical techniques in OA, imaging 
technique studies, studies of OA where serum biomarkers are the only structural 
outcome measure, review articles, editorials and letters, animal studies, studies 
not meeting the inclusion criteria, studies where the bone feature was not in the 
subchondral bone adjacent to the joint being analysed and abstracts of any study 
already included as a formal and full publication. Any analysis of less than 20 
patients with confirmed OA was excluded to remove papers at risk of study 
imprecision. These exclusion criteria are listed in Figure 43. The inclusion criteria 
were in vivo observational studies of a human population with clinical and/or 
radiographic OA, which included an imaging description of the adjacent 
subchondral bone pathology to the OA-joint and the relationship of this with pain, 
structural progression or joint replacement. Analyses describing the relationship 
between OA bone manifestations and structural severity (cross-sectional) or 
progression (prospective cohorts) in populations without clinical and radiographic 
OA were included to incorporate early structural features of joint degeneration. 
The outcome measures of structural severity or progression included cartilage 
defects, cartilage thickness, cartilage volume, denuded subchondral bone, 
Kellgren-Lawrence grade, joint space width and joint space narrowing.  Other 
outcome measures included joint replacement and any pain measures. 
The articles identified by the preliminary search were screened by two reviewers 
(DH, AB) for relevance and for references not identified by the preliminary 
search, although no additional citations were found. Discordance in opinion was 
resolved by a third reviewer (SK). We applied the methods for reporting meta-
analyses of observational studies in epidemiology that are recommended by the 
Cochrane collaboration[522, 523].  
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3.3.2 Data extraction 
Data extraction was performed by two reviewers (DH, AB). Papers meeting the 
inclusion/exclusion criteria were divided into longitudinal and cross-sectional 
papers. Longitudinal papers included prospective and retrospective cohorts and 
case-control studies with longitudinal data (i.e. nested case control studies). 
Extracted data included (a) patient demographics (age, sex and body mass 
index) (b) OA (clinical, radiographic or diagnostic) classification used, with the 
definition and prevalence of radiographic OA, (c) subchondral bone pathology 
feature, (d) joint replacement, pain or structural progression outcome measure 
(e) presence/absence of a relationship between feature and outcome (f) 
statistical results with or without adjustment for confounders and (g) the 
ipsicompartmental or contralateral compartment structural progression in relation 
to the compartment of the subchondral bone pathology feature for longitudinal 
studies.  
3.3.3 Quality assessment 
The quality of each observational study was independently assessed by two 
reviewers (TC, AB). A standardised quality scoring tool, previously used in other 
similar systematic reviews[132, 524] was adapted to assess the following 
components: (a) study population, (b) MRI subchondral bone feature, (c) pain or 
joint replacement or structural progression outcome, (d) study design and (e) 
analysis and data presentation (Figure 12). A score of ‘1’ or ‘0’ was allocated for 
each question according to whether the study fulfilled the criteria or not 
respectively. Where multiple bone features were assessed per article (e.g. 
criteria 11) the mean score was used. Any discordance in opinion was recorded 
and where consensus could not be achieved a third reviewer (PC) was 
consulted. The total number of criteria applied to each type of study (e.g. cohort 
n=18 and cross-sectional n=14) varied and therefore scores were compared as 
percentages of the maximum score. A study was considered to be high quality if 
it exceeded or equaled the mean score in its class. However quality was not 
universally considered to be dichotomous. Where inconsistent associations were 
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observed between studies of high and low quality, the real difference in 
percentage quality score was acknowledged in drawing conclusions. 
Most studies selected patients from existing cohorts rather than from the general 
population (criteria 1) and patients were selected by a minimum of evidence of 
OA (e.g. KL≥2) rather than at a uniform stage of OA severity (e.g. KL=2) (criteria 
2). Most studies did not provide evidence of assessing the bone image feature 
before the knee OA outcome (criteria 9) and similarly did not indicate a 
prospective analysis plan for the relationship between bone image feature and 
OA outcome (criteria 17) 
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Table 10 Search terms EMBASE (1980 to September 2014) 
1 osteoarthri* 42 
25 or 26 or 27 or 28 or 29 or 30 or 31 
or 32 or 33 or 34 or 35 or 36 or 37 or 
38 or 39 or 40 or 41 
2 osteoarthro* 43 "magnetic resonance imag*".ti,ab 
3 (arthri* adj2 degenerative) 44 mri.ti,ab 
4 exp OSTEOARTHRITIS 45 mr.ti,ab 
5 1 or 2 or 3 or 4 46 "magnetic resonance".ti,ab 
6 knee*.ti,ab 47 
NUCLEAR MAGNETIC 
RESONANCE IMAGING/ 
7 KNEE/ 48 43 or 44 or 45 or 46 or 47 
8 hand*.ti,ab 49 24 AND 42 and 48 
9 HAND/ 50 DEXA 
10 Hip*.ti,ab 51 DXA 
11 HIP/ 52 
DUAL ENERGY X RAY 
ABSORPTIOMETRY 
12 foot* 53 50 OR 51 or 52 
13 exp FOOT/ 54 "bone mineral density" 
14 ankle* 55 BMD 
15 exp ANKLE/ 56 BONE DENSITY/ 
16 
6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or 14 or 15 57 54 or 55 or 56 
17 5 and 16 58 24 and 53 and 57 
18 HAND OSTEOARTHRITIS 59 "Computed tomography" 
19 HIP OSTEOARTHRITIS 60 CT 
20 coxarthr*.ti,ab 61 
COMPUTER ASSISTED 
TOMOGRAPHY 
21 KNEE OSTEOARTHRITIS/ 62 "micro-computed tomography" 
22 gonarthr*.ti,ab 63 pQCT 
23 18 or 19 or 20 or 21 or 22 64 HR-pQCT 
24 17 or 23 65 59 or 60 or 61 or 62 or 63 or 64 
25 "subchondral bone".ti,ab 66 57 or 42 
26 bml.ti,ab 67 24 and 65 and 66 
27 "bone marrow lesion*".ti,ab 68 PET 
28 "bone marrow oedema".ti,ab 69 24 and 68 
29 "bone marrow edema".ti,ab 70 scintigraphy 
30 BONE MARROW EDEMA/ 71 24 and 70 
31 osteophyte*.ti,ab 72 Bone shape 
32 OSTEOPHYTE/ 73 24 and 72 
33 "bone cyst*".ti,ab 74 49 or 58 or 67 or 69 or 71 or 73 
34 BONE CYST/ 75 74 limit to humans 
35 "bone area*".ti,ab   
36 "bone shape".ti,ab   
37 "bone attrition".ti,ab   
38 "trabecular".ti,ab   
39 TRABECULAR BONE/   
40 "volume fraction".ti,ab   
41 "BV/TV".ti,ab   
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Table 11 Search Terms Medline (1950 to September 2014) 
1 osteoarthri* 40 "magnetic resonance imag*" 
2 osteoarthro* 41 mri 
3 (arthri* adj2 degenerative) 42 mr 
4 exp OSTEOARTHRITIS 43 "magnetic resonance" 
5 1 or 2 or 3 or 4 44 
MAGNETIC RESONANCE 
IMAGING/ 
6 knee* 45 40 OR 41 or 42 OR 43 OR 44  
7 knee/ OR exp KNEE JOINT/ 46 23 AND 39 and 45 
8 hand* 47 DEXA 
9 hand/ OR exp HAND joint 48 DXA 
10 Hip* 49 Absorbtiometry, photon/ 
11 hip/ OR exp HIP JOINT 50 47 or 48 or 49  
12 foot*.ti,ab 51 "bone mineral density" 
13 foot/ OR exp FOOT JOINTS/ 52 BMD 
14 ankle*.ti,ab 53 BONE DENSITY/ 
15 ankle / OR exp ANKLE JOINT/ 54 51 OR 52 or 53 
16 
6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
or 14 or 15 55 23 AND 50 and 54 
17 5 and 16 56 "Computed tomograph*" 
18 osteoarthritis hip 57 CT 
19 coxarthr* 58 
tomography, X-RAY 
COMPUTED/ 
20 osteoarthritis knee 59 "micro-computed tomography" 
21 gonarthr* 60 pQCT 
22 18 or 19 or 20 or 21 61 HR-pQCT 
23 17 or 22 62 56 or 57 or 58 or 59 or 60 or 61 
24 "subchondral bone" 63 54 or 39 
25 bml 64 23 and 62 and 63 
26 "bone marrow lesion*" 65 PET 
27 "bone marrow oedema" 66 23 and 65   
28 "bone marrow edema" 67 Scintigraphy 
29 osteophyte* 68 23 and 67 
30 OSTEOPHYTE/ 69 Bone shape 
31 "bone cyst*" 70 23 and 69 
32 BONE CYSTS/ 71 46 or 55 or 64 or 66 or 68 or 70 
33 "bone area*" 72 71 limit to humans 
34 "bone shape"   
35 "bone attrition"   
36 trabecular   
37 "volume fraction"   
38 "BV/TV"   
39 
24 OR 25 OR 26 OR 27 OR 28 OR 
29 OR 30 OR 31 OR 32 OR 33 OR 
34 OR 35 OR 36 OR 37 OR 38   
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Table 12 Quality scoring tool 
Item Criterion CC CH CS 
Study population 
1 Recruitment from the general population 1 1 1 
2 Selection occurred before disease onset or at a uniform point. 
A uniform point was considered to be equal baseline grade of 
structural  progression (e.g. Kellgren Lawrence grade) or an 
analysis within the same osteoarthritic joint 
1 1 1 
3 Cases and controls drawn were from the same population 1   
4 Participation rate >80% for cohort studies (retrospective cohort 
studies score zero automatically) 
 1  
5  Sufficient description of baseline characteristics - must include 
age, gender and BMI (or height and weight) 
1 1 1 
6 Baseline characteristics comparable between cases and 
controls - must include age, gender and BMI (or height and 
weight) 
1   
Assessment of Imaging-detected subchondral bone risk factor or feature 
7 Risk factor / feature assessed with a standardised method (e.g. 
WORMS BML scoring or an automated calculation of bone area 
but not a subjective opinion of a radiologist on the presence of 
bone attrition) 
1 1 1 
8 Risk factor / feature assessment was identical (performed the 
same way) in the studied population(s) 
1 1 1 
9 Risk factor / feature was assessed prior to the outcome 
(structural progression or pain). A score of zero was allocated if 
the methods did not describe this. 
1 1 1 
Assessment of joint OA outcome (pain or structural  progression) 
10 Outcome assessment was identical in the studied population(s) 1 1 1 
11  Outcomes were assessed reproducibly (intraclass correlation 
coefficient > 0.81 with a standardised assessment). If multiple 
outcomes were measured the mean reproducibility score was 
used. 
1 1 1 
12  Outcome classification was standardised (e.g. the WOMAC pain 
score but not a subjective opinion of a patient’s pain) 
1 1 1 
Study design 
13  Prospective study design used  1  
14  Follow up time > 3 years 1 1  
15 Information provided on completers vs withdrawls in cohorts 
(without prospective trial data cohorts automatically score zero) 
 1  
16  Outcome evaluators were blinded to  feature (risk factor) 1 1 1 
17 Analysis of relationship between feature and outcome was 
planned prospectively  
1 1 1 
Analysis and data presentation 
18 The frequency of most important outcomes were given 1 1 1 
19  appropriate analysis techniques used (statistical or comparative 
techniques) 
1 1 1 
20  adjusted for at least age, BMI and gender 1 1 1 
Maximum Score 17 18 14 
CC: case control, CH cohort (prospective and retrospective), CS: cross sectional  
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3.3.4 Best evidence synthesis 
Statistical pooling of the data was considered inappropriate in light of the 
heterogeneous study populations, methodological quality and bone feature or 
outcome measurements for OA. For example the feature bone marrow lesions 
(BMLs) could be described by their crude presence, ordinal size, metric size, 
volume or change in volume. Therefore a qualitative summary of the evidence for 
each bone feature (e.g. BML) and its association with pain or structural 
progression and joint replacement was provided based on the study design, 
adequacy of adjustment for confounders (age, gender and body mass index) and 
quality score. An association of a bone feature with a longitudinal OA outcome 
(i.e. structural progression, longitudinal change in pain, incident pain or joint 
replacement) was determined from cohort studies only. If a prospective cohort 
study analysis was of above average quality and found a statistically significant 
association between a bone feature and a longitudinal outcome after adjustment 
for at least age, gender and body mass index (referred to in the text as ‘well-
adjusted’), this association was referred to as an ‘independent’ association. 
These three criteria were determined for all longitudinal analyses and if any of 
these three criteria were not fulfilled, the association was referred to simply as an 
association. The validity of cross-sectional associations was determined using 
cross-sectional and case-control studies and establishing whether the analysis of 
the association of severity was well-adjusted or not. This data is summarized 
inTable 21. 
Studies which investigated the association between multiple bone features and 
OA pain or structural progression outcomes were considered as a single study 
for each bone feature.  Included studies that established a significant correlation 
between bone and pain, structural progression or joint replacement were 
described as positive (+) or negative (-) accordingly. If no association or 
inconclusive findings were described this was reported as no association (NA) or 
no conclusion (NC) respectively.  
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3.4 Results  
3.4.1 Systematic literature search and selection 
The PRISMA diagram (Figure 43) describes the literature flow. Following 
exclusion of duplicates and triplicates, 2456 articles met the search criteria. 
After applying inclusion/exclusion criteria, 139 articles were included for data 
extraction and quality scoring. In total, 71 papers provided longitudinal data 
(55 cohorts, 16 case-controls), 70 provided cross-sectional data, and two 
papers provided both.  
3.4.2 Data extraction from selected studies 
In only 12 studies did the mean age fall below 50 years[31, 96, 101, 261, 
312, 353, 525-531]. Most (n=93) described both genders; two included men 
only[529, 532], 14 studies included females only [215, 276, 312, 349, 442, 
530, 531, 533-539] and there was an undisclosed gender ratio in six[209, 
282, 540-546]. Knee OA was defined using clinical and radiographic criteria 
and is described in Table 16. Radiographic OA was invariably defined as KL 
grade ≥2 or any radiographic OA abnormality from the Altman atlas[85]. 
Individual pain or structural progression measures were examined in 88 
studies; 52 studies examined multiple features (Table 17,Table 18,Table 
19,Table 20). Subchondral bone was analysed with MRI in 113 articles, DXA 
in eight[206, 208, 209, 532-534, 547, 548], CT in four[214, 215, 539, 549], 
scintigraphy in eight[216, 526, 536, 537, 550-553] and no articles using PET 
met the inclusion criteria. Included articles described 116 knee, 15 hip, six 
hand and two ankle studies. Of these studies 13 described structural 
associations without clinical or radiographic OA[31, 210, 259, 261, 301, 313, 
353, 527, 528, 535, 554-556]. No foot articles met the inclusion criteria. 
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Figure 43 Search strategy results and article exclusion 
 
*Two articles included both cross-sectional and longitudinal data. 
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3.4.3 Quality assessment of studies  
Concordance of opinion in quality scoring was observed in 2040 (89%) of 
the 2242 scoring items assessed which are recorded in Table 13, Table 14, 
Table 15.  The majority of discordant scoring was for study design (criteria 
17) and data presentation (criteria 18). Quality scores were converted to 
percentages of the maximum scores for each class of paper. The mean 
(range) quality score was 59% (29-79), 54% (22-83) and 59% (47-76) for 
cross-sectional, cohort and case-control studies respectively.  
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Table 13 Quality scoring results cross-sectional studies 
  
Quality Scoring Criteria 
No. Cross-sectional Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Total % 
1 Ai 2010 [557] 0 0     0   1 1 0 1 1 1       1 0 1 1 0 8 57% 
2 Akamatsu 2014 [533]  0 0     1   1 1 0 1 0 1       1 0 1 1 0 8 57% 
3 Antoniades 2000 [534] 0 0     1   1 1 0 1 1 1       1 0 1 1 0 9 64% 
4 Baranyay 2007 [554]  0 1   1  1 1 0 1 1 1    0 0 1 1 1 10 71% 
5 Bilgici 2010 [558]  0 0     1   1 1 0 1 1 1       1 0 0 1 0 8 57% 
6 Burnett 2012 [549] 0 0     0   1 1 0 1 1 1       1 0 1 1 0 8 57% 
7 Chaganti 2010 [532] 0 0     1   1 1 0 1 0 1       1 0 1 1 1 9 64% 
8 Chiba  2011[215] 0 0     0   1 1 1 1 0 1       1 0 1 1 0 8 57% 
9 Chiba 2012 [349] 0 0     1   1 1 0 1 0 1       1 0 1 1 0 8 57% 
10 Crema 2010 [315] 0 0     1   1 1 0 1 1 1       0 0 1 0 0 7 50% 
11 Dawson 2013 [556] abstract  0 0   1    0 0 0 0 0 0    0 0 0 0 1 2 14% 
12 Ding 2005  [353] 0 0   1  1 1 0 1 1 1    0 0 1 1 1 9 64% 
13 Dore [547] 2009 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
14 Driban [545] 2011 0 0     1   1 1 0 1 1 0       1 0 1 1 1 9 64% 
15  Driban [546]2011 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
16 Eckstein [483] 2010 0 0     1   1 1 0 1 0 1       0 0 1 0 0 6 43% 
17 Felson  2001 [133] 0 0     1   1 1 0 1 0.5 1       0 0 1 1 0 7.5 54% 
18 Fernandez-Madrid1994 [559] 0 0     1   0 0 0 1 0.5 1       1 0 1 1 0 6.5 46% 
19 Frobell 2010 [560] 0 0     1   1 1 0 1 0 1       0 0 1 1 1 8 57% 
20 Gosvig 2010 [561] 0 0   0  1 1 0 1 0 1    0 0 1 1 1 7 50% 
21  Gudbergsen [562] 0 0     1   1 1 0 1 0 1       0 0 1 1 1 8 57% 
22 Guymer 2007 [535] 0 1   1  1 1 0 1 1 1    0 0 1 1 1 10 71% 
23 Haugen  2012 [563] 0 0     1   1 1 0 1 1 1       1 0 1 1 0 9 64% 
24  Haugen  2013 [564] 0 0     0   1 1 0 1 0 1       0 0 1 1 0 6 43% 
25  Haugen  2012 [565] 0 0     1   1 1 0 1 1 1       1 0 1 1 0 9 64% 
26 Haverkamp 2011  [276] 0 0   1  1 1 0 1 0 1    0 0 0 1 0.5 6.5 46% 
27 Hayashi [566] 0 0     1   0 1 0 1 1 1       1 0 1 1 0 8 57% 




No. Cross-sectional Study 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Total % 
28 Hayes [312] 0 0     1   1 1 0 1 0.5 1       1 0 1 1 0 8.5 61% 
29 Hernandez-Molina 2008 [139]  0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
30 Ip [567] 0 0     1   1 1 0 1 0.5 1       1 0 1 1 1 9.5 68% 
31 Jones 2004  [31] 0 0   0  1 1 0 1 1 1    0 0 0 1 1 7 50% 
32 Kalichman [568] 2007 0 0     1   1 1 0 1 0 1       1 0 1 1 1 9 64% 
33  Kalichman [569] 2007 0 0     1   1 1 0 1 0 1       0 0 1 1 1 8 57% 
34 Kim [570] 0 0     0   1 1 0 1 1 1       1 0 1 1 1 9 64% 
35 Knupp 2009 [526] 0 0   0  1 1 0 1 1 1    1 0 1 1 0 8 57% 
36  Kornaat [571] 2006 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
37  Kornaat [572] 2005 0 0     1   1 1 0 1 1 1       0 0 1 1 0 8 57% 
38 Kraus 2009 [550] 0 0   1  1 1 0 1 1 1    1 0 1 1 1 10 71% 
39 Kraus 2013 [551] 0 0   1  1 1 0 1 1 1    1 0 1 1 1 10 71% 
40 Kumar [573] 1 0     1   1 1 0 1 1 1       1 0 1 1 0 10 71% 
41 Lindsey [350] 0 0     1   1 1 0 1 1 1       1 0 1 1 0 9 64% 
42  Link [319] 2003 0 0     0   1 1 0 1 0.5 1       1 0 1 1 0 7.5 54% 
43 Lo   2005 [574] 0 0     1   1 1 0 1 1 1       0 0 1 0 0 7 50% 
44 Lo [575] 2009 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
45 Lo [206] 2012  0 0     1   1 1 0 1 1 1       1 0 1 1 0 9 64% 
46 Lo [208] 2006 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
47 Macfarlane 1993 [552] 0 0   0  1 1 0 1 1 1    1 0 1 1 0 8 57% 
48 Maksymowych  2014 [576] 0 0     1   1 1 0 1 1 1       1 0 1 1 0 9 64% 
49 McCauley 2001  [528] 0 0   0  1 1 0 1 0 1    0 0 0 0 0 4 29% 
50 McCrae 1992 [553] 0 0   1  1 1 0 1 0 1    0 0 1 1 0 7 50% 
51 Meredith 2009 [555] 0 1   0  1 1 0 1 0 1    0 0 1 1 0 7 50% 
52 Moisio [456] 2009 0 0     1   1 1 0 1 1 1       1 0 0 1 1 9 64% 
53 Neumann  2007 [542] 0 0     0   1 1 0 1 0 1       0 0 1 1 0 6 43% 
54 Ochiai [543] 2010 0 0     0   0 1 0 1 1 1       1 0 1 1 0 7 50% 
55 Okazaki [539] 2014 0 0     0   1 1 0 1 0 1       1 0 1 1 0 7 50% 
56  Ratzlaff [577] 2013 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
57  Ratzlaff [544] 2014 0 0     1   1 1 0 1 1 1       1 0 1 1 0 9 64% 
- 165 - 
165 
 
58  Reichenbach  2008 [306] 0 0     1   1 1 0 1 0 1       0 0 1 0 0 6 43% 
No. Cross-sectional Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Total % 
59 Reichenbach 2011  [529] 0 1   1  1 1 0 1 0 1    0 0 1 1 1 9 64% 
60  Roemer [578]  2012 0 0     1   1 1 0 1 0 1       0 0 1 1 1 8 57% 
61 Scher 2008 [579]  0 0     0   1 1 0 1 0 1       0 0 1 1 0 6 43% 
62 Sengupta [580] 2006 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
63 Sharma [131] 2014 0 0     1   1 1 0 1 1 1       1 0 1 1 1 10 71% 
64 Sowers  2003 [531] 0 0     1   1 1 0 1 0.5 1       0 0 1 1 0 7.5 54% 
65  Stefanik [581] 2014 0 0     1   1 1 0 1 1.0 1       1 0 1 1 1 10 71% 
66 Stefanik [274] 2012 0 0     1   1 1 0 1 0 1       0 0 1 1 1 8 57% 
67 Stehling 2010  [313] 0 1   1  1 1 0 1 1 1    0 0 1 1 1 10 71% 
68 Torres  2006 [135] 1 0     1   1 1 0 1 0.5 1       0 1 1 1 0 9.5 68% 
69 Wang 2005  [259] 0 0   0  1 1 0 1 1 1    0 0 1 1 1 8 57% 
70 Zhai  2006 [582] 1 0     1   1 1 0 1 1 1       1 0 1 1 1 11 79% 
                    Mean 8.3 59% 
                    Max 14  
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Table 14 Quality scoring results cohort studies 
  
Quality Scoring Criteria 
  
No. Cohort Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 total % 
1 Agricola 2013 [74] 0 1  1 1  1 1 0 1 1 1 0 1 0 0 0 1 1 1 12 67% 
2 Agricola 2013 [394] 0 1  1 1  1 1 0 1 1 1 0 1 0 0 0 1 1 1 12 67% 
3 Agricola 2013  [583] 0 1  1 1  1 1 0 1 1 1 0 1 0 1 0 1 1 1 13 72% 
4 Bruyere[209] 2003 0 0   0 0   1 1 0 1 0 1 0 0 0 1 0 1 1 1 8.0 44% 
5 Carnes [584] 2012 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
6 Carrino [585] 2006 0 0   0 0   0 1 0 1 0 1 0 0 0 0 0 1 0 0 4.0 22% 
7 Cicuttini 2004 [270] 0 0  1 1  1 1 0 1 1 1 1 1 1 1 0 1 1 1 14 78% 
8 Crema 2013 [586] 0 0   0 1   1 1 0 1 0 1 0 0 0 0 0 1 1 1 8.0 44% 
9 Crema 2014 [587] 1 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 10.0 56% 
10 Davies-Tuck [588] 2008 0 0   0 1   1 1 0 1 1 1 0 0 1 0 0 1 1 1 10.0 56% 
11 Davies-Tuck 2010  [301] 0 1  0 1  1 1 0 1 1 1 0 0 1 0 0 1 1 1 11 61% 
12 De-Lange  2014 [589] 0 0   0 1   1 1 0 1 0 1 1 1 0 1 0 1 1 1 11 61% 
13 Dieppe 1993 [216] 0 0  0 1  1 1 0 1 0 1 0 1 0 1 0 1 1 0 9.0 50% 
14 Ding 2006  [261] 1 0  1 1  1 1 0 1 1 1 0 0 0 0 0 1 1 1 11 61% 
15 Ding [96] 2008 1 0   0 1   1 1 0 1 1 1 1 0 1 0 1 1 1 1 13 72% 
16 Dore 2010 [99] 1 0   0 1   1 1 0 1 1 1 0 0.5 0 1 0 1 1 1 11.5 64% 
17 Dore 2010 [590] 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
18 Dore 2010 [210] 0 0  0 1  1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
19  Driban[591] 2011 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
20  Driban [592] 2012 0 0   0 1   0 1 0 1 0 1 0 0 0 0 0 0 1 0 5.0 28% 
21 Driban [100] 2013 0 0   0 1   1 1 0 1 1 1 0 1 0 1 0 1 1 1 11.0 61% 
22 Everhart [102] 2014 0 0   0 1   1 1 0 1 1 1 0 1 0 1 0 1 1 1 11.0 61% 
23 Felson [294] 2003 0 0   1 1   1 1 1 1 1 1 1 0 1 1 1 1 1 1 15.0 83% 
24 Foong  [101] 2014 0 0   0 1   1 1 0 1 1 1 0 1 1 1 0 1 1 1 12.0 67% 
25  Guermazi [124] 2014 0 0   0 1   1 1 0 1 0 1 0 1 0 1 0 1 1 1 10.0 56% 
26  Haugen [39] 2014 0 0   0 1   1 1 0 1 1 1 0 1 0 1 0 1 1 1 11.0 61% 
27  Haugen [593] 2014 0 0   0 1   1 1 0 1 1 1 0 1 0 1 0 1 1 1 11.0 61% 
28 
Hernandez-Molina 
[594]2008  0 0   0 1   0 1 0 1 1 1 0 0 0 0 0 1 1 1 8.0 44% 
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No. Cohort Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 total % 
29 Hochberg 2014  [540] 0 0  1 0  1 1 0 1 1 1 0 1 0 1 0 1 1 1 11.0 61% 
30 Hudelmaier [595] 2013 0 0   0 1   1 1 0 1 1 1 0 0 0 1 0 1 1 0 9.0 50% 
31 Hunter [596] 2006 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 0 8.0 44% 
32 Kornaat  [302] 2007 0 0   0 1   1 1 0 1 1 1 0 0 0 1 0 1 1 1 10.0 56% 
33 Koster 2011  [527] 0 0  0 1  0 1 0 1 0 1 1 0 1 0 0 1 1 0 8 44% 
34 Kothari  [478] 2010 1 0   0 1   1 1 0 1 0 1 0 0 0 0 0 1 1 1 9.0 50% 
35  Kubota[597] 2010 0 0   0 1   0 1 0 1 0 1 1 0 0 0 0 1 1 0 7.0 39% 
36 Liu 2014  [541] 0 1  1 0  1 1 0 1 1 1 1 0 0 0 0 0 1 0 9.0 50% 
37 Lo [548] 2012 0 0   0 1   1 1 0 1 0 1 0 0 0 1 0 1 1 1 9.0 50% 
38 
Madan-Sharma [417] 
2008 0 0   0 1   1 1 0 1 0.5 1 0 0 0 0 0 1 1 1 8.5 47% 
39 Mazzuca 2004 [536] 0 0  1 1  1 1 0 1 1 1 0 0 0 1 0 1 1 1 11 56% 
40 Mazzuca 2005 [537] 0 0  1 1  1 1 0 1 1 1 0 0 0 1 0 1 1 0 10 56% 
41 Moisio [456] 2009 0 0   0 1   1 1 0 1 1 1 0 0 0 1 0 1 1 1 10.0 56% 
42 Parsons [598] 2014 0 0   0 1   1 1 0 1 0 1 0 0 0 1 0 1 1 1 9.0 50% 
43 Pelletier [123] 2007 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
44 Raynauld [599] 2008 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
45 Raynauld 2011 [457] 0 0  0 1  1 1 0 1 1 1 0 1 0 1 0 1 1 1 11.0 61% 
46 Raynauld 2013 [103] 0 0  0 1  1 1 0 1 1 1 0 1 0 1 0 1 1 1 11.0 61% 
47 Roemer [443] 2009 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
48 Roemer [444] 2009 0 0   0 1   1 1 0 1 0 1 0 0 0 0 0 1 1 1 8.0 44% 
49 Roemer [500] 2012 0 0   0 1   1 1 0 1 0 1 0 0 0 0 0 1 1 1 8.0 44% 
50 Scher 2008 [579] 0 1  0 1  1 1 0 1 1 1 0 0 0 1 0 1 1 0 10 56% 
51 Sowers [530] 2011 0 0   0 1   1 1 0 1 0.5 1 0 1 0 1 0 1 1 0 9.5 53% 
52 Tanamas [600] 2010 0 0   0 1   1 1 0 1 1 1 0 0 1 0 0 1 1 0 9.0 50% 
53 Tanamas [601] 2010 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 0.5 8.5 47% 
54 Wildi [602] 2010 0 0   0 1   1 1 0 1 1 1 0 0 0 0 0 1 1 1 9.0 50% 
55  Zhang [26] 2011 0 0   0 1   1 1 0 1 1 1 0 0 0 1 0 1 1 0 9.0 50% 
  
      
            
       
mean 9.7 54% 
  
      
            
       
Max 18.0   
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Table 15 Quality scoring results case-control studies 
  
Quality Scoring Criteria 
  No. Case control study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 total % 
1 Aitken 2013 [525] 0 0 0   0 0 1 1 0 1 0 1   1   0 0 1 1 1 8 47% 
2 Barr 2012  [603] 0 1 1  1 0 1 1 0 1 1 1  1  1 0 1 1 1 13 76% 
3 Bennell 2008 [214] 0 0 0   1 0 1 1 0 1 1 1   0   1 0 1 1 1 10 59% 
4 Bowes 2012 [604]  0 1 1   1 0 1 1 0 1 0 1   1   1 0 1 1 1 12 71% 
5 Doherty 2008 [282] 0 0 0  1 0 1 1 0 1 1 1  0  0 0 1 1 1 9 53% 
6 Felson 2007 [134] 0 1 1   1 0 1 1 0 1 1 1   0   1 0 1 1 1 12 71% 
7 Hunter 2013 [605] 0 0 1   1 0 1 1 0 1 0 1   1   1 0 1 1 0 10 59% 
8  Javaid 2012 [606]  0 0 1   1 1 1 1 0 1 1 1   0   0 0 1 1 0 10 59% 
9 Javaid 2010 [607] 0 1 1   1 1 1 1 0 1 1 1   0   1 0 1 1 1 13 76% 
10 Neogi 2013 [75] 0 1 1   1 0 1 1 0 1 0 1   0   1 0 1 1 1 11 65% 
11 Neogi 2009 [307] 0 0 1   1 1 1 1 0 1 0 1   0   0 0 1 1 1 10 59% 
12 Nicholls 2011  [538] 0 0 1  1 1 1 1 0 1 1 1  1  1 0 0 1 1 12 71% 
13 Ratzlaff 20148 [608] 0 1 1  0 0 1 1 0 1 1 1  0  1 0 1 1 1 11 65% 
14 Stahl 2011 [442] 0 0 1   1 0 1 1 0 1 1 1   0   0 0 1 0 0 8 47% 
15 Wluka 2005 [269] 0 0 0   1 0 1 1 0 1 1 1   0   0 0 0 1 1 8 47% 
16 Zhao 2010 [609] 1 0 0   1 0 1 1 0 1 0.5 1   0   0 1 1 1 0 9.5 56% 
  
                    
mean 10.1 59% 
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severity / pain 
measure 
Statistical analysis Quality 
(score 
%) 
Knee cohort studies 
Bruyere 2003 
[209] 
56 Knee OA (ACR criteria), gender 
distribution unknown, mean age 65 
yrs 
Subchondral 
tibial bone BMD 
(DXA) (C) 
Minimum medial 







Carnes 2012  
[584] 
395 Randomly selected older adults with 
over 52% knee ROA. 50% female, 
mean age 63 yrs. TASOAC 
MRI tibial Bone 











32 Chronic knee pain with MRI features 
of OA. 63% female, mean age 51 yrs. 
USA 
Crude presence 
of MRI BML, 
bone cyst TFJ 
(C) and (L) 
Graded cartilage 
defect TFJ (L) 
Crude comparison Low 
(22) 
Cicuttini 2004  
[270] 
113 Symptomatic, clinical (ACR) knee OA 
with mild to moderate TFJ ROA, 




tibial bone area 
(C) 
TKR incidence (L) 







1351 Knee OA or at high risk of it. 39% 









cartilage defect  







163 Clinical knee OA, 37% knee ROA, 
54% female, Mean age 58 yrs.  
MRI BML (semi-
quantitative) 











117 ACR knee OA. 58% female, mean 
age 64 yrs.  Australia 
Baseline MRI 
tibial bone 





score (L) medial 
and lateral TFJ 
Linear regression High 
(56) 
Davies-Tuck 2010  
[301] 
271 No clinical knee OA (ACR clinical 
criteria) and no current or historic 
Incident BML 






















severity / pain 
measure 
Statistical analysis Quality 
(score 
%) 
knee pathology, mean age 58yrs, 
65% female, mean BMI 25. 
Melbourne. 
years with no 
BMLs at baseline) 
MRI TFJ (L) 
MRI cartilage 
defects score after 
2 years. TFJ  (L) 
De-Lange 2014 
abstract [589] 
133 Symptomatic OA knee. ROA Knee 
(>50%), 80% female, mean age 60 
yrs. GARP study 
MRI osteophytes 













94 Symptomatic and ROA knee (100%). 
96% women, mean age 64 yrs, mean 
BMI 26. Referrals to hospital 
rheumatology unit 







JSN by ≥2mm or 
knee operation 





Ding 2006  
[261] 
325 Mostly no ROA knee (17% ~ KL =1), 
58% female, Mean age 45 yrs. Mean 
BMI 27. Offspring study 
Baseline MRI 





scores over 2.3 yrs 





Ding 2008 [96] 252 Randomly selected adults with 15% 
knee ROA. 58% female, mean age 
45 yrs. 
Baseline MRI  









Dore 2010 [99] 
 
395 Symptomatic knee OA, knee ROA 
(58%). 51% female, mean age 63 
yrs, mean BMI  28. TASOAC 
MRI BML size (L) 
regional or whole 
TFJ over 2.7 
years 
Change in 
WOMAC pain (L) 
over 2.7 years 
Incident TKR over 






Dore 2010  
[590] 
12(6)  
405 Prevalent knee OA, 50% female,  
Mean age 63 yrs. TASOAC 
Baseline semi-
quantitative BML 












Dore 2010  341 Older adult cohort. Right knees only. Baseline Increase or no Logistic Low 















severity / pain 
measure 
Statistical analysis Quality 
(score 
%) 
[210] Mean age 63 yrs, ~48% female, 





bone area MRI 
(C)  
increase in semi-
quantitative MRI  
cartilage defects 







44 ACR knee OA(100%). 100% knee 
ROA, , 52% female, Mean age 65 
yrs. Clinical trial of Vitamin D 
Baseline 3D BML 
volume (C) and 
24 month change 
in 3D BML 
volume (L) in  
TFJ 
compartments 















38 Knee ROA (100%). 66% female, 
mean age 61 yrs. OAI 
MRI BML volume 
change (L) TFJ 




and denuded area 
of bone (L) TFJ 









404 Prevalent ROA knee (71%) 49% 
female, mean age 63 yrs. OAI 
Knee baseline 
BML volume (C) 




48 month change 
in WOMAC pain 
(L) and  










1338 Prevalent ROA knee (74%) 60% 
female, Mean age 62 yrs. OAI 
Baseline TFJ 
subchondral 






knee pain at 48 
months or 
radiographic 
progression of  
lateral or medial  








Felson 2003  223 ACR knee OA and 75% ROA. 42% Baseline OARSI JSN grade Generalised High 















severity / pain 
measure 
Statistical analysis Quality 
(score 
%) 
[294] female, mean age 66 yrs. BOKS presence of BML 
in medial or 
lateral TFJ (C) 







198 17% ROA knee, 42% female, Mean 
age 47 yrs. Offspring study 
Change in 
quantitative BML 
size (L) and  
incident BMLs (L) 
In all three knee 
compartments 
over 8 years 
WOMAC Knee 
pain severity over 
8 years (L) 




196 Knee ROA (24%), 62% female,  














Molina  2008  
[594] 
258 ACR knee OA and 77% ROA. 43% 
female, mean age 67 yrs. BOKS 
Crude presence 
of central BMLs  
on MRI (C) TFJ 
Semi-quantitative 
cartilage defect 








1024 100% Symptomatic and radiographic 




BML size (C) 
Incident TKR over 










899 Prevalent ROA knee, ROA 60%, 60% 
women, mean age 62 yrs, OAI 
Annual change in 
Segmented MRI 
knee bone area 
(L) 
Baseline KL grade 
(C) 




217 ACR knee OA. 44% female, mean 
age 66 yrs. BOKS 
Change in MRI   
semi-quantitative 












Kornaat  2007 
[302] 
182 OA knee symptoms (38%) and ROA 
(38%). 80% female, mean age 59 
yrs. GARP 
Semi-quantitative 
MRI BML change 
over 2 years (L) 
TFJ 
Mean WOMAC 




















severity / pain 
measure 
Statistical analysis Quality 
(score 
%) 
Koster 2011  
[527] 
117  One year follow up after acute knee 
trauma in primary care, 12% ROA 
knee, mean age 41yrs, 43% female, 
mean BMI 26, HONEUR  
Baseline BML 
presence (C) TFJ 
Any progression in 
KL grade over 1 







177 Some WOMAC dysfunction and 
>74% ROA knee, 79% female, mean 
age 66 yrs. MAK-2 
Semi-quantitative 
baseline MRI 






score change over 











122 Clinical and ROA (80%) of the knee.  





change over 6 
months (L) TFJ  
KL grade 
progression over 6 





Lo 2012  
[548] 
497 52% ROA knee, 47% female , Mean 
age 64 yrs. OAI 
DXA measured  
medial:lateral 
periarticular BMD  





OARSI medial TFJ 
JSN grade 
progression 






Liu 2014 S470 
Abstract 
[541] 





Incident TKR at 6 
months follow up 
(L)  
Mann Whitney-U 






186 Prevalent ROA knee (40%). 81% 
female, mean age 60 yrs. GARP 
Baseline MRI 
semi-quantitative 
BML, bone cyst 
(C) TFJ 
OARSI medial TFJ 
JSN grade 
progression over 2 







86 100% female, mean age 55 yrs, 
























severity / pain 
measure 






uptake) of the 
medial tibia and 
whole knee (C) 
the medial TFJ 






174 100% female, mean age 56 yrs, 
mean BMI 36. A placebo controlled 






uptake) of the 
medial tibia and 
whole knee (C) 
Progression of 
minimum JSN of 
the medial TFJ 









168 Some WOMAC dysfunction and 90% 
ROA knee. 78% female, mean age 
66 yrs. MAK-2 
Baseline MRI 
semi-quantitative 
BML score (C) 
TFJ and PFJ 
 
Incident frequent 
knee pain 2 years 








559 Knee ROA (100%), 73% female, 




 Annual TFJ JSN 
(L) 




107 100% radiographic OA knee, 64% 





score (medial or 
lateral TFJ) (C) 
Regional cartilage 
volume over 24 
months (medial or 







86 64% female, Mean age 61 yrs. Trial 
of bisphosphonate 
Change in BML 
size (L) at 24 
months in TFJ 
Medial cartilage 
volume loss (L) at 





Raynauld 2011  
[457] 
123 Symptomatic knee OA of the medial 
TFJ, 65% female, mean age 61 yrs, 
mean BMI 32.  
Baseline semi-
quantitative BML 
score (C) TFJ 
Incidence of TKR 





Raynauld 2013 57 Patients from a chondroitin trial Baseline semi- Incident TKR (L) 4 Logistic High 















severity / pain 
measure 





81% female, mean age 63, mean 





year follow up 
 




Roemer 2009  
[443] 
395 Knee OA or at high risk of it. 33% 
ROA. 68% female, mean age 63 yrs. 
MOST 
Change in MRI 
semi-quantitative  
BML size over 30 
months 
(WORMS) (L) 
TFJ and PFJ 
Progression in 
semi-quantitative 
cartilage defects in  
(WORMS) over 30 









347 Knee OA or at high risk of it. 14% 

















Roemer 2012  
[500] 
 
177 Chronic knee pain, 71% knee ROA, 
















363 Minor OA symptoms with18% ROA 






 in TFJ (C)  
Progression in KL 
grade 
and WOMAC pain 
score 
(11 years follow up ) 
(L) 
Chi-square tests 








109 ACR knee OA, 73% ROA. 40% 
female, mean age 63 yrs. Australia 
Semi-quantitative 
change  in MRI 
Bone cyst or 
BML size (L) 
Knee cartilage 
volume loss over 2 
years (L) TFJ 









109 ACR knee OA, 72% ROA. 50% 




BML size (C) 
Cartilage volume 
change over 2 




















severity / pain 
measure 
Statistical analysis Quality 
(score 
%) 
Annual change in 
WOMAC pain(L) 
Incident TKR over 
4 years    
Wildi 2010 
[602] 
161 Symptomatic medial TFJ OA knee 
(ACR criteria). 100% ROA knee, 66% 
female, Licofelone trial 
24 month change 
in regional TFJ 
BML score 
WORMS  (L) 
24 months change 
in WOMAC pain  
(L) or regional 






Zhang 2011 [26] 570 Patients with knee OA or at high risk 
of it. 41% ROA knee. 68% female, 
mean age 62 yrs. MOST 
Semi-quantitative 
change in MRI 
BML size (L) TFJ 











Knee case-controls studies 
Aitken 2013 
[525] Abstract  
220  57% female, Mean age 45 yrs. 
Prevalence of ROA unknown. 
Offspring 
Semi-quantitative 
BMLs tibia, femur 
& patella (C) 
Cartilage volume 
and defect score 
Tibia and femur (L) 






2197 Cases of clinical knee OA (100% 
ROA, n=1312), control healthy knees 
(0% ROA, n=885). 56% female, 
mean age 61 yrs. OAI dataset 
Change in 
segmented MRI 
3D Bone area 
over 4 year (L) 
KL grade defined 
ROA knee (C) 
 




116 Cases of ACR medial knee OA 
(100% medial TFJ ROA) (n=75), 
asymptomatic control knees (n=41). 











Felson  2007 
[134] 
330 Patients at high risk of knee OA , 
cases with incident pain  (n=110, 
ROA 30%), controls without pain 
(n=220,ROA 20%); 66%female, 
mean age 63 yrs. MOST 
Semi-quantitative 
MRI BML size 
increase 
(WORMS) (L) 
TFJ & PFJ 
Incident frequent 






Hunter 2013 636 636 knees at risk of OA (ROA=0% at MRI bone area 8 Incident ROA knee  Discrete-time Cox Low 















severity / pain 
measure 





baseline). Cases of incident ROA 
n=318, Controls without incident ROA 
n=318, 67% female. Mean age 60 
yrs. OAI 









636 Patients with prevalent ROA. Cases 
have painful knees (n= 546), controls 
have no knee pain (n=90); 65% 
female, mean age 73 yrs. Health 
aging and body composition study 
Baseline Semi-
quantitative MRI 
BML, bone cyst 
and attrition size 
(WORMS) (C) 
TFJ & PFJ 
Presence of 
frequent knee pain 






Javaid  2010 
[607] 
155 Clinical knee OA, cases with incident 
pain  (n=33), controls without pain 
(n=122); 67% female, mean age 59 




bone cyst size 
(WORMS) (C) 
TFJ & PFJ 
Incident frequent 








531 Incident knee TFJ ROA 
cases (n=178), controls did not 
develop ROA (n=353); 62% female, 
mean age 61 yrs. OAI dataset 
MRI 3D bone 
shape 
(Tibia, Femur 
and patella) (C) 
Incident TFJ ROA 






Neogi  2009 
[307] 
4446 Clinical knee OA. Within-knee 
subregion cases (n=973) had 
cartilage loss, controls (n=3473) had 
not. 64% female, mean age 63 yrs; 














Ratzlaff 2014  
[608] 
278 59% female, mean age 64, mean 
BMI 30. 138 cases of TKR and 138 
ROA matched controls. OAI 
Total tibial BML 
volume 12 and 
24 months before 
TKR and interval 
change between 
12 and 24 (C) 
and (L) 




Scher 2008 65 Patients with OA knee based upon Presence of any Incident TKR (L) Generalised High 















severity / pain 
measure 





radiography (>50% ROA), 54% 




over 3 years estimating 
equations 
(56) 
Stahl 2011 [442] 60 Clinical and 100% ROA knee cases 
(n=30) ; controls – healthy knees 
ROA 0% (n=30); All female, mean 
age 58 yrs. USA 
Semi-quantitative 














149 ACR knee OA cases (n=68), controls 
(n=81) without OA; 54% female, 
mean age 64 yrs. Australia 
Change in MRI 









Zhao 2010  
[609] 
38 Clinical and ROA cases (n=24), 
control (n=14) knees (KL=0); 54% 
female, mean age 52 yrs 




after one year 
(WORMS) (L) TFJ 
WOMAC pain 










Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







Knee cross-sectional studies 
Ai 2010 [557] 28 Clinical knee OA. 55% 
ROA, 57% female, 
mean age 61 yrs. China 
Semi-quantitative 
MRI BML and 
osteophytes (C) 
Pain verbal rating 
scale (Likert) (C) 
Fisher exact test Low (57) 
Akamatsu 2014 
[533] Abstract 
192 Varus ROA Knee 94%, 
100% female, mean 
age 70 yrs. Japan 
BMD (DXA) (C) 
(medial tibia & 
femoral condyle) 






Baranyay 2007  
[554] 
297 No clinical knee OA 
(ACR clinical criteria) 
and no current or 
MRI BML defined as 
large or not large / 
absent in the medial 
MRI semi-quantitative 
cartilage defects of 













Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







historic knee pathology, 
mean age 58yrs, 63% 
female, mean BMI 25. 
Melbourne 
and lateral 
compartments of TFJ 
(C) 
compartments of TFJ 
 
Quantitative Cartilage 
volume medial and 
lateral TFJ 
(C) 
Bilgici 2010 [558] 34 ACR knee OA. ROA 
65%, 71% female, 
mean age 50 yrs. 
Turkey 
MRI BML (WORMS) 
(C) 
WOMAC pain & pain 
VAS (C) 
Linear regression Low (57) 
Burnett 2012  
[549] 
42 Knees with OA awaiting 
total knee replacement, 
100% ROA, 60% 
Female, mean age 64 
yrs. Canada 
BMD of patellar 
facets (qCT) (C) 
WOMAC pain – knee 





  [349] 
60 Prevalent Knee OA. 
ROA 50%. 100% 
female, mean age 68 
yrs Japan 
MRI Bone volume 
fraction & trabecular 
thickness of the 
medial & lateral 
femur & tibia. (C) 
Metric JSW 
(radiographic) (C) of 





Crema 2010 [315] 1283 Knee OA or at high risk 
of OA. ROA knee 44%. 
60% female, mean age 
62 yrs. 







Ding 2005  
[353] 
372 Mostly no ROA knee 
(17% ~ KL =1), 58% 
female, Mean age 45 
yrs. Mean BMI 27. 
Offspring study 
MRI quantitative tibial 
bone area (C) 
Semi-quantitative 
MRI knee cartilage 
defect severity scores 
(C) TFJ 
Linear regression High (64) 
Dore 2009 [547] 
 
740 >15% ROA knee, 52% 
female, Mean age 62 
yrs. TASOAC 
DXA Tibial 
subchondral BMD (C)  
Radiograph JSN 
grade and MRI 





Driban 2011 [545] 421 NR MRI Bone volume Radiographic JSN (C) Multiple linear High (64) 









Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







Abstract fraction (C) regression 
Driban 2011 [546] 
Abstract 
 
285 OAI Progression 
Cohort. No other 
demographic data 
available. 
MRI bone volume 
fraction, trabecular 
number, spacing & 
thickness of medial 
tibia (C) 
The presence of any 
grade of radiographic 





Eckstein 2010 [483] 73 ROA knee (100%), 63% 
female with mean age 
of 61 yrs. OAI 
MRI Tibial bone area 
(segmented) (C)  
OARSI JSN grade (C) Paired t-tests Low (43) 
 
Felson 2001  
[133] 
401 Prevalent knee OA 
(ACR criteria) and 
assumed ROA knee of 
100%. 41% female, and 
mean age of 67 yrs. 
BOKS 
Semi-quantitative 
MRI BMLs (C) 
KL grade 
chronic knee pain 
presence (C) 
Chi-square or 







90 ACR knee OA, 66% 
knee ROA, 65% 
female, mean age 55 
yrs. USA 
Crude presence of 
MRI BMLs, 
osteophytes (C) 
KL grade and crude 
pain presence (C) 
Chi-square Low (46) 
Frobell 2010 [560] 891 Three groups; pre-
radiographic OA (KL 
grade <2), ROA and 
controls without OA, 
(total ROA knee 89%), 
60% female, mean age 
61 yrs. OAI 
MRI Bone area – 
manual segmentation 
(C) 
KL grade, OARSI 
JSN grade (C) 






192 Obesity and knee OA 
(ACR criteria). 81% 
female, mean age 63 
yrs. Denmark 
Semi-quantitative 
MRI BML (BLOKS) 
(C) 




Guymer 2007  
[535] 
 
176 No clinical knee OA 
(ACR clinical criteria) 
and no current or 
historic knee pathology, 
Presence or absence 
of MRI BMLs 
(C) TFJ 
















Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







mean age 52 yrs, 100% 
female, mean BMI 27. 
Melbourne. 
Haverkamp 2011  
[276] 
609 1201 knees with 6% 
knee ROA and 25% 
knee pain prevalence,  
100% female, and 
mean age 54 yrs, mean 
BMI 27. Rotterdam 
study 
2D bone shape knee 
1. femur & tibial width 








2.Presence of ROA 
knee (KL≥2) 










Hayashi 2012 [566] 40 ROA knee 57% with 
and without pain, 75% 
female, mean age 57 
yrs. USA 
Crude presence of 
MRI osteophytes, 
bone cysts (C) 






Hayes 2005 [312] 232 Clinical and ROA knee 
or healthy patients. 
36% ROA knee, 100% 
female, mean age 46 






KL grade and chronic 









1627 Patients >50 yrs of age 
with and without knee 
pain. ROA knee 22%, 
59% female, mean age 
64 yrs. Framingham OA 
cohort 
Semi-quantitative 
MRI bone attrition 
(WORMS) (C) 






Ip 2011  
[567] 
255 Knee pain. ROA 38%, 
56% female, median 
age 62 yrs. Canada 
Semi-quantitative 
MRI BML (C) 
WOMAC pain, 






Jones 2004  
[31] 
372 Mean age 45yrs, right 
knees, early ROA knee 
(3-14%), 58% female, 
Tibial bone area 
(MRI) (C) 
Radiographic JSN (C) Linear 
Regression 
Low (50) 









Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







mean BMI 27. Offspring 
Kalichman 2007 
[568] 
213 Predominantly knee OA 
(ACR criteria). ROA 
knee 75%, 41% female, 
mean age 67 yrs. 
BOKS 
MRI patellar length 
ratio, trochlea sulcus 
angle (C) 





213 Predominantly knee OA 
(ACR criteria). ROA 
knee 75%, 41% female, 
mean age 67 yrs. 
BOKS 
MRI patellar length 







Kim 2013  
[570] 
358 Aging population with 
35% ROA knee. 51% 
female, mean age 72 
yrs. Hallym Aging Study 
Summary score and 
severity of MRI BML 
(WORMS) (C) 
WOMAC pain (C) or 





Kornaat 2006 [571] 205 Symptomatic (35%)and 
ROA (47%) knee. 80% 
female, median age 60 
yrs. GARP 
 Semi-quantitative 
 MRI osteophyte 






Kornaat 2005 [572] 205 Symptomatic (35%)and 
ROA (47%) knee. 80% 
female, median age 60 
yrs. GARP 
Semi-quantitative 
MRI BML (KOSS) 
TFJ and PFJ (C) 
Semi-quantitative  
cartilage defects 
(KOSS) TFJ and PFJ 
(C) 
Odds ratio Low (57) 
Kraus 2009 
[550] 
159 Unilateral symptomatic 
and ROA knee 
(100%);74% female, 
mean age 63 yrs, mean 
BMI 32. POP 
Ipsicompartmental 
late phase bone 
scintigraphy, semi-
quantitative retention 
scoring of TFJ (C) 
Ipsicompartmental 








 2004 [350] 
74 Prevalent knee ROA 
(71%), 53% female, 
mean age 64 yrs,  
MRI bone volume 
fraction & trabecular 
spacing (lateral TFJ) 
(C) 






Link  2003 [319] 50 Symptomatic knee OA, 
ROA 80%, 60% female, 
Semi-quantitative 
MRI BML, 














Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







mean age 64 yrs. USA osteophytes, and 
crude presence of 
bone cysts (C) 
Chi-squared test 
Lo 2005 [574] 498 Patients >50 yrs of age 
with and without knee 
pain. ROA knee 23%, 
59% female, mean age 





KL grade≥2 (C) Crude 
comparison 
Low (50) 
Lo 2006 [208] 1612 Prevalent Knee OA, 
18% ROA knee, 56% 
female, mean age 64 
yrs. Framingham OA 
Study Cohort 
DXA Medial:lateral 
BMD ratio at the tibial 
plateau (C) 
Radiographic JSN 
grade (medial and 




Lo  2009 [575] 160 Symptomatic OA knee, 
100% ROA. 50% 
female, mean age 61 
yrs. OAI 
Semi-quantitative 
MRI BML (BLOKS) 
(C) 




Lo 2012 [206] 482 Prevalent knee OA, 
54% ROA, 47% female, 
mean age 64 yrs. OAI 
MRI bone volume 
fraction, trabecular 
thickness, number 
and DXA BMD of 
proximal medial tibia 
(C) 
Radiographic medial 
JSN grade (C) 
Kruskal-Wallis 
and Mann-
Whitney U tests 
High (64) 
McCauley 2001  
[528] 
193 Knees referred for MRI 
43% female, mean age 





MRI cartilage lesion 







30 Clinical or ROA knee 
(100%). 73% female, 
mean age 66yrs, 
Overweight or obese 
(65%). Recruited from 
Late phase ‘extended 
bone uptake’ pattern 
bone scintigraphy, 
presence around the 
TFJ (C) 
Radiographic TFJ 
JSN presence (C) 
Chi squared test Low (50) 









Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 








Meredith 2009  
[555] 
140 Knees with MRIs before 
arthroscopic partial 
meniscectomy. Median 
age 61 yrs, 61% female   
Sum of semi-
quantitative MRI 
Osteophyte and BML 




cartilage defect  








Moisio  2009 [456] 305 Patients with some 
WOMAC dysfunction 
and 90% ROA knee. 
78% female, mean age 
66 yrs. MAK-2 
Baseline MRI semi-
quantitative BML 
score (C) TFJ and 
PFJ 
 
Presence of baseline 
moderate to severe  




Ochiai 2010 [543] 48 Patients with clinical 
medial knee OA and 
ROA knee (76%), mean 
age 73 yrs. Gender 
distribution unknown. 
Japan 
MRI irregularity of 
femoral condyle 
contour (C) 
Knee pain VAS (C) Pearson’s 
correlation 
Low (50) 
Okazaki 2014 [539] 29 Radiographic knee OA 
(100%), 100% female, 
Mean age 65 yrs 
Number of CT bone 
cysts (medial femur 
and tibia) (C) 
Knee KL grade (C) NR Low (50) 
Ratzlaff 2013 [577] 115 Radiographic knee OA 
(95%), 48% female, 
age range 45-79 yrs 
Total BML volume in 
the femur or tibia (C) 
Weight bearing knee 
pain WOMAC 
subscale (C)  
Wilcoxon rank 




Ratzlaff 2014 [544] 
abstract 
115 Knee ROA (90%) Median BML volume 
(PFJ, TFJ) (C) 
Stair-climbing knee 






964 Patients over 50 yrs of 
age with and without 
knee pain. ROA knee 
18%, 57% female, 
Semi-quantitative 
MRI Bone attrition 
(WORMS) (C) 
KL grade and semi-
quantitative cartilage 













Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







mean age 63 yrs. 
Framingham OA cohort 
Roemer  2012[578] 
 
1248 Patients over 50 yrs of 
age with and without 
knee pain. ROA knee 
23%, 58% female, 
mean age 64 yrs. 











Scher 2008 [579] 
 
73 Patients with OA knee 
based upon 
radiography (>50% 
ROA), 54% female, 
mean age 51 yrs. USA 
Semi-quantitative 
MRI BML (C) 
Semi-quantitative 
cartilage defect 





Sengupta  2006 
[580] 
217 Patients with prevalent 
knee OA (ACR criteria). 
ROA knee >75%, 25% 













837 At risk of Knee OA but 
without ROA knee, 0% 
ROA knee, 57% 
female, mean age 60 
yrs. OAI 
Semi-quantitative 
MRI BML (WORMS) 
TFJ or PFJ (C) 
Prevalent  frequent 




Sowers  2003  
[531] 
231 Patients with infrequent 
OA knee symptoms and 
15% ROA knee, 100% 
female, mean age 47 
yrs. SWAN 
Semi-quantitative 
MRI BML (C) 
Semi-quantitative 
cartilage defect, 










Stefanik 2012 [274] 881 Patients with knee OA 
or at high risk of it. 
(ROA knee % 
unknown), 63% female, 
MRI lateral trochlear 
inclination and 
















Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 











2087  Prevalent clinical knee 
OA, 60% female, mean 
age 67 yrs 
BML (WORMS) 
 PFJ (C) 
Prevalent knee pain 
(any pain in last 30 





Stehling 2010  
 [313] 
236 Knees without pain and 
with 6% ROA. Mean 
age 51yrs, 58% female, 
mean BMI 24. OAI 
Presence of any MRI 
semi-quantitative 
BMLs, osteophytes or  
cysts (C) 







Torres  2006 [135] 143 Patients with some 
WOMAC dysfunction 
and >55% ROA knee, 
78% female, mean age 
70 yrs. MAK-2 
MRI BML, 
osteophyte,  attrition, 
bone cyst (WORMS) 
TFJ & PFJ (C) 
Pain VAS, semi-
quantitative cartilage 










(ACR) knee OA with 
mild to moderate TFJ 
ROA, mean age 64yrs, 
mean BMI 29, males 
and females. Australia 
Annual % change in 
tibial bone area (L) 
2 yr follow up. 
Baseline JSN (C) Linear regression Low (57) 
Zhai 2006 [582] 500 Randomly selected 
older adults with over 
23% knee ROA. 50% 
female, mean age 63 
yrs. TASOAC 
Semi-quantitative 
MRI BML (C) 
WOMAC pain>1 (C) Multivariable 
analysis 
High (79) 




723 Early symptomatic hip 
OA, the majority had no 
ROA hip (with doubtful 
ROA in 26%), 80% 
female, mean age 56 
yrs, mean BMI 26.1, 
CHECK 
Baseline alpha angle 





Incident ROA hip 
(KL>1) 
Incident end-stage 
ROA hip  
(KL>2 or THR) 















Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 










720 Early symptomatic hip 
OA, the majority had no 
ROA hip (with doubtful 
ROA in 24%), 79% 
female, mean age 
56yrs, mean BMI 26.1. 
CHECK 







Incident ROA hip 
(KL>1 or THR) 






Agricola 2013  
[583] 
723 Early symptomatic hip 
OA, the majority had no 
ROA hip (with doubtful 
ROA in 24%), 79% 
women, mean age 
56yrs, mean BMI 26.1. 
CHECK 
Baseline 2D femoral 
and acetabular shape 
modes (segmented 
by statistical shape 
modelling) 
(C) 
Total hip replacement 












radiographic hip OA 
cases (n=965), 
asymptomatic controls 
without radiographic hip 
OA (n=1111) – GOAL 
Non-spherical 2D 
femoral head shape 
assessment:  
1) Appearance of  
‘Pistol grip 
deformity’ (C) 
 2) Maximum femoral 
head diameter 
divided by minimum 
parallel femoral neck 
diameter (C) 
Presence of 









141 First presentation of hip 
pain to primary care, 
32% ACR hip OA 
criteria, 68% female, 
mean age 63 yrs, mean 
BMI 27.  
2D Shape measures 
of centre edge angle 
(acetabular shape) 
(C) 
THR vs no 
radiographic 







268 100% women, mean 
age, 55yrs, mean BMI 
2D CAM deformity; 
mean modified 














Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







[538] 66. 243 controls, 25 




height, alpha angle. 
Acetabular dysplasia;  
mean lateral center 
edge angle (C) 




3529 10% ROA hip, 100% 
male, Mean age 78 
years. Cohort of the 
Study of Osteoporotic 
Fractures in Men 
Femoral neck BMD 
(C) DXA 
Hip ROA Modified 
croft score 
(categorical 0-4) (C) 
Linear regression High (64) 
Chiba 2011 
[215] 
47 ROA, 100% female, 










Hip joint space 







161 142 asymptomatic hips 
without clinical OA, 19 
with hip OA. 56% 
female, mean age 
63yrs, mean BMI 27,  














3620 Mean age 61yrs, 63% 
female, ROA hip 10.6%  
 (OA substudy - CCHS 
III) 
2D Categorical Hip 
deformity:  
1) Normal  
2)‘Pistol grip’ 











Maksymowych 2014 40 55% female, mean age Semi-quantitative Baseline WOMAC Univariable High (64) 









Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 







[576] 65yrs, symptomatic but 
not radiographic hip OA 
BML HIP 
(HOAMS) (C) 
pain (C) regression model 
Neumann 2007  
[542] 
100 Symptomatic hip OA Semi-quantitative 
BMLs (C) 
Semi-quantitative  




Reichenbach 2011  
[529] 
244 Asymptomatic men 
(100%). Mean age 20 
yrs, mean BMI 23, 
Sumiswald cohort 
The presence or 




















1148 White female twins, 
29% hip RO 
A, 100% female, 
median age 53 yrs. St. 
Thomas’ UK Adult Twin 
Register (C) 
DXA BMD 
of the femoral neck of 
left (nondominant) hip 
with ROA  (C) 
Radiographic OA 






85 Members of the public 
with 35% ROA hip, 48% 
female , mean age 56 
yrs (C) 
Total hip semi-
quantitative BML and 
subchondral cysts 
score (C) 






Hand case-series studies 
Haugen 2014 
 [39] 




At 2nd to 5th IPJs (C) 
Progression of hand 
ROA (JSN, KL grade 







70 90% female, mean age 
68 yrs 
Sum scores (0-48) for 
BMLs (Oslo Hand OA 
MRI score) (C) IPJS  
AUSCAN pain scale 
(L) 
Linear regression High (61) 





108 91% women, mean age 
69 years, 100% ROA 
hand Oslo hand 
osteoarthritis cohort 
BML (Oslo MRI hand 
score) (C) IPJs 
Radiographic JSN 








Haugen  106 92% women, mean age BML, cyst, attrition, Hand KL grade of Generalised High (64) 









Study demographics Subchondral bone 
feature assessed 
(method)  region 
Structural progression 









69 years, 100% ROA 
Oslo hand osteoarthritis 
cohort 
osteophyte (Oslo MRI 
hand score) (C) 
IPJs 
IPJs (C) estimating 
equations 
Haugen 2012 [563] 
 
85 91% female, mean age 
69 years, 100% ROA 
hand. Oslo hand 
osteoarthritis cohort 
BML, cyst, attrition, 
osteophyte (Oslo MRI 
hand score) (C) 
IPJs sum scores 
AUSCAN pain scale 
(C) 




35 100% ROA Hand, 91% 
female, mean age 
62yrs. Rheumatology 
clinic attenders 
Late phase isotope 
bone scan small 
joints of the hand 
(C) 
Hand Pain VAS (C) Kendall’s 
correlation 
Low (57) 
Ankle cross-sectional studies 
Knupp 2009 
[526] 
27 Symptomatic ankle 
varus or valgus 
deformities refractory to 
conservative therapy, 
37% female, mean age 
49 yrs.  
Late phase bone 
scintigraphy, semi-
quantitative retention 
scoring of tibiotalar 
joint (C) 










138 Symptomatic ankle OA 
(23%), ROA ankle 
(79%), 74% female, 
mean age 64yrs, mean 
BMI 31. POP 
Ipsilateral late phase 
bone scintigraphy, 
retention presence in 
tibiotalar joint (C) 
Tibiotalar ROA KL 





Australian/Canadian Osteoarthritis Hand Index (AUSCAN); Bone mineral density (BMD); Bone marrow lesion (BML); Boston Osteoarthritis 
of the Knee Study (BOKS), Boston–Leeds. Osteoarthritis Knee Score (BLOKS); a feature or outcome described in cross-section (C); 
Copenhagen City Heart Study (CCHS); Cohort hip and cohort knee (CHECK); knee pain on most days for at least the last month (chronic pain); 
Dual-energy X-ray absorptiometry (DXA); Genetics, Osteoarthritis and Progression study (GARP); GOAL (Genetics of Osteoarthritis and 
Lifestyle); Hip Osteoarthritis MRI scoring system (HOAMS); Hip dysfunction and Osteoarthritis Outcome Score (HOOS); interphalangeal 
joint (IPJ); joint space narrowing (JSN); joint space width (JSW); Kellgren Lawrence (KL); Knee Osteoarthritis Scoring System (KOSS); a 
feature or outcome described longitudinally (L); mechanical factors in arthritis of the knee 2 (MAK-2); patellofemoral joint (PFJ); quantitative 
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computed tomography (qCT); radiographic osteoarthritis (ROA); Michigan study of Women’s Health across the Nation (SWAN); Multicentre 
Osteoarthritis Study (most); osteoarthritis (OA); Osteoarthritis Initiative (OAI); Osteoarthritis Research Society International (OARSI); 
Strategies to Predict Osteoarthritis Progression (POP); Tasmanian Older Adult Cohort (TASOAC);  tibiofemoral joint (TFJ); Total hip 
replacement (THR); visual analogue scale (VAS); Western Ontario and McMaster Universities arthritis index (WOMAC); whole-organ 
magnetic resonance imaging score (WORMS). 




3.4.4 Relationship between knee bone feature and structural 
progression  
The association of knee bone features with knee structural progression and 
joint replacement are described in Table 17, and Table 21. 
 
3.4.4.1 Knee bone marrow lesions: 
(31 cohort, 15 cross-sectional, four case-control) MRI 
In prospective cohorts with high quality, well-adjusted analyses the presence 
and increasing size of baseline BMLs and incidence of BMLs conferred 
greater odds of structural progression [100, 124, 294, 301, 587]. Similarly 
increasing baseline BML size increased the risk of total knee replacement 
(TKR) and expedited the outcome of TKR[103, 457, 540, 590]. The 
association of BMLs with structural progression was maintained in cohorts 
without clinical features of knee OA[301] and in analyses with poorer quality 
or statistical adjustment [123, 443, 478, 500, 527, 530, 579, 585, 586, 590-
592, 594, 598-601]. Only five low quality cohort analyses did not support 
these findings[417, 444, 596, 597, 602]. 
All cross-sectional analyses found positive correlations between BMLs and 
structural severity[133, 135, 312, 313, 319, 531, 535, 554, 555, 559, 562, 
567, 572, 574, 579]. Three case-control analyses found similar 
associations[525, 608, 609].   
Summary: BMLs are independently associated with knee structural 
progression, and incident TKR. 
 
3.4.4.2 Knee osteophytes:  
(Three cohort, eight cross-sectional) MRI 
In one prospective cohort with high quality and well-adjusted analysis, the 
increasing size of osteophytes conferred greater odds of structural 
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progression[589]. In lower quality inadequately adjusted, prospective 
cohorts, increasing osteophyte size increased the risk of incident TKR and 
structural progression[530, 541]. The increasing size and presence of 
osteophytes was associated with greater structural progression or severity in 
all included analyses[135, 312, 313, 319, 528, 530, 541, 555, 559, 560, 578, 
589].  
Summary: Osteophytes are independently associated with knee structural 
progression and associated with TKR incidence. 
 
3.4.4.3 Knee bone attrition:  
(One cohort, two cross-sectional, one case-control) MRI 
One prospective, well-adjusted, but below average quality cohort analysis 
found an association with baseline attrition severity and structural 
progression that became insignificant after covariate adjustment[478]. The 
unadjusted cross-sectional analyses and case-control analysis found similar 
associations with structural severity [135, 306, 307]. 
Summary: Bone attrition is associated but not independently associated with 
structural progression.  
 
3.4.4.4 Knee bone shape / dimension:  
(Eight cohort, seven cross-sectional, four case-control) MRI 
In prospective cohorts with high quality well-adjusted analyses, greater 
baseline tibial plateau bone area conferred greater odds of structural 
progression of OA and incidence of TKR [96, 261, 270, 588]. The same 
association was observed in a lower quality, prospective cohort, well-
adjusted analysis[584] and in a study of the knee in patients who 
predominantly had no radiographic evidence of knee OA[261]. The 
mismatch ratio of the femoral and tibial articulating areas was not associated 
with structural progression after adjustment[102], but the trochlear sulcus 
angle and shape was associated with cross-sectional patellofemoral 
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structural severity demonstrated on MRI[274, 569]. All cross-sectional [31, 
259, 483, 560] and case control [75, 269, 604, 605] analyses of tibial bone 
area or 3D knee bone shape found association with structural severity [31, 
75, 259, 269, 483, 560, 604, 605].  
Summary: Tibial bone area is independently associated with knee OA 
structural progression and incidence of TKR.  
 
3.4.4.5 Knee bone cyst:  
(Four cohort, five cross-sectional) MRI & CT 
Two prospective cohorts with well-adjusted but below average quality 
analyses of cysts reported no association with structural progression before 
or after adjustment[417, 478]. Two prospective cohorts with low quality 
unadjusted analyses of cysts found an association with structural 
progression[585, 601]. Cross-sectional well-adjusted [313]  and unadjusted 
[312, 315, 319, 539] cyst analyses found an association with structural 
severity.    
Summary: There is no independent association of cysts with structural 
progression after covariate adjustment.  
 
3.4.4.6 Knee trabecular bone morphometry:  
(One cohort, five cross-sectional) MRI 
One prospective cohort, unadjusted, below average quality analysis reported 
increasing bone volume fraction, trabecular number and thickness and 
decreasing trabecular spacing were associated with structural 
progression[548]. The same bone changes were associated with structural 
severity in cross-sectional unadjusted analyses[206, 349, 350, 545, 546].  
Summary: Increasing bone volume fraction, trabecular number, trabecular 
thickness, and decreasing trabecular spacing are associated with knee 
structural progression and severity. 




3.4.4.7 Knee peri-articular bone mineral density: 
(Three cohort, four cross-sectional one case control) DXA and CT 
Two prospective cohorts with well-adjusted but below average quality 
analyses reported increasing tibial subchondral bone mineral density was 
associated with structural progression[209, 210]. In one prospective cohort 
with an unadjusted below average quality analysis, the medial to lateral ratio 
of tibial peri-articular bone mineral density (BMD) was associated with 
structural progression[548]. All of the cross-sectional analyses[206, 208, 
533, 547], including two well-adjusted analyses[208, 547], reported 
increasing BMD with greater structural severity. One well-adjusted analysis 
using quantitative CT (qCT) reported higher and lower BMD in the anterior 
and posterior tibial plateau respectively, of knees with moderate OA relative 
to asymptomatic controls.  
Summary: Increasing peri-articular radiographic BMD is associated with 
structural progression and severity.  
 
3.4.4.8 Knee scintigraphy: 
(Three cohort, two cross-sectional) 
Prospective cohorts with high quality analyses found greater late-phase 
bone signal was associated with structural progression, with no or 
inadequate covariate adjustment[536, 537], but not after adequate covariate 
adjustment[536]. A prospective cohort, with below average quality, 
unadjusted analysis found greater bone signal was associated with structural 
progression[216]. Bone signal was associated with structural severity in well-
adjusted and unadjusted cross-sectional analyses[550, 553]. 
Summary: Bone scintigraphy signal is associated, but not independently 
associated, with structural progression.   
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3.4.4.9 2D knee bone shape 
One cross-sectional, well-adjusted analysis identified an association of 
enlarging femoral and tibial bone width and elevating tibial plateau with 
greater structural severity[276]. 
Summary: 2D bone shape is associated with structural severity 
 
3.4.5 Relationship between knee bone features and pain  
The association of knee bone features with knee pain are described in Table 
18 and Table 21. In all types of study, bone features were compared with the 
presence, chronicity and severity of pain. In longitudinal studies, features 
were also compared with change in the presence or severity of pain (e.g. 
change in WOMAC pain score). Change in the presence of pain included 
developing new frequent pain, [545], or the resolution of existing pain.  
 
3.4.5.1 Knee bone marrow lesions:  
(Nine cohort, 18 cross-sectional, five case-control) MRI 
In three prospective cohort, well-adjusted, high quality analyses the baseline 
or longitudinal increase in size of BMLs was associated with longitudinally 
increasing knee WOMAC pain severity[99-101]. This association was 
maintained in one[530] but not two[600, 602] similar prospective cohort, 
unadjusted, lower quality analyses. Baseline BML size in the lateral but not 
the medial tibiofemoral joint was associated with incident frequent knee pain 
in a prospective cohort, well-adjusted, high quality analysis[456]. 
Longitudinally increasing BML size was associated with incident frequent 
knee pain in a similar but inadequately adjusted analysis of below average 
quality[26]. In cross-sectional studies the size or presence of BMLs were 
inconsistently associated with the presence of a heterogenous range of pain 
measures, irrespective of adequate covariate adjustment[131, 133, 135, 
312, 319, 456, 531, 544, 557-559, 567, 570, 571, 575, 577, 581, 582].  
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Summary: BMLs are independently associated with longitudinally increasing 
pain severity and are associated with incident frequent knee pain.  
 
3.4.5.2 Knee osteophytes:  
(One cohort, eight cross-sectional, one case-control) MRI 
One prospective cohort, unadjusted, below average quality analysis reported 
increasing baseline osteophyte size was associated with increasing 
WOMAC pain severity[530]. In well-adjusted cross-sectional analyses, 
osteophyte size was associated with the presence[571] but not severity of 
pain[580]. In unadjusted cross-sectional analyses osteophytes were 
inconsistently associated with a heterogenous range of pain measures[135, 
312, 319, 557, 559, 566]. 
Summary: Osteophytes are associated with longitudinally increasing pain 
severity and the cross-sectional presence of pain.     
 
3.4.5.3 Knee bone attrition: 
(Zero cohort, two cross-sectional, one case-control) MRI 
Cross-sectional analyses found greater attrition was associated with greater 
pain severity, without covariate adjustment[135, 139], but not after adequate 
covariate adjustment[139]. An unadjusted case-control analysis found an 
association of attrition and prevalent pain[606]. 
Summary: Bone attrition is associated but not independently associated with 
pain severity.  
 
3.4.5.4 Knee bone shape / dimension: 
(One cohort, one cross-sectional) MRI 
One prospective, well-adjusted, high quality analysis found the femoro-tibial 
articulating surface mismatch was associated with incident frequent knee 
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pain[102]. One unadjusted cross-sectional analysis found the irregularity of 
the femoral condyle surface was associated with knee pain severity[543].  
Summary: Specific features of bone shape are independently associated 
with incident frequent knee pain and also severity.  
 
3.4.5.5 Knee bone cyst:  
(One cohort, five cross-sectional, two case-control) MRI 
One prospective cohort, unadjusted, low quality analysis found no 
association between bone cyst size and increasing WOMAC pain[530]. In 
mostly unadjusted cross-sectional[135, 312, 319, 566, 571] and case control 
analyses[606, 607] of heterogenous cyst measures and pain measures, an 
association between cysts and pain was inconsistently found.  
Summary: Bone cysts may not be associated with longitudinal pain severity 
and a cross-sectional association with pain is uncertain. 
 
3.4.5.6 2D knee bone shape: 
One inadequately adjusted cross-sectional analysis found an association 
between the elevation of the lateral tibial plateau and pain severity[276].  
Summary: 2D lateral tibial bone shape is associated with cross-sectional 
pain severity. 
 
3.4.6 Relationship between hand bone feature and structural 
progression  
The association of hand bone features with hand structural progression are 
described in Table 19 and Table 21. 
3.4.6.1 Hand bone marrow lesions:  
(One case series, two cross-sectional) MRI 
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One well-adjusted, high quality analysis of a prospective OA case series, 
found that increasing BML number and size in the interphalangeal joints at 
baseline conferred greater odds of structural progression[39]. Two adjusted 
cross-sectional analyses found increasing BML number and size scores 
were associated with increasing structural severity[564, 565].  
Summary: BMLs are independently associated with hand structural 
progression.  
 
3.4.6.2 Hand osteophytes bone attrition and cysts: 
One cross-sectional, adjusted analysis found greater MRI attrition or MRI 
osteophyte number and size was associated with greater structural 
severity[565]. However greater MRI cyst presence was not associated with 
greater structural severity[565]. 
 
Summary: Osteophytes and attrition, but not cysts, are associated with hand 
structural severity. 
 
3.4.7 Relationship between hand bone feature and pain  
The association of hand bone features with hand pain are described in Table 
20and Table 21. 
 
 3.4.7.1 Hand bone marrow lesions:  
(One case series, one cross-sectional) MRI 
One well-adjusted, high quality analysis of a prospective OA case series, 
found that BML number and size at baseline was not associated with 
longitudinal change in hand pain[593]. One adjusted cross-sectional analysis 
found no association of BMLs with pain severity[563].  
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Summary: BMLs are not independently associated with longitudinal or cross-
sectional pain severity. 
 
3.4.7.2 Hand osteophytes, bone attrition and cysts: 
One cross-sectional, adjusted analysis found no association between the 
features, MRI osteophytes, attrition or cysts, and pain severity[563].  
Summary: Osteophytes, attrition and cysts are not associated with hand pain 
severity. 
 
3.4.7.3 Hand scintigraphy 
(One cross-sectional): 
One cross-sectional unadjusted analysis found no significant association 
between bone signal of the hands and pain severity. 
Summary: Bone scintigraphy signal is not associated with hand pain severity 
 
3.4.8 Relationship between hip bone feature and structural 
progression  
The association of hip bone features with hip structural progression and joint 
replacement are described in Table 19 and Table 21. 
 
3.4.8.1 Hip bone marrow lesions:  
(Two cross-sectional) MRI 
One well-adjusted [556] and one unadjusted [542] cross-sectional analysis 
both found that BMLs were associated with greater structural severity.    
Summary: BMLs are associated with hip structural severity 
 
3.4.8.2 Hip trabecular bone morphometry:  
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One unadjusted cross-sectional analysis found greater MRI bone volume 
fraction, trabecular thickening, trabecular number and lower trabecular 
spacing were associated with greater structural severity[215]. 
Summary: Bone volume fraction, trabecular thickening, number and spacing 
are associated with hip structural severity 
 
3.4.8.3 Hip peri-articular bone mineral density: 
(Two cross-sectional) DXA 
One well-adjusted [532] and one adjusted[534]cross-sectional analysis 
found greater BMD was associated with greater structural severity. 
Summary: BMD is associated with structural severity of the hip.  
 
3.4.8.4 2D and 3D hip bone shape 
(Three cohort, two cross-sectional, three case-control)  
In two prospective cohort, well-adjusted, high quality analyses an increasing 
asphericity of the femoral head (measured as an elevated alpha angle, or in 
shape modes 11 and 15) was associated with total hip replacement 
(THR)[583] or with structural progression and THR[74] respectively. In one 
prospective cohort, well-adjusted, high quality analysis acetabular 
undercoverage of the femoral head (a low centre edge angle) was 
associated with structural progression or THR[394].In one well-adjusted 
cross-sectional analysis, 2D asphericity deformity of the femoral head (cam-
type deformities) was associated with structural severity[561]. In one well-
adjusted cross-sectional analysis of MRI-determined femoral head 
asphericity in asymptomatic young men, there was a significantly lower 
cartilage thickness between those with than those without any detectable 
asphericity. This became insignificant after covariate adjustment[529]. Case-
control analyses identified the same associations as the cohort 
analyses[282, 538, 603]. 
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Summary: Asphericity of the femoral head and acetabular undercoverage of 
the femoral head are independently associated with structural progression 
and THR. 
 
3.4.9 Relationship between hip bone feature and pain  
The association of hip bone features with hip pain are described in Table 20 
and Table 21. 
 
3.4.9.1 Hip bone marrow lesions:  
(Two cross-sectional) MRI 
Two cross-sectional, unadjusted analyses found that increasing semi-
quantitative BML scores were associated with greater pain severity[573, 
576]. Summary: BMLs are associated with hip pain severity.  
 
3.4.9.2 Hip bone cyst:  
One cross-sectional, unadjusted analysis found that increasing MRI semi-
quantitative cyst scores were associated with greater pain severity[573].  
Summary: Cysts are associated with hip pain severity. 
 
3.4.10 Relationship between ankle bone features and structural 
progression 
The association of ankle bone features with ankle structure are described in 
Table 19 and Table 21. 
 
3.4.10.1 Ankle scintigraphy  
(Two cross-sectional)  
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One well-adjusted[550] and one unadjusted[553] cross-sectional analysis 
found the presence or semi-quantitative scoring of late phase bone signal in 
the tibiotalar joint was associated with greater structural severity. 
Summary: Bone scintigraphy signal is associated with ankle structural 
severity.  
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Association Quality (score %) 














Age, sex, and BMI NR OR 6.5 












size (C) TFJ 
Incident TKR 
over 5 years 
(L) 
 
Age, sex, BMI, 
knee baseline pain, 
leg strength, 
cartilage defects, 
tibial bone area, 
ROA 
OR (95% CI) 
2.04 (1.55 to 2.69) 
p<0.01 
OR (95% CI)  
2.10 (1.13 to 3.90) 
p=0.019 














grade  (L) 
(TFJ) 
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OR 1.27 (95% CI 1.11 
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BML volume regression 
OR 3.36 (95% CI 1.55 
to 7.28) 
+ High (61) 
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at baseline) 
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TKR over 3 
years (L) 
Age, sex, BMI, 
JSW, WOMAC,  
NR OR (95%CI) 
BML medial plateau 
1.81 (1.08 to 2.03) 
p=0.025 












(L) 4 year 
follow up 
 
Time to TKR 
(L) 
Age, BMI, gender 
WOMAC, CRP 
NR TKR incidence 
OR (95% CI) 
2.107 (1.26 to 3.54) 
p=0.005 
Time to TKR incidence 
Hazard ratio (95%CI) 
2.13 (1.38 to 3.30) 
p= 0.001 
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NR Combined BML score 
in the  medial and 
lateral TFJ 
compartment 
OR 1.9 95%CI (1.1-3.3) 











(L) over 3 
years 
Age NR OR (95% CI) 
8.95 (1.49 to 53.68) 
p=0.02 







in TFJ (C) 
Progression in 
KL grade 
(11 year follow 
up) (L) 
 
Nil R (CI 95%) Medial 
tibia   ~ 0.46 (0.35 to 
0.55) 
Lateral tibia ~0.23 
(0.13 to 0.33) 
NR + Low (53) 
Kothari  Semi- Semi- Age, sex, BMI, OR 4.04 OR 3.75 + Low (50) 









































volume (L) at 
24 months in 
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and tear, pain and 
bone 
lesions at baseline, 
NR Change in BML size 
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volume loss 
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TFJ and PFJ 
Age, sex, BMI, 
baseline KL grade 
NR OR (95%CI) 
Incident BML OR 3.5 
(2.1 to 5.9) 
Progression of BML 2.8 
(1.5 to 3.2) 
Resolution of BML OR 
0.9 (0.5 to 1.6) 
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(reference) 
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NR Lateral compartment 
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Β=-0.31, p=0.001 
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NR Baseline BML volume  r 
= 0.48 (95% CI) (0.20 
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Age, sex, BMI, 
baseline tibial 
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R (CI 95%) 
Total cartilage loss 
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family effect 
NR 0.9 RR 
CI 95% (0.18 to 3.0) 
NA Low  (47) 
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p=0.08 
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OR (CI 95%) 
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(11 year follow 
up) (L) 
 
Nil R (CI 95%) Medial 
tibia   ~ 0.65 (0.59 to 
0.71) 
Lateral tibia ~0.57 
(0.49 to 0.63) 
NR + Low (53) 














age, gender and 
BMI, KL score, 
knee injury or knee 
surgery,  family 
history of TKR and 
Heberden’s nodes 












& PFJ (C) 
Nil R=0.73 NR + High (68) 
Hayes Semi- KL grade (C) Nil p<0.001 NR + High (61) 




























scores in the 






defect  scores 
in the TFJ and 
PFJ (C) 












Nil Crude association of 






















CI 95% (249.8, 
22,643.4) 
OR 108.8 
CI 95%(14.2, 834.9) 
p for trend<0.0001 
+ Low (57) 

















KL grade(C) Nil P<0.001 NR + Low (46) 











Age, sex BMI, 
other bone lesions 
OR 3.17 
CI 95%(1.64 to 6.16) 
OR 1.85 
CI  95% (0.71 to 4.82) 
NA Low (50) 
















Association Quality (score %) 
(WORMS) 
(C) TFJ 




MRI bone attrition – cross-sectional studies 
Torres 
2006[135] 
MRI  attrition 
(WORMS) 






& PFJ (C) 


















NR + Low (43) 
















Age, sex, BMI OR 5.5 
CI 95% (3.0, 10.0) 
OR 3.0 
CI 95% (2.2, 4.2) 
+ Low (59) 










(L) over 4 
years 




NR OR (CI 95%) 
1.2 (1.0 to 1.4)  
p=0.02 














β (CI 95%) 
Medial femoral 
cartilage 
β=0.17 (0.04 to 0.29) 
Total femoral cartilage 
β (CI 95%) 
Medial femoral 
cartilage 
β=0.35 (0.14 to 0.56) 
Total femoral cartilage 
- High (72) 
















Association Quality (score %) 
β =0.07 
(0.003 to 0.14) 
β=0.13 (0.02 to 0.25) 












over 2.3 yrs (L) 
TFJ  
Age, Sex, BMI, 
Radiographic OA 
features 
NA OR (95%CI) 
Medial TFJ 
1.24 (1.01 to 1.51) 
p=0.04 
Lateral TFJ 
2.07 (1.52 to 2.82) 
p<0.001 













progression of  
lateral or 
medial  TFJ 




sex, race, age, 
BMI, tobacco use, 





history, KL grade, 
and JSW 
Unadjusted Medial 
SSR vs progression of 
medial JSN 




Medial SSR vs 
progression of lateral 
JSN 




Neither medial nor 
lateral SSR was 
associated lateral or 
medial ROA 


















(L) medial and 
lateral TFJ 





and baseline tibial 
plateau area 
Lateral TFJ 




OR (CI 95%) 
Lateral TFJ 
0.06 
(0.004 to 0.11) 
p=0.03 
Medial TFJ 
0.07 (0.03 to 0.12) 
p=0.002 












Age, sex, BMI, 
cartilage defects, 
BML 
Lateral tibial bone 
area 
OR 1.11 
CI 95% (1.0, 1.23) 
OR (CI 95%) 
Bone area 
Medial 1.12 (1.01 to 
1.26) 
and lateral tibial ( 1.35 
+ Low (50) 
















Association Quality (score %) 






area MRI (C)  







2.7 years (L) 







NR OR (CI 95%) 
Medial Tibia 
1.6 (1.0 to 2.6) 
p=0.04 
Lateral Tibia 























Nil Medial tibia 
P<0.05 
NR + 
The higher the 





MRI bone shape / dimension – cross-sectional studies 











scores (C) TFJ 
Age, sex, BMI, 
family history, 
cartilage volume  
β (CI 95%) 
Medial TFJ 
 0.06 (0.03 to 0.09) 
Lateral TFJ 
0.09 (0.05 to 0.13) 
 
β (CI 95%) 
Medial TFJ 
 0.11 (0.07 to 0.15) 
Lateral TFJ 


















JSN grade (C) Age, sex, BMI NR Trochlea sulcus angle 
p for trend 
Medial JSN p=0.0162 
Lateral JSN 
p= 0.1206 













Age, sex, BMI NR Trochlea sulcus angle 
p for trend 
Medial cartilage loss 
p=0.0016 










Age, sex, BMI NR Lateral trochlear 
inclination OR 2.6 
+ Low (57) 







































Age & BMI Medial tibia 




JSN & KL 
p <0.0125 
 


















tibial plateau bone 
area. 
β (CI 95%) 
Medial tibia  
β=0.35  





 (-2.35 to 0.61) 
p=0.25 
β (CI 95%) 
Medial tibia  
1.88  










tibia but not in 










age, sex, height, 
weight 
β (CI 95%) 
Medial tibia  
β=-0.03  




 (-0.07 to 0.06) 
β (CI 95%) 
Medial tibia  
β=-0.00  




 (-0.04 to 0.05) 









Nil P<0.01 NR + Low (43) 






























Association Quality (score %) 
[604] MRI 3D Bone 
area over 4 
year (L) 
knee (C) and 
(L) 
 
significantly faster in 
















KL grade ≥2 
(L) 
Age, sex, BMI NR OR 3 




















(KL grade ≥2) 
(L) 
NR NR Hazard ratio (CI 95%) 
range from 1.17 (1.08 
to 1.27) to 3.97 (2.38 to 
6.63) all highly 
statistically significant 

















Age, BMI, pain, 
physical activity 
Medial tibial bone 
area 
R=160 (CI 95% 120 to 
201) 
P<0.001 
Medial tibial bone area 
R=145 (CI 95% 103 to 
186) 
P<0.001 
+ Low (47) 

















Age, sex BMI, 
other bone lesions 
OR 1.66 
CI 95% (0.55, 4.99) 
OR 0.47 
CI 95% (0.11, 2.03) 






change  in 
MRI Bone 
Knee Cartilage 
volume loss  
over 2 years 
(L) TFJ 
Nil β (CI 95%) 
Lateral tibial cartilage 
loss in cyst regression 
relative to stable and 
NR + Low (47) 
















Association Quality (score %) 
cyst size (L) progressive cysts 








bone cyst (C) 
TFJ 
OARSI medial 
TFJ JSN grade 
progression 
over 2 years 
(L) TFJ 
Age, sex, BMI and 
family effect 
NR RR 1.6 
CI 95% (0.5, 4.0) 







cyst TFJ (C) 
and (L) 
Any grade of 
cartilage 
defect TFJ (C) 
and (L) 
Nil NR NR + 
 
Low (22) 













age, gender and 
BMI, KL score, 
knee injury or knee 
surgery,  family 
history of TKR and 
Heberden’s nodes 












& PFJ (C) 







KL grade (C) Nil p=0.02 NR + High (61) 
















Nil NR NR + 
 
Low (50) 
















Association Quality (score %) 
(C) 









Knee KL grade 
(C) 
Nil p<0.05 Nil +with KL grade 
in medial TFJ 
Low (50) 














and 48 months 
(L) 
































of any grade of 
radiographic 
medial & 
lateral JSN  
(C) 
























































volume of tibia 





Nil Medial TFJ cartilage 
with Lateral TFJ BVF 
and trabecular 
number. 
β =0.29 to 0.36 
p=0.0020 to 0.02 







































the medial & 
lateral femur 




of the medial 
and lateral TFJ 
(C) 




NR - Low (57) 









 (C)  











NR OR (CI 95%) 
Medial Tibia 
1.6 (1.2 to 2.1) 
p<0.01 
Lateral Tibia 




in medial tibia 
Low (50) 
















Association Quality (score %) 
defects over 















Nil OR 8.4 95%CI (2.8-
25.0) p<0.0001 














TFJ after one 
year (L) 
Age, sex, BMI, 
minimum JSW 





JSW or less 
JSN 
Low (44) 













Age, sex BMI NR Medial tibial BMD vs 
JSN R=0.11, p<0.01, 





















lateral TFJ) (C) 
Age, sex, BMI P<0.0001 NR + with medial 






















Nil Tibia R=0.571, 
p<0.001 





















Association Quality (score %) 
Abstract Femoral 
Condyle) 
(C) p<0.001 condyle BMD 
correlated with 
medial JSN 









KL grade (C) Age, sex, BMI NR P<0.05 NC 
BMD falls in 
posterior tibial 


























of the medial 
TFJ from 
baseline to 30 
months 
(L) 
Age, BMI, KL 
grade (NB all 
women) 
r = 0.22 to 0.30, (p < 
0.05) 





















of the medial 
TFJ from 





NR Coefficient 0.221, 







the greater the 
JSN 
High (56) 



































5 years (L) 
Nil p<0.005 NR + 
 
Low (50) 















of JSN (C) 





Coefficient 0.47 to 
0.48 (p<0.0001) 
Coefficient 0.26 to 0.29 
(p=0.0005 to0.001) 















Nil OR 47.3, 95%CI (6.4 
to 352) p<0.01 
NR + Low (50) 
























adjusted for  
Age, BMI, 
OR (95% CI) 
Bone width vs Knee 
ROA 
2.03 (1.55 to 2.66) 
p<0.001 
Bone width Presence 
of diffuse cartilage 
OR (95% CI) 
Knee ROA 
1.94 (1.44 to 2.62) 
p<0.001 
+ 




the presence of 
ROA knee.  
Low (46) 
























models adjusted for 






with bone width 
Positive correlation reported between bone feature and outcome measure (+); Negative correlation reported between bone feature and 
outcome measure (-); Bone mineral density (BMD); Body mass index (BMI); bone marrow lesion (BML); Boston Osteoarthritis of the 
Knee Study (BOKS);  Boston–Leeds. Osteoarthritis Knee Score (BLOKS); bone volume fraction (BVF); a feature or outcome described in 
cross-section (C); confidence interval (CI); Computed tomography (CT); Dual-energy X-ray Absorptiometry (DXA); Genetics, 
Osteoarthritis and Progression Study (GARP); joint space narrowing (JSN); joint space width (JSW); Kellgren Lawrence (KL); knee 
osteoarthritis scoring system (KOSS); a feature or outcome described longitudinally(L);mechanical factors in arthritis of the knee 2 (MAK-
2); No conclusion could be found for an association between bone feature and outcome measure (NC); Michigan study of women’s 
health across the nation (SWAN); multicentre osteoarthritis study (MOST); Magnetic resonance imaging (MRI); No association (NA);No 
conclusion could be found for an association between bone feature and outcome measure (NC); not reported (NR); osteoarthritis (OA); 
osteoarthritis initiative (OAI); odds ratio (OR); P value (p); Patellofemoral joint (PFJ); relative risk ratio (RR); Subchondral surface ratio 
(SSR); Tasmanian Older Adult Cohort (TASOAC); Tibiofemoral joint (TFJ); Visual analogue scale (VAS); Western Ontario and McMaster 
Universities arthritis index (WOMAC); whole-organ magnetic resonance imaging score (WORMS).   
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NR Incident or change 
in total BML size 
β=1.53(95%CI 
0.37 to 2.70 
 
Medial tibial 
change in BML 
size 
β = 2.96 (95%CI 
0.59-5.34 
+ 
Incidence of BML 
or increase in size 
associated with 
increase in pain in 


























Changes in BML 
correlated with (L) 






MRI BML size 
(L) regional or 
whole TFJ 









quality of life, 
and baseline 
pain, function 
β (95% CI)  
Total BML size 
change 
 β=1.06 
 (0.10 to 2.03) 
β (95% CI) Total 
BML size change 
β= 1.13 
(0.28 to 1.98) 








pain over 2 
Age, sex and 
BMI 
NR β (95% CI) 
β=2(-8 to 11) 
NA High (56) 


















change over 2 







BML score (C) 

















Medial tibia & 
femur 
OR 1.41 
(0.86 to 2.33) 
Lateral tibia & 
femur OR 1.70 
(1.07 to 2.69) 
+ 
Lateral TFJ BML 
score associated 
with incident 







MRI BML, size 













change in MRI 
BML size (L) 
















OR 3.0 (1.5 to 
6.0)  
OR (CI 95%) 
Incident frequent 
knee pain 
P for trend =0.006 
Severity of 
frequent knee pain 







































WORMS  (L) 
WOMAC 
pain  (L) 













Nil NR NR NA Low (50) 













NR OR 1.44 
CI 95% (1.04, 
2.00) 





















NR BMLs in any 
compartment 
OR 1.96 (95% CI 
1.38 to 2.77 














Age, sex, and 
BMI 
NR OR, 1.13 
CI 99%  (0.41, 
3.11) 
p=0.76 











p for trend 
p=0.0009 
p for trend 
p=0.006 
+ High (71) 









































NR Isolated BML  of 
the: 
Lateral PFJ 






PFJ BMLs OR 6.6 
(1.7 to 11.5) 




volume in the 













NR Total BML 
volume 























CI 95% (-0.04 to 
0.14) 
Stair climbing pain 
R=0.09 (0.00 to 
NC High (68) 























& PFJ (C) 
Pain VAS 
(C) 
Age, BMI Coefficient 5.00 
CI 95% (3.00, 
7.00) 
Coefficient  3.72 
CI 95%  (1.76, 
5.68) 


















NR BML summary 
score medial TFJ 
OR 2.33 




Severity of BML is 
proportional to 









BML score (C) 












NR Bone marrow 
lesion score 
OR 0.95 
CI 95% (0.63, 
1.44) 



















NR + High (64) 




















































p<0.01   
Pain VAS 
r=0.488,p<0.01  











Nil OR 5.0 
CI 95% (2.4, 
10.5) 





MRI BML (C) 
WOMAC 
pain (C) 
















p<0.001 OR 3.31 
CI 95% (1.54 to 
7.41) 
+ Low (54) 




























Nil NR NR NA Low (46) 






MRI BML size 
(WORMS) (C) 








NR Whole knee OR 
2.8 









MRI BML size 
increase 
(WORMS) (L) 
TFJ & PFJ 
Incident 
frequent 











CI 95% (2.1, 
8.1) 
OR 3.2, 
CI 95% (1.5, 6.8) 












(C) after 2 
years 
Nil OR 1.70 
CI 95% (1.08, 
2.67) 















Nil NR Data not shown NA Low (47) 









































NR + Low (53) 
















CI 95% (1.06 to 
4.77) 













Age, sex, BMI NR OR 0.97 
CI 95% (0.86 to  
1.10) 






& PFJ (C) 
Pain VAS 
(C) 
Nil Coefficient 1.18 
CI 95% (0.63, 
1.72) 
Coefficient 0.50 
CI 95% (0.07, 
0.94) 







Nil P<0.001 NR + High (61) 


















































Nil OR 4.2-6.4, 
p=0.001-0.011 

























Nil NR NR NA 
 
Low (46) 














NR Whole knee 
Severe osteophyte 
OR 4.7 






















(C) TFJ & PFJ months (L) 






















OR (CI 95%) 
Pain severity  
OR 1.6 
(1.1 to 2.3) 
Nocturnal Pain 
OR 1.1 (0.5 to 
2.1) 
OR (CI 95%) 
Pain severity OR 
0.9 
(0.6 to 1.4) 
Nocturnal Pain 









& PFJ (C) 
Pain VAS 
(C) 
Nil Coefficient  
3.33 
CI 95% (1.79, 
4.87) 
Coefficient  1.91 
CI 95% (0.68 to 
3.13) 
+ High (68) 












(C) after 2 
years 
Nil OR 2.40 



























NR Medial SSR 




































OR 1.27 95%CI 
(0.86, 1.88) 
p=0.19 
















NR + Low (50) 





MRI bone cyst 
size 




Nil NR NR analysis 
described as not 
significant but data 
not shown 
NA Low (53) 











Nil NR Patellofemoral 
OR 1.83 
CI 99% (0.80 to 
4.16) 
NA High (71) 
Torres 
2006[135] 




Age, BMI Coefficient  
2.50 
Coefficient 0.82 
CI 95%(-0.50 to 
NA High (68) 































Age, sex, and 
BMI 













Nil OR 6.7-17.8 
p=0.004 to 
0.03 






bone cyst (C) 
WOMAC 
pain (C) 
Nil p>0.05 NR NA Low (54) 





MRI bone cyst 
size (WORMS) 






Nil NR NR 
p>0.1 






MRI bone cyst 
size (WORMS) 




(C) after 2 
years 
Nil OR 1.61 
CI 95% (1.03, 
2.52) 
NR + Low (59) 
qCT Bone mineral density – cross-sectional studies 























facet (qCT) (C) 
WOMAC – 
knee pain 
at rest (C) 





NR -  Low (57) 




2D bone shape 
knee 
1. femur & 
tibial width 










adjusted for  
Age, BMI 











bone width with 
pain severity 
Low (46) 
Positive correlation reported between bone feature and outcome measure (+); Negative correlation reported between bone feature and 
outcome measure (-); body mass index (BMI); bone marrow lesion (BML); a feature or outcome described in cross-section (C); knee pain 
on most days for at least the last month (chronic pain) confidence interval (CI); Kellgren Lawrence (KL); a feature or outcome described 
longitudinally(L); No association (NA); No conclusion could be found for an association between bone feature and outcome measure 
(NC); not reported (NR);  osteoarthritis (OA); Osteoarthritis Initiative (OAI); odds ratio (OR); Patellofemoral joint (PFJ); Subchondral 
surface ratio (SSR); Tibiofemoral joint (TFJ); visual analogue scale (VAS); Western Ontario and McMaster Universities arthritis index 









































OR 2.73 95% CI 
(1.29 to 5.78) 
NR + 
Bigger the BML, 
the more the 
JSN 
High (61) 








BML (Oslo MRI 
hand score) (C) 
IPJs 
Radiographic 
JSN grade IPJ 
(OARSI atlas.) 
(C) 
Age, sex,  OR 10.0 95%CI 
(4.2–23) 










BML (Oslo MRI 
hand score) (C) 
IPJs 
Hand KL 
grade of IPJs 
(C) 
Age, sex NR OR (95%CI) 
BMLs 11(5.5 to 
21) p<0.001 
+ High (64) 






hand score) (C) 
IPJs 
Hand KL 
grade of IPJs 
(C) 
Age, sex NR OR (95%CI) 
Osteophytes 
415 (189 to 908) 
p<0.001 
+ High (64) 





























grade of IPJs 
(C) 
Age, sex NR OR (95%CI) 
Attrition 87 (37 to 
204) 
p<0.001 
+ High (64) 





Cyst (Oslo MRI 
hand score) (C) 
IPJs 
Hand KL 
grade of IPJs 
(C) 
Age, sex NR OR (95%CI) 
Cysts 2.0 (0.6 to 
6.3) 
P=0.26 
nil High (64) 


































NA OA hip presence 
OR (95% CI) 





coefficient (95% CI) 
+ 
BMLs associated 





























(-456 to -36) 
p=0.02 


























































NR p<0.0001 + 
Higher BMD for 
higher grade of 
OA of hip 
High (64) 



























of the femoral 
neck of left 
(nondominant) 























and hip ROA 


























































stage ROA hip  







6.82 (3.55 to 
13.10) 
OR (95%CI) 
Incident ROA hip 






















































within 5 years 
of: 
1.ROA hip (KL>1)  
2.End-stage OA  








































2D deformity:  














NR RR (95% CI) 
Pistol grip 

























































CAM deformity  
-0.24 mm (95% 






CAM deformity  
-0.19 mm (95% 












































5.75 (4.00 to 
8.27) 
Femoral head-
to-neck ratio  










12.08 (8.05 to 
18.15) 
 
+ Low (53) 





























THR vs no 
radiographic 
progression 

























































































ROA KL grade 
and JSN (C) 
Age, 
gender, BMI 





+ High (71) 








































Nil 0.62 to 0.75 
(p<0.01) 
NR + Low (57) 
Positive correlation was reported between bone feature and outcome measure (+); Negative correlation reported between bone feature 
and outcome measure (-);  bone mineral density (BMD); bone marrow lesion (BML); a feature or outcome described in cross-section (C);  
Computed tomography (CT); dual-energy X-ray absorptiometry (DXA); Hip Osteoarthritis MRI scoring system (HOAMS); interphalangeal 
joint (IPJ); joint space narrowing (JSN); joint space width (JSW); Kellgren Lawrence (KL); a feature or outcome described 
longitudinally(L); No association (NA); magnetic resonance imaging (MRI); patellofemoral joint (PFJ); radiographic osteoarthritis (ROA); 
osteoarthritis (OA); Osteoarthritis Research Society International (OARSI);  odds ratio (OR); relative risk (RR); tibiofemoral joint (TFJ); 
total hip replacement (THR);  total knee replacement (TKR); visual analogue scale (VAS); Western Ontario and McMaster Universities 
arthritis index (WOMAC); whole-organ magnetic resonance imaging score (WORMS).   
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Table 20 Hand and Hip Pain associations by feature and quality score 
Author Feature 
(method) 


















Hand OA MRI 
score) (C) 
AUSCAN 
pain scale (L) 
Age, sex, BMI, 
follow up time 
NR β=-0.26 95%CI  
(-0.55 to 0.03) 
NA High (61) 









pain scale (C) 
Age, sex NR OR (95%CI) 
0.96 (0.82 to 
1.12) 
NA High (64) 










pain scale (C) 
Age, sex NR OR (95%CI) 
1.04 (0.98 to 
1.10) 
NA High (64) 











pain scale (C) 
Age, sex NR OR (95%CI) 
1.15 (0.98 to 
1.34) 
NA High (64) 
























pain scale (C) 
Age, sex NR OR (95%CI) 
0.93 (0.56 to 
1.55) 
NA High (64) 
















NR NA Low (57) 










Nil NR p correlation -
0.29 (p<0.01) 
-  
A higher BML 
score means a 














Nil p<0.001 NR + High (64) 








Nil NR p correlation 
-0.37 (p<0.001) 
- 
a higher cyst 
High (71) 















 cyst score (C) HOOS score 
(C) 
score means a 




Positive correlation reported between bone feature and outcome measure (+); Negative correlation reported between bone feature and 
outcome measure (-);  Australian/Canadian Osteoarthritis Hand Index (AUSCAN); bone marrow lesion (BML); a feature or outcome 
described in cross-section (C); knee pain on most days for at least the last month (chronic pain); Hip Osteoarthritis MRI scoring system 
(HOAMS); Hip Dysfunction and Osteoarthritis Outcome Score (HOOS); interphalangeal joint (IPJ); a feature or outcome described 
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Pain and structural associations  










No LPS (w) 
No severity (n)  





LPS (n) Severity (n) No severity (n)    
MRI bone 
attrition 
No Progression (0) No severity 
(0) 








  No severity (0)   
MRI bone cyst No progression 
?severity  
No LPS (n) No severity (n) No severity (n)  Severity (n)  
MRI or CT 
trabecular 
morphometry 
Progression (n)    Severity (n)   
DXA or CT  
Peri-articular 
BMD 
Progression (n)    Severity (w)   
2D bone 
shape 
Severity (w)  Severity (n)   Progression (i) 
THR (i) 
  
Scintigraphy No Progression (0)   No severity (n)   Severity (w) 
Computed tomography (CT), dual energy X-ray absorptiometry (DXA). independent association (i), incident frequent pain (IFP), 
association with no or inadequate covariate adjustment (n), total knee replacement (TKR), total hip replacement (THR), mean change in 
longitudinal pain severity (LPS), well-adjusted association (w), association insignificant after covariate adjustment (0).. 





This systematic review is the first to have incorporated quality scoring 
alongside statistical adjustment in the comprehensive examination of the 
relationship of subchondral bone pathology with both structural progression 
of OA and pain for all non-conventional types of radiological imaging of 
peripheral joints with OA. This systematic review has concluded that there 
were independent associations between imaging-assessed bone 
pathologies and structural progression and pain in the knee, hand, and hip.  
Subchondral bone pathology may lead to cartilage degeneration by altering 
the biomechanical force distribution across joint cartilage or disruption of the 
osteochondral junction and release of soluble biomediators influencing the 
cartilage[15, 219] (as discussed in 2.6.1 Subchondral bone cellular changes 
in OA). In OA the homeostatic process of subchondral bone remodelling fails, 
leading to increased bone turnover, volume and change in stiffness and 
shock-absorbing capacity[227, 610, 611]. BMLs histologically represent 
increased bone turnover[297] as discussed in 2.6.3.4 Subchondral bone 
marrow lesions. Cartilage overlying altered bone demonstrates greater 
damage than healthy bone in human cadaver knees[226]. That study, and an 
excluded study[612], concur with the independent association between 
BMLs, and structural progression of OA in knees and hands and total knee 
replacement, as concluded by  this analysis.  Although randomised control 
trials were not excluded from this review, several such trials were excluded 
on the basis of failure to formally quantify any correlation between BMLs with 
structural progression outcomes. These include the strontium[336], intensive 
weight-loss therapy [613] and glucosamine [614] trials and some of these 
describe a concordant reduction in BML size and cartilage volume loss.  
Osteophytes represent subchondral bone hypertrophy typical of OA as 
discussed in 2.6.3.6 Osteophytes. They represent endochondral and direct 
bone formation and create a circumferential increase in bone area around 
each knee cartilage plate, particularly on the medial side in OA, which 
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concurs with the independent association of  MRI osteophytes with structural 
progression observed in this analysis. 
In terms of bone morphology,  knee OA is associated with shallow trochlear 
patellar grooves in multiple epiphyseal dysplasia[273]. These findings concur 
with the findings of Stefanik and Kalichman and colleagues in knee OA in 
this review[274, 568, 569].  Anterior-cruciate ligament (ACL) rupture 
represents a risk factor for developing knee OA. In cases of ACL tear in 
previously normal knees of young healthy adults, the 3D shape of the femur, 
tibia and patella expands more rapidly than controls without radiographic 
knee OA in the subsequent 5 years[615]. The 3D shape of the same knee 
bones have also been associated with the outcome of joint 
replacement[616]. This highlights the importance of bone shape, as 
discussed in 2.6.3 Bone shape and subchondral bone MRI features in OA, 
and concurs with the conclusion from this systematic review that 3D knee 
shape and 2D hip shape are independently associated with structural 
progression and total joint replacement.  
The literature review (in 2.6.3.5 Subchondral bone attrition and 2.6.3.7 
Subchondral bone cysts) indicated that bone attrition and cysts were 
associated with structural severity of OA. However this more rigorous 
systematic review identified that bone attrition and cysts were associated 
with structural progression or severity but not after covariate adjustment, 
which included other OA subchondral bone features. This suggests these 
bone features are epiphenomenon of the pathogenic process of structural 
progression rather than a primary cause. This hypothesis is supported by 
bone cysts and attrition frequently occurring synchronously with BMLs[139, 
601] and incident bone attrition has been strongly associated with the 
presence of BMLs within the same compartment[300].  
Increasing bone volume fraction, trabecular number and thickness, but 
decreasing trabecular spacing on CT and MRI studies were associated with 
structural progression. These specific associations concur with numerous 
human histological and histomorphometric analyses of peripheral joint OA 
subchondral bone samples removed at the time of joint replacement or from 
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post-mortem joints with early OA and subsequently compared with normal 
post-mortem joints with age and gender matching [207, 617, 618].  
Subchondral bone, particularly BMLs, have been found to be associated with 
knee, hip and hand OA pain. However some analyses measuring pain with 
heterogenous pain outcomes, report an absence of a longitudinal or cross-
sectional association with BMLs [302, 319, 619]. Furthermore previous 
systematic reviews have concluded an at-most moderate association of 
BMLs with knee pain[132, 365]. With the benefit of incorporating more well-
adjusted analyses in this systematic review, we have highlighted that BMLs 
are independently associated with change in longitudinal pain severity but 
are only associated with incident frequent knee pain. In analyses excluded 
from the current review, incident knee BMLs predicted incident knee pain in 
healthy community-based adults at risk of OA[121].  Concurrent trends in 
reduction of pain and BML size are observed in  the zoledronic acid trial[330] 
and the intensive diet and exercise for arthritis trial [620]. These were not 
included because they did not make a formal comparison of pain and BMLs. 
The mechanism by which BMLs may cause pain is unknown but may include 
subchondral microfractures, angina from a decreased blood supply causing 
ischaemia and raised intraosseous pressure[136-138].   
The independent association of a mismatch of the femoral and tibial 
articulating surface areas with incident frequent knee symptom indicates that 
bone shape may predict not only the incidence of radiographic knee OA[75] 
but also symptomatic OA.   
3.6 Limitations 
In terms of limitations, stratifying observational studies by quality may 
artificially create relatively high quality studies from a collection of generally 
low quality studies. However the distribution and summary statistics of 
quality scores indicate a suitably broad range of quality, particularly in the 
influential cohort studies with a mean of 54% and range of 22-83%.  The 
decision to exclude articles with any association analysis of less than 20 
patients with OA may seem arbitrary. However several papers report the 
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presence or absence of pain or structural progression associations based 
upon small numbers of patients. Our threshold decision reflects the absence 
of specific guidelines on how to exclude such papers, with inherent risk of 
imprecision, in the context of heterogenous populations and statistical 
analyses. Had these papers been included there would have been no 
change in any of the conclusions in Table 21 (data not shown).  The use of 
joint replacement as an outcome measure has a number of limitations 
including the effect of patient willingness, orthopaedic variation in opinion, 
availability of health services and health insurance and therefore may be 
influenced depending upon which country and context the study is 
performed in.  
Each of the analyses of association of bone features with the outcomes of 
structural progression, pain or joint replacement include a variety of different 
covariates for adjustment. For the purposes of this systematic review the 
persistence of an association after adjustment for age, gender and BMI 
represented an association that was ‘well-adjusted’ for important covariates 
of OA. However OA is a multi-tissue disease where the pathology of tissues 
other than subchondral bone also contribute to structural progression and 
pain. Therefore when describing bone feature associations with structural 
progression or joint replacement, the lack of adjustment for other tissue 
degeneration or the interaction of obesity and alignment may represent 
residual confounding (2.11.2.1.3  Categorical Alignment of the knee). 
However the association of BMLs with cartilage loss persists after adjusting 
for alignment[124], meniscal degeneration[599], baseline cartilage volume 
and bone area[600], as well as bone attrition and bone cysts[478]. 
Similarly when describing the association of bone features with pain, the lack 
of adjustment for synovitis (which is moderately associated with knee OA 
pain[132]) may represent residual confounding. However the association of 
BMLs with pain severity and incident frequent knee pain persists after 
adjustment for synovitis in an analysis performed by Zhang and 
colleagues[26].  
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Publication bias could not be assessed with a funnel plot as there were 
insufficient results for odds and relative risk ratios. The heterogenous nature 
of the measures of bone features and structural or pain outcomes, precluded 
a meta-analysis or calculation of an effect size. This was because there 
were insufficient analyses describing the same association between the 
same bone feature and outcome measure pair. 
Ultrasound represents an important and increasingly accessible imaging 
modality for use in routine clinical practice. It is a sensitive imaging 
technique for detecting 3D, early and established structural pathology in OA 
joints and can directly visualise osteophytes, sclerosis and cysts in the 
subchondral bone[621]. Therefore this modality could have been included in 
this review.   
3.7 Conclusions 
In conclusion subchondral bone plays an integral role in the pathogenesis of 
OA. BMLs, MRI osteophytes and tibial bone area are independently 
associated with structural progression of the knee. BMLs and 2D tibial bone 
area are independently associated with total knee replacement. BMLs are 
independently associated with hand OA structural progression and 2D hip 
bone shape is associated with structural hip progression and total hip 
replacement. BMLs are independently associated with longitudinal change in 
pain severity and femorotibial articulating area mismatch is independently 
associated with incident frequent knee pain  
The existing standard for measuring structural progression, radiographic 
joint space narrowing (JSN), poorly correlates with the clinical syndrome and 
remains a relatively insensitive measure (see  2.11 Imaging biomarkers in 
OA). When JSN is used as a trial outcome measure this demands that 
clinical trials are large, long  and expensive. Therefore the unmet need for 
more sensitive and validated imaging biomarkers is huge. 
The independent associations of subchondral bone features with important 
patient-centred outcomes (pain and TKR) and structural progression  
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suggest they may be valid surrogate measures of these outcomes. While 
many of these are MRI-derived measures, they are intrinsically more 
sensitive than radiographic JSN (see  2.11Imaging biomarkers in OA), their 
use as clinical outcomes may substantially reduce the cost, duration and 
size of future trials. They may also improve the precision of OA phenotypic 
stratification to facilitate pathology-specific treatment, prioritisation of 
individuals most in need of OA modification and measuring treatment 
response.  
This systematic review highlights the need for greater information on the 
validity of subchondral bone features to be used as surrogate measures of 
OA patient-centred outcomes in all joints. There was very little evidence 
describing the validity of 3D bone shape as a surrogate measure. This 
unmet need was addressed in writing the following chapters. 
 
3.8 Thesis findings and the recent literature 
The systematic literature review undertaken here in Chapter 3 was inclusive 
of studies up to September 2014. However in order to ensure this literature 
review is up to date, the literature in the intervening period has been 
reviewed to assess whether it would change the conclusions made in this 
Chapter. Cohort studies are described separately from cross-sectional and 
case-control studies in accordance with the methods of this chapter.  
 
3.8.1 The relationship between knee bone feature and structural 
progression  
3.8.1.1 Cohort studies 
In total three new cohort studies were identified. Sharma and colleagues 
identified a subcohort of knees ‘at risk’ of knee OA that did not have 
radiographic OA within the OAI. Knee BMLs at baseline were independently 
associated with an increased risk of incident radiographic OA [622]. Wluka 
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and colleagues described an analysis of knees in a community cohort 
without knee OA symptoms. Knee BMLs at baseline were associated with 
medial tibiofemoral cartilage volume loss[623]. Wang and colleagues 
established a longitudinal cohort of knees of older adults and patellar BMLs 
at baseline were independently associated with progressive cartilage 
loss[624]. These associations have already been described as independent 
associations already and therefore these new reports would not change the 
conclusions of this chapter. 
3.8.1.2 Cross-sectional or case-control studies 
In total two new case-control studies were identified and both were nested 
within the OAI. Roemer and colleagues described an association of incident 
radiographic knee OA[122] with knee bone marrow lesions. Hunter and 
colleagues performed a case-control study that identified that longitudinal 
change in bone shape biomarkers of bone area (tAB) and 3D bone shape 
were both associated with medial tibiofemoral structural progression [625]. 
In this chapter, the methods clarify that case-controls cannot be used to 
describe the independence of an association and therefore the conclusions 
of this chapter would not change with these new findings. 
 
3.8.2 The relationship between subchondral bone features and 
pain 
3.8.2.1 Cohort studies 
In total three new cohort studies were identified. Sharma and colleagues 
identified a subcohort of knees ‘at risk’ of OA that did not have radiographic 
OA within the OAI. Within this subcohort knee BMLs at baseline were 
independently associated with an increased risk of incident persistent knee 
pain [622]. Wluka and colleagues described an analysis of knees in a 
community cohort without knee OA symptoms.  Knee BMLs at baseline were 
associated with incident pain [623]. Wang and colleagues established a 
longitudinal cohort of knees of older adults and patellar BMLs at baseline 
were independently associated with progressive knee pain[624]. 
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These associations have already been described as independent 
associations and therefore these new analyses will not change the 
conclusions within this thesis.  
3.8.2.2 Cross-sectional or Case control studies 
In total one new case-control study and one cross-sectional study were 
identified. Hunter and colleagues performed a case-control study nested 
within the OAI that identified that longitudinal change in bone shape 
biomarkers of bone area (tAB) and 3D bone shape were both associated 
with knee pain progression. However the associations with pain progression 
were less strong compared to structural progression [625]. 
Stefanik and colleagues described a cross-sectional sample of knees within 
the MOST and Framingham OA participants. An association between the 
presence of knee BMLs in the patellofemoral joint and pain was 
observed[626]. The methods in this chapter clarify that case-controls cannot 
be used to describe the independence of an association and therefore the 
these new analyses will not change any previous conclusions. 
 
3.8.3 The relationship between subchondral bone features and 
joint replacement  
3.8.3.1 Cohort studies 
In total two new cohort studies were identified. Agricola and colleagues 
established that in the Cohort Hip and Cohort Knee and Chingford cohorts 
femoral bone shape based upon hip radiograph segmentation was 
independently associated with incident joint replacement of the hip[627]. 
Hafezi-Nejad and colleagues established that in a subcohort of knees within 
the OAI, baseline semi-quantitative knee BMLs were  associated with 
incident total knee replacement [628]. These associations have already been 
described as independent associations and therefore these new analyses 
will not change the conclusions of this chapter. 
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3.8.3.2 Cross-sectional and case-control studies 
In total only one new case-control study was identified. Roemer and 
colleagues described an association of incident total knee replacement [105] 
with knee BMLs. This was a case-control study nested within the OAI. This 
association has previously been described in this chapter and will not 
change the conclusions in This chapter. 
 
  




Chapter 4 The relationship between clinical characteristics, 
radiographic osteoarthritis and 3D bone area 
4.1 Introduction 
In chapter three the systematic literature review identified the need for 
evidence of the validity of 3D bone measures as imaging biomarkers. This 
chapter describes construct validity by exploring the relationship of 3D bone 
structure of OA with the established constructs of radiographic structural OA 
severity.  
Until recently, structural modification trials have relied upon conventional 
radiography to define both the OA phenotype for participant inclusion and for 
measuring structural progression. Conventional radiography is less sensitive 
and specific in detecting structural pathology and structural progression than 
magnetic resonance imaging (MRI) [23, 86]( 2.11 Imaging biomarkers in OA). 
MRI is therefore increasingly used to provide assessment of OA pathology.  
Another advantage of MRI is that its three dimensional data can be 
harnessed to provide quantification of important tissues using manual 
segmentation [31, 269, 440, 560], or automated analysis techniques such as 
active appearance modelling (AAM) that enables relatively rapid, accurate 
quantification of large datasets [629, 630](2.10 Statistical Shape modelling, 
active shape modelling and active appearance modelling). 
Modern imaging approaches recognise that OA is a whole joint disease 
which may involve multiple tissues which confer different phenotypes[631]; 
subchondral bone in particular is integral to the pathogenesis and 
progression of OA [255, 631](2.6 Subchondral bone in OA). In particular, the 
area of subchondral bone (Figure 23) at the femorotibial articulation is larger 
in OA knees than healthy controls and correlates with knee joint space 
narrowing, osteophytes and Kellgren Lawrence (KL) grade after adjusting for 
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at least age and body mass index in cross-sectional studies[31, 269, 560]. 
While the severity of conventional radiographic OA may correlate with 
subchondral bone area expansion, the additional value of bone area 
expansion of OA and the extent to which radiographic measures explain 
variation in this is unknown. Height, weight, gender and age are 
determinants of bone area in healthy knees [256, 257].Therefore the 
objective of this study was to determine the bone area expansion attributable 
to OA and then establish what proportion of the variation of this is explained 
by radiographic measures of knee OA (metric joint space width, osteophyte 
grade and, subchondral sclerosis grade).  
 
4.2 Methods 
Data used in the preparation of this cross-sectional analysis were obtained 
from the NIH Osteoarthritis Initiative (OAI) database, which is available for 
public access at http://www.oai.ucsf.edu/  and is described in 2.12 The 
Osteoarthritis Initiative. This is a database of a multi-centre, prospective, 
longitudinal observational study of knee OA including approximately 4796 
participants [515]. Knee radiographs and knee MRI scans were performed at 
baseline for all participants.  
The main subsample of knees was selected from those with available 
Kellgren Lawrence (KL) and other radiographic OA measure scoring from 
the central Boston University reads of plain films in the OAI. The availability 
of osteophyte and subchondral sclerosis scores was limited to knees of 
individuals who have had confirmed presence of radiographic OA (KL grade 
≥2) in either knee at any time point. Participants without available KL, 
osteophyte and subchondral sclerosis grade data were excluded and the 
knee with the highest KL grade for each participant was selected. When the 
grades for both knees were the same, the right knee was chosen. Baseline 
MRI, radiographic and clinical data were included. A second subsample of 
‘normal’ knees was selected in order to establish a formula for predicting 
‘normal’ bone area based upon height, weight, age and gender. From the 
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whole OAI cohort only knees were included with KL and WOMAC scores of 
zero at baseline, one, two and four year time points and the absence of any 
historic OA knee symptoms prior to baseline. 
MRI sequences collected in the OAI are described in detail by Peterfy and 
colleagues [497].  The current study utilised the double-echo-in-steady-state 
sequence (DESS-we) of the Siemens 3T trio systems [497]. A training set of 
96 knee MRIs, using the DESS-we sequence, were used to build active 
appearance models for the tibia and femur. This training set was selected to 
contain examples of each stage of OA with approximately equal numbers of 
knees fulfilling each KL grade. The mean bone shape had anatomical 
regions outlined as described previously (Figure 44)[632]. We used a 
definition of the area of subchondral bone or ‘tAB’ similar to that designated 
by a nomenclature committee [271]. However this definition was modified to 
include bone (‘peripheral osteophytes’) from around the cartilage plate. The 
boundary between the medial femur (MF) / medial trochlear femur and the 
lateral femur / lateral trochlear femur boundary in the femur was defined as a 
line on the bone corresponding to the anterior edge of the medial or lateral 
meniscus, and extended smoothly to the edge of the tAB. Active appearance 
models were used for the calculation of tAB from knee MRIs which 
measured the undulating 3D surface of bone. The surface area of the 3D 
subchondral bone (tAB) was measured in mm2.  
The medial compartment of the tibiofemoral joint was selected to compare 
medial femur (MF) tAB and medial tibia (MT) tAB with medial joint 
radiographic measures on the basis that this compartment is more frequently 
affected with OA. The following baseline radiographic OA measures are 
described earlier (2.11.1.1 Conventional radiographic quantitative 
measures263 and 2.11.2.1 Conventional radiographic semi-quantitative 
measures). These were selected and divided into three non-KL (OARSI and 
metric) measures and KL grade: metric minimum joint space width (mJSW) 
of the medial compartment on continuous scale, subchondral sclerosis score 
of the medial femur or tibia (OARSI categorical scale 0-3), osteophyte score 
of the medial femur or tibia (OARSI categorical scale 0-3), KL grade 
- 264 - 
264 
 
(categorical scale 0-4). These assessments were provided by the OAI. A 
semi-automated tool, shown to be as sensitive as manual measures, was 
used to measure mJSW [424, 633]. Further details of the methodology for 
these assessments is available [634]. 
Clinical baseline characteristics, provided by the OAI, included the known 
important clinical risk factors for knee OA: age, gender, weight, height and 
ethnicity and goniometer-measured knee alignment [59, 635, 636]. It was 
this existing clinical knowledge, not a data-driven strategy, that guided the 
selection of covariates for statistical modelling. 
 
Figure 44 Anatomical Bone areas 
 
LF (lateral femur), MF (medial femur), MT (medial tibia), LT (lateral tibia), MP 
(medial patella), LP (lateral patella), LatPF (lateral trochlear), MedPF (medial 
trochlear) 





4.2.1 Statistical analysis 
Statistical analysis was conducted using STATA software, version 12 
(College Station, TX, 2009). For categorical socio-demographic variables, 
chi- square tests were performed comparing participants with radiographic 
OA and those without radiographic OA. Alignment was trichotomised into 
extreme valgus (<-6°) intermediate alignment (-6° to 6°; reference category) 
and extreme varus (>6°).  
To establish which covariates might operate as potential confounders, 
mediators or competing exposures in the multivariable regression analyses 
exploring the amount of variation explained by radiographic measures, a 
causal path diagram was constructed in the form a Directed Acyclic Graph 
(DAG) [637].This was drawn from established and hypothesized functional 
relationships between bone area and each covariate. No non-causal 
structural association between the radiographic exposure and the bone area 
outcome was identified (Figure 45).   
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Figure 45 A directed acyclic graph 
 
A DAG is used to establish which factors are confounders and mediators to 
ensure a parsimonious model is achieved and that over-adjustment does not 
in the statistical analysis.  
 
The benefit of this approach is that it provides an explicit a priori model of 
the postulated relationships between the exposure, outcome variables and 
each of the available covariates. Such models are invaluable for the 
specification and verification of the statistical analyses and results in 
appropriate adjustment and the most parsimonious model being chosen 
without the risk of over adjustment and thus reduction of statistical power 
which would otherwise occur.  
The first analyses used the ‘normal’ subsample to obtain estimates of what 
normal bone area should be in the normal population. These estimates were 
obtained by modelling bone area with height, weight and age, stratified by 
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sex thereby producing estimates that accounted for the sex differences in 
bone area (2.6.3.1.1 Knee subchondral bone cross-sectional area). Having 
obtained the estimates, predicted bone area could be calculated for each of 
the 2588 knees in the main subsample. 
Bone area (MF) =intercept + (A)(HEIGHT) + (B)(WEIGHT) + (C)(AGE) +ε  
 This was subtracted from the measured bone area (tAB) in each of the 2588 
knees to provide the area of bone attributable to OA (OA-tAB) 
Multivariable linear regression models were then constructed to determine 
the proportion of OA-tAB for MF and MT that could be explained by either 
non-KL measures of radiographic damage (joint space width, sclerosis, 
osteophytes) or KL grade. Although the methods of scoring non-KL 
measures of damage are different to that included in the KL scoring system, 
they measure similar pathology therefore models did not include both to 
avoid multicollinearity. These models were adjusted for alignment and 
ethnicity in different combinations and at each stage.   
 For univariable analyses two-tailed p-values have been presented (p<0.05 
was considered evidence of association without adjustment for multiplicity); 
for multivariable analyses 95% confidence intervals have been provided to 
give an indication of significance at the 5% level. However due to the large 
sample size we have considered both statistical significance and the 
associated improvement in R-squared when reporting which variables were 
associated with tAB to a substantive extent.  Normality of residuals and 
homoscedasticity of errors was assessed using residual diagnostic plots as 
well as formal tests of heteroscedasticity (White`s test and Breusch-Pagan 
test) and underlying assumptions of a Gaussian distribution and 
homoscedasticity were met. 
4.3 Results 
Of the 4796 participants in the OAI database 131 met the criteria for ‘normal’ 
knees (Figure 46). Mean age was 60 years and 58 % were female with 12 % 
being obese (BMI greater than 30kg/m²). Of the 4796 participants in the OAI 
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database, 4490 had KL data available. After applying the inclusion criteria 
for selection of the main subsample, 2588 (57%) knees had radiographic 
and clinical data available for analysis (Figure 47). Mean age was 61 years 
and 58% were female with 37% being obese.  
Figure 46 Participant flow diagram for the ‘normal’ knee subsample 
 
Identifying suitable knees for describing the association of bone area with 
height, weight and age in knees without OA.  
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Figure 47 Participant flow diagram 
 
Identifying suitable knees for describing the association of OA-attributable 
bone area with conventional radiographic measures of OA.  
4.3.1 Models of the ‘normal’ knee subsample with clinical data 
When considering the clinical covariates stratified by sex, height, weight, and 
age in males explained 22.5%, 21.6%, and 3.5% of the MF tAB variance 
respectively in univariable analyses. In females these clinical covariates 
explained 43.1%, 32.1% and 0.1% of the MF tAB (Table 22). Similar values 
were identified for MT tAB (Table 23). The greatest variance in tAB was 
explained by height in both medial compartment models in both sexes. 
When all the clinical covariates were entered in the model they explained 
26.6% and 28.9% variance in MF and MT tAB respectively for males, while 
in females they accounted for 54.4% and 53.7% in MF and MT tAB 
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respectively (Table 24, Table 25). In general, taller and heavier individuals 
had greater tAB (Figure 48). Females were more likely to have smaller tAB 
having adjusted for height and weight compared to males (Table 26, Table 
27).  Considering Table 22 and 23, age was not statistically significantly 
associated with tAB (p=0.08 in Table 23). However it was included in the 
non-exposed group models due to existing clinical knowledge that bone 
expands with age and hence it was included in the DAG. 
In order to check whether the linearity assumption held between age and the 
outcome variable (bone area), a formal statistical test (linktest) was 
performed for each shape model and this was found to be not significant i.e. 
the null model is that the model is linear. 
The hatsq variable using linktest was found to be not significant (p=0.93) and 
coupled with linearity plots which suggested a linear relationship, albeit only 
minimal (Figure 49), there was therefore no evidence of non-linearity or need 
to use higher order terms for age. Hence it was modelled in its original form. 
The augmented component-plus-residual plots (Figure 49, Figure 50) 
suggest mild departure from normality which suggested probably adding a 
squared version of age, however the model fit and other linearity checks 
were satisfactory to suggest a linear relationship between age and MF and 
MT. Therefore the addition of higher order terms (e.g. adding (age)2 for ease 
of interpretation) was considered unnecessary. 
Another non-graphical test, the Breusch –Pagan test was performed to test 
that the model residuals were homoscedastic. The test was not significant 
(p=0.60) and therefore the conclusion was drawn that the model residuals 
were homogenous.  
4.3.2 Models with OA-attributable bone area  
In univariable analysis both varus and valgus alignment tended to be 
associated with larger bone area, and explained 2% and 1.2% of the 
variation in  MF OA-tAB and MT OA-tAB respectively (Model 2; Table 30, 
Table 31). Having adjusted for radiographic measures (models 7 & 8; Table 
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30, Table 31) extreme valgus alignment was not consistently associated with 
differences in bone area to a significant degree.  
When using the non-KL radiographic variables on a univariable basis, JSW, 
osteophytes and sclerosis were each significantly associated with MF OA-
tAB, however each explained just 5.3%, 14.9% and 10.1% of the variance of 
MF OA-tAB (Table 28). Higher grades for osteophytes and sclerosis were 
associated with larger bone areas, whilst wider joint spaces were associated 
with smaller bone areas. In the univariable MT OA-tAB models, the variance 
explained by JSW, osteophytes and sclerosis was 6.0%, 10.1% and 8.3% 
respectively (Table 29).  
When entered simultaneously into a model that did not adjust for alignment, 
the non-KL radiographic variables were associated with OA-tAB 
independently of each other, but accounted for just 17.4% and 12.9.% of the 
variance in MF and MT OA-tAB respectively (Model 3: Table 30, Table 31). 
In the MF OA-tAB model some counter-intuitive trends were observed such 
as a wider JSW being associated with a larger bone area.  
Adjusting for  alignment, when entered individually JSW, osteophytes and 
sclerosis were still independently associated with OA-tAB in the expected 
direction, and explained an additional 6.7%, 17.2.% and 11.5% of MF OA-
tAB variance (Models 4, 5 & 6: Table 30). When entered simultaneously the 
radiographic variables explained 18.7% of MF OA-tAB variance having 
adjusted for alignment (Model 7, Table 30). Comparing models 4 and 7, after 
adjusting, alignment and the non-KL radiographic variables the association 
between JSW and OA-tAB was reduced in magnitude, to the extent that it 
did not differ significantly from zero. Similarly in model 7 the differences in 
OA-tAB between knees with sclerosis grades 1-3 and those without sclerosis 
were reduced compared to model 6, although grades 2 & 3 still differed from 
grade 0. The coefficients for osteophyte grades 1, 2 & 3 remained 
comparatively stable between models 5 & 7.  
Adjusting for alignment, JSW, osteophytes and sclerosis explained an 8.3%, 
12.8% and 10.4% MT OA-tAB variance individually (models 4, 5 & 6: Table 
31); when entered simultaneously they explained   approximately 13.5% of 
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variance in MT OA-tAB (Model 7,Table 31). Similar trends to those found for 
MF OA-tAB were observed in the differences in the non-KL radiographic 
variable coefficients between models 4-6 and model 7. 
When using the KL grade on a univariable basis, grades 1-4 were 
associated with greater OA-tAB compared to grade 0; the higher the grade, 
the greater the difference (Table 28, Table 29). Having adjusted for 
alignment, (Model 8: Table 30, Table 31) the differences were slightly 
reduced in magnitude for KL3 and KL4, but KL remained independently 
associated with both MF and MT OA- tAB. Compared to the model in which 
the non-KL radiographic variables were entered simultaneously whilst 
adjusting for clinical variables (Model 7: Table 30, Table 31), the adjusted KL 
model explained slightly more variance for both MF OA-tAB (adjusted R² 
KL= 0.209 vs non-KL=0.187) and MT OA-tAB (adjusted R² KL=0.147 vs non-
KL=0.135) but the differences were not substantive.




Table 22 Univariable models between medial femur bone area and selected clinical variables in non-exposed group 
Medial femur                               Male model  
Coefficient (95% CI),significance     R-squared                   
                            Female model 
Coefficient (95% CI),significance      R-squared 
Clinical characteristic     
Height (mm)  1.47(0.75,2.18), p<0.001                  0.225 2.13(1.55,2.71), p<0.001                          0.413 
Weight (Kg)  6.57(3.29,9.84), p<0.001                  0.216 10.25(6.87,13.63), p<0.001                     0.321 
Age (yrs)  -4.69(-10.12,0.73), p=0.09                0.035 -0.19(-5.28,4.90),p=0.94                           0.013 
 
Table 23 Univariable models between medial tibia bone area and selected clinical variables in non-exposed group 
Medial tibia                              Male model  
Coefficient (95% CI),significance     R-squared                   
                            Female model 
Coefficient (95% CI),significance      R-squared 
Clinical characteristic     
Height  0.80(0.41,1.20), p<0.001                  0.220 0.98(0.70,1.26), p<0.001                          0.394 
Weight (Kg)  3.92(2.15,5.69), p<0.001                  0.254 4.90(3.31,6.48), p<0.001                          0.329 
Age (yrs)  -2.68(-5.67,0.32), p=0.08                0.039 0.09(-2.31,2.49),p=0.94                           0.013 
 




Table 24 Associations between medial femur bone area and selected clinical variables in non-exposed group 
Medial femur                               Male model  
Coefficient (95% CI),significance     R-squared                   
                            Female model 
Coefficient (95% CI),significance      R-squared 
Clinical characteristic     
Height (mm)  1.01(0.14,1.89) p=0.023    1.79(1.21,2.38) p<0.001 
Weight (Kg)  4.27(0.45,8.10) p=0.029 0.266 6.47(3.38,9.58) p<0.001  0.544 
Age (yrs)  0.84(-4.55,6.24) p=0.755  2.24(-1.46,5.95)p=0.231 
 
Table 25 Associations between medial tibia bone area and selected clinical variables in non-exposed group 
Medial tibia                              Male model  
Coefficient (95% CI),significance     R-squared                   
                            Female model 
Coefficient (95% CI),significance      R-squared 
Clinical characteristic     
Height (mm)  0.50(0.03,0.98) p=0.039    0.83(0.55,1.10) p<0.001 
Weight (Kg)  2.79(0.71,4.87) p=0.010 0.289 3.14(1.67,4.61) p<0.001  0.537 
Age (yrs)  0.44(-2.50,3.38) p=0.767  1.19(-0.57,2.95)p=0.182 
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Table 26 Relationship between medial femur bone area and clinical model not stratified by sex 
Medial femur Coefficient (95%CI) p-value 
Height (mm)  1.48 (0.98,1.98) <0.001 
 
Weight (Kg)  5.08 (2.74,7.42) <0.001 
 
Age (yrs)  2.28 (-0.76,5.32) 0.14 
 
*Sex (female) -253.74 (-339.94,-167.54) <0.001 
 
Table 27 Relationship between medial tibia bone area and clinical model not stratified by sex 
Medial tibia Coefficient (95%CI) p-value 
Height (mm)  0.69 (0.44,0.95) <0.001 
 
Weight (Kg)  2.89 (1.70,4.08) <0.001 
 
Age (yrs)  1.03 (-0.51,2.57) 0.19 
 
*Sex (female) -135.56 (-179.32,-91.80) <0.001 
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Figure 48 The relationship between height and weight on medial femur 
area 
 































1500 1600 1700 1800 1900
Height
weight at m+1sd weight at m-1sd
broken line  represents individuals with weight at mean -1SD
Joint relationship between height and weight on femur area






Figure 49 Augmented component-plus-residual plot of age and MF 
 
MF – medial femur area (mm2), Age (yrs) 
This augmented component-plus-residual plot suggests a mild departure 
from normality suggesting a higher order term (i.e. age2 may be necessary. 
However the model fit and other linearity checks were satisfactory to suggest 
a linear relationship between age and MF. 
 






Figure 50 Augmented component-plus-residual plot of age and MT 
 
MT- medial tibia area (mm2), Age (yrs) 
This augmented component-plus-residual plot suggests a mild departure 
from normality suggesting a higher order term (i.e. age2 may be necessary. 
However the model fit and other linearity checks were satisfactory to suggest 










Table 28 Univariable regression analysis of non-KL radiographic 
variables with medial femur area 
Medial femur Coefficient (95%CI) p-value Adjusted r-
squared 













































































Table 29 Univariable regression analysis of non-KL radiographic 
variables with medial tibia area 
Medial tibia Coefficient (95%CI) p-value Adjusted r-
squared 











































































Table 30 Multivariable associations between OA-attributable medial femur area and radiographic variables 
Clinical 
characteristic 
Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 
Alignment** 
Less than -6º 
Greater than 6º 
 
39.58 (6.44, 72..73) 
146.53 (111.49, 181.58) 
  
71.59 (30.84, 112.33) 
131.78 (89.61, 173.96) 
 
8.09 (-30.87, 47.05) 
158.18 (116.53, 199.84) 
 
53.37 (13.06, 93.68) 
124.89 (81.09, 168.70) 
 
17.21 (-22.44, 56.87) 
131.39 (88.97, 173.81) 
 
-3.04 (-32.91, 26.84) 
82.54 (50.79, 114.29) 
Radiographic 
variables 
       






12.58 (-8.55, 33.70) 
58.89 (29.75, 88.02) 
193.38 (166.87, 219.90) 
  
23.98 (3.90, 44.06) 
90.39 (63.44, 117.35) 
240.28 (217.65, 262.92) 
  
13.52 (-7.53, 34.57) 
59.56 (30.44, 88.68) 







-0.17 (-24.72, 24.38) 
89.53 (55.95, 123.11) 
171.52 (109.59, 233.44) 
   
24.55 (3.12, 45.99) 
157.30 (134.30, 180.30) 
276.89 (225.62, 328.15) 
 
-0.23 (-24.66, 24.20) 
83.74 (50.32, 117.18) 







       
32.20 (13.52, 50.88) 
66.42 (50.91, 81.93) 
170.33 (153.03,187.63) 
375.86 (349.88, 401.74) 
        
R-squared 0.02 0.174 0.067 0.172 0.115 0.187 0.209 
Model F (p=) 36 (p<0.001) 70 (p<0.001) 52 (p<0.001) 93(p<0.001) 58 (p<0.001) 60 (p<0.001) 161 (p<0.001) 
JSW – joint space width, KL – Kellgren Lawrence. *For all categorical variable models, the reference group is grade zero. ** The alignment reference group is -6 to +6 º 
 
- 282 - 
282 
 
Table 31 Multivariable associations between OA-attributable medial tibia area and radiographic variables 
Clinical 
characteristic 
Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 
Alignment ** 
Less than -6º 
Greater than 6º 
 
4.25 (-11.07, 19.57) 
60.72 (44.52, 76.91) 
  
20.46 (1.82, 39.09) 
52.43 (33.14, 71.72) 
 
5.80 (-12.71, 24.30) 
52.00 (31.97, 72.05) 
 
12.53 (-6.28, 31.35) 
51.54 (30.95, 71.93) 
 
10.06 (-8.79, 28.91) 
44.82 (24.47, 65.17) 
 
-10.66 (-24.96, 3.65) 
37.00 (21.80, 52.20) 
Radiographic 
variables 
       






15.47 (5.37, 25.58) 
48.20 (32.61, 63.80) 
98.60 (78.49, 118.72) 
  
22.56 (13.32, 31.81) 
67.91 (54.51, 81.32) 
128.28 (111.85, 144.72) 
  
15.26 (5.16, 25.37) 
46.65 (31.04, 62.26) 







7.93 (-3.48, 19.35) 
26.08 (10.32, 41.84) 
45.07 (15.95, 74.20) 
   
23.28 (13.42, 33.15) 
63.20 (52.39, 74.01) 
113.66 (91.69, 135.63) 
 
8.54 (-2.87, 19.97) 
24.71 (8.96, 40.46) 







       
14.76 (5.82, 23.71) 
15.56 (8.13, 22.99) 
62.04 (53.76, 70.33) 
138.47 (126.08, 150.87) 
        
R-squared 0.012 0.129 0.083 0.128 0.104 0.135 0.147 
Model F (p=) 27 (p<0.001) 49 (p<0.001) 66 (p<0.001) 66 (p<0.001) 53 (p<0.001) 41 (p<0.001) 106 (p<0.001) 
JSW – joint space width, KL – Kellgren Lawrence. *For all categorical variable models, the reference group is grade zero. ** The alignment reference group is -6 to +6 º 
 




This cross-sectional analysis is the first to establish the proportion of OA-
attributable tAB variance explained by a comprehensive set of traditional 
radiographic measures of OA using automated imaging analysis technology 
in a large OA cohort. The accuracy of the relationship between radiographic 
OA and tAB is uniquely described with the use  of 3D images of knee bones 
and the lowest coefficient of the variance of tAB measurement, in the 
published literature, of less than 1%[632]. 
When considering the regression models of ‘normal’ knees the largest 
proportion of variance in tAB in the current study was described by 
participant height for both MF and MT tAB. This allometric relationship has 
previously been described in young healthy individuals with normal knee 
joints using manual segmentation of knee MRIs and multi-linear regression 
modelling [257]. We similarly observed that this allometric relationship 
explained a greater proportion of variance in tAB  in females.  
Tibial tAB has been reported to significantly correlate with increasing age in 
healthy populations [258, 638]. A similar relationship has been described 
both in populations with knee OA and in healthy participants, although this 
correlation significantly reduced in magnitude  after adjusting for the 
presence of radiographic OA, suggesting tAB enlargement is directly 
relevant to OA [639]. In this analysis of a population with normal knees a 
linear relationship between tAB and age was also noted. However this 
association was not considered substantive; age explained only 0.1% of the 
variance in tAB and thus may only be a minor determinant of tAB. 
Gender appeared to explain a large amount of the variance of tAB in this 
analysis. However the magnitude decreased substantively when adjusted for 
height. Similar gender differences in height have been observed in patients 
with healthy knees which accounts for the large proportion of tAB variance 
explained by gender in unadjusted regression modelling [256]. 
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When considering radiographic data, osteophytes, joint space narrowing and 
KL grade correlated with tAB in previous cross-sectional analyses of OA 
knees [31, 269, 483, 560]. These analyses did not adjust for the tAB 
attributable to OA. This study used OA-attributable tAB and demonstrated 
the same statistically significant associations, however they did not explain a 
substantive proportion of OA-attributable tAB variance in uni- and multi-
variable models. This may reflect the lack of sensitivity of traditional 
radiographic measures in detecting structural progression and the additional 
structural information afforded by the 3D measure we employed. Indeed 
approximately 80% of the variance of OA-attributable tAB was not explained 
by radiographic covariates. The apparent lack of substantive association 
with the radiographic measures may reflect the limitations of 2D projection 
images of conventional radiography. Semi-quantitative MRI scores (2.11.2.2 
MRI semi-quantitative measures) based on similar 3D imaging may prove to 
be more strongly associated with 3D bone area that is attributable to OA. 
Unfortunately only 115 OAI knee MRI scans have this scoring available in 
the public domain which currently precludes an analysis of significant size. 
Of the three non-KL radiographic variables, osteophytes explained the 
largest variance in tAB. This may reflect the expansion of subchondral tAB in 
OA being largely a product of endochondral and direct bone formation in the 
medial and lateral peripheral articular cartilage plate [640](2.6.1.2 
Subchondral bone and the osteochondral junction).   
4.5 Limitations 
There are limitations to this study. We have aimed to be cautious in only 
presenting substantive associations. The OAI is a large cohort and therefore 
we wanted to demonstrate whether significant statistical associations were 
substantiated by a significant proportion of tAB variance explained. Although 
JSW and KL grades were available for 4490 participants in the OAI 
database, we were limited to approximately 2588 participants by the 
availability of osteophyte and sclerosis variables.  
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Bone shape or bone area may be influenced by confounding factors that we 
did not adjust for, including the use of bisphosphonates. 
Magnetic resonance cannot directly identify the presence of calcium. In the 
segmentation of knee DESS-we MRI sequence the material imaged is 
assumed to represent bone rather than another tissue type. Confirmation 
that these surfaces are actually bone requires further work. Finally the 
automated segmentation used here is both accurate and repeatable 
however all subtle details of particular diseases may not be identified [259, 
267]. The majority of the cohort was Caucasian with smaller numbers of 
other ethnic groups. Therefore conclusions cannot be readily generalised to 
non-Caucasian groups  
4.6 Conclusions 
The analyses within this chapter confirm that radiographic measures, 
derived from a single radiographic projection, are significantly associated 
with OA-attributable bone area measured in 3D but do not explain a 
substantive proportion of OA-attributable bone area. This may reflect the 
additional 3D MRI structural information, unaccounted for by these 2D 
radiographic measures. We also confirmed the substantive allometric 
relationship of bone area with body size. Future analyses of bone area as a 
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Chapter 5 The relationship between three-dimensional knee 
MRI bone shape and total knee replacement – a case control 
study 
5.1 Introduction 
In chapter three the systematic literature review identified the need for 
evidence of the validity of 3D bone measures as imaging biomarkers. In 
chapter four the significant association of 3D bone structure of OA with 
conventional radiographic OA measures provided evidence of construct 
validity but also highlighted the additional structural information provided by 
3D bone measures that could not be substantively explained by the 2D 
projection images of conventional radiography. Conventional radiographic 
measures of OA are associated with outcomes such as joint replacement. 
Therefore it is important to know the relationship of the novel bone shape 
biomarker with important clinical outcomes such as joint replacement, 
independent of the structural assessment of conventional 2D radiography. 
This chapter describes evidence of criterion validity by describing the 
association of 3D bone shape with the patient-centred outcome of total knee 
replacement.  
5.2 Methods 
Data used for this nested case-based, case-control analysis, with cumulative 
incidence sampling, were obtained from the NIH Osteoarthritis Initiative 
(OAI) database, which is available for public access at 
http://www.oai.ucsf.edu/ (2.12 Summary of the OAI). This database houses 
a multi-centre, prospective, longitudinal observational study of knee OA 
currently including approximately 4,796 participants[515]. Baseline 
demographic data were collected and MRI scans were performed for all 
participants. At each site the institutional review board approved the study 
and informed consent was given by all patients. The OAI study and public 
use of clinical and imaging data used in this study was approved by the 
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committee on Human Research, University of California, San Francisco (IRB 
approval number 10-00532). 
During the eight-year period of follow up for the OAI cohort, the MRI systems 
at all four recruiting centres underwent one hardware upgrade[641]. The 
timing of this upgrade varied by recruiting centre and by stage of each 
participant’s follow up. This upgrade created a statistically significant 
difference in the geometric measurement of a phantom[642] that is used to 
assess reproducibility of MRI scans in the OAI by independent centralized 
QA analyses[641]. The MRI upgrade conferred a systematic change in 3D 
bone shape equivalent to about 2-years change. This therefore precluded a 
longitudinal analysis of 3D bone shape. The decision to use a case-control 
analysis rather than a time-survival analysis was based upon the following 
factors. The outcome of TKR is rare and there is significant variation in 
multiple strong confounding factors for TKR incidence between participants 
at baseline in the OAI. These include pain, radiographic severity, obesity and 
previous injury. The primary objective was not to estimate the effect of these 
well described, strong predictors of TKR but to determine if 3D bone shape 
vectors were independently associated with the outcome of TKR after 
effectively adjusting for these confounding factors. Therefore a case-control 
analysis was chosen 
For the current study, definition of case knee or control knee status required 
baseline records of age, gender, knee numeric pain scale, weight and 
Kellgren Lawrence (KL) grade.  A pre-requisite for eligibility also included 
having a baseline MRI knee scan and confirmed knee replacement status by 
the 72 month follow-up visit. Cases were defined as any knee with; 
confirmed TKR status(patient-reported TKR and adjudicated confirmed 
status on subsequent radiograph between baseline and the 72 month follow-
up visit); confirmed OA indication for TKR or, where this was unrecorded, an 
OA indication was highly likely (the presence of baseline radiographic and 
symptomatic evidence of OA) for the replaced knee. Where a participant had 
both knees replaced during the follow-up (n=69), the first knee to be 
replaced was included (n=50).  Where both knees were replaced on the 
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same day (n=19) one knee was randomly selected. Knees that ‘survived’ 
were eligible for selection as controls if they had neither patient-reported nor 
post-knee replacement adjudicated confirmation on follow-up radiograph at 
the 6 year follow up point. The OAI cohort has excellent follow up retention 
rates at 6 years (approximately 88%).  Where two ‘control’ knees were 
available for the same participant, the knee with the highest pain score, or 
the right side if they reported equal pain, was selected. Control knees were 
matched 1:1 with case knees using propensity score (PS) matching 
(described below). With multiple strong confounders (e.g. age, gender and 
body mass index), PS matching was chosen as an efficient way of creating 
an unbiased comparison and improving precision. 
MRI sequences collected in the OAI are described in detail by Peterfy and 
colleagues [497].  The current study utilised the double-echo-in-steady-state 
sequence (DESS-we) of the Siemens 3T trio systems [497].  
The quantitative analysis of 3D bone shape was achieved by automated 
segmentation of the 3D MRI double-echo steady-state water excitation 
sequences. Active appearance models (AAMs) are statistical shape 
modelling methods that learn the variation in shape and gray-scale texture 
(‘appearance’) of objects from a training set (such as the bones from an 
MRI), and encodes shape and appearance as principal components [629, 
630](2.10 Statistical Shape modelling, active shape modelling and active 
appearance modelling). 
The AAM methodology has been previously published [75]. In summary a 
training set of 96 knees with equal numbers of knees from each KL grade 
was used to build AAMs for each knee bone so that the trained AAMs can 
automatically segment bones in MR images. The validation of the accuracy 
of the knee segmentations has been previously described [630, 643]. For 
each particular models, the accuracy of the automated segmentations was 
further assessed using test–retest MRIs for 19 participants (38 images) with 
no OA to moderate degrees of clinical OA, prepared as a pilot study for the 
OAI, using the same MRI sequence [644]. The bone surface was manually 
segmented as previously described[632]. Mean point-to-surface distances 
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were calculated between the manual and automated segmentations. Mean 
point-to-surface errors were as follows: for the femur, 0.49 mm; for the tibia, 
0.53 mm; and for the patella, 0.57 mm (i.e. each approximately the size of 1 
voxel)[75]. The reliability of the automated segmentations has been 
established [632, 644]. The reliability of the automated segmentations of 
bone and cartilage has been described [632, 644] While segmentation for 
cartilage thickness has a coefficient of the variance of over 2%, bone 
segmentation has a coefficient of the variance of 0.8-1.9%[632] 
In order to identify vectors within this shape space that represented average 
change of the bone with disease we separated the 96 training set cases into 
OA (KL grade 2-4, n =53) and non-OA groups (KL0-1, n=43)  
The shape vector for each bone is calculated by taking the principal 
components of the mean shape of the OA and non-OA groups, and drawing 
a straight line through them.   Individual bone shapes from knees in this 
study, represented as principal components following the AAM search, were 
projected orthogonally onto the vector.   The distance along the vector was 
normalized by treating the mean non-OA shape as -1 and the mean OA 
shape as +1 (Figure 51, Figure 52). 
The reproducibility or test-retest reliability of the method was described in a 
set of 35 OA knees that underwent magnetic resonance imaging one week 
apart at one single OAI site, using the same OAI image acquisition 
sequence [632]. The reproducibility for the OA vector was good, with the 
smallest detectable difference for the femur, tibia and patella bone shape 
vectors was 0.22, 0.86 and 0.24 units normalised to the mean non-OA 
shape respectively[625].  [75].  
5.2.1 Statistical analysis 
Statistical analysis was conducted using STATA software, version 13 
(College Station, TX, 2013). Matching of control knees  to case knees 1:1 
was performed using PS matching. The PS is the conditional probability of 
assignment to a particular treatment given a vector of covariates and has 
been shown to be sufficient in removing bias due to observed covariates in 
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observational studies [645]. In this analysis the PS is the conditional 
probability of receiving a TKR given a vector of covariates. The model was 
based on the probability of having the outcome of TKR conditional on 
observed covariates. This is stratification score matching which has been 
previously described [646] and is referred to as PS matching in this 
retrospective analysis. The propensity model was estimated using logistic 
regression based on a priori known relationships between the outcome TKR, 
and clinically important risk factors such as age, gender, weight, KL grade, 
and pain [647], which may influence the surgeon`s decision to operate. We 
considered whether health insurance could affect the outcome with 
participants potentially not offered a TKR for financial reasons; however on 
exploration of the data we found that 98% of participants that had a TKR had 
some form of health insurance while 96% of those not having a TKR  had 
insurance. 
The final logistic regression model included baseline age, gender, weight 
category, ipsilateral knee pain severity numeric rating scale (Range 0-10), 
and knee side (right or left) (Table 42). KL grade was deliberately omitted 
because it directly influences the decision for TKR by the orthopaedic 
surgeon, resulting in over-matching. Furthermore the KL grade is used to 
define the scalar 3D bone shape variable and hence the two are moderately 
correlated (unpublished data).  
Age was categorised into 5-year groupings prior to inclusion in the PS 
model. Weight was categorised using WHO BMI categories, underweight 
(<18.5kg/m²), normal (18.5-24.9), overweight (25-29.9) and obese (≥30). 
Underweight and normal categories were subsequently merged because 
very few patients were underweight (n=10). Control knees were matched to 
case knees with the nearest PS (nearest neighbour matching) without 
replacement. Matching between case and control knees was confirmed 
graphically and by comparing the means or medians for the PS and the 
distribution of the components of the PS between case and control knees. 
Age, BMI and pain were analysed as continuous variables and gender kept 
as dichotomous. The variables were considered well balanced if the 
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standardised difference percentage (the mean difference as a percentage of 
the average standard deviation) for continuous variables was less than 10% 
as values greater than this are reported to represent meaningful imbalance 
[648], and for dichotomous variables a standardised difference (difference 
between prevalence in treatment and control group divided by an estimate of 
with-in group standard deviation) less than 0.1 represented good balance 
[649]. 
For simple comparison between the matched groups, Student`s t-tests for 
paired samples were used to compare 3D bone shapes of the femur, tibia 
and patella between case and control knees. Univariable and multivariable 
conditional logistic regression analyses were performed to establish the 
association of each baseline 3D bone shape vector as continuous variables 
with the outcome of TKR. Multivariable analyses included KL grade and the 
Akaike information criterion (AIC) was used to compare models with and 
without 3D bone shape, in order to assess any additional association beyond 
that between KL grade and TKR.  Model fit was assessed by examining 
leverage plots to identify pairs that did not fit the data well, and also 
observations exerting a strong influence on the estimated coefficients. The 
model fitted the data well based on diagnostic checks. We also analysed 3-D 
bone shape vectors categorized into tertiles with the highest tertile 
containing values closer to mean OA shape and the lowest tertile contained 
values closer to the mean non-OA shape. 
 Additional exploratory analyses (conditional logistic regression models) 
aimed to determine if any association of bone shape with TKR was 
maintained over all KL grades and to establish if there were any differences 
in association between 3D bone shape and TKR depending on the time from 
baseline to TKR date in years.  
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Figure 51 Scalar continuous vector of 3D bone shape of the femur 
 
Legend: Anterior and posterior views of right knees. The femoral shape 
vector is scaled to -1 as the mean shape without radiographic OA and +1 
with established radiographic OA 
 
Figure 52 Scaling of the 3D bone shape vectors relative to KL grade 
 
The distance along the vector was normalized by treating the mean non-OA 
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Of the 4,796 participants in the OAI database, 336 individuals with at least 
one confirmed knee replacement during follow-up were identified. In total 
405 knees had been replaced (right 198, left 207). Of the 69 patients who 
had both knees replaced; 50 patients’ knees were replaced on separate 
days, and from them 25 right knees and 25 left knees were selected for 
analysis on the basis that they were replaced first. From the remaining 19 
patients whose knees were replaced on the same day; 11 right knees and 8 
left knees were randomly selected. Only one knee was excluded by TKR 
indication which was recorded as rheumatoid arthritis. Having excluded 
patients with missing MRI data, 310 cases knees met the selection criteria 
and were suitable for PS matching (Figure 53). The 336 individuals with 
knee replacements differed from the rest of the OAI cohort in baseline mean 
age (3 years older), KL grades, obesity and  numeric rating scale pain 
scores (Table 32). The number of exact PS matches was 244 (79%) with all 
remaining case knees having a PS within 0.01 PS units of their control knee. 
A minority of case knees had been matched with contralateral control knees 
(n=12[4 %]). There was a concordant gender match in all case-control knee 
pairs.  
There were no substantive differences between the cases and matched 
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Figure 53 Participant flow diagram for the selection of case knees 
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Table 32 Characteristics of 4796 participants according to presence or 
absence of at least one (1) confirmed, adjudicated total knee 
replacement (TKR) before matching 
 TKR, n=336 No TKR, n=4460 

























































   
Figures are n (%) unless stated. 
NRS – Numerical Rating Scale for pain 
KL - Kellgren Lawrence grade 
SD – Standard deviation 
IQR – Inter-Quartile Range 








Table 33 Demographics characteristics of participants with knee 
replacement and their controls from propensity matching 





















































Side, right 159 (51) 161 (52) 
 
NRS ,median (IQR) 
Left knee score 







































Figures are n (%) unless stated. 
*not used in propensity matching 
NRS – Numerical Rating Scale for pain 
KL - Kellgren Lawrence grade 
SD – Standard deviation 
IQR – Inter-Quartile Range 
TKR – Total Knee Replacement 
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The standardised differences for age, BMI and NRS pain were 3.3%; 0.5% 
and 1.8% respectively (all within 10%) while gender was matched perfectly. 
The mean baseline 3D bone shape scalar variable indicated significantly 
greater structural severity in cases of TKR than in controls. Mean, (SD) in 
the femur cases was 0.98 (1.51) compared with controls mean of -0.11 
(1.40), with a statistically significant difference of 1.10 (95% CI, 0.89 to 1.31), 
t (309) =10.31, p<0.001. Mean, (SD) in the patella cases was 0.95 (1.86) 
compared with controls mean of 0.03 (1.83), with a statistically significant 
difference of 0.92 (95% CI, 0.65 to 1.20), t (309) =6.61, p<0.001. The femur 
had the largest mean difference in 3D shape of the three knee bones (Table 
34). 
The conditional logistic regression models of each individual bone estimated 
increased odds of TKR with more positive 3D bone shape, indicating greater 
OA structural severity (Table 35).







Table 34 The mean differences between bone shape vectors of cases and controls 
Bone vector Mean Control Mean TKR Mean difference 95% CI Paired T-test 
  (mean, SD) (mean, SD)     p value 
Femur -0.11, 1.40 0.98, 1.51 1.10 0.88, 1.31 <0.001 
Tibia -0.07, 1.39 0.86, 1.42 0.94 0.72, 1.16 <0.001 
Patella +0.03, 1.83 0.95, 1.84 0.92 0.65, 1.20 <0.001 
SD – Standard deviation 
  




Table 35 The associations between 3D bone shape vectors or KL grade with TKR 
 
Univariable (unadjusted) Multivariable* 
Imaging 
variable 
OR 95% CI p value AIC OR 95% CI p value AIC 
Femur vector 1.85 1.59, 2.16 <0.001 341.11 1.24 1.02, 1.51 0.03 241.33 
Tibia vector 1.64 1.42, 1.89 <0.001 367.80 1.09 0.90, 1.32 0.40 245.60 
Patella vector 1.36 1.22, 1.50 <0.001 390.84 1.06 0.92, 1.23 0.40 245.58 
Combined bone vectors 
 
    
Femur vector     1.26 1.00, 1.60 0.05  
Tibia vector     0.97 0.78, 1.21 0.80  
Patella vector     1.00 0.85, 1.17 0.96 245.26 
KL grade 
(ref=KL zero)  
    
1 1.66 0.58, 4.73 0.34 
 
    
2 5.66 2.55, 12.55 <0.001      
3 17.18 7.43, 39.72 <0.001 
 
    
4 39.77 14.64,108.0 <0.001 244.31     
* Adjusted for KL grade 
OR – Odds ratio from conditional logistic regression, KL - Kellgren Lawrence grade, CI – Confidence Interval, AIC – Akaike’s 
Information Criterion, TKR – Total Knee Replacement 
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Odds ratios (95% confidence intervals) per normalised unit of 3D bone 
shape vector for the femur, tibia and patella were 1.85 (1.59, 2.16), 1.64 
(1.42, 1.89), 1.36 (1.22, 1.50) respectively, all p<0.001. The order of strength 
of association of bone shape with TKR, from strongest to weakest, was 
therefore the femur, the tibia and finally the patella. The odds on TKR 
increased significantly with KL grade. When KL was included in multivariable 
conditional logistic regression models, the femur remained significantly 
associated with TKR but the association with the tibia and patella was 
attenuated. The odds ratios (95% confidence intervals) per normalised unit 
of 3D bone shape vector were 1.24 (1.02, 1.51), 1.09 (0.90, 1.32), 1.06 
(0.92, 1.23) for the femur, tibia and patella respectively.  The AIC of the 
univariable KL model was lower than any of the univariable bone vector 
models and multivariable tibia and patella models and the strength of 
association was in the expected direction (OR for KL3 were greater than that 
of KL2 when compared to KL0 as reference). However the multivariable 
model of the femur vector had a small improvement in AIC indicating 
including bone shape contributes to the association with TKR in addition to 
KL grade.Those in the highest tertile for the femur bone shape vector had 
12.7 times higher chance than those in the lowest tertile group of having a 
TKR (95% CI 6.93-23.40, P<0.001). In all analyses a similar trend was noted 
with those in the highest tertile having increased chances of having a TKR 
than both the middle tertile and lowest tertile. After adjusting for KL grade in 
the tertile model, only the highest tertile of the femur model remained 
significantly associated with TKR (Table 36). The association between bone 
shape and TKR was not significantly modified when stratified by KL grade 
severity (Table 37,Table 38,Table 39).  
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Table 36 The associations between 3D bone shape vectors TKR using lowest tertile as reference 

































































Ref = reference 
95% CI= 95% confidence interval. 






Table 37 The number of propensity score matched pairs of cases and 




Pairs of knees Number of knees 
0 2 4 
1 4 8 
2 14 28 
3 18 36 
4 3 6 




Table 38 The number of propensity score matched pairs of cases and 





Pairs of knees Number of knees 
0,1 6 12 
2 14 28 
3,4 21 42 
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Table 39 The difference in mean bone shape vector between propensity 
score matched cases and controls with equal KL grades after 
























Femur 0,1 0.78 1.56 -0.85, 2.42 0.50 
 2 0.66 1.55 -0.23, 1.56 0.43 
 3,4 0.12 2.45 -0.99, 1.23 0.05 
Tibia 0,1 0.45 0.99 -0.58, 1.50 0.46 
 2 0.59 1.39 -0.21, 1.39 0.42 
 3,4 0.38 2.17 -0.61, 1.37 0.18 
Patella 0,1 0.07 1.43 -1.43, 1.57 0.05 
 2 0.74 2.77 -0.86, 2.35 0.27 
 3,4 0.32 2.66 -0.89, 1.53 0.12 
The difference in mean bone shape vector between propensity score 
matched cases and controls with equal KL grades after division into strata. 
The association between bone shape and TKR was not significantly 
modified by KL grade severity strata. However this is an exploratory analysis 
with large confidence intervals, using small numbers of matched case 
control pairs. aThe mean bone shape vector difference (column 3) divided by 
the standard deviation (column 4). TRK: Total Knee Replacement; KL: 
Kellgren Lawrence grade. 
 
The association between bone shape and TKR was not significantly 
modified by KL grade severity strata. However this is an exploratory analysis 
with large confidence intervals, using small numbers of matched case 
control pairs. 
Similarly the association between bone shape and TKR was not significantly 
modified by the length of the interval between baseline and TKR incidence 
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(Table 40, Table 41). However these were exploratory analyses which 
included small numbers in each stratum with large confidence intervals. The 
cumulative incidence of the 310 TKR cases over approximately seven years 




Table 40 The cumulative incidence of the TKR cases used for the case-
control analysis 
Year of case TKR Incidence of case 
TKRs 
Cumulative 
Incidence of case 
TKRs 
0-1 23 23 
1-2 37 60 
2-3 39 99 
3-4 52 151 
4-5 54 205 
5-6 48 253 
6-7 51 304 
7-8 6 310 
Total 310 310 
 
Table 41 The association of 3D femur bone shape vector with TKR by 
annual TKR incidence 
The year of 
incidence of case 
TKR 
OR 95% CI P value 
All years 
combined 
1.85 1.59, 2.16 <0.001 
0 to 1 1.92 1.17, 3.18 0.010 
1 to 2 1.85 1.20, 2.87 0.006 
2 to 3 2.68 1.44, 4.99 0.002 
3 to 4 1.57 1.12, 2.18 0.008 
4 to 5 1.82 1.25, 2.66 0.002 
5 to 6 2.30 1.39, 3.81 0.001 
6 to 8 1.60 1.15, 2.24 0.006 
  




Table 42 Results from propensity model used to match cases and 
controls 
Outcome -TKR Coefficient  95% CI P value 
Age category (ref 0)    
 1 0.58 -0.05, 1.22 0.072 
2 1.15 0.55, 1.76 <0.001 
3 1.28 0.68, 1.88 <0.001 
4 1.60 1.00, 2.19 <0.001 
5 1.47 0.87, 2.08 <0.001 
6 1.76 1.13, 2.39 <0.001 
    
Sex (ref male)    
Female  -0.00027 -0.24, 0.24 0.99 
    
NRS 0.17 0.13, 0.21 <0.001 
    
    
Weight category(ref 
normal) 
   
Overweight  0.38 0.14, 0.62 0.002 
    
Side (ref Right) 0.60 0.36, 0.84 <0.001 
    
Constant  -4.87 -5.47, -4.27 <0.001 
NRS – numeric rating scale for pain 
 
5.4 Discussion 
This is the first study to describe the association between 3D bone shape 
and TKR. We demonstrated that people having TKR exhibited significantly 
more advanced 3D shape changes of OA structural progression than 
controls at baseline. Total knee replacement has been previously associated 
with age, obesity, pain characteristics, radiographic OA severity and MRI 
features such as cartilage damage [105, 479, 540, 600, 650]. MRI-
determined bone shape is related to OA structural progression[75]. The 
association of OA subchondral bone pathology with TKR is supported by the 
association of bone marrow lesions with TKR, though bone shape and BMLs 
are likely to be measuring a different pathological construct [105, 540, 600]. 
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The odds ratio of TKR per normalised unit of 3D bone shape vector 
increased with greater baseline 3D shape structural severity for each of the 
femur, tibia and patella. However femoral bone shape has the strongest 
association with TKR. It is worth noting that the femoral bone shape had the 
largest scalar value difference between case and control knees and is the 
only bone shape that, after adjusting for KL grade, remained significantly 
associated with the outcome of TKR.  These findings concur with the same 
3D femur shape having the largest hazard ratio of the three knee bones in 
predicting incident radiographic knee OA [605].  
Furthermore the 3D bone area of femoral trochlear and tibio-femoral 
articulations were the most responsive and had the greatest percentage 
change in size of all articulating surfaces in the knee[604]. Cartilage loss 
from the femur was better than loss from the tibia in distinguishing OA knees 
requiring and not requiring knee replacement in a previous study [647]. 
Femoral bone undergoes greater 3D shape change than tibial bone after 
anterior cruciate ligament rupture[651]. In knee OA the tibial 3D shape 
changes in a more uniform and symmetric pattern than the femur where the 
shape change distinctly occurs around the cartilage plates where an 
increased ridge of “osteophytic” material forms[75]. This may explain why 
femoral 3D shape has a greater responsiveness and association with TKR. 
While bone shape readily changes in response to mechanical forces acting 
upon it (Wolff’s law) [173, 197] it is reasonable that the femur shape should 
change more than the tibia or patella because the femur receives more load 
from twice the number of weight bearing surfaces of the tibia and patella. 
The association of TKR with femoral, but not tibial or patellar bone shape 
persists after adjusting for KL grade and is greatest for the femur in the 
higher tertiles (Table 5). This may reflect the observation that in more 
advanced structural progression, tibial and patellar shape change is more 
uniform and symmetrical than the femur [75, 652]. This more readily 
detectable shape change in the femur may explain the stronger association 
with TKR in more advanced structural progression (the higher tertiles). The 
additional structural information provided by 3D bone imaging compared to 
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conventional radiography[516] may explain why in the exploratory analyses 
the association with TKR was maintained after stratifying for KL grade 
severity, indicating the stage of structural severity does not affect this 
association.  
The requirements of biomarker validation have been described [653]. The 
findings of this study in conjunction with previous data on construct validity, 
reliability and responsiveness of 3D bone shape, indicates that novel 
quantitative measures of bone shape are  increasingly validated biomarkers 
of OA structural progression [75, 605, 652]. 3D bone shape has advantages 
over conventional ordinal and metric radiographic measures of structural 
progression in that it provides a continuous measurement variable that is a 
more responsive measure than radiographic measures of knee OA[652] and 
it is sensitive to pre-radiographic knee OA[75].   
5.5 Limitations 
There are limitations to this study. Joint arthroplasty is an end-point 
reflecting symptom and structural damage severity, but many variables 
influence both the timing and the decision to perform this outcome measure. 
The surgeon’s opinion and the patient’s comorbidities and willingness to 
undergo surgery are examples of these, in addition to local and national 
health system variations in surgical waiting lists which may cause residual 
confounding. 
There is no consensus on which variables to include in the propensity model 
with studies showing a similar effect if all measured baseline covariates, all 
potential confounders or all true confounders are used interchangeably 
[649].  It has however been demonstrated that in order to maximize the 
number of matched pairs, the propensity model specified should have only 
the true or potential confounders [648]. In the final sample 79% of case and 
control knees were matched exactly. This PS method adjusted for 
imbalances at baseline but not over time. Body mass index may increase 
before TKR and this may cause residual confounding conceivably with 
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greater BMI increases in the TKR cases than in the controls. This may 
influence the size of the associations described in this analysis.  
An alternative study design considered was cox-regression analysis, 
modelling the time-to-event (in this case TKR) which could have compared 
different survival times based on the 3D bone vector as well as estimates of 
covariates using the full cohort. However since the stated objectives did not 
include estimating the effect of these well described and strong predictors of 
TKR, and knee replacement satisfied the “rare outcome” assumption 
(prevalence of 7%), we chose to perform a well-matched case-control 
analysis instead of a whole cohort survival analysis. Essebag and 
colleagues highlighted this relative advantage of well-matched case-control 
analysis where the effect of the confounding factors is ‘not of interest’[654]. 
A case-control analysis therefore represented a more precise analysis by 
efficient matching of multiple strong confounding factors to minimise the 
effect of bias. 
We also acknowledge that by effectively matching cases and controls we 
may inadvertently ‘overmatch’ which may reduce any effect of 3D bone 
shape on the outcome of TKR and my chosen method was therefore at risk 
of underestimating the magnitude of the association of bone shape vector 
with the outcome of TKR. 
The multivariable analyses are potentially subject to the effects of multiple 
collinearity. This is because KL grade is moderately correlated with bone 
shape vectors and the three bone shape vectors from within the same knee 
are used in the same multivariable models,  
Bone shape or bone area may be influenced by confounding factors that we 
did not adjust for, including the use of bisphosphonates. 
The OAI is predominantly a caucasian cohort with smaller numbers of other 
ethnic groups. This means that any attempt to match cases and controls 
based on ethnicity would limit the available pool for matching. We 
acknowledge that by not matching on ethnicity there may be residual 
confounding although race was not associated with TKR incidence after 
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covariate adjustment in the OAI dataset [479]. Health insurance was 
available for 98% of participants in the study suggesting any differences in 
ethnicity between cases and controls did not reflect their access to TKR 
surgery.  The associations reported in this analysis should not be 
generalised to non-caucasian populations due to the lower representation of 
non-white participants in this analysis. 
Additionally, as with any observational study, it is impossible to rule out 
residual bias from unknown or unmeasured confounders. 
Magnetic resonance cannot directly identify the presence of calcium. In the 
segmentation of knee DESS-we MRI sequence the material imaged is 
assumed to represent bone rather than another tissue type. Confirmation 
that these surfaces are actually bone requires further work. Finally the 
automated segmentation used here is both accurate and repeatable; 
however some subtle details of particular diseases may not have been 
identified [259, 267].  
5.6 Conclusions 
This chapter has demonstrated that 3D bone shape was associated with the 
important patient-centred outcome of total knee replacement. The femur  
had the greatest association of the three 3D knee bone shape vectors. This 
may reflect the superior responsiveness of this bone shape in the structural 
progression of knee OA. The predictive (criterion) validity demonstrated here 
further underpins the value of quantitative bone measures in future 
therapeutic trials of DMOADs.  
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Chapter 6 The relationship between 3D MRI bone shape and 
knee osteoarthritis symptoms in knees with and without 
radiographic knee osteoarthritis. 
 
6.1 Introduction 
The systematic literature review in chapter three identified the requirement 
for evidence of the validity of 3D bone measures as imaging biomarkers. In 
chapter four the significant association of 3D bone structure of OA with 
conventional radiographic OA measures provided evidence of construct 
validity but also highlighted the additional structural information provided by 
3D bone measures that could not be substantively explained by the 2D 
projection images of conventional radiography. This additional structural 
‘information’ appeared to confer an association of 3D bone shape with joint 
replacement, that is independent of the structural assessment of 
conventional 2D radiography. This provided evidence of criterion validity, 
This chapter describes evidence of criterion validity by describing the 
association of 3D bone shape with the patient-centred outcome of current 
and incident knee OA symptoms. OA is a major cause of chronic pain and 
disability and by 2020 is estimated to be the commonest chronic condition 
seen in primary care [655]. OA is a heterogenous condition characterised by 
the failure of the whole synovial joint organ[656] (2.4.2 Microscopic). It is 
widely accepted that OA is present when typical structural pathology is 
identified by conventional radiography. However the concordance between 
structural pathology determined by radiographic knee OA (ROA) and knee 
OA symptoms is poor. Only 50% of knees with ROA have knee OA 
symptoms [17] and little change is observed in knee pain in knees with ROA 
over six years [97] except when large increases in radiographic structural 
severity are observed[98]. However conventional radiography is less 
sensitive and specific in detecting structural pathology and progression than 
magnetic resonance imaging (MRI)[23, 86]. MRI-detected OA joint tissue 
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lesions and structural pathology are prevalent in knees without ROA[23] and 
these (including bone marrow lesions, cartilage damage and meniscal tears) 
are associated with incident symptomatic [131] and radiographic OA[75]. As 
discussed in chapter 5 three dimensional MRI scans can be segmented 
manually or in an automated manner with methods such as active 
appearance modelling (AAM) that permit the analysis of large data sets such 
as the OAI (2.10 Statistical Shape modelling, active shape modelling and 
active appearance modelling). 
Subchondral bone pathology, in particular bone marrow lesions (BMLs), is 
important in the pathogenesis of knee OA pain in established ROA and in 
knees at risk of knee OA but without radiographic OA. In cohort studies of 
knees with prevalent ROA, ranging from 18-71%, longitudinal increase in 
BML size or baseline BML size are associated with longitudinal increase in 
knee OA pain severity in the Osteoarthritis Initiative[100], the Tasmanian 
Older Adult Cohort[99] and the Michigan site of the Study of Women’s 
Health Across the Nation[530]. In cohort studies of knees at risk of OA but 
without radiographic knee OA, BMLs are also associated with incident 
frequent knee OA pain. This includes a subcohort study of knees at risk of 
OA but without any ROA (Kellgren Lawrence zero) within the OAI 
cohort[131] and the longitudinal structural progression of BMLs in these ‘pre-
radiographic’ OA  knees is associated with incident radiographic knee OA 
and persistence of knee symptoms[622]. This association of BMLs and 
incident knee pain is also observed in the MOST cohort study where the 
majority of knees (60%) lacked radiographic knee OA[26]. While much of the 
relevant OA literature has focussed on MRI-detected BMLs, several recent 
studies have suggested the importance of bone shape in the structural 
progression of OA including the pre-radiographic OA stage[75, 197, 604, 
605]. The association of OA symptoms with structure in early knee OA 
represents an important but understudied stage in knee OA. The association 
of ‘pre-radiographic’ OA knee bone shape with prevalent frequent knee 
symptoms (PFKS) and incident persistent knee symptoms (IPKS) in persons 
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with no evidence of OA anatomical changes on plain radiography has not 
been previously reported.  
The objective of this analysis was to determine the relationship between 
scalar 3D bone shape with PFKS and IPKS in all knees in the OAI but also 
in knees without ROA but at risk of OA. 
6.2 Methods 
Data used for this were obtained from the NIH Osteoarthritis Initiative (OAI) 
database, which is available for public access at http://www.oai.ucsf.edu/ 
(2.12 Summary of the OAI). This database houses a multi-centre, 
prospective, longitudinal observational study of knee OA currently including 
approximately 4,796 participants[515] . Baseline demographic data were 
collected and MRI scans were performed for all participants. At each site the 
institutional review board approved the study and informed consent was 
given by all patients.  
Prevalent frequent knee symptoms (PFKS) was defined as having  knee 
symptoms (pain aching or stiffness) or medication use for knee symptoms 
most days of one month in the past 12 months which was assessed at 
baseline and subsequently at every annual review up to the 60-month OAI 
visit. The outcome of PFKS for the PFKS analysis was defined at the 12-
month visit. The outcome of IPKS varied by analysis but universally required 
the absence of PFKS at enrolment and incident PFKS reported after 
enrolment at two consecutive annual OAI visits by the 60-month visit. All 
analyses used 3D bone shape derived from right knee MRIs performed at 
the 12-month visit to determine its association with PFKS and IPKS. 
The inclusion criteria for each analysis is summarised in the figures below 
(Figure 55, Figure 56). The eligibility for the first subcohort analysis identified 
all knees within the OAI, with or without radiographic OA, and is referred to 
as the ‘whole’ OAI subcohort. The eligibility criteria for the PFKS analysis in 
this subcohort included adequate right knee MRI scans at 12 months with 
available covariate data at 12 months(see ‘covariate measurement’ below) 
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along with PFKS status data. Eligibility criteria for the IPKS analysis of all 
knees in the OAI required adequate right knee MRI scans at 12 months with 
available covariate data at 12 months and PFKS status data from enrolment 
up to the 60 month visit. Further enrolment knee symptom data was also 
required to help identify knees with no previous history of knee pain 
including any history of previous knee pain, any difficulty walking downstairs 
or upstairs. This stricter eligibility criteria differed for the subcohort without 
radiographic OA, in an attempt to more precisely identify knees with early 
symptomatic OA amongst a subcohort of knees with prevalent radiographic 
OA that were more likely to have had historic pain. Therefore to be eligible 
for the IPKS subcohort amongst all knees, this required the lack of any of 
these previous knee symptoms and PFKS at enrolment (Figure 55).  
The eligibility criteria for the second subcohort without radiographic OA but 
‘at risk’ of knee OA, were deliberately chosen to replicate (and facilitate 
comparison of findings with) the dataset used by Sharma and colleagues in 
their recent study of the association of pre-radiographic structural lesions 
(e.g. BMLs) with PFKS and IPKS[131]. However unlike Sharma and 
colleagues we stratified analyses by gender. The eligibility criteria for the 
subcohort without radiographic OA,  for the analysis of the association of 3D 
bone shape with PFKS and IPKS, required individuals to have the absence 
of radiographic OA with Kellgren Lawrence (KL) grades available and equal 
to zero in both knees at the twelve month visit from the OAI. This minimised 
the risk of the presence of OA in this subcohort because the risk of incident 
knee OA is increased by contralateral knee OA. Inclusion required both 
knees had available MRI scans of adequate quality at 12 and 48 months. 
Finally each participant required appropriate covariate data and PFKS 
outcome data for defining PFKS and IPKS respectively. The right knees of 
all eligible individuals were selected for the PFKS subcohort. The right knees 
with a lack of PFKS at enrolment were eligible for the IPKS subcohort.   
6.2.1 Knee radiograph acquisition and assessment. 
The OAI protocol utilised postero-anterior fixed-flexion weight-bearing knee 
radiography with a Plexiglas positioning frame (Syna-Flexer see  
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2.12.4 Knee radiography protocol). All knee radiographs were assessed by 
two separate experts that were blinded from each other’s assessments and 
all data. The weighted kappa coefficient for inter-reader K/L grade 
agreement was 0.79. A third expert resolved pre-specified radiograph 
assessment discrepancies in a consensus session. 
 
6.2.2 MRI acquisition and assessment 
MRI sequences collected in the OAI are described in detail by Peterfy and 
colleagues [497].  The current study utilised the double-echo-in-steady-state 
sequence (DESS-we) of the Siemens 3T trio systems [497].  
The quantitative analysis of 3D bone shape was achieved by automated 
segmentation of the 3D MRI double-echo steady-state water excitation 
sequences and 3D bone shape in a similar manner to chapter 5 (5.2 
Methods).  
Bone shape varies between males and females and therefore 3D bone 
shape should be defined separately for men and women. In order to identify 
gender specific vectors within this shape space that represented average 
change of the bone with disease we separated  training set cases for men 
and women separately into OA (one knee per individual with KL grade two to 
four at all time points up to four years) and non-OA groups (KL grade zero at 
all time points up to four years in both knees and picked one knee from each 
individual).  
The gender-specific shape vector for each bone was calculated by taking the 
principal components of the mean shape of the OA and non-OA groups, and 
drawing a straight line through them.  
Individual bone shapes from  knees used in this analysis, represented as 
principal components following the AAM search, were projected orthogonally 
onto the appropriate  vector. This raw vector data for every bone in every 
knee was scaled or normalised. This was achieved by subtracting the 
gender- and bone-specific mean non-OA shape from the corresponding raw 
vector data for each bone. The result of this subtraction was then divided by 
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one standard deviation of the normally distributed gender- and bone-specific 
non-OA shape raw vector values to provide the final normalised 3D bone 
shape for use in these analyses. Approximately 400 male and 400 female 
knees fulfilled the non-OA criteria (KL zero at baseline and for the first 4 
years) and were used to scale or normalise the vector. Previous analyses 
have used bone shape vectors normalised using KL grade. To minimise the 
dependence on KL grade to define the presence of OA, this latest method 
was used to normalise the vector based upon mean non-OA shape and 
hence the absence of radiographic OA.  
The reproducibility or test-retest reliability of the method has been described 
in 5.2 Methods). 
6.2.3 Covariate measurement 
Body mass index (BMI) was calculated from body weight, measured with a 
standard balance beam scale, and height, measured with a wall-mounted 
stadiometer at the 12 months visit. The definition of knee injury was if the 
study knee was “ever injured badly enough to limit walking ≥2 days” and 
surgery as “any previous surgery”. 
6.2.4 Statistical analysis 
Statistical analysis was conducted using STATA software, version 13 
(College Station, TX, 2013). All analyses used one right knee per person. 
For all analyses, BMI was categorized as normal (<25 kg/m²), overweight (≥ 
25 to < 30 kg/m²), or obese (≥30 kg/m²), and age as < 60 years, >60 to < 70 
years, or >70 years at enrolment into the OAI.  
We used separate logistic regression models to estimate the direction and 
magnitude of association between each 3D bone shape measure and PFKS 
at 12-month visit and IPKS up to 60-month visit and adjusting for age, sex, 
BMI, and previous knee injury and previous surgery. The analyses were not 
adjusted for KL grade in the first ‘whole’ OAI subcohort because the bone 
shape vectors were derived from KL grade and there was a significant risk of 
over-adjustment. KL grade adjustment was not required in analyses of the 
second ‘at-risk’ subcohort because all knees were KL grade zero, None of 
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the analyses were adjusted for MRI features known to be associated with 
knee pain (e.g. BMLs or synovitis) because the semi-quantitative scores of 
these were available in too few knees. Results are reported as unadjusted 
and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs).  
6.3 Results 
 6.3.1 PFKS in the ‘whole’ OAI subcohort 
The participant flow chart for this analysis is described in (Figure 55). Of the 
4,796 participants in the OAI database, 4048 right knees with and without 
radiographic knee OA had available bone vector data for PFKS unadjusted 
analysis. This included 1718 males and 2330 females of which 610 (36%) 
males and 921 (40%) females had PFKS at the 12-month visit. The 
distribution of the 3D bone shape vector values is described in (Table 43) for 
males and females and those with PFKS had generally larger vector values 
than those without PFKS, indicating greater structural severity.  
The unadjusted logistic regression models of each individual male bone 
estimated increased odds of PFKS with more positive 3D bone shape, 
indicating greater OA structural severity (Table 44). Odds ratios (95% 
confidence intervals) per normalised unit of 3D bone shape vector for the 
femur, tibia and patella were 1.32 (1.23, 1.42), 1.31 (1.20, 1.43), 1.30 (1.19, 
1.41) respectively, all p<0.001. The strength of association of 3D bone 
shape with PFKS was similar for all male bones. In logistic regression 
models the femur, tibia and patella remained significantly associated with 
PFKS, after adjustment for covariates, with modest attenuation of the 
association for all bones. The adjusted odds ratios (95% confidence 
intervals) per normalised unit of 3D bone shape vector were 1.25 (1.16, 
1.35), 1.25 (1.14, 1.37), 1.25 (1.14, 1.37) for the femur, tibia and patella 
respectively, all p<0.001.    
The same analyses amongst females identified very similar findings (Table 
44). Similarly no single bone demonstrated a greater association with PFKS 
than any other. In both males and female adjusted models, the covariates of 
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body mass index and previous surgery were both significantly associated 
with PFKS, all p<0.01 (Table 45, Table 46). 
 
Figure 55 Participant flow diagram for the case selection of knees 
regardless of the presence of radiographic OA 
 
KL – Kellgren Lawrence grade 
M:F - male to female ratio 
PFKS – Prevalent frequent knee symptoms 
IPKS – Incident persistent knee symptoms 
  




Table 43 The distribution of 3D bone shape vectors in male and female 
participants a) with and without prevalent frequent knee 
symptoms and b) with and without incident persistent knee 
symptoms in the ‘whole OAI’ subcohort of right knees. 
 Mean (SD) Mean (SD) Mean (SD) 










   Femur 1.09 (1.53) 0.55 (1.28) 0.75 (1.40) 
   Tibia 0.72 (1.21) 0.36 (1.10) 0.49 (1.16) 










   Femur 1.69 (1.82) 0.86 (1.51) 1.18 (1.69) 
   Tibia 0.39 (1.10) 0.12 (1.09) 0.23 (1.10) 
   Patella 1.20 (1.43) 0.59 (1.25) 0.83 (1.35) 










   Femur 0.80 (1.44) 0.39 (1.17) 0.42 (1.20) 
   Tibia 0.24 (1.20) 0.12 (1.05) 0.15 (1.06) 










   Femur 0.98 (1.61) 0.53 (1.32) 0.59 (1.37) 
   Tibia 0.16 (0.99) -0.01 (1.08) 0.02 (1.06) 
   Patella 0.59 (1.26) 0.31 (1.22) 0.37 (1.24) 
Mean 3D bone shape vectors (SD) 
PFKS – persistent frequent knee symptoms 
IPKS - incident persistent knee symptoms 
 
  




Table 44 Associations between 3D bone shape vectors and prevalent 
frequent knee symptoms at 12 month visit (cross-sectional) and 
incident persistent knee symptoms by 60-month visit 
(longitudinal) of all right knees 
 OR (95%CI)¥ Adjusted OR (95%CI)† 
(a) Outcome: prevalent frequent knee symptoms 
3D Bone shape 
vector(males)  
n=1718 
(610 with pain) 
n=1692 
   Femur 1.32 (1.23, 1.42)** 1.25 (1.16, 1.35)** 
   Tibia 1.31 (1.20,1.43)** 1.25 (1.14, 1.37)** 
   Patella 1.30 (1.19, 1.41)** 1.25 (1.14, 1.37)** 
3D Bone shape 
vector(females)  
n=2330 
(921 with pain) 
n=2308 
   Femur 1.35 (1.28, 1.43)** 1.29 (1.22, 1.37)** 
   Tibia 1.26 (1.17,1.36)** 1.24 (1.14, 1.34)** 
   Patella 1.41(1.32, 1.51)** 1.33 (1.24, 1.43)** 
(b) Outcome: incident persistent knee symptoms 
3D Bone shape 
vector (males) 
n=358 
(42 with pain) 
n=353 
   Femur 1.31 (1.01, 1.69) p=0.04* 1.20 (0.91, 1.59) p=0.20 
   Tibia 1.11 (0.83, 1.50) p=0.47 1.06 (0.78, 1.44) p=0.71 
   Patella 1.10 (0.83, 1.45) p=0.52 0.97 (0.71, 1.32) p=0.83 
3D Bone shape 
vector(females) 
n=476 
(69 with pain) 
n=472 
   Femur 1.25 (1.05, 1.49) p=0.01* 1.17 (0.97, 1.41) p=0.09 
   Tibia 1.15 (0.91, 1.46) p=0.24 1.16(0.91, 1.48) p=0.22 
   Patella 1.20 (0.98, 1.46) p=0.08 1.12 (0.90, 1.38) p=0.30 
¥ Right knees with MRIs at 12 months with adequate quality 
† Right knees adjusted for age (categorical age (<60, 60-70, >70); BMI 
(categorical normal <25 kg/m2, overweight ≥25 to <30kg/m2, obese ≥30 
kg/m2), previous injury (yes/no), previous surgery (yes/no) 
*p<0.05, **p<0.001, 
  




Table 45 The associations between 3D bone shape vectors with 
prevalent frequent knee symptoms at 12 months – Multivariable 
models in males. 
MALES (n=1692) OR 95% CI p-value 
Bone – Femur (n=1692) 1.25 1.16, 1.35 <0.01* 
























Injury (ref No injury) 1.11 0.88,1.41 0.37 
Surgery (ref No surgery) 1.60 1.20, 2.12 <0.01* 
Bone – tibia (n=1692) 1.25 1.14, 1.37 <0.01* 
























Injury(ref No injury) 1.13 0.90, 1.43 0.30 
Surgery(ref No surgery) 1.69 1.27, 2.23 <0.01* 
Bone - Patella (n=1692) 1.25 1.14, 1.37 <0.01* 
Age (ref <60) 
Between 60-70 






















Injury(ref No injury) 1.14 0.90, 1.44 0.27 
Surgery(ref No surgery) 1.76 1.33, 2.33 <0.01* 
*p<0.05, **p<0.001, Bone - refers to bone shape vector 
  




Table 46 The associations between 3D bone shape vectors with 
prevalent frequent knee symptoms at 12 months – Multivariable 
models in females. 
FEMALES (n=2308) OR 95% CI p-value 
Bone – Femur (n=2308) 1.25 1.16, 1.35 <0.01* 
























Injury (ref No injury) 1.11 0.88,1.41 0.37 
Surgery (ref No surgery) 1.60 1.20, 2.12 <0.01* 
Bone – tibia (n=2308) 1.25 1.14, 1.37 <0.01* 
























Injury(ref No injury) 1.13 0.90, 1.43 0.30 
Surgery(ref No surgery) 1.69 1.27, 2.23 <0.01* 
Bone - Patella (n=2308) 1.25 1.14, 1.37 <0.01* 
Age (ref <60) 
Between 60-70 






















Injury(ref No injury) 1.14 0.90, 1.44 0.27 
Surgery(ref No surgery) 1.76 1.33, 2.33 <0.01* 
*p<0.05, **p<0.001, Bone - refers to bone shape vector 
 
 
6.3.2 IPKS in the ‘whole’ OAI subcohort 
The participant flow chart for this analysis is described in (Figure 55). Of the 
4,796 participants in the OAI database, 834 right knees with and without 
radiographic knee OA had available bone vector data for IPKS unadjusted 
analysis. This included 358 males and 476 females of which 42 (12%) males 
- 322 - 
322 
 
and 69 (14%) females had IPKS by the 60-month visit. The distribution of the 
3D bone shape vector values is described in Table 43)for males and females 
and those developing IPKS had generally larger vector values than those not 
developing IPKS, indicating greater structural severity.  
The unadjusted logistic regression models of individual male bones 
estimated increased odds of IPKS with more positive 3D femoral bone 
shape, indicating greater OA structural severity (Table 44) but there was no 
association of the tibia or patella with IPKS. Odds ratios (95% confidence 
intervals) per normalised unit of 3D bone shape vector for the femur, tibia 
and patella were 1.31 (1.01, 1.69), 1.11 (0.83, 1.50), 1.10 (0.83, 1.45) 
respectively. The association of femoral 3D bone shape with IPKS was 
significant (p=0.04). In logistic regression models neither the femur, tibia nor 
the patella were significantly associated with IPKS, after adjustment for 
covariates, with attenuation of the unadjusted femoral association. The 
adjusted odds ratios (95% confidence intervals) per normalised unit of 3D 
bone shape vector were 1.20 (0.91, 1.59), 1.06 (0.78, 1.44), 0.97 (0.71, 
1.32) for the femur, tibia and patella respectively, all p>0.05.    
The same analyses amongst females identified very similar findings (Table 
44). Similarly no single bone demonstrated a greater association with IPKS 
than any other.  
 
6.3.3 PFKS in the ‘at-risk’ subcohort without radiographic OA 
The participant flow chart for this analysis is described in (Figure 56). Of the 
4,796 participants in the OAI database, 858 right knees without radiographic 
knee OA had available bone vector data for PFKS unadjusted analysis. This 
included 370 males and 488 females of which 91 (25%) males and 112 
(23%) females had PFKS at the 12-month visit. The distribution of the 3D 
bone shape vector values is described in (Table 47) for males and females 
and those with and without PFKS had generally similar vector values 
indicating similar structural severity.  
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The unadjusted logistic regression models of each individual male bone 
estimated no association of PFKS with any 3D bone shape (Table 48). Odds 
ratios (95% confidence intervals) per normalised unit of 3D bone shape 
vector for the femur, tibia and patella were 1.03 (0.81, 1.32), 1.15 (0.90, 
1.46), 1.17 (0.92, 1.48) respectively, all p>0.05. In adjusted logistic 
regression models the femur, tibia and patella remained unassociated with 
PFKS   
The same analyses amongst females identified very similar findings (Table 
48) although the unadjusted logistic regression models of only the patella 
female bone estimated increased odds of PFKS with more positive 3D 
patellar bone shape, indicating greater OA structural severity (Table 49). 
Odds ratios (95% confidence intervals) per normalised unit of 3D bone 
shape vector for the femur, tibia and patella were 1.17 (0.95, 1.43), 1.11 
(0.91, 1.37), 1.25 (1.01, 1.55). However the association of the patellar bone 
shape with PFKS was attenuated after adjustment for covariates (Table 5 & 
6) especially BMI and previous injury. 
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Figure 56 Participant flow diagram for the case selection of knees without radiographic OA 
 
M:F male to female ratio 
PFKS – Prevalent frequent knee symptoms 
IPKS – Incident persistent knee symptoms 




Table 47 The distribution of 3D bone shape vectors in male and female 
participants a) with and without prevalent frequent knee 
symptoms and b) with and without incident persistent knee 
symptoms in all right knees without radiographic knee OA at 12 
months. 
 Mean (SD) Mean (SD) Mean (SD) 










   Femur 0.09 (0.97) 0.06 (0.98) 0.07 (0.99) 
   Tibia -0.01 (1.04) -0.14 (0.96) -0.11 (0.98) 










   Femur 0.19 (1.07) 0.02 (1.03) 0.07 (1.04) 
   Tibia -0.06 (0.97) -0.17 (1.04) -0.14 (1.03) 
   Patella 0.18 (1.00) -0.04 (0.99) 0.01 (0.99) 










   Femur -0.04 (0.92) 0.01 (0.98) 0.01 (0.97) 
   Tibia 0.15 (1.13) -0.19 (0.96) -0.14 (0.99) 










   Femur 0.24 (0.98) -0.01 (1.00) 0.04 (1.02) 
   Tibia 0.01 (1.05) -0.22 (1.00) -0.18 (1.01) 
   Patella 0.15 (0.87) -0.03 (1.01) -0.01 (0.98) 
Mean 3D bone shape vectors (SD) 
PFKS – persistent frequent knee symptoms 
IPKS - incident persistent knee symptoms 
  




Table 48 Associations between 3D bone shape vectors and prevalent 
frequent knee symptoms at 12 month visit (cross-sectional) and 
incident persistent knee symptoms by 60-month visit 
(longitudinal) of all right knees without radiographic OA at 12 
months 
 OR (95%CI) ¥ Adjusted OR (95%CI)† 
(a) Outcome: prevalent frequent knee symptoms 
3D Bone shape 
vector (males) 
n=370 
(91 with pain) 
n=365 
   Femur 1.03 (0.81, 1.32) p=0.81 0.93 (0.72, 1.20) p=0.58 
   Tibia 1.15 (0.90, 1.46) p=0.27 1.20 (0.93, 1.55) p=0.16 
   Patella 1.17 (0.92, 1.48) p=0.20 1.08 (0.84, 1.40) p=0.53 
3D Bone shape 
vector (females) 
n=488 
(112 with pain) 
n=485 
   Femur 1.17 (0.95, 1.43) p=0.13 1.12 (0.91, 1.38) p=0.31 
   Tibia 1.11 (0.91, 1.37) p=0.30 1.14 (0.92, 1.41) p=0.23 
   Patella 1.25 (1.01, 1.55) p=0.04* 1.19 (0.95, 1.49) p=0.12 
(b) Outcome: incident persistent knee symptoms 
3D Bone shape 
vector (males) 
n=257 
(35 with pain) 
n=254 
   Femur 0.94 (0.65,1.36) p=0.76 0.86 (0.58,1.27) p=0.45 
   Tibia 1.42 (0.99,2.05) p=0.06 1.47(1.00, 2.17) p=0.05 
   Patella  0.98(0.68, 1.42) p=0.93 0.90 (0.60, 1.35) p=0.62 
3D Bone shape 
vector (females) 
n=329 
(52 with pain) 
n=327 
   Femur 1.27 (0.94,1.71) p=0.11 1.21 (0.89,1.64) p=0.23 
   Tibia 1.26 (0.94,1.69) p=0.13 1.28 (0.94, 1.73) p=0.11 
   Patella 1.19 (0.88, 1.61) p=0.25 1.14 (0.84, 1.56) p=0.4 
¥ Right knees with MRIs at 12 months with adequate quality 
† Right knees adjusted for age (categorical age (<60, 60-70, >70); BMI 
(categorical normal <25 kg/m2, overweight ≥25 to <30kg/m2, obese ≥30 
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Table 49 The associations between patellar 3D bone shape vector with 
prevalent frequent knee symptoms in right knees without 
radiographic osteoarthritis at 12 months – Multivariable model 
FEMALES (n=488) OR 95% CI p-value 
Bone - Patella (n=488) 1.19 0.95, 1.49 0.121 
Age (ref <60) 
Between 60-70 






















Injury(ref No injury) 2.03 1.19, 3.45 <0.01* 
Surgery(ref No surgery) 2.63 0.85, 8.18 0.09 
Bone - refers to bone shape vector 
 
 
6.3.4 IPKS in the ‘at-risk’ subcohort without radiographic OA 
The participant flow chart for this analysis is described in (Figure 56). Of the 
4,796 participants in the OAI database, 586 right knees without radiographic 
knee OA had available bone vector data for IPKS unadjusted analysis. This 
included 257 males and 329 females of which 35 (14%) males and 52 (16%) 
females had IPKS by the 60-month visit. The distribution of the 3D bone 
shape vector values is described in (Table 47) for males and females and 
those with IPKS had generally no difference in bone shape vector values, 
than those not developing IPKS.  
The unadjusted logistic regression models of each individual male bone 
estimated no association with PFKS (Table 48). Odds ratios (95% 
confidence intervals) per normalised unit of 3D bone shape vector for the 
femur, tibia and patella were 0.94 (0.65, 1.36), 1.42 (0.99, 2.05), 0.98 (0.68, 
1.42) respectively, all p>0.05. 
In logistic regression models the femur, tibia and patella remained 
unassociated with the development of IPKS, after adjustment for covariates 
although the tibia approached borderline significance. The same analyses 
amongst females identified very similar findings (Table 48).  




6.3.5 Diagnostics and linearity checks 
In order to check whether the linearity assumption holds between log 
Incidence pain and outcome variable (bone shape) a formal statistical test 
was performed for each shape model (linktest) and this was found not to be 
significant. In other words the null model was that the model is linear.  
 
P-value for _hatsq=0.89, however linktest alone cannot be used to rule out 
misspecification therefore a collection of other checks were performed. I 
have explored the use of Box-Tidwell transformations on bone shape 
because it is the only one that may have linearity issues to check because  
the other predictors are categorical (BMI, age, surgery, injury, sex) and I’ve 
explored if there are any differences if I have BMI and age maintained as a 
continuous variable. Results from this suggest that the predictor should be 
modelled in its current form and there are no misspecification errors in 
specifying the model in this form and no transformations are needed .Non 
linearity is related to misspecification.  
                                                                              
       _cons     .1077006   .9288484     0.12   0.908    -1.712809     1.92821
      _hatsq     .0524457   .3950597     0.13   0.894    -.7218571    .8267485
        _hat     1.158629   1.223321     0.95   0.344    -1.239036    3.556294
                                                                              
   Incidence        Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                              
Log likelihood = -235.07716                       Pseudo R2       =     0.0298
                                                  Prob > chi2     =     0.0007
                                                  LR chi2(2)      =      14.44
Logistic regression                               Number of obs   =        573





Figure 57 Leverage Plot 1 
 
After dropping all the IDs with leverage greater than 0.04 and refitting the 
model there were no differences hence everyone retained. 
-Pregibon`s beta was assessed and not many individuals had values that 
had undue influence. This is similar to leverage and assesses if there are 
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Figure 58 Leverage Plot 2 
 
 
6.3.5.2 Use of polynomials and interactions 
From earlier diagnostics there was no suggestion to use any polynomial 
terms but I just explored these and the results suggested the original form of 
the variable was sufficient as there was no association seen when the 
polynomial terms for each bone were included. I have modelled interaction 
terms separately for the bone measure with BMI and age and no significant 
interactions were seen and also no change to the odds ratios and therefore 

















































































































































92 55 792 0666 670712










































































9 61469 78 93
9378288
81 819 9 5
9382992






















































































95087 895 9 46
9 10301




































































































96532 49 9 0
9656070




































































































































































































9000000 9200000 9400000 9600000 9800000 10000000
ID




This is the first study to describe the relationship of 3D bone shape with 
PFKS and IPKS in knees with or at risk of OA. This analysis identifies that 
3D bone shape is associated with current knee symptoms amongst knees 
with radiographic OA but not in the ‘at risk’ subcohort without radiographic 
OA. 3D bone shape is not associated with incident persistent knee OA 
symptoms regardless of the presence or absence of radiographic knee OA 
after adjusting for known associations of IPKS. IPKS is associated with 
female gender, obesity, and knee injury[657].  
The analyses within this chapter imply that 3D bone shape is not involved in 
the pathogenesis of incident knee OA symptoms.  Amongst cohorts of knees 
with prevalent radiographic OA, other subchondral bone pathologies of knee 
OA have been analysed for their relationship with knee OA symptoms. The 
best described of these is the bone marrow lesion. BMLs are independently 
associated with incident frequent knee pain[26, 456] and this has been 
reported in a recent systematic literature review[658]. However current knee 
pain in similar cohorts has been reported to have both an association [133, 
575, 577] and the absence of a clear association with concurrent BMLs [319, 
456, 559, 571]. Systematic literature reviews have identified the association 
of BMLs with current knee pain in radiographic knee OA as moderate [132] 
or inconsistent[658]. With appropriate adjustments for important covariates 
an increasingly larger weight-bearing femoral relative to the tibial 
subchondral surface area was protective against the incidence of knee OA 
symptoms in a subcohort of the OAI that included individuals with prevalent 
knee ROA[102]. Amongst ‘at risk’ subcohorts of knees without  radiographic 
knee OA, PFKS and IPKS in knees at risk of OA have been associated with 
BMLs, cartilage lesions and meniscal degeneration and these lesions are 
independently associated with risk of IPKS [131]. In contrast, this study 
found no clear or consistent evidence that in the same population 3D bone 
shape vectors for the femur, tibia and patella were related to current frequent 
knee symptoms or with an increased future risk of the persistence of such 
symptoms up to 4 years. 
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The TASmanian Older Adult Cohort examined the relationship between 
change in BML size and change in ipsilateral knee pain with and without 
radiographic OA. A change in BML size was associated with changes in 
ipsilateral pain in those without and not with established ROA implying a 
greater significance of BMLs in early stage disease [99] 
Therefore there is no single knee OA subchondral bone imaging biomarker 
that has consistently demonstrated both concurrent and predictive criterion 
validity in relation to knee OA symptoms in knees with and without 
radiographic OA. However the greatest evidence supporting an association 
of OA subchondral bone pathology with pain is provided by BMLs and these 
are likely to be measuring a different pathological construct to bone shape. 
The pathophysiology by which BMLs may cause pain is unknown but this 
might include a decreased blood supply causing ischaemia, subchondral 
microfractures, and raised intraosseous pressure[136-138].  BMLs are and 
3D bone shape is not associated with current and future knee symptoms in 
the ‘at risk’ subcohort without radiographic OA. 3D bone shape is derived 
from the difference in shape of knees with and without radiographic  knee 
OA. However  BMLs are prevalent  in knees at risk of OA without 
radiographic OA and are associated in this group with incident symptoms 
and radiographic OA[131, 622]. Therefore BMLs may be a more sensitive 
measure of ‘early’ or pre-radiographic knee OA. The evidence supporting 
this explanation from my analysis and the association of 3D bone shape with 
knee OA symptoms  is discussed here.3D bone shape change may be 
involved in the pathogenesis of incident knee symptoms at a more advanced 
stage of OA, but may be relatively insensitive to knee symptoms in the pre-
radiographic phase due to the very narrow distribution of bone vector values 
at this stage. This is suggested by the fact that the femur, which is the most 
responsive of the three bone shape vectors[652], was associated with IPKS 
in univariable analyses in males and females in the ‘whole’ OAI subcohort 
(Table 2b) but not in the ‘at risk’ subcohort without radiographic OA(Table 
5b). It is noteworthy that femoral 3D bone shape changes in a less uniform 
and symmetric manner in OA progression than the tibia and patella with its 
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two articulating surfaces and bone expansion occurring around the cartilage 
plates where increased ridges of “osteophytic” material form[75].  BMLs may 
represent an early OA focal remodelling that causes future knee symptoms 
and macroscopic bone remodelling which confers the change in 3D bone 
shape which is most readily detected in radiographic stages of OA when 
changes to the bone and joint geometry can adversely affect the congruity of 
the joint surfaces and impair the effective dissipation of load through the joint 
tissues. This overloading of the articulating tissues may indirectly cause pain 
through microfractures and further BMLs or drive cartilage degradation and 
subsequent synovitis which are both associated with knee pain in a 
systematic literature review[132]. 
Amongst knees without radiographic OA BMLs are whilst 3D bone shape is 
not associated with knee OA symptoms. Amongst knees with established 
radiographic OA, the association of current knee OA symptoms appears to 
be more consistent with 3D bone shape than with BMLs after covariate 
adjustment. This may reflect different mechanisms of pain in radiographic 
and pre-radiographic OA. 3D bone shape change is closely associated with 
3D osteophyte formation (endochondral ossification) which is initiated by 
vascular invasion of cartilage along with osteoclastogenesis [201-203] which 
are involved in the innervation and neurovascular invasion of premorbidly 
aneural cartilage. Therefore 3D bone shape change may correlate with the 
potential for nociception in cartilage[15]. 3D bone shape change may 
therefore better reflect the concurrent innervation of cartilage and the 
potential for concurrent nociception rather than predicting this mechanism of 
nociception in the future.  
3D bone shape was independently associated with TKR in Chapter 5, but 
the association with knee OA symptoms in this chapter was limited to the 
presence of radiographic OA. Similarly Waarsing and colleagues[292] 
identified that 2D bone shape models of the hip correlated well with 
structural severity but did not correlate well with clinical symptoms and vice-
versa.  
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The validity of 3D bone shape as an outcome measure in clinical trials of 
knee OA, in light of this chapter’s analysis, should be considered. 
Participants enrolled in all knee OA trials have required symptomatic knee 
OA and therefore no clinical trial has used incident knee OA symptoms as 
an outcome.  However future clinical trials may attempt to prevent the 
incidence of knee OA symptoms. If a clinical trial were to attempt to prevent 
the incidence of knee OA symptoms by targeting the subchondral bone, 
patients could be selected on the presence of BMLs and incident symptoms 
would be the primary outcome. However the change in BML size could be a 
secondary mechanistic outcome[330, 659]. In this context 3D bone shape 
change could also be used as a sensitive secondary outcome measure of 
OA structural progression but not for incident symptoms. 
6.5 Limitations 
There are limitations to this study. Covariates such as BMI may increase 
between baseline and the onset of IPKS and therefore any association of 
IPKS may in fact be a consequence of the residual confounding of weight 
gain. We did not include BML, synovitis, cartilage or meniscal lesion scores 
because of the limited availability of MOAKs scores in the OAI participants 
and there could be additional unknown or unmeasured confounders, as with 
any observational study, that may confer bias. Unmeasured confounders 
may systematically be different in the subcohorts where we selected right 
knees only and knees ‘at risk’ without radiographic OA.  
Confounding factors that might influence bone shape could include use of 
bisphosphonates. Confounding factors for knee OA symptoms could include 
bone marrow lesions, synovitis, level of activity, muscle strength and 
increasing BMI after baseline which we did not account for. BMLs and 
synovitis may reflect failure of the joint to dissipate load effectively and the 
amount of load put through the joint.  Therefore BMLs and synovitis may be 
on the causal pathway to pain and driven by increased level of activity[660], 
reduced by pain-related avoidance of activity[661], increased loading of the 
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joint conferred by increasing BMI or weak muscles which are independently 
associated with knee OA pain[662, 663].  
While the association of 3D bone shape with knee symptoms is conditional 
to the symptoms being current, and the subcohort including radiographic 
OA, the limitations of annual pain measurement may confound this analysis. 
With such large intervening periods between measurement of knee 
symptoms, these may not be representative of actual knee symptoms. More 
frequently assessed knee symptoms may be a more precise method for 
determining pain. 
Activity-related pain of OA is typically present in a prodromal phase of ‘early’ 
OA before the incidence of ROA[18]. This pain in early OA is typically 
mechanical [128] and pain on stair climbing appears to be the first 
mechanical symptom to manifest amongst knees with ROA and at risk of 
ROA[32]. Therefore incident pain might better be assessed more frequently 
than annually and with more precise symptoms.  
The analysis within this chapter relies upon a single time-point measure of 
3D bone shape. It remains possible that longitudinal changes in 3D bone 
shape (within-person pattern of bone shape growth) may confer greater 
precision, sensitivity to change and association with knee OA 
symptoms[625]. 
Magnetic resonance cannot directly identify the presence of calcium. In the 
segmentation of knee DESS-we MRI sequence the material imaged is 
assumed to represent bone rather than another tissue type. Confirmation 
that these surfaces are actually bone requires further work. We are 
reassured that the automated segmentation used here is both accurate and 
repeatable.  
6.6 Conclusions 
This chapter has demonstrated that 3D bone shape vectors are associated 
with current frequent knee symptoms but not with incident persistent 
symptoms of knees with radiographic OA. This chapter therefore provides 
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evidence of concurrent validity of 3D bone shape which is restricted to knees 
with radiographic knee OA. This chapter also identified that unlike bone 
marrow lesions, 3D bone shape is not associated with either current knee 
symptoms or incident persistent knee symptoms in knees without 
radiographic OA but at risk of knee OA. Therefore 3D bone shape has 
evidence of validity for use as an outcome measure in interventional clinical 
trials and may represent and important tissue target for knee OA structural 
modification. However 3D bone shape is unlikely to be an important tissue 
target for preventing the onset of symptomatic knee OA.   
 
 
6.7 Recent evidence for  3D bone biomarker validation 
Further validation work has recently been published in parallel with the novel 
research contained within this PhD. This includes evidence of the reliability 
and responsiveness and further construct validity of the 3D bone shape 
biomarkers. This is described here using the domains of the Outcome 
Measures in Rheumatology (OMERACT) filter[355, 356] which are described 
in 2.7.2 Validation of biomarkers using the OMERACT filter 
6.7.1  Construct validity 
Longitudinal change in 3D bone area was described in approximately 1300 
knees with established radiographic OA and in 900 knees without 
radiographic OA. The longitudinal percentage increase in bone area was 
three fold greater in knees with than those without radiographic OA. 
Furthermore all bones in the knee increased in 3D bone area, particularly 
around each cartilage plate in a circumferential pattern, which is likely to 
represent the 3D characteristics of the 2D osteophytes ‘lip’ seen on 
conventional radiography. Together this provides evidence of construct 
validity as bone area correlated with established features of pathology within 
the same domain of structure[664].  
6.7.2  Predictive validity  
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The association of the longitudinal change in 3D bone shape or bone area 
with longitudinal medial tibiofemoral radiographic structural progression and 
pain progression was recently described in a case-control study of knees 
nested within the OAI [625]. Case knees (n=200) were defined as knees with 
mild to moderate structural disease with structural and pain progression over 
48 months. Controls (n=400) were defined as neither structural or pain 
progression or only progression in either structure or pain.  
Both of the 3D bone biomarkers were independently associated with 
structural progression but only weakly with pain progression. However this 
highlights their potential use in prospective DMOAD clinical trials as 
surrogate measures of these important patient-centred endpoints[625].  
A similar hierarchy of strength of association of each of the bones, to the 
associations identified in this PhD, was observed. The medial femur 3D 
bone area was most strongly associated with radiographic progression and 
pain progression. The 3D femoral shape vector was most strongly 
associated with structural progression but not with pain progression as in the 
analysis in Chapter 6. It is interesting to note that a similar analysis using 




For the active appearance models used in this thesis, the accuracy of the 
automated segmentations has been further assessed using test–retest MRIs 
for 19 participants (38 images) with no OA to moderate degrees of clinical 
OA, that were originally prepared as a pilot study for the OAI, to test the 
accuracy and precision of knee cartilage qMRI with a fast double echo, 
steady state (DESS) sequence which is the same as used in the OAI [644]. 
The bone surface was manually segmented as previously described[632]. 
Mean point-to-surface distances were calculated between the manual and 
automated segmentations. Mean point-to-surface errors were as follows: for 
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the femur, 0.49 mm; for the tibia, 0.53 mm; and for the patella, 0.57 mm (i.e. 
each approximately the size of 1 voxel)[75]. 
It is often difficult to obtain inter-occasion reliability data as this involves re-
imaging subjects within a short period of time and causes patient 
inconvenience. The reliability of the method of measuring 3D bone area and 
3D bone shape vector was assessed in a set of 35 knees with OA that 
underwent the same image acquisition as in the OAI on two separate 
occasions one week apart. The inter-occasion reliability for the 3D bone 
shape vector was good with the smallest detectable difference (SDD) for the 
femur, tibia and patella vectors as 0.22, 0.86 and 0.24 units normalised to 
the mean non-OA shape respectively [625].  
The reliability of the tAB or 3D bone area was also good with the SDD (SDD 
%  of baseline bone area) being described in units of area (mm2) for the 
medial femur, medial femoral trochlea, medial tibia and medial patella as 
24.4 (1.07%), 12.8 (1.98%), 21.6 (1.99%), 20.6 (4.02%)[625].  
The root-mean-square coefficient of the variance (CoV) has been calculated 
to describe the repeatability of bone area within the same test-retest 
assessment of 35 knees. The CoV of medial femur, medial trochlea femur, 
medial tibia and medial patella were 0.38%, 0.67%, 0.69%, 1.45% 
respectively[625]. This compares favourably to a mean CoV of 
approximately 2-3% for automated segmentations of cartilage thickness in 
the same test-retest reliability assessment[632].  
The reliability of the method of measuring 3D bone area (tAB) and medial 
joint space (mJSW) width was assessed in a set of 147 knees without 
radiographic OA that underwent the same image acquisition as in the OAI on 
two separate occasions one year apart. Considering the absence of 
radiographic OA, it was therefore expected that little real difference should 
be expected. The CoV of 3D bone areas and mJSW was <1% and 5.1% 
respectively[664]. Therefore the reliability of 3D bone shape biomarkers is 
good and superior to the current standard of measuring structural 
progression that relies upon JSW. There is substantial measurement error in 
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JSW and using 3D bone biomarkers may therefore improve the 
measurement noise to signal ratio.  
 
6.7.4 Responsiveness 
The responsiveness of bone area, cartilage thickness and joint space 
narrowing (JSN) was determined by describing the change in these 
measures in 350 knees with radiographic OA within the OAI cohort, over two 
years. Bone area was measured by automated segmentation using active 
appearance models and cartilage thickness was computed from manual 
segmentations of the femorotibial joint. JSN was measured using mJSW 
measures provided by the OAI. The mJSW was measured using a 
semiautomated tool shown to be as sensitive as manual measures. The 
responsiveness over two years (standardised response mean) for the medial 
femur bone area, the most responsive cartilage thickness measure (central 
medial femorotibial composite) and mJSW was 0.83, 0.38 and 0.35 
respectively. The longitudinal changes in bone area in the medial 
tibiofemoral joint are displayed in (Figure 59). Therefore in comparison to 
cartilage volume or mJSW, 3D bone area was much more responsive. The 
responsiveness of 3D bone area is also highlighted by the fact that almost 
half of all individuals had a change in bone area during the two year period 
that was greater than the SDD[664].  
 




Figure 59 The longitudinal changes in bone area in the medial 
tibiofemoral joint 
 
Legend: Percentage change in bone area (tAB) from baseline for medial 
regions in OA (dark grey) and non-OA groups (light grey) (95% CI). All 
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6.7.5  Feasibility 
3D bone shape biomarkers require specialised automated segmentation and 
imaging analysis technology along with technical experts in image analysis 
and MRI radiographers. 
While proprietary software was used for the active appearance models that 
defined the 3D bone shape biomarkers in this thesis, there are several other 
research groups that are using similar segmentation methods to define 3D 
shape of joint structures and the importance of these in OA. These include 
researchers at Imperial College, London, that have defined the 3D shape of 
the meniscus and its relationship to cartilage load [666, 667], and 
researchers at the University of North Carolina that have described the 3D 
shape of the mandible in temporomandibular joint OA at [668]. Researchers 
at Parcelsus University have used automated segmentation to describe 3D 
shape of bone and cartilage[102]. Semi-automated shape recognition 
technology has been used by researchers at the University of Cambridge to 
investigate the shape of the femoral head in hip OA[669] and at University of 
California San Francisco to investigate the shape of the tibia and femur after 
anterior cruciate ligament injury.[670]. As this technology becomes more 
readily available, the access to bone shape and joint tissue biomarkers will 
continue to increase. 
The superior responsiveness and reliability of 3D bone shape biomarkers 
over conventional radiography, should very substantially reduce the number 
of participants and duration of a clinical trial required, to adequately power a 
study of a prospective DMOAD[664]. While manual semi-quantitative or 
quantitative scoring of joint images can be expensive and hugely time 
consuming for radiologists in clinical and observational trials, the bone shape 
biomarkers for all 4790 participants in the OAI, in all knees at all time points 
can be generated using automated active appearance modelling in 24-48 
hours. Furthermore a substantial reduction in the number of trial participants 
required to adequately power a trial, may similarly substantially reduce the 
burden and practical demands associated with conducting interventional 
clinical trials in OA. The overall reduction in cost, size and duration of trials 
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and clinical trial staff labour may substantially facilitate interventional OA 
researchers in performing vital trials to identify novel therapies in OA.   
In the future it remains possible that these bone shape biomarkers and this 
technology may enter routine clinical practice. Patients at-risk of OA or with 
OA could be appropriately stratified into those in need of intervention by 
using  bone shape biomarkers. This could be feasible in the clinic setting, if 
the cost of AAM software becomes cheaper and appropriate decision 
making tools are developed tool, in a similar manner to the FRAX tool 
(University of Sheffield) that is used for the management of osteoporosis. 
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Chapter 7 Discussion, future directions and conclusions 
7.1 Thesis synopsis 
This thesis is concerned with the role of subchondral bone in knee OA and 
specifically describes the relationship of 3D knee bone shape with 
established measures of OA structural severity and important patient-
centred outcomes in knee OA including total knee replacement and knee OA 
symptoms. This provides evidence supporting the validity of bone shape for 
use as a biomarker in OA clinical trials. The analyses performed in this 
thesis in Chapters three, four, five and six are summarised as follows: 
 
Chapter 3 
The aim of this chapter was to systematically collect all literature pertaining 
to the relationship between imaging-assessed subchondral bone pathology 
and the important outcomes of joint replacement, structural progression and 
pain, with a suitable systematic stratification by quality scoring system and 
assessment of adequacy of confounder adjustment. This systematic 
literature review concluded that there were independent associations 
between imaging-assessed bone pathologies and TKR, structural 
progression and pain in the knee, hand, and hip. The most substantive 
evidence for independent associations was for knees: 
 MRI BMLs were independently associated with structural progression, 
TKR and  longitudinal change in knee pain severity 
 MRI osteophytes were independently associated with knee structural 
progression only 
 MRI 2D tibial bone area was independently associated with structural 
progression, TKR and the ratio of the medial tibiofemoral articulating 
bone surface areas was independently associated with incident 
frequent knee pain  
 Trabecular morphometry and bone densitometry were associated with 
structural progression but this was not independent of confounders 
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 MRI bone attrition and cysts were not associated with structural 
progression and may be epiphenomenon of knee OA rather than 
being on the causal pathway.  
2D hip bone shape measures were independently associated with structural 
progression and total hip replacement. Hand OA structural progression was 
independently associated with BMLs. The existing standard for measuring 
structural progression, radiographic (JSN), poorly correlated with the clinical 
syndrome and remains a relatively insensitive measure (see 2.11 OA 
biomarkers). When JSN is used as a trial outcome measure this demands 
that clinical trials are large, long  and expensive. Therefore the unmet need 
for more sensitive and validated imaging biomarkers is huge. 
The independent associations of certain subchondral bone features with 
important patient-centred outcomes (pain and TKR) and structural 
progression suggest subchondral bone can provide valid surrogate 
measures of these outcomes. While many of these are MRI-derived 
measures, they are intrinsically more sensitive than radiographic JSN (see 
2.11 OA biomarkers), their use as clinical outcomes may substantially 
reduce the cost, duration and size of future trials. Bone measures may also 
improve the precision of OA phenotypic stratification to facilitate pathology-
specific treatment, prioritisation of individuals most in need of structure 
modification and measuring treatment response.  
This systematic review highlighted the need for greater information on the 
validity of subchondral bone features to be used as surrogate measures of 
OA patient-centred outcomes in all joints. There was very little evidence 
describing the validity of 3D bone shape as a surrogate measure. This 




The aim of this chapter was to describe the association of the 3D bone 
structure of OA with established constructs of radiographic structural OA. 
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The objective was to determine if there was evidence of construct validity of 
the 3D bone structure. The articulating regions of knee bones typically 
expand in 3D with structural progression of OA. Their physiological ‘starting’ 
shape is determined by height, age, weight. The 3D bone structure of OA 
(described as OA-attributable bone area) was determined by subtracting the 
actual bone area from the predicted physiological bone area based upon 
available demographic data.  Regression analyses were then performed to 
establish whether conventional radiographic measures of knee OA were 
independently associated with corresponding OA-attributable bone area 
after adjusting for alignment and other conventional radiographic features.  
This analysis confirmed metric JSW, osteophyte grade, subchondral 
sclerosis grade and KL grade all were significantly associated with OA-
attributable bone area. None of these measures explained a substantive 
proportion of the OA-attributable bone area. However the greatest 
explanation of area variance was provided by osteophyte score. An 
explanation for this is that OA-attributable bone area is in part a 
representation of three-dimensional endochondral ossification and 
osteophyte formation which is less precisely quantified by the 2D projection 
images of conventional radiography.  
The association of OA-attributable 3D bone area with established standards 
of radiographic OA provides evidence of construct validity. The association 
of this 3D knee bone shape change of OA with important knee outcomes 
such as TKR and knee symptoms was subsequently explored and is 
described in Chapters 5 and 6.  
 
Chapter 5 
The aim of this chapter was to establish if 3D bone shape was associated 
with the important patient-centred outcome of total knee replacement (TKR). 
A case-control analysis, nested within the OAI, achieved effective matching 
of multiple strong confounding factors using propensity score matching 
(without matching for radiographic severity). The 3D bone shape vectors of 
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the femur, tibia and patella were all significantly associated with the outcome 
of TKR with the femur having the strongest association which is concordant 
with other analyses of femur shape. After adjustment for KL grade, the 
association of TKR with the patella and tibia shape was attenuated but the 
femur remained associated and improved the model ‘fit’ indicating femoral 
bone shape has an independent association with TKR after adjustment for 
KL grade. This was considered to reflect the additional 3D structural 
information that is not captured by conventional radiography in addition to 
the observation that femoral bone shape is more responsive and changes in 
more heterogenous manner with OA structural progression, indicating it may 
be a more suitable biomarker for use in clinical trials. This provided evidence 
of predictive validity and further underpinned the value of quantitative bone 
measures in future therapeutic trials of disease modifying osteoarthritis 
drugs.  
 
Chapter 6  
The aim of this chapter was to establish if 3D bone shape was independently 
associated with current knee OA symptoms (concurrent validity) and incident 
persistent knee symptoms (predictive validity). The first analysis was 
performed upon the ‘whole’ OAI subcohort of knees which included knees  
with and without radiographic OA with available demographic covariate data 
and an MRI of suitable quality at the 12 month visit in the OAI. In this 
analysis 3D bone shape was independently associated with current  
symptoms but not incident persistent symptoms. The second analysis was 
performed upon knees ‘at-risk’ of knee OA but without radiographic knee 
OA. Neither current nor incident knee symptoms were associated with 3D 
bone shape. In conclusion 3D bone shape was independently associated 
with current knee OA symptoms when extant radiographic knee OA is 
present. This provided evidence of conditional concurrent validity. It may be 
that knee bone shape is more relevant to pain when more advanced 
structural severity is present, such as when endochondral ossification occurs 
and the neurovascular invasion of cartilage occurs. However while the 
- 347 - 
347 
 
association of 3D bone shape with knee symptoms was conditional, the 
limitations of annual pain measurement may have confounded this analysis. 
With such large intervening periods between measurements of knee 
symptoms, these may not be representative of actual knee symptoms.  
 
Overall Summary 
The hypothesis underlying this thesis was that subchondral knee bone 3D 
shape, defined using 3D knee MRI segmentation and (AAM), would 
demonstrate validity as a biomarker through association with existing 
radiographic measures of structural knee OA pathology, TKR and knee OA 
symptoms as part of the validation of biomarkers for use in knee OA clinical 
trials. In summary, this thesis has indeed provided evidence supporting the 
OMERACT biomarker tool validation domain of truth, that 3D knee bone 
shape biomarkers have construct validity as measures of knee OA 
radiographic severity, predictive validity by association with total knee 
replacement (TKR) and concurrent validity by association with knee OA 
symptoms in knees with radiographic OA. While 3D bone shape is 
independently associated with knee OA radiographic structural disease and 
total knee replacement, like many other structural imaging biomarkers, the 
association with symptoms is weaker.  
Evidence for 3D bone shape biomarkers fulfilling the OMERACT domain of 
discrimination has been provided by the demonstration of good reliability and 
responsiveness in work performed in parallel to this PhD which is described 
in full in (6.7.3 Reliability, 6.7.4 Responsiveness). 
Finally 3D bone shape biomarkers may fulfil the OMERACT domain of 
feasibility. The cost and technical demands of performing clinical trials with 
endpoints defined by conventional radiography and MRI might favour 
conventional radiography at first glance. However while conventional 
radiography is inexpensive and easily accessible, the relative insensitivity 
and poor responsiveness confers the need for relatively large number of 
participants with long duration compared to MRI bone biomarkers. The 
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additional expense of MRI and image analysis is very likely to be offset by 
the substantial reduction in trial size and duration.  
 
7.2 Improving understanding of the relationship between 
bone features and symptoms 
The unmet need for evidence describing the association of 3D bone shape 
with patient-centred outcomes (e.g. TKR and pain) was highlighted in 
Chapter 3. In Chapter 3 the only previous analysis of knee bone shape with 
knee OA symptoms reported an increasingly larger medial weight-bearing 
femoral relative to tibial subchondral surface area (mSSR) was protective 
against the incidence of knee OA symptoms in a subcohort of the OAI that 
included individuals with prevalent knee ROA[102]. This association was 
independent of important determinants of knee OA symptoms. This applied 
outcome of incident knee OA symptoms referred to the incidence of these 
symptoms at one time point in this study which should be distinguished from 
the definition used in Chapter 6 where the incidence of frequent knee OA 
symptoms must have been reported at two consecutive annual reviews. 
Everhart and colleagues used a less strict definition of pain incidence and 
used bone area measurements focussing on the medial joint space where 
greater pathological bone shape changes are observed relative to the whole 
bone shape. These differences in methodology may explain why the vectors 
of whole 3D bone shape (tibia, femur and patella) used in this thesis were 
not associated with incident persistent knee OA symptoms in Chapter 6 
whilst Everhart and colleagues found an association of mSSR with incident 
knee OA symptoms in Chapter 3[102].  
As described in Chapter 3 BMLs were independently associated with 
incident frequent knee pain[26, 456, 658] . However in a systematic literature 
review, BMLs were only moderately associated with knee pain [132]. In 
cross-sectional analyses BMLs have [133, 575, 577] and have not been 
found to be associated with current knee pain[319, 456, 559, 571]. However 
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Sharma and colleagues established that BMLs were associated with current 
frequent knee symptoms and incident persistent knee symptoms in a 
subcohort of knees in the OAI that are at risk of knee OA but without 
radiographic OA knee[131]. By replicating this analysis and replacing BMLs 
with 3D bone shape, we established that bone shape has neither concurrent 
nor predictive validity. However by including all knees, including those with 
radiographic OA, bone shape demonstrated concurrent validity.  
The evidence from Chapter 3 and Chapter 6 identified that BMLs and 3D 
bone shape respectively, are independently associated with future total knee 
replacement and both have construct validity[516, 671].  
There are several possible (non-exclusive) explanations for the variation in 
association of knee OA symptoms with BMLs and 3D bone shape: firstly the 
measurement of prevalent frequent knee symptoms in the preceding year is 
prone to recall bias and fails to distinguish activity-related pain and resting 
pain which may be measuring different pathologies; secondly knee OA 
symptoms may be caused by different pathologies at different stages of 
structural progression; thirdly that unmeasured confounding factors may be 
responsible for all or some associations observed; fourthly that BMLs cause 
both knee symptoms and 3D bone shape changes. 
In the first explanation it should be acknowledged that self-reported chronic 
pain assessments are prone to recall biases (e.g. recency and memory 
effects)[672] particularly where participants are asked to recall frequency of 
pain over the preceding year as in the methods used by Sharma and 
colleagues[131] and in Chapter 6. Furthermore by not distinguishing whether 
the pain described is present whilst resting or on activity, the composite 
measure of the two of these that is used to describe prevalent knee 
symptoms may represent residual confounding with a greater association 
with BMLs rather than bone shape. It is possible that different associations 
of the BMLs and bone shape may be observed with more precise definitions 
of pain.  
In the second explanation knee OA symptoms may be caused by different 
pathogenic mechanisms within the subchondral bone and these 
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predominate at different stages of structural progression. For example BMLs 
may predominate in the pre-radiographic phase whilst 3D bone shape 
changes may be the predominant cause of symptoms in the radiographic 
stages. This is supported by an analysis within the TASmanian Older Adult 
Cohort which examined the relationship between change in BML size and 
change in ipsilateral knee pain in knees with and without radiographic OA. A 
change in BML size was associated with changes in ipsilateral pain in those 
without and not with established ROA implying a greater significance of 
BMLs in early stage disease [99]. BMLs are likely to be measuring a different 
pathological construct to bone shape. The pathophysiology by which BMLs 
may cause pain is unknown but this might include a decreased blood supply 
causing ischaemia, subchondral microfractures, and raised intraosseous 
pressure[136-138].These processes may be more relevant to pain in the 
pre-radiographic stage of OA.  
3D bone shape change is closely associated with 3D osteophyte formation 
(endochondral ossification) which is initiated by vascular invasion of cartilage 
along with osteoclastogenesis [201-203] which are involved in the 
innervation and neurovascular invasion of premorbidly aneural cartilage. 
Therefore 3D bone shape change may correlate with the potential for 
nociception in cartilage[15]. 3D bone shape change may therefore better 
reflect the concurrent innervation of cartilage and the potential for concurrent 
nociception rather than predicting future nociception. This issue of the 
change in bone shape is important because this occurs most noticeably in 
the non-weight bearing regions of the knee which can be described 
histologically but can also be quantified more specifically using AAMs. This 
quantitative measure may represent a better biomarker than existing bone 
shape measures (see 7.4.1.1 Future analyses to elucidate the validity of 3D 
bone shape as a surrogate measure of knee OA)  
3D bone shape, which is in part determined by radiographic severity, may 
also be relatively insensitive to knee symptoms in the pre-radiographic 
phase due to the very narrow distribution of bone vector values at this stage. 
This is suggested by the fact that the femur, which is the most responsive of 
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the three bone shape vectors[664], was associated with IPKS in univariable 
analyses in males and females in the ‘whole’ OAI subcohort (Table 2b) but 
not in the ‘at risk’ subcohort without radiographic OA(Table 5b).  
 
In the third explanation it is important to consider that while we have 
identified associations of bone features with knee symptoms, these do not 
imply causation. There may be additional unknown or unmeasured 
confounders that may directly cause both BMLs and symptoms and future 
change in 3D bone shape and therefore the subchondral bone features are 
not on the causal pathway of knee OA symptoms. For example knee OA 
pain is typically activity-related. The level of activity (or load placed through 
the joint) is recognised to correlate with BMLs [673], knee OA symptoms and 
may drive bone remodelling with future 3D change in knee bone shape. 
Therefore neither BMLs nor 3D bone shape may be independently 
associated with knee OA symptoms after adjustment for level of activity.  
In the fourth explanation bone shape may not be associated with knee OA 
symptoms but is a consequence of bone remodelling driven by BMLs. In this 
scenario BMLs may directly cause knee pain and after adjusting the 3D 
bone shape model for BMLs, 3D bone shape would no longer be 
independently associated with pain.  
7.3 Future Directions 
Conventional radiography (CR) is inexpensive and widely available. CR  joint 
space width (JSW) is the traditionally used surrogate for assessing hyaline 
articular cartilage thickness and is used to define and measure structural 
progression of OA. Joint space narrowing (JSN) remains the current 
standard for measuring cartilage loss or structural progression in disease 
modification trials, where it is used as a primary end point[367]. However 
there are a number of limitations of using JSN. 
Knee JSN lacks tissue-specificity because it reflects a construct of reduction 
in hyaline articular cartilage thickness along with meniscal extrusion and 
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degeneration[86]. The measurement of JSN has relatively poor reliability and 
responsiveness in comparison to MRI-based measures[664] which is in part 
due to significant repositioning variability (2.11.1.1 Conventional 
radiographic quantitative measures)[402, 414]. The smallest detectable 
difference  least 0.2mm is large relative to the mean rate of annual knee JSN 
of 0.13 ± 0.15mm/year, with change occurring in only a small group of 
“progressors”[93, 94]. 
There is no consensus on the threshold for defining relevant structural 
progression using JSN[485], which was highlighted by a systematic literature 
review describing the heterogeneity of opinion amongst experts [415]. 
OA is a whole joint disease and can involve a heterogenous combination of 
joint tissues that are indistinguishable by clinical or conventional 
radiographic assessment[25]. Participants in clinical trials are typically 
recruited by the presence of a homogenous clinical and CR phenotype 
which belies the heterogeneity in tissue pathology. Therefore CR fails to 
distinguish the variation in OA tissue phenotype. CR is also insensitive to 
pre-radiographic structural pathology or early OA which is prevalent in 
individuals at risk of OA with and without symptoms[23]. The presence and 
changes in tissue pathologies (e.g. BMLs) are relevant to knee OA 
symptoms and structural progression at this stage but are not detectable by 
CR[131, 622].  
The severity of CR knee OA is also poorly correlated with knee OA 
symptoms[674], where only 50% of knees with radiographic OA have 
symptoms  and only large changes in conventional radiographic knee OA 
severity are associated with changes in knee pain[98]. 
JSN is used by orthopaedic surgeons to determine the need for joint 
replacement and therefore is associated with TKR[675]. However using JSN 
as a clinical endpoint in clinical trials  confers the need for large numbers of 
participants for two years or more in order to adequately power the study. 
This represents a major barrier to performing trials of prospective disease 
modifying agents. This highlights the need for better biomarkers. This 
section will discuss further important research required to determine the 
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validity of 3D bone shape as a surrogate measure of patient-centred 
outcomes and the potential to segment all of the joint tissues with AAM to 
provide quantitative measures of whole joint OA-tissue pathology. This 
section will also describe the potential advantages of using more precisely 
defined OA phenotypes using multiple modalities in addition to imaging 
biomarkers and developing improved concepts of early OA. Finally I will 
discuss the implications of the application of the novel imaging analysis 
technology used in this thesis in other joints and clinical scenarios beyond 
the knee.  
 
7.3.1. Further validation and use of bone and multi-tissue 
biomarkers in clinical research as outcome measures 
7.3.1.1 Future analyses to elucidate the validity of 3D bone shape as an 
outcome for knee OA trials.  
While this thesis has provided evidence for the validity of novel imaging 
bone shape biomarkers towards their use as surrogate measures in future 
clinical OA trials and parallel work has identified that they 3D bone area is 
highly responsive and associated with knee OA pain progression, further 
analyses of their validity will be required. 
 A better understanding of the relationship between BMLs and bone shape 
and their relationship with patient centred outcomes such as TKR and OA 
symptoms is of great interest and relevance to understanding the 
pathogenesis of OA. With this in mind a number of future analyses should be 
considered. 
The first analysis would be to establish the construct validity of the novel 3D 
bone shape and tAB (bone area) bone biomarkers in relation to important 
MRI bone pathologies, including BMLs and osteophytes measured semi-
quantitatively using the MOAKs scores (which are publically available for 
600 knees in the OAI including knees with both structural and pain 
progression, knees with structural progression only, knees with pain 
progression only and knees with neither progression). This could be 
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performed by establishing the correlation coefficients for corresponding 
regional tAB and BMLs or osteophytes. For whole 3D bone shape the BMLs 
and osteophyte scores could be summated for each bone for each region.  
The objective of this analysis would be to explore the association of these 
subchondral bone pathologies at various stages of disease.  
A second analysis would explore the association of different anatomical 
regions within the current 3D bone shape with knee OA pain and symptoms. 
This comes from the observation that knee OA pain progression was 
associated with change in tAB. I have also observed that the 3D change in 
knee bone shape occurs in two distinct regions of the bones involved. There 
is a weight-bearing bone area (A) on each knee bone, and the non-weight-
bearing area (B) (Figure 60,Figure 61). I have briefly explored the data and 
realise the weight-bearing area (A) undergoes minor expansion in area 
whilst the non-weight-bearing area (B) undergoes significant increase in 
area. The objective would be to first repeat the case-control analysis 
conducted by Hunter and colleagues[625] to establish if the change in areas 
A and B are more strongly associated with pain progression or incidence. A 
subsequent analysis of interest would also be to repeat analysis of Chapter 
6 using areas A and B to establish if the specific changes in bone shape are 
independently associated with incident and prevalent pain. This analysis 
should include adjustment for confounding factors for pain such as level of 
activity. A more precise definition of knee OA symptoms could also be used 
including the prodromal symptoms of pain that precede radiographic OA[18] 
and the first symptoms of knee OA pain that appear to occur during weight-
bearing activities involving bending of the knee, such as using stairs[32] in 
addition to pain at rest (7.2 Improving understanding of the relationship 
between bone features and symptoms). The association of the 3D bone 
shape biomarkers should also be assessed with these measures. 
Future validation of bone biomarkers may also include a composite measure 
of BMLs and bone shape to enhance the validity of the biomarker. This may 
draw upon the concurrent and predictive validity against knee OA symptoms 
in the pre-radiographic phase of BMLs.  
- 355 - 
355 
 
Clinical trials of knee OA enrol symptomatic knee OA and therefore no 
clinical trial has used incident knee OA pain as an outcome. However future 
clinical trials may attempt to prevent the incidence of knee OA pain. If a 
clinical trial were to attempt to prevent the incidence of knee OA pain by 
targeting the subchondral bone, patients could be selected on the presence 
of BMLs and incident pain would be the primary outcome. However the 
change in BML size could be a secondary mechanistic outcome[330, 659].  
Therapeutic interventions targeting or inhibiting the general expansion of 3D 
knee bone shape would be unlikely to prevent the onset of knee OA 
symptoms. However 3D bone shape expansion measures a construct called 
“OA structural progression” and is the most responsive measure of OA 
structural progression. Therefore 3D bone shape change could be used as a 
sensitive secondary outcome measure of OA structural progression in 
clinical trials attempting to prevent the onset of symptomatic knee OA.  
More suitable tissue targets for such a clinical trial would include BMLs and 
synovitis. This contrasts with the findings of Chapter 5 that indicate that 3D 
bone shape is associated with TKR and has validity for use as an outcome 
measure in typical interventional OA trials attempting to modify structural 
progression. Therapies inhibiting the changes observed in 3D bone shape in 
knee OA might therefore be targeting an important structural process in the 
pathogenesis of joint failure and may be an important tissue target in trials 
attempting to modify structural progression. 
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Figure 60 Area A – Weight-bearing 
 
The area of the femur shown in red represents the weight-bearing 
region 
 
Figure 61 Area B  Non-weight-bearing 
 
The area of the femur shown in red represents the non-weight-bearing 
region 
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7.3.1.2 Future analyses to elucidate the validity of quantitative multi-
tissue measures and a whole joint biomarker as a surrogate 
measure of knee OA.  
The technology to automatically segment and quantify the structural status 
of all the joint tissues represents a unique opportunity to provide highly 
accurate quantitative biomarkers describing the phenotype and extent of 
tissue damage in a precise manner. For example, the articular cartilages, 
subchondral bone and menisci are segmented separately in the image 
below (Figure 62).  
Quantitative measures would be provided more rapidly with an automated 
segmentation, than semi-quantitative scoring such as the WORMS scores. 
Multiple quantitative tissue scores could facilitate a more appropriate 
description of the association of pathology within each of the tissues of the 
joint in OA. This provides an advantage over semi-quantitative scores which 
are time-consuming to score and may not represent interval measures.   
Finally a composite quantitative measure of whole joint OA pathology may 
better capture the extent of global structural pathology and in doing so 
confer greater validity in terms of its association with patient centered 
variables such as symptoms and TKR which would be re-examined in a 
similar manner to chapters 5 and 6.   
For example BMLs can be subdivided on the basis of their location and 
association with adjacent tissues. BMLs occurring at the ligament and 
meniscal attachments may be typical of tractional or repetitive microtrauma 
whilst ‘kissing’ BMLs may occur where two bones impact as a consequence 
of meniscal and hyaline cartilage defects are likely a consequence of 
trauma[671]. 
In section 7.3, the advantages of using BMLs as surrogate measures of 
patient-centered outcomes are highlighted. These include construct validity 
along with predictive and concurrent criterion validity for structural 
progression and symptoms. One might consider why bone shape should be 
further pursued as a biomarker. For the purposes of clinical trials, BMLs as 
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clinical endpoints have several limitations. These included the fact they can 
change in size over 6 weeks. Any clinical trial without regular monitoring with 
MRI scans may not capture this rapid variation and false conclusions may be 
drawn about the trend in BML size or volume based upon two 
measurements at the beginning and end of the trials. In contrast bone shape 
and bone area do not reduce in size but continue to increase in OA and 
therefore are more reliable in considering the underlying trend in structure. 
Furthermore the identification of the edge of singe, multiple or coalescing 
BMLs in multiple regions of the knee is a more complex segmentation than 
bone shape and tAB. This potential error may influence any association with 
knee pain and highlights the importance of the use of composite measures 
of joint structure. Bone shape provides a convenient continuous scale which 
can be measured less frequently to determine the true trend in bone shape.  
Figure 62 A whole joint biomarker 
 
A knee joint with articular cartilage (orange), meniscus (blue) and bone 
(grey) segmented.  
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7.3.1.3 The suitability of 3D bone shape biomarkers for use as outcome 
measures in knee OA trials 
To date all clinical knee OA trials have investigated the potential for 
structural or symptomatic disease modification in established knee OA. The 
suitability of the two bone shape biomarkers described in this thesis (3D 
bone shape and bone area) for use as outcome measures in disease 
modification trials is supported by the predictive validity for TKR described in 
Chapter 5, the concurrent validity for frequent pain in Chapter 6 and the work 
done in parallel with this thesis indicating the predictive validity for pain and 
structural progression[625]. However the lack of predictive validity for 
incident persistent knee pain reflects the lack of predictive validity for 
symptomatic disease onset. Therefore clinical trials of prospective structural 
or symptom disease modification could arguably use these bone shape 
biomarkers as outcome measures. However the lack of predictive validity for 
symptom onset indicates these bone shape biomarkers would not be 
suitable for clinical trials of interventions designed to prevent the onset of 
symptomatic knee OA. There are other structural biomarkers that have 
predictive validity for symptom onset including bone marrow lesions and 
cartilage defects [131, 134, 607] and synovitis [26] and for incident 
radiographic structural disease including BMLs, cartilage defects and 
meniscal degeneration and extrusion[622]. 
 
7.3.2 Towards a more precisely defined OA phenotype and tissue 
target  
7.3.2.1 The benefits of an improved OA phenotype 
The immense burden of OA on a personal, health service and 
socioeconomic level highlights the need for disease modifying therapies. 
With each and every failure of prospective DMOADs, the OA research 
community has attempted to better define the tissue targets and the OA 
phenotype and this progressive approach may hold future merit with the 
application of 3D structural biomarkers. 
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In chondroprotection trials to date, the failure to modify structure and 
symptoms of knee OA was explained by the chondro-centric approach failing 
to target non-cartilaginous pathologies in the multi-tissue pathology setting. 
Thus when oral bisphosphonates failed to modify radiographic structural 
progression in knee OA in the KOSTAR trial, this was explained by the 
failure to target individuals with knee OA with confirmed subchondral bone 
pathology[676]. By selecting an OA subchondral bone phenotype of 
prevalent BMLs in knee OA, the ZAP trial demonstrated structural 
modification but not a sustained reduction in symptoms[330]. More recently 
BMLs are recognised to be phenotypically heterogenous because those 
appearing on T1 and T2 sequences are more likely to be associated with 
more cartilage loss and pain[623] than those appearing on T1 alone. This 
may, in part, explain why treating the acutely painful OA knee with 
intravenous neridronate or placebo in a randomised placebo controlled trial 
was able to demonstrate structural modification and sustained reduction in 
pain[677]. This more recent success in apparently fulfilling the FDA’s 
DMOAD requirement, to improve structure and symptoms, highlights the 
possible advantages of a more precise definition of OA pathology and 
phenotype. An imprecise population of knees selected from a population 
with heterogenous pathologies may represent important confounding factors 
compared to a more homogenous tissue-pathology-specific cohort. The 
interaction of different tissue pathologies may establish a non-modifiable and 
irreversible degeneration trajectory and hence explain the failure of previous 
DMOAD trials.  
Acknowledging the limitations of existing bone biomarkers, I would  better 
define OA phenotypes by using a broad range of potential phenotype 
determinants. This includes symptom and demographic data, MRI imaging 
biomarkers, serological soluble biomarkers, along with genetic and 
epigenetic data. Kerkhof and colleagues have used similar methods[678].  
Patients may be better stratified by ‘whole joint’ quantitative assessments as 
described above (7.4.1.4). For example, individuals with BMLs and articular 
cartilage degeneration and pain may be best treated using weight loss and 
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intravenous bisphosphonates. In the absence of obesity, such individuals 
should be considered for knee braces to reduce BMLs and symptoms of 
OA[659] . Knee OA phenotypes and their prognosis have previously been 
described by stratifying individuals by their trajectories of structural and 
symptomatic progression as described by Felson and colleagues[92]. 
Although this phenotyping with greater precision has not been used in 
clinical trials or in general clinical practice, the broader application of this 
concept introduces the opportunity for targeted interventions.  
A further advantage of improved phenotyping of patients with OA is that the 
identification of novel genetic associations with these more precise tissue 
phenotypes is more likely. Currently the known genetic associations are 
weak, complex, polygenic and are unlikely alone to stratify individuals into 
those who will or will not develop the generic clinical syndrome of knee OA. 
However genetic and epigenetic associations exist in OA and these should 
ideally be incorporated in phenotyping. Should these match the tissue 
pathology observed, this provides a potentially important tissue target for 
individual joints[82] and important novel therapeutic targets [83]. 
 
7.3.2.2 Improved concepts of early OA 
Advances in MRI techniques have facilitated the identification of the pre-
radiographic stage of OA, in particular demonstrating pathology of the 
menisci, synovitis and BMLs[679]. These pathologies play an integral role in 
the multi-tissue concept of OA pathogenesis. Attempts to define pre-
radiographic or ‘early’ OA of the knee using MRI features have been 
previously described[680]. Should attempts to precisely define ‘early’ OA be 
enhanced by quantitative bone or whole-joint composite measures, this may 
significantly improve the prospects of capturing the early interaction of these 
important tissue pathologies for a more validated ‘whole joint’ clinical 
staging. This could be used to optimally describe the natural history of 
structural progression in knee OA and the inter-relationship between tissues 
in the pathogenesis of OA at early. This may process may also identify 
potential pathogenic tissue targets of particular interest in ‘early’ OA when 
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disease modification is more feasible. In summary a validated definition of 
such a clinical stage would significantly improve the prospects of 
interventional clinical studies identifying strategies for prevention and 
modification of structural and symptomatic  OA progression. 
7.3.3 Implications for novel imaging analysis  
This thesis has been concerned with the validation of two novel AAM -
derived bone shape biomarkers in the knee. Their validation may 
substantially reduce the practical and financial barriers to performing clinical 
trials of prospective DMOADs in the future.  
However there is clearly a massive potential for applying the same 
technology to other weight-bearing as well as non-weight-bearing joints, has 
the potential to advance our understanding of the pathogenesis of OA, to 
identify prospective tissue targets and to yield more imaging biomarkers. 
 
7.3.3.1 Other peripheral joints 
The limitations of conventional radiography in describing complex 3D 
structures has been described earlier for knees. These same limitations 
apply to other joints as well and many other joints are being described using 
3D imaging techniques in order to improve the precision of the diagnosis and 
severity of OA along with identifying patients that may benefit from surgery. 
Hip bone shape is known to be integral in the pathogenesis of hip OA. 
Turmezei and colleagues have established a 3D computerised tomography 
cortical bone mapping tool of the proximal femur. This is an accurate and 
reliable novel quantitative grading system for hip OA[681]. Turmezei and 
colleagues have recently reported evidence of construct validity in relation to 
radiographic measures of hip OA. Increases in KL grade corresponded with 
increasing cortical bone thickness which was typically seen at the 
superolateral femoral head-neck junction and superior subchondral bone 
plate. Increasing severity of CT-defined osteophytes corresponded to an 
increase in circumferential cortical thickness and also joint space loss[682, 
683]. Further validation of this application of novel AAM technology  to 
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provide apparently superior biomarkers may establish the concurrent and 
predictive nature of this biomarker and facilitate clinical trials of hip OA as 
well[669]. 
Dysplasia of the hip joint is associated with increased risk of hip OA[287]. 
The structural abnormalities within dysplastic hips are now being more 
accurately described using 3D CT [684]. The identification of global 
incongruity of the dysplastic femoro-acetabular joint with 3D imaging, may 
stratify those in need of earlier surgical intervention and may permit custom 
made prosthetic joint replacements[685, 686].  
Finally 3D imaging of the hip may improve the identification of both cartilage 
and bone pathology in individuals at risk of OA[687] and this can be used to 
better determine the suitability of surgical or non-surgical intervention. This 
may also facilitate pre-operative planning in femoro-acetabular 
impingement[688]. 
The relevance of 3D imaging includes other joints including the jaw, 
shoulder, hand and foot. The relevance to the temporomandibular joint 
(TMJ) has been described [689] and this is being used to better define the 
presence of OA of the TMJ[668]. The effect of glenohumeral joint (GHJ) 
morphology on GHJ movement may be relevant to the pathogenesis of 
rotator cuff pathology, is of great interest[690] and may lead to a more 
precise way to predict and treat the pathogenesis of shoulder pathology. 
Finally 3D imaging of the hand [691] and foot [692] may better stratify 
patients into those that will or will not benefit from surgery.  
 
7.3.3.2 The spine 
Vertebrae can now be segmented from 3D CT and MR imaging. The shape 
modelling may be more able to discriminate normal vertebral deformities 
from pathological one. This may improve the diagnosis of vertebral 
fractures[693] and abnormal shapes in individuals at risk of osteoporotic 
fracture for suitable osteoporosis prophylaxis[694] 
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Spinal OA is common and an important cause of chronic back pain. The 
normal kinematics and articulation of intervertebral joints has been poorly 
understood. These joints can now be imaged in three dimensions during 
movement in healthy individuals and individuals with degenerative changes. 
This may facilitate better understanding of the pathogenesis of 
discovertebral degeneration and biomechanical interventions to help restore 
‘normal’ movement[695]. This may be used before and after surgical 
interventions to assess the correlation of structural biomechanical changes 
in relation to symptomatic changes and determine the efficacy of such 
interventions.[696] 
There are also great potential advantages for the use of AAM technology in 
inflammatory arthritis where shape change is an important feature in the 
articular and periarticular tissues. This particularly includes axial and 
peripheral spondyloarthritis and rheumatoid arthritis. 
In summary 3D imaging may improve the precision of defining joint 
pathology, our ability to describe pathogenesis and the potential to measure 
the success or failure of any intervention in all joints. 
7.4 Conclusions 
The hypothesis underlying this thesis was that knee OA subchondral bone, 
defined using 3D knee MRI segmentation with AAMs, would provide novel 
imaging biomarkers that demonstrate associations with existing radiographic 
measures of structural knee OA pathology, total knee replacement and knee 
OA symptoms as part of the validation of biomarkers for use in knee OA 
clinical trials. A systematic literature review identified the limited validity of 
existing imaging biomarkers, and hence the need for the work presented in 
this thesis, but also the potential importance of MRI-assessed bone shape. 
In conclusion, this thesis has provided good evidence supporting the 
OMERACT biomarker tool validation domain of truth: 3D knee bone shape 
biomarkers have construct validity as measures of knee OA radiographic 
severity, predictive validity by association with total knee replacement and 
concurrent but not predictive validity by association with knee OA symptoms 
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in knees with radiographic OA. While 3D bone shape is independently 
associated with knee OA radiographic structural disease and total knee 
replacement, like other structural imaging biomarkers, the association with 
symptoms is weaker.  
Evidence for 3D bone shape biomarkers fulfilling the OMERACT domain of 
discrimination has been provided by the demonstration of good reliability and 
reproducibility in work performed in parallel to this PhD which is described in. 
This is the first stage in improving existing biomarkers of OA. Future 
surrogate measures of patient-centred outcomes are likely to include 
composite quantitative whole-joint biomarkers along with novel genetic 
biomarkers. Clinical trials in OA will seek to use these measures to reduce 
the size, duration and cost of clinical trials that currently hinder progression 
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